Introduction {#S6}
============

Understanding global trends in the health status of populations and changes in the leading causes of disease burden over time is crucial to tracking progress towards the Sustainable Development Goal to ensure healthy lives and promote wellbeing for all at all ages.[@R1] Robust assessment of these trends requires objective and comparable measures of population health that can help countries identify priorities and address challenges to achieving this goal. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, the third annual update in the series, uses all available up-to-date epidemiological data and improved standardised methods to provide a comparative assessment of health loss across 359 diseases and injuries and 73 age and sex groups for 195 countries and territories. The availability of GBD 2017 data for years of life lost (YLLs) because of premature mortality and years lived with disability (YLDs) provides an opportunity to assess trends in population health over the past 28 years by analysing two complementary summary measures: healthy life expectancy (HALE), which quantifies the number of years expected to be lived in good health, and disability-adjusted life-years (DALYs), which quantifies the health loss due to specific diseases and injuries. HALE provides a snapshot of overall population health and DALYs are useful for quantifying and ranking disease burden due to specific causes. DALYs can be utilised to help decision makers and the public understand the leading causes of health burden and whether improvement occurs over time.

The continuing trend of increasing life expectancy and decreasing mortality because of improvements in living conditions, income per capita, education, and medical practices is well known and understood.[@R2]--[@R5] Previous GBD papers have reported that increases in HALE have been slower than increases in life expectancy, resulting in more years of poor health, and suggesting an absolute expansion of morbidity.[@R6]--[@R9] However, details of how many of the additional years of life gained are spent in good health versus poor health across countries and sociodemographic groups have not been well characterised. As people live longer, such information becomes increasingly relevant for policy development, health systems planning, and resource allocation, the effects of which cannot be understated for population health. The estimates herein provide insight into the importance of access to services and appropriate health care, and the potential societal burden of caregiving and excess health-care expenditure for years lived in poor health.[@R10]

In this study, we present GBD 2017 results for HALE and DALYs by age and sex from 1990 to 2017 for 195 countries and territories. GBD 2017 includes new morbidity and mortality data (epidemiological surveillance data, disease registry data, scientific literature sources, survey sources, verbal autopsy studies, vital registration systems, cancer registries, complete birth history sources, summary birth history sources, and sibling history surveys); refined methods; and new estimations at the subnational level for Ethiopia, Iran, Norway, and Russia, and stratified by ethnicity for New Zealand. Also, the disaggregation of larger cause categories (eg, diabetes) has allowed separate estimation for several additional diseases (eg, type 1 and type 2 diabetes). GBD 2017 provides a complete reanalysis of all available data by country from 1990 to 2017, and thus supersedes all previously published GBD estimations of HALE and DALYs.

Methods {#S7}
=======

Overview {#S8}
--------

The GBD study comprehensively and systematically quantifies the comparative magnitude of health loss due to diseases and injuries by age, sex, and location over time. We estimated all-cause and cause-specific mortality using the following key principles: identification of all data sources that are available, assessment of the quality of the data and correction for known bias, application of highly standardised analytical procedures, and assessment of model performance using cross-validation analysis. We used similar principles to identify, enhance comparability, and analyse data to estimate the incidence, prevalence, and YLDs of diseases and injuries.[@R7] Using the GBD 2017 results for YLLs and YLDs, we calculated DALYs for 359 diseases and injuries.[@R11],[@R12] We used age-specific mortality and YLDs per person to calculate HALE, defined as the average number of years that a person at a given age can expect to live in good health, taking into account mortality and loss of functional health.[@R13] Additional details for computing HALE can be found in [appendix 1](#SD1){ref-type="supplementary-material"}. We calculated years lived in poor health (ie, years lived with functional health loss) as life expectancy minus HALE. Estimations for GBD 2017 cover the period 1990 to 2017 for 195 countries and territories. We did analyses using Python versions 2.7.12 and 2.7.3, Stata version 13.1, and R version 3.2.2.

For this study, we followed the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER),[@R14] which include recommendations on documentation of data sources, estimation methods, and statistical analysis ([appendix 1](#SD1){ref-type="supplementary-material"}). Interactive online tools are available to explore GBD 2017 data sources in detail using our online sourcing tool, the [Global Health Data Exchange](http://ghdx.healthdata.org). Data before and after adjustments and the fit of the model to the data for causes of death and non-fatal outcomes can be explored with the available [data visualisation tool](https://vizhub.healthdata.org).

Cause and location hierarchies {#S9}
------------------------------

In GBD 2017, as in previous GBDs, causes of mortality and morbidity are structured using a four-level classification hierarchy to produce results that are mutually exclusive and collectively exhaustive. GBD 2017 estimates 359 causes of DALYs, 77 of which are a source of disability but not a cause of death (eg, attention-deficit hyperactivity disorder, headache disorders, low back pain, and neck pain), and five of which are causes of death but not sources of morbidity (sudden infant death syndrome, aortic aneurysm, late maternal deaths, indirect maternal deaths, and maternal deaths aggravated by HIV/AIDS). In the GBD hierarchy, the number of mutually exclusive and collectively exhaustive fatal and non-fatal causes in each level for which GBD estimates is three at Level 1, 22 at Level 2, 169 at Level 3, and 293 at Level 4. The full GBD cause hierarchy, including corresponding International Classification of Diseases (ICD)-9 and ICD-10 codes and detailed cause-specific methods, is in GBD 2017 publications on cause-specific mortality[@R11] and non-fatal health outcomes[@R12] in the corresponding appendices.

GBD 2017 includes 195 countries and territories that are grouped into 21 regions on the basis of epidemiological similarities and geographical proximity.[@R15] For the purposes of statistical analyses, we further grouped regions into seven super-regions (central Europe, eastern Europe, and central Asia; high income; Latin America and Caribbean; north Africa and Middle East; south Asia; southeast Asia, east Asia and Oceania; and sub-Saharan Africa). Each year, GBD includes subnational analyses for a few new countries and continues to provide subnational estimates for countries that were added in previous cycles. Subnational estimation in GBD 2017 includes five new countries (Ethiopia, Iran, New Zealand, Norway, and Russia) and countries previously estimated at subnational levels (GBD 2013: China, Mexico, and the UK \[regional level\]; GBD 2015: Brazil, India, Japan, Kenya, South Africa, Sweden, and the USA; and GBD 2016: Indonesia and the UK \[local government authority level\]). All analyses are at the first level of administrative organisation within each country except for New Zealand (by Māori ethnicity), Sweden (by Stockholm and non-Stockholm), and the UK (by local government authorites). All subnational estimates for these countries were incorporated into model development and evaluation as part of GBD 2017. To meet data use requirements, we present all subnational estimates excluding those pending publication (Brazil, India, Japan, Kenya, Mexico, Sweden, the UK, and the USA); these results are presented in appendix tables and figures ([appendix 2](#SD2){ref-type="supplementary-material"}). Subnational estimates for countries with populations larger than 200 million people (as measured according to our most recent year of published estimates) that have not yet been published elsewhere are presented wherever estimates are illustrated with maps but are not included in data tables.

Estimation of mortality and non-fatal health loss {#S10}
-------------------------------------------------

We estimated age-specific mortality using data from vital registration systems, sample registration systems, household surveys, censuses, and demographic surveillance sites.[@R13] We estimated cause-specific mortality and YLLs using the GBD cause of death database, composed of vital registration and verbal autopsy data, survey and census data for injuries and maternal mortality, surveillance data for maternal and child mortality, cancer registries, and police records for interpersonal violence and road injuries.[@R11] The quality and comparability of the cause of death data were evaluated and improved through several steps, including adjustment of data from vital registration systems for incompleteness, conversion of causes found in the original data to the GBD 2017 cause list, and redistribution of deaths assigned to ICD codes that cannot be underlying causes of death. Detailed methods for each step are available in the appendix of the GBD 2017 causes of death paper.[@R11] We estimated cause-specific mortality using standardised modelling processes, most commonly the Cause of Death Ensemble model (CODEm), which uses a covariate selection algorithm to generate several plausible combinations of covariates that are then run through four model classes---namely, mixed effects linear models and spatiotemporal Gaussian process regression models for cause fractions and death rates. For a given cause, we categorised covariates into three groups on the basis of the following criteria: evidence of proximal or causal association (Level 1), strong evidence for an association but without adequate evidence of a causal link (Level 2), and covariates that are distal in the causal pathway and therefore might be mediated by other factors in Levels 1 or 2 (Level 3).[@R16] The programme then selects an ensemble of models that performs best on out-of-sample predictive validity tests for each cause of death. Ensemble models have been shown to produce smaller errors in estimated cause-specific mortality and more accurate trends than single-component models.[@R16] Additional detail, including model specifications and data availability for each cause-specific model, can be found in the appendices of the GBD 2017 causes of death[@R11] and mortality[@R13] publications. We calculated YLLs from the sum of each death multiplied by the standard life expectancy at each age. The standard life expectancy was taken from the lowest observed risk of death for each 5-year age group in all populations greater than 5 million people. For consistency across all fatal and non-fatal estimates in GBD 2017, we calculated our own population and fertility estimates.[@R17] We then used the GBD world population age standard to calculate age-standardised rates for cause-specific deaths and YLLs. The GBD world population age standard and the standard life expectancies are available in the appendix of the GBD 2017 mortality publication.[@R13]

Changes we have implemented since GBD 2016 for cause-specific mortality include the addition of important sources of new mortality data (detailed at the beginning of this section) and the expansion of the GBD location hierarchy, refinements in the calculation of Socio-demographic Index (SDI), and disaggregation of specific causes into subgroupings to provide additional detail. We estimated the following specific causes separately for the first time: invasive non-typhoidal salmonella disease; liver cancer due to non-alcoholic steatohepatitis (NASH); cirrhosis due to non-alcoholic steatohepatitis; myelodysplastic, myeloproliferative, and other haemopoietic neoplasms; benign and in-situ intestinal neoplasms; benign and in-situ cervical and uterine neoplasms; other benign and in-situ neoplasms; subarachnoid haemorrhage; non-rheumatic valvular heart disease; non-rheumatic calcific aortic valve disease; non-rheumatic degenerative mitral valve disease; other non-rheumatic valve diseases; gastro-oesophageal reflux disease; type 1 diabetes; type 2 diabetes; chronic kidney disease due to type 1 diabetes; chronic kidney disease due to type 2 diabetes; poisoning by carbon monoxide; and poisoning by other means. Specific data sources are available in the appendices of the GBD 2017 non-fatal diseases and injuries[@R12] and causes of death[@R11] publications. Additional information on data sources used can be found in our online source tool.

For estimation of non-fatal health loss, we most commonly used the Bayesian meta-regression tool DisMod-MR 2.1, which synthesises variable data sources to produce internally consistent estimates of incidence, prevalence, remission, and excess mortality.[@R18] If DisMod-MR 2.1 did not capture the complexity of the disease, or if incidence and prevalence needed to be calculated from other data, we used custom models; detailed methods for each cause are in the appendices of the GBD 2017 non-fatal diseases and injuries publication.[@R12]

We estimated each non-fatal sequela separately and assessed the occurrence of comorbidity for each age group, sex, location, and year separately using a micro-simulation framework.[@R12] Disability estimated for co-morbid conditions was distributed to each contributing cause during the comorbidity estimation process. Although the distribution of sequelae and the severity and cumulative disability per case of a condition might be different by age, sex, location, and year, previous studies have found that disability weights do not substantially vary between locations, income per capita, or levels of educational attainment.[@R19],[@R20] Additional details, including model specifications, data availability, data adjustments to enhance comparability for each cause-specific model, and the development of disability weights by cause and their use in the estimation of non-fatal health loss, are available in the appendices of the GBD 2017 non-fatal diseases and injuries publication.[@R12]

Estimation of DALYs, HALE, and corresponding uncertainty {#S11}
--------------------------------------------------------

To calculate HALE, we used the following inputs from GBD 2017: age-specific mortality rates; estimates of the prevalence of sequelae by age, sex, location, and year; and disability weights for all unique health states. We used the method originally developed by Sullivan[@R21] to estimate HALE ([appendix 1](#SD1){ref-type="supplementary-material"}). We calculated DALYs as the sum of YLLs[@R11] and YLDs[@R12] for each location, year, age group, and cause, by sex.

We calculated 95% uncertainty intervals (UIs) on the basis of 1000 draws from the posterior distribution of each step in the estimation process using the 2·5th and 97·5th percentiles of the ordered 1000 values. We attributed the uncertainty associated with estimation of mortality and YLLs to multiple sources, including sample size variability in data sources, adjustment and standardisation methods applied to data, and model specifications. We attributed the uncertainty associated with estimation of YLDs to sampling error of data inputs, adjustment and standardisation methods applied to data, the uncertainty in coefficients from model fit, and the uncertainty of severity distributions and disability weights.

Estimation of SDI and expected DALYs and HALE on the basis of SDI {#S12}
-----------------------------------------------------------------

The SDI is the geometric mean of three rescaled components: total fertility rate under age 25 years (ie, the number of births expected per woman aged 10--24 years), lag-distributed income per capita, and average educational attainment in populations aged 15 years or older. The methods we used to calculate the SDI are in [appendix 1](#SD1){ref-type="supplementary-material"}. SDI scores were scaled from 0 (lowest income, fewest years of schooling, and highest fertility) to 1 (highest income, most years of schooling, and lowest fertility). We estimated the association between SDI and cause-specific mortality using a generalised additive model with a Loess smoother on SDI; we then used this association to calculate expected YLLs. Expected YLDs were calculated on the basis of the relationship between SDI and YLD rates. We then calculated expected DALYs as the sum of expected YLLs and YLDs, and expected HALE using expected YLDs and expected life tables. All results are available both in [appendix 2](#SD2){ref-type="supplementary-material"} and through our online visualisation tool.

Role of the funding source {#S13}
--------------------------

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results {#S14}
=======

Levels and trends in life expectancy and HALE at birth {#S15}
------------------------------------------------------

Globally, life expectancy at birth for both sexes combined increased by 7·4 years (95% UI 7·1--7·8), rising from 65·6 years (65·3--65·8) in 1990 to 73·0 years (72·7--73·3) in 2017 ([appendix 2](#SD2){ref-type="supplementary-material"}). The increase in life expectancy at birth was 7·3 years (6·9--7·7) for males (from 63·2 years \[62·9--63·4\] in 1990 to 70·5 years \[70·1--70·8\] in 2017) and 7·5 years (7·2--7·9) for females (from 68·0 years \[67·8--68·3\] in 1990 to 75·6 years \[75·3--75·9\] in 2017; [table 1](#T1){ref-type="table"}). During the same period, global HALE at birth for both sexes combined increased by 6·3 years (5·9--6·7), from 57·0 years (54·6--59·1) in 1990 to 63·3 years (60·5--65·7) in 2017 ([appendix 2](#SD2){ref-type="supplementary-material"}). The increase in HALE at birth was 6·2 years (5·8--6·7) for males (from 55·6 years \[53·5--57·5\] in 1990 to 61·8 years \[59·4--64·0\] in 2017) and 6·4 years (6·0--6·8) for females (from 58·4 years \[55·7--60·8\] in 1990 to 64·8 years \[61·7--67·4\] in 2017; [table 1](#T1){ref-type="table"}). The number of years lived in poor health from birth increased globally by 1·1 years (95% UI 0·9--1·4), in the low SDI countries by 1·5 years (1·2--1·9), and in the high SDI countries by 1·3 years (1·0--1·7; [appendix 2](#SD2){ref-type="supplementary-material"}).

The increases from 1990 to 2017 in life expectancy and HALE varied across SDI quintiles and countries, with the greatest increases in life expectancy and HALE seen in the low SDI quintile and the smallest increases seen in the high SDI quintile. The increase in life expectancy varied from 5·1 years (5·0--5·3) in high SDI countries to 12·0 years (11·3--12·8) in low SDI countries. HALE increased for both sexes in low SDI countries by 10·5 years (95% UI 9·8--11·2; by 10·1 years \[9·3--10·9\] for males and by 10·9 years \[10·1--11·7\] for females), and in high SDI countries by 3·8 years (3·4--4·1; by 4·4 years \[4·0--4·8\] for males and by 3·2 years \[2·9--3·5\] for females; [table 1](#T1){ref-type="table"}, [figure 1](#F1){ref-type="fig"}; [appendix 2](#SD2){ref-type="supplementary-material"}). Increases in HALE in the middle SDI quintiles for both sexes follow a gradient, with increases of 6·8 years (6·3--7·4) for low-middle SDI, 5·7 years (5·3--6·2) for middle SDI, and 5·5 years (5·1--5·8) for high-middle SDI ([figure 1](#F1){ref-type="fig"}; [appendix 2](#SD2){ref-type="supplementary-material"}).

Increases in HALE at birth between 1990 and 2017 were smaller than increases in life expectancy over the same period in all SDI quintiles, resulting in an increase in years lived in poor health. Of the additional years of life expected at birth, 26·3% (20·1--33·1) were spent in poor health in high SDI countries compared with 11·7% (8·8--15·1) in low-middle SDI countries ([figure 2](#F2){ref-type="fig"}). The largest increase in years lived in poor health was for females in low SDI quintile countries, by 1·6 years (1·2--2·1), and the smallest increase was for males in middle SDI quintile countries, by 0·8 years (0·6--1·0; [figure 1](#F1){ref-type="fig"}). Although males and females in all SDI quintiles had increases in HALE at birth, the increase was disparate between the sexes. In 1990, high SDI quintile countries had the largest gap in HALE between males and females, at 4·1 years (3·4--4·8; [figure 3](#F3){ref-type="fig"}); this gap decreased to 2·9 years (2·3--3·5) by 2017. In 2017, the high-middle SDI quintile countries had the largest gap in HALE between males and females (3·8 years \[3·1--4·5\]); this gap had increased from 1990 to peak in 1995 at 4·8 years (4·5--5·2) and then decreased gradually thereafter. Low SDI quintile countries had the smallest gap in HALE between males and females in 2017 ([figure 3](#F3){ref-type="fig"}). The difference in HALE at birth between the sexes during the period 1990--2017 increased in countries in the low SDI, low-middle SDI, and middle SDI quintiles. South Asia was the only region where males had higher HALE at birth than females did in 1990, and this trend lasted until 2000, after which point females had higher HALE at birth ([appendix 2](#SD2){ref-type="supplementary-material"}). In all other regions, females had higher HALE at birth than males did in all study years. Eastern Europe had the biggest difference in HALE at birth between females and males throughout the period 1990--2017, with a difference of 7·7 years (6·8--8·4) in 2017. North Africa and the Middle East had the smallest difference in HALE at birth between females and males in 1990, and south Asia had the lowest difference in 2017 ([appendix 2](#SD2){ref-type="supplementary-material"}).

At the country level, countries that had the largest increases in HALE at birth for both sexes combined between 1990 and 2017 were Eritrea (23·7 years \[95% UI 21·9--25·6\], Ethiopia (18·5 years \[17·2--19·9\], and Uganda (16·3 years \[13·5--19·0\]). The smallest increases were seen in Saint Vincent and the Grenadines (1·0 years \[0·4--1·7\]), South Africa (1·1 years \[0·3--1·8\]), and Uzbekistan (1·4 years \[0·4--2·4\]). Decreases in HALE at birth for both sexes combined occurred in Lesotho (5·0 years \[3·1--6·8\]), Swaziland (eSwatini; 2·3 years \[0·4--4·3\]), and Guam (1·2 years \[0·5--1·9\]). In 2017, the highest HALE at birth was estimated to be in Singapore for both females (75·8 years \[72·4--78·7\]) and males (72·6 years \[69·8--75·0\]; [table 1](#T1){ref-type="table"}). The lowest HALE at birth in 2017 for both males and females was estimated to be in the Central African Republic, at 47·0 years (43·7--50·2) for females and 42·8 years (40·1--45·6) for males. The largest differences in HALE at birth in 2017 between males and females were in Ukraine \[8·7 years (7·5--9·8), Lithuania (7·8 years \[6·6--8·9\]), and Russia (7·4 years \[6·6--8·1\]).

Trends in HALE for males and females at age 65 years {#S16}
----------------------------------------------------

Globally, HALE at age 65 years for females was 11·9 years (95% UI 10·8--12·9) in 1990 and 13·7 years (12·4--14·9) in 2017, an increase of 1·8 years (1·6--2·0; [table 2](#T2){ref-type="table"}). For males, HALE at age 65 years increased by 1·7 years (1·5--1·9), from 10·3 years (9·4--11·1) to 12·0 years (10·9--12·9). At the SDI level, both males and females in the high SDI quintile had the largest increases in HALE at age 65, increasing from 13·9 years (12·7--15·1) in 1990 to 16·2 years (14·6--17·6) in 2017 for females, and increasing from 11·3 years (10·3--12·1) in 1990 to 13·8 years (12·6--15·0) in 2017 for males. The countries with the largest increases in HALE for females at age 65 years from 1990 to 2017 were the Maldives (by 7·0 years \[6·3--7·8\]), Singapore (by 4·9 years \[4·4--5·5\]), and Ethiopia (by 4·6 years \[4·0--5·3\]). For males, the largest increases were in Iraq (by 4·7 years \[3·8--5·6\]), the Maldives (by 4·5 years \[4·0--5·1\]), and South Korea (by 4·5 years \[4·0--5·0\]). In 2017, the largest difference between HALE at age 65 years between females and males was in Bermuda (17·7 years \[16·2--19·2\] for females, and 13·4 years \[12·4--14·5\] for males).

Decomposition of years of life gained at birth and at age 65 years {#S17}
------------------------------------------------------------------

Although life expectancy at birth increased for both males and females globally during the period 1990--2017, the proportion of additional years spent in poor health was 15·3% (95% UI 11·8--19·2) of the additional 7·5 years (7·2--7·9) for females and 14·9% (11·3--19·0) of the additional 7·3 years (6·9--7·7) for males, with substantial variations across SDI quintiles, regions, and countries ([figure 2](#F2){ref-type="fig"}). The proportion of additional years spent in poor health varied from 11·1% (8·3--14·3) of the additional 8·2 years (7·5--8·8) among females in low-middle SDI countries, to 27·3% (20·8--34·4) of the additional 4·4 years (4·2--4·6) among females in high SDI countries. From 1990 to 2017, life expectancy at birth increased the most for both males and females in eastern sub-Saharan Africa compared with other regions ([table 1](#T1){ref-type="table"}), but of the additional years gained, 11·1% (8·3--14·3) of 13·8 years (12·8--14·8) for males and 13·1% (10·0--16·7) of 14·6 years (13·7--15·5) for females were spent in poor health. At the country level, 179 countries gained additional years of life from 1990 to 2017, and 16 did not ([appendix 2](#SD2){ref-type="supplementary-material"}). The most additional years of life were gained by males in Eritrea (28·6 years \[25·7--31·4\]), Ethiopia (21·1 years \[19·5--22·8\]), and Equatorial Guinea (18·6 years \[15·1--21·8\]). Of these years gained, the proportion spent in poor health was 11·3% (8·0--14·9) for Eritrea, 12·1% (9·2--15·6) for Ethiopia, and 13·7% (9·4--18·7) for Equatorial Guinea. Females gained the most additional years of life in Eritrea (22·4 years \[19·7--25·4\]), Ethiopia (21·5 years \[20·0--23·2\]), and Rwanda (19·5 years \[17·1--22·1\]). Of these years gained, the proportion spent in poor health was 10·4% (7·1--14·6) for Eritrea, 13·6% (10·2--17·4) for Ethiopia, and 16·1% (11·8--21·1) for Rwanda. Males spent over a third of the years of life gained in poor health in Belize (45·9% \[5·5--155·6\]), Ukraine (39·3% \[14·1--128·7\]), the Federated States of Micronesia (34·2% \[7·0--55·9\]), and the USA (33·6% \[25·1--42·2\]). Similarly, females spent over a third of their years of life gained in poor health in the USA (47·9% \[35·2--61·6\]), Northern Mariana Islands (40·7% \[25·9--70·7\]), and the UK (34·3% \[25·8--43·6\]; [appendix 2](#SD2){ref-type="supplementary-material"}).

Globally, between 1990 and 2017, life expectancy for females at age 65 years increased by 2·5 years (95% UI 2·4--2·6) and they spent 27·6% (21·2--35·0) of those years in poor health ([appendix 2](#SD2){ref-type="supplementary-material"}). Similarly, males at age 65 years gained 2·4 years (2·2--2·5) of life and spent 26·6% (20·1--34·0) of those years in poor health. Between 1990 and 2017, at the SDI quintile level, females in the high SDI quintile spent the largest proportion of years gained in poor health (29·9% \[22·9--37·5\] of 3·2 years \[3·1--3·4\] gained), and females in the low-middle SDI quintile spent the smallest proportion of years gained in poor health (23·8% \[17·1--31·6\] of 2·0 years \[1·7--2·3\] gained; [appendix 2](#SD2){ref-type="supplementary-material"}). Similarly, males in the high SDI quintile spent the largest proportion of additional years in poor health in the same period (30·0% \[22·9--37·8\] of 3·7 years \[3·6--3·8\] gained), and males in the low-middle SDI quintile spent the smallest proportion of additional years in poor health (23·7% \[17·2--30·9\] of 1·5 years \[1·2--1·8\] gained). At the country level, life expectancy between 1990 and 2017 for females at age 65 years increased the most in the Maldives (9·3 years \[8·6--9·9\]), Singapore (6·4 years \[5·9--6·8\]), and Iraq (6·2 years \[5·0--7·4\]), with the proportion of years spent in poor health being 24·4% (18·2--31·3) for those in the Maldives, 23·2% (17·4--29·7) for those in Singapore, and 28·5% (21·3--36·3) for those in Iraq ([appendix 2](#SD2){ref-type="supplementary-material"}). For males at age 65 years, life expectancy increased the most for Iraq (6·8 years \[5·6--7·9\]), South Korea (6·1 years \[5·6--6·6\]), and the Maldives (5·9 years \[5·3--6·4\]), with the proportion of those years spent in poor health being 30·3% (22·9--38·2) for Iraq, 26·1% (19·6--33·1) for South Korea, and 22·5% (16·6--29·4) for the Maldives ([appendix 2](#SD2){ref-type="supplementary-material"}).

Decomposition of extra years lived by females compared with males in 2017 {#S18}
-------------------------------------------------------------------------

In 2017, females had longer life expectancy than males in 180 of 195 countries ([appendix 2](#SD2){ref-type="supplementary-material"}). Of these countries, the largest differences (\>10 years) between female and male life expectancy at birth were in Ukraine (76·5 years \[95% UI 75·8--77·2\] for females and 64·7 years \[63·9--65·4\] for males), Lithuania (80·2 years \[79·4--81·0\] for females and 69·6 years \[68·7--70·5\] for males), Russia (77·2 years \[77·1--77·4\] for females and 66·8 years \[66·6--66·9\] for males), and Swaziland (eSwatini; 65·1 years \[62·1--68·4\] for females and 54·9 years \[52·6--57·6\] for males). For the other 15 countries, life expectancy was not significantly different between the sexes.

Globally, in 2017, females lived an additional 5·1 years (95% UI 4·9--5·3) compared with males, and of those extra years 57·5% (46·2--67·4) were spent in good health and 42·5% (32·6--53·8) in poor health ([figure 4](#F4){ref-type="fig"}). The proportion of additional years spent in poor health varied a lot across SDI quintiles, regions, and countries. Compared with all other SDI quintiles, females in the high-middle SDI quintile lived the most extra years of life compared with males, living longer than males by 6·1 years; however, 37·8% (29·1--47·6) of those extra years were lived in poor health. At the regional level, the proportion of extra years lived in poor health among females in 2017 ranged from 21·9% (16·2--28·4) in central Europe to 92·2% (87·2--96·2) in south Asia ([figure 4](#F4){ref-type="fig"}). Extra years lived by females varied from 11·9 years (10·9--12·9) in Ukraine to 1·4 years (0·6--2·3) in Algeria ([appendix 2](#SD2){ref-type="supplementary-material"}). Of the extra years lived, the proportion spent in poor health varied largely at the country level, with less than 20% of the additional years spent in poor health for females in Bosnia and Herzegovina, Burundi, and Slovakia, whereas females lived all extra years in poor health in Bahrain (1·6 years \[0·2--3·1\]; [appendix 2](#SD2){ref-type="supplementary-material"}).

Globally, at age 65 years, women lived an additional 2·7 years (95% UI 2·6--2·9) compared with men, but 63·9% (55·2--72·2) of those years were spent in good health and 36·1% (27·8--44·8) in poor health ([appendix 2](#SD2){ref-type="supplementary-material"}). Compared with other SDI quintiles, the difference in life expectancy was greatest between females and males in the high SDI quintile, with females living 3·3 years (3·1--3·5) longer than males, but 28·4% (21·3--36·1) of those years were spent in poor health. In the low SDI quintile, females are estimated to live the largest proportion of extra years in poor health compared with other SDI quintiles (58·0% \[43·8--74·6\] of 1·1 years \[0·7--1·4\]). For females aged 65 years in Iran and India, of the extra years lived compared with males, more than 60% of extra years were spent in poor health, 70·1% (53·5--88·2) for those in Iran and 63·4% (49·0--79·6) for those in India ([appendix 2](#SD2){ref-type="supplementary-material"}).

Global levels and trends for DALYs {#S19}
----------------------------------

The global level of all-age all-cause DALYs in 2017 was 2·50 billion (95% UI 2·29--2·74). The estimated DALY counts and age-standardised rate of DALYs, and changes in these metrics between 2007 and 2017, are in [table 3](#T3){ref-type="table"}. The largest contribution to global DALYs was from non-communicable diseases, which, combined, accounted for 62·0% (60·3--63·8) of total DALYs, whereas communicable, maternal, neonatal, and nutritional (CMNN) causes accounted for 27·9% (26·4--29·4), and injuries 10·1% (9·7--10·5) of total DALYs.

For non-communicable diseases, global DALYs increased by 40·1% (95% UI 36·8--43·0), although age-standardised DALY rates decreased by 18·1% (16·0--20·2). Between 2007 and 2017, 12 causes at Level 2 of the GBD cause hierarchy (diabetes and kidney diseases, sense organ diseases, neurological disorders, neoplasms, musculoskeletal disorders, substance use disorders, cardiovascular diseases, chronic respiratory diseases, skin and subcutaneous diseases, mental disorders, digestive diseases, and self-harm and interpersonal violence) had significant increases in DALY counts. The greatest number of DALYs among Level 3 non-communicable disease causes in 2017 were estimated for ischaemic heart disease (170 million \[167--174\]), stroke (132 million \[126--137\]), and chronic obstructive pulmonary disease (81·6 million \[76·0--86·8\]) which, combined, accounted for 15·4% (14·2--16·4) of all-cause DALYs ([table 3](#T3){ref-type="table"}). By contrast with the overall decrease in DALYs during 2007--17 for many causes, total all-age DALYs from non-communicable diseases increased from 1·11 billion (1·00--1·23) in 1990 to 1·34 billion (1·19--1·51) in 2007, and continued to increase to 1·55 billion (1·38--1·75) in 2017 ([appendix 2](#SD2){ref-type="supplementary-material"}): a change of 20·7% (18·4--22·8) from 1990 to 2007, and 16·0% (15·1--16·9) from 2007 to 2017. At Level 4 between 1990 and 2007, the largest significant increases in total DALYs were estimated for HIV/AIDS and multidrug-resistant tuberculosis co-infection without extensive drug resistance (5329·0% \[3143·5--8492·9\]), multidrug-resistant tuberculosis without extensive drug resistance (700·6% \[335·0--1,431·6\]), and HIV/AIDS resulting in other diseases (454·3% \[389·5--529·2\]; [appendix 2](#SD2){ref-type="supplementary-material"}. From 2007 to 2017, the largest significant increases in DALYs were for liver cancer due to NASH (37·4% \[32·8--42·9\]), chronic kidney disease due to type 2 diabetes (34·3% \[30·9--37·2\]), and diabetes type 2 (34·0% \[30·3--38·1\]). Relative to changes in the population, the age-standardised DALY rate for non-communicable diseases decreased by 13·2% (11·7--14·7), from 24 017·4 DALYs (21 861·4--26 509·6) per 100 000 in 1990 to 20 852·2 DALYs (18 710·2--23 388·5) per 100 000 in 2007, and decreased by a further 5·6% (4·8--6·6) to 19 676·5 DALYs (17 509·8--22 177·9) per 100 000 in 2017. From 1990 to 2017, the greatest significant decreases in age-standardised DALY rates were for visceral leishmaniasis (97·8% \[97·0--99·2\]), maternal haemorrhage (78·7% \[73·4--83·0\]), and ascariasis (70·8% \[66·0--75·3\]). Significant increases in age-standardised DALY rates from 1990 to 2017 were observed for 17 Level 4 non-communicable diseases, with other benign and in-situ neoplasms (35·1% \[7·8--81·7\]), type 2 diabetes (28·2% \[24·1--32·3\]), and opioid use disorders (24·8% \[20·1--31·0\]) having the most pronounced changes.

Among CMNNs, at Level 3 of the GBD cause hierarchy the greatest contributors to global DALYs in 2017 were neonatal disorders (186 million \[95% UI 175--197\] DALYs), lower respiratory infections (106 million \[100--112\] DALYs), and diarrhoeal diseases (81·0 million \[70·1--97·2\] DALYs). Globally, total DALYs from all CMNNs decreased from 1·19 billion (1·14--1·23) in 1990 to 0·946 billion (0·910--0·987) in 2007, to 0·696 billion (0·660--0·740) in 2017, a decrease of 41·3% (38·8--43·5) from 1990 to 2017. In parallel, the age-standardised DALY rate for all CMNN causes decreased by 49·8% (47·9--51·6) from 1990 to 2017. For 2007--17, the largest decreases were for visceral leishmaniasis (by 63·9% \[40·0--84·5\]), HIV/AIDS and drug-susceptible tuberculosis co-infection (by 54·9% \[51·0--57·9\]), and maternal haemorrhage (52·4% \[44·3--59·5\]; [table 3](#T3){ref-type="table"}). Significant decreases of more than 50% in age-standardised DALY rates between 2007--17 were estimated for five Level 4 CMNN causes, specifically, visceral leishmaniasis (66·2% \[44·3--86·0\]), HIV/AIDS and drug-susceptible tuberculosis co-infection (59·8% \[56·3--62·5\]), HIV/AIDS and multidrug-resistant tuberculosis without extensive drug resistance co-infection (56·6% \[40·1--69·1\]), maternal haemorrhage (56·4% \[49·1--62·8\]), and HIV/AIDS resulting in other diseases (53·7% \[51·1--56·1\]). Against this general decreasing trend, seven CMNN causes at Level 4 were estimated to have Significant increases in age-standardised DALY rate between 1990 and 2017, specifically, HIV/AIDS and multidrug-resistant tuberculosis without extensive drug resistance co-infection (1805·0% \[1016·3--3049·2\]), HIV/AIDS resulting in other diseases (103·1% \[76·3--134·9\]), and cutaneous and mucocutaneous leishmaniasis (40·5% \[7·0--106·0\]).

In 2017, the top five leading causes of DALYs were communicable diseases (lower respiratory infections, malaria, diarrhoeal diseases, HIV/AIDS, and tuberculosis) and neonatal disorders ([table 3](#T3){ref-type="table"}). For low-middle SDI countries, both communicable and non-communicable diseases ranked highly as leading causes of DALYs, and the top five causes were neonatal disorders, lower respiratory infections, ischaemic heart disease, diarrhoeal diseases, and stroke ([figure 5](#F5){ref-type="fig"}). In high SDI countries, non-communicable diseases (ischaemic heart disease, low back pain, stroke, lung cancer, and chronic obstructive pulmonary disease) were the leading causes of DALYs ([figure 5](#F5){ref-type="fig"}). Younger age groups contributed more to total DALY counts in low SDI countries than did older age groups, and mostly from communicable diseases. In low SDI countries in 2017, 136 million (95% UI 130--143) DALYs were estimated for neonatal age groups to be from communicable diseases, with a further 18·9 million (17·2--21·0) from non-communicable diseases, and 2·95 million (2·60--3·26) from injuries. For low and low-middle SDI countries, the burden is more equal across age groups than in other SDI quintiles. The burden from DALYs in high-middle and high SDI countries occurs mostly from age 15 years and consists largely of non-communicable diseases ([figure 5](#F5){ref-type="fig"}).

Leading causes of DALYs and changes during 1990--2017 {#S20}
-----------------------------------------------------

Globally in 2017, the leading causes of DALYs were predominantly CMNN and non-communicable causes for both men and women ([figure 6](#F6){ref-type="fig"}). Of the top 30 causes of DALYs for men, four were injuries: road injuries (49·8 million \[95% UI 47·3--52·1\] DALYs), self-harm (22·9 million \[20·9--24·0\] DALYs), falls (21·0 million \[17·6--24·9\] DALYs), and interpersonal violence (19·8 million \[17·8--21·0\] DALYs; [table 3](#T3){ref-type="table"}). By contrast, two of the top 30 causes of DALYs for women were injuries: road injuries (18·0 million \[16·6--19·4\] DALYs) and falls (15·0 million \[12·3--18·0\] DALYs). Our results showed disparities in disease burden between males and females. Females are more likely than males to have a higher burden from disabling conditions such as most musculoskeletal disorders except for gout, iron-deficiency anaemia, and major depressive disorder. Iron-deficiency aneaemia is common especially at reproductive ages for females, and for boys and girls (aged 5--14 years) equally ([appendix 2](#SD2){ref-type="supplementary-material"}). Males are more likely than females to be affected by fatal conditions including different types of cancer, injuries, and ischaemic heart disease. Globally, the all-age DALY count of HIV/AIDS for females increased sharply from 1990 to 2007, rising from 36th to third leading cause of DALYs with an increase of 610·7% (548·5--680·6), then decreased from 2007 to 2017 by 53·9% (51·6--53·9), dropping to 12th leading cause of DALYs ([figure 6](#F6){ref-type="fig"}). Similarly, the global age-standardised DALY rate for females increased from 1990 to 2007 by 483·0% (431·4--540·5), and then decreased from 2007 to 2017 by 58·8% (56·8--60·6; [appendix 2](#SD2){ref-type="supplementary-material"}). Males had similar patterns in all-age DALY counts and age-standardised DALY rates for HIV/AIDS during the same period. The all-age DALY count of HIV/AIDS for males increased by 297·3 (259·8--338·4) from 1990 to 2007, rising from the 25th leading cause of DALYs to seventh ([figure 6](#F6){ref-type="fig"}; [appendix 2](#SD2){ref-type="supplementary-material"}). By 2017, all-age DALYs from HIV/AIDS for males dropped to 13th leading cause of DALYs, a decrease of 44·8% (42·8--46·6) between 2007 and 2017. Similarly, the age-standardised DALY rate of HIV/AIDS for males increased sharply from 1990 to 2007, with an increase of 212·9% (182·8--246·4), and then decreasing by 51·1% (49·0--52·6) in 2017. The global all-age DALY count of malaria for females increased from 1990 to 2007 by 28·6% (11·7--51·2), rising from the tenth leading cause of DALYs to the seventh leading cause of DALYs. Malaria age-standardised DALY rates for females also increased, with an increase of 23·2% (7·4--44·2) between 1990 and 2007, and then decreased from 2007 to 2017 by 40·2% (30·7--49·2). DALYs from malaria for males also increased from 1990 to 2007, increasing by 30·5% (12·9--55·7) from the 11th to the tenth leading cause of DALYs. Similarly, the age-standardised DALY rate for malaria in males increased between 1990 and 2007 by 23·6% (7·0--46·0), and then decreased by 37·7% (27·6--46·8) in 2017.

The leading 30 causes of DALYs for men and women varied between SDI quintiles ([appendix 2](#SD2){ref-type="supplementary-material"}). In the low SDI quintile countries, males and females had similar CMNN causes as the leading causes of DALYs in 2017, with the greatest total DALYs for both sexes being from neonatal disorders, lower respiratory infections, diarrhoeal diseases, and malaria for both sexes, and thereafter for females the fifth leading cause was congenital defects and for males was ischaemic heart disease. In the low SDI quintile, males had more injury sources of DALYs than females, whereas CMNN causes of DALYs were more common among the leading DALY causes for females than males. An epidemiological shift in sources of DALYs was evident in the leading causes for both men and women at middle to high SDI levels, which were dominated by non-communicable disease causes. In high SDI quintiles, two CMNN causes of DALYs were in the leading 30 causes for both men and women, lower respiratory infections and neonatal disorders, and the age-standardised DALYs rate for these causes decreased between 1990 and 2017, by 36·2% (95% UI 33·9--38·6) for lower respiratory infections and 30·1% (25·1--36·7) for neonatal disorders for men, and by 37·8% (35·8--39·9) for lower respiratory infections and 27·5% (22·3--34·1) for neonatal disorders for women ([appendix 2](#SD2){ref-type="supplementary-material"}).

YLLs and YLDs composition by age, sex, and SDI {#S21}
----------------------------------------------

Globally in 2017, males had 1·34 billion (95% UI 1·24--1·46) DALYs and females had 1·16 billion (1·04--1·29) DALYs. For males, 29·4% (23·8--34·9) of DALYs were from YLDs and 70·6% (65·1--76·2) were from YLLs. For females, 39·4% (33·0--45·6) of DALYs were from YLDs and 60·6% (54·4--67·0) were from YLLs. A greater proportion of DALYs were from YLDs for females than for males, particularly for those older than 65 years ([figure 7](#F7){ref-type="fig"}). Globally, among females YLDs were the larger fraction of DALYs for many age groups, whereas for males this was only the case for those aged 10--14 years. Across SDI quintiles, the composition of DALYs varied. Females aged 1--69 years in the high SDI quintile had more DALYs from YLDs than from YLLs, whereas in the low SDI quintile all age groups except those aged 10--29 years had more DALYs from YLLs than from YLDs. In all quintiles, women older than 65 years had more DALYs from YLDs than men older than 65 years did.

Observed and expected values of HALE and DALYs based on SDI level {#S22}
-----------------------------------------------------------------

Maps of observed minus expected HALE can highlight which countries have worse or better HALE than expected based on SDI quintile, as shown in [figure 8](#F8){ref-type="fig"}. The three countries with the greatest difference between expected HALE at birth and observed HALE at birth for males, with observed HALE much lower than expected on the basis of their SDI value, were Lesotho, with a difference of 13·4 years, Swaziland (eSwatini), with a difference of 11·7 years, and Central African Republic, with a differences of 7·9 years. For females, the countries with the greatest differences were Lesotho, with a difference of 10·0 years, Congo (Brazzaville), with a difference of 9·3 years, and Swaziland (eSwatini), with a difference of 8·1 years. The three countries that had the greatest difference between observed and expected HALE at birth for males, where HALE was much better than expected, were Niger, Nicaragua, and the Maldives, with differences of 11·9 years for Niger, 9·5 years for Nicaragua, and 9·2 years for the Maldives. For females, these countries were Niger, Nicaragua, and Ethiopia, with differences between observed and expected HALE at birth of 11·5 years for Niger, 8·3 years for Nicaragua, and 8·2 years for the Maldives. We saw a similar trend in countries having differences in observed and expected HALE at age 65 years for both males and females ([appendix 2](#SD2){ref-type="supplementary-material"}). The greatest differences in observed and expected HALE at age 65 years for males, where HALE was worse than expected, were seen in Lesotho (3·1 years), Swaziland (eSwatini; 2·8 years), and Papua New Guinea (2·3 years), and for females were seen in Congo (Brazzaville; 2·7 years), Papua New Guinea (2·6 years), and Marshall Islands (2·2 years). HALE at age 65 years was better than expected on the basis of SDI level for males in Peru (by 5·0 years), Colombia (by 5·0 years), and Nicaragua (by 4·9 years), and for females in Colombia (by 4·5 years), Peru (by 4·3 years), and Nicaragua (by 3·7 years).

Higher ratios of observed to expected age-standardised DALY rates indicate more DALYs experienced than expected on the basis of SDI ([appendix 2](#SD2){ref-type="supplementary-material"}). Males had the highest ratio of observed to expected age-standardised DALY rates in Lesotho (1·94), Swaziland (eSwatini; 1·86), and Central African Republic (1·60). Females had the highest ratio of observed to expected age-standardised DALY rates in Congo (Brazzaville; 1·67), Lesotho (1·62), and Equatorial Guinea (1·57). Alternatively, males in the Maldives, Niger, and Nicaragua experience DALYs at a much lower rate than expected, with observed to expected ratios of 0·54 in the Maldives, 0·56 in Niger, and 0·57 in Nicaragua. Females had low ratios of observed to expected age-standardised DALY rates in Niger, Nicaragua, and Ethiopia, with ratios of 0·57 in Niger, 0·58 in Nicaragua, and 0·62 in Ethiopia.

Discussion {#S23}
==========

Main findings {#S24}
-------------

Globally, HALE at birth increased by 6·3 years (95% UI 5·9--6·7) and the number of years lived in poor health from birth increased by 1·1 years (0·9--1·4) during the period 1990--2017, with substantial variation across socio-demographic quintiles and countries. People in low SDI countries gained an additional 10·5 years (9·8--11·2) of life in good health and 1·5 years (1·2--1·9) in poor health from birth, whereas people in high SDI countries gained an additional 3·8 years (3·4--4·1) in good health and 1·3 years (1·0--1·7) in poor health from birth. Women are expected to live longer than men (both at birth and at age 65 years) in most countries, but the number of extra years lived and the proportions of extra years spent in poor health vary greatly across countries. In 2017, the global leading causes of DALYs were neonatal disorders, ischaemic heart disease, stroke, lower respiratory infections, and chronic obstructive pulmonary disease. Communicable diseases and neonatal disorders were the leading causes of DALYs in low SDI countries in 2017. Non-communicable diseases were the leading causes of DALYs in the remaining SDI quintiles in the same year.

Sex disparities in health {#S25}
-------------------------

Sex differences in HALE exist across SDI quintiles, with the smallest difference seen in low SDI countries. Although societal factors, biological factors, and men's risk behaviours probably contribute to their shorter HALE,[@R22],[@R23] the smaller male--female gap in HALE in low SDI countries might be explained by the increased risk of mortality in both sexes due to the high occurrence of infectious diseases. Additionally, women are affected by pregnancy-related conditions, and maternal disorders were a leading cause of DALYs in low SDI countries in 2017. In several high SDI countries, the difference between male and female HALE has decreased over time, which could partly be attributable to the decreasing gap between the sexes in the prevalence of specific risk factors---eg, smoking and alcohol use.[@R24],[@R25]

Our results show increased life expectancy and more years lived in poor health for women than men in most countries. This finding could be attributable to sex differences in the patterns of disease burden. For example, women are more likely than men to have a higher burden from disabling conditions (eg, most musculoskeletal disorders except for gout, iron-deficiency anaemia, and major depressive disorder), whereas men are more likely than women to be affected by fatal conditions including different types of cancer (eg, liver cancer, lung cancer, leukaemia, colorectal cancer, and pancreatic cancer), injuries, and ischaemic heart disease. Various explanations have been suggested for the sex difference in disease risk, including social norms (eg, heavy drinking is socially acceptable for men in Russian tradition), health-related beliefs and behaviours, and biological factors (eg, sex hormones).[@R22],[@R26]

In 2017, the widest difference between male and female HALE at birth was observed in the eastern European region (7·7 years \[95% UI 6·8--8·4\]), where the age-standardised DALY rate from all causes among men was also 1·7 times higher than among women. A large proportion of DALYs in men in these countries was attributable to alcohol use and smoking, which led to high incidence and prevalence of cardiovascular disease and other leading causes of DALYs.[@R27] Interventions aiming to reduce these risk factors could help decrease the difference. Ukraine and Lithuania had the biggest sex difference in HALE at birth globally (8·7 years \[7·5--9·8\] for Ukraine and 7·8 years \[6·6--8·9\] for Lithuania) in 2017. Age-standardised DALY rates due to cardiovascular diseases and alcohol use disorders were two times higher in both these countries for men than for women, whereas self-harm and drug use disorders were four or more times higher.

Longevity and functional health status {#S26}
--------------------------------------

With increasing life expectancy in almost all locations worldwide, the question of whether the years of life gained are spent in good health or poor health is increasingly relevant because of the associated policy implications, ranging from health-care provisions to extending retirement ages.

In the context of improving longevity, the age of retirement versus extending working life has been much debated. Some key questions need to be considered in this debate, including whether the increase in life expectancy is accompanied by an equivalent increase in years in good health, and whether the common causes of early retirement,[@R28],[@R29] such as mental disorders and musculoskeletal disorders, have improved over time. Our results showed that the additional years of life were accompanied by poor health to some extent, but varied widely across countries, and the burden from musculoskeletal disorders and mental disorders has not improved over time. A lack of progress in reducing the burden of these causes and other conditions associated with ageing, such as sense organ disorders and Alzheimer's disease, might restrict the ability of older workers to contribute to the workforce.[@R30]

Globally, 12 Level 2 causes have had significant increases in DALY counts since 2007. Causes with the largest increases in DALY counts include musculoskeletal disorders, sense organ diseases, neurological disorders, diabetes and kidney diseases, and neoplasms. The large and increasing number of people living with these diseases necessitates careful planning by governments and health-care providers to ensure adequate funding and staff for treatment and rehabilitation services. Some of these diseases are expensive to manage.[@R31] Despite the large amount of spending on health in some countries, such as India and Nigeria, the spending is inefficient because most of it is through out-of-pocket expenditures (ie, direct payments by individuals to health-care providers); additional health services could be provided if the money was consolidated.[@R32]

Cross-national variation in health gains {#S27}
----------------------------------------

Our results showed that substantial variations in health gains exist even between countries within the same SDI quintile. For example, between 1990 and 2017, the increase in HALE at birth among females in Singapore was more than six times greater than the increase among females in the USA (7·3 years \[95% UI 6·6--7·9\] *vs* 1·1 years \[0·8--1·4\]), and the females in Singapore spent a smaller proportion of the extra years in poor health (17·7% \[12·7--23·1\] *vs* 33·6% \[25·1--42·2\]). The comparatively small increase in HALE in the USA is probably due to inequalities in access to health care.[@R33] The burden attributable to drug use disorders has also been increasing in the USA, with the age-standardised DALY rates due to drug use disorders almost three times higher in 2017 compared with 1990. This trend coincides with a sharp increase between 2015 and 2016 in the use of and deaths from synthetic opioids such as fentanyl, suggesting the need to improve harm-reduction efforts in the USA.[@R34],[@R35]

Over the past 28 years, several countries in sub-Saharan Africa have had substantial increases in HALE. But at the same time, some countries in this region, especially those with major HIV epidemics, had a stagnation or reduction in HALE. Although HIV control efforts have resulted in a decrease in HIV-related mortality and an increase in life expectancy and HALE in the past decade, countries such as Lesotho and Swaziland (eSwatini) still have yet to catch up with the level of HALE in 1990.

In addition to examining improvements in health, we compared the observed HALE and disease burden with those expected based on development status to discern which countries are lagging behind and identify priority areas that need to be addressed to further improve HALE. In 2017, several countries, most of them from southern sub-Saharan Africa and eastern Europe, had higher disease burden and lower HALE than expected on the basis of their sociodemographic development. Our study also identified countries that outperformed expectations based on their development status (eg, in Niger and the Maldives, males had more than 9 years higher HALE at birth than expected based on the countries' SDI). The approaches used in these countries to accelerate improvements in health (eg, the child survival programme in Niger[@R36]) could inform successful programmatic strategies for countries with poor performance with similar levels of development.

Disease burden related to undernutrition and obesity {#S28}
----------------------------------------------------

Although child and maternal undernutrition is the main risk factor for the leading causes of disease burden in low SDI countries (eg, lower respiratory infections, diarrhoea, and neonatal disorders), obesity remains a key driver of the leading causes of burden in high-middle and high SDI countries (eg, ischaemic heart disease, ischaemic stroke, diabetes, low back and neck pain).[@R27] With changing diets and lifestyle over time, obesity-related diseases are emerging, especially in low-middle and middle SDI countries where diseases related to both undernutrition and obesity contribute substantially to the total burden of disease. Evidence suggests that the disease burden associated with undernutrition and obesity can potentially be reduced.[@R37] For example, nutritional counselling, food supplementation, and conditional cash-transfer programmes have been shown to substantially reduce stunting and associated burdens of disease in settings with food insecurity.[@R37] Randomised controlled trials have shown that a lifestyle intervention with a small amount of weight loss (5--7%) decreases the incidence of type 2 diabetes by 58% during a 3-year follow-up and by 34% during a 10-year follow-up.[@R38]--[@R40] However, weight maintenance after weight loss is challenging and requires continuing support to help maintain diet, physical activity, and behavioural changes.[@R41] For countries with a dual burden of malnutrition, an integrated approach addressing both undernutrition and obesity to simultaneously reduce the burden associated with both risk factors has been recommended.[@R42],[@R43]

Dietary iron deficiency was the fifth leading cause of DALYs among women of reproductive age and the top leading cause of DALYs among children of both sexes at ages 5--14 years in 2017. Age-standardised DALY rates due to dietary iron deficiency were similar between boys and girls aged 5--14 years, but for adult women the rates were almost double those for men. Despite its high burden, iron deficiency remains commonly under-diagnosed and undertreated.[@R44] Iron deficiency is not only a problem in low SDI countries, but also in high SDI countries, and reduction of iron deficiency among children and women of reproductive age, for example, is one of the objectives of the US Public Health Service's Healthy People 2020 initiative.[@R45] Various options are available to treat iron deficiency, ranging from iron supplementation to biofortification of crops.[@R46],[@R47] Although iron supplementation has been shown to be efficacious, challenges exist in terms of distribution, cost and compliance, and inability to tolerate it because of potential adverse gastrointestinal effects.[@R46] Food fortification is highly cost-effective but can be a challenge in rural populations with little access to marketed fortified food.[@R47] Biofortification of crops is considered to be a sustainable strategy to prevent iron deficiency, especially in settings with few resources; this strategy has been shown to improve iron status in iron-deficient individuals, but the longer-term effects on functional outcomes has yet to be determined.[@R48]

Communicable diseases with increasing trends {#S29}
--------------------------------------------

A global shift has occurred from communicable to non-communicable causes of disease burden with sociodemo-graphic development. However, a few key exceptions exist among communicable diseases. In most tropical and subtropical countries, the burden of dengue has been increasing over time, in terms of both DALY counts and age-standardised DALY rates, with the highest number of DALYs occurring in south Asia. A dengue vaccine has been licensed for use in people aged 9--45 years living in several endemic settings;[@R49] however, the vaccine efficacy varies from 76% in seropositive individuals to only 39% in seronegative individuals.[@R50] In the absence of specific treatment for dengue, prevention and control measures are crucial. Top-down vector-control efforts have restricted effectiveness and sustainability, and innovative community-based vector-control strategies are being developed.[@R51]

All-age DALY counts and age-standardised DALY rates due to HIV/AIDS have been decreasing since 2007, but for adolescents (aged 15--19 years) age-specific DALY rates continued to increase after 2007. The HIV/AIDS YLL and YLD trends among adolescents also differ from the all-age trends. The all-age YLL rate increased after 1990, peaked around 2005, and then declined steadily afterwards[@R11] as antiretroviral treatment became more widely available. Among adolescents, the YLL rate continued to increase after 2005, reaching a plateau since 2013. The all-age YLD rate due to HIV/AIDS has decreased slightly since 2007, but the adolescent YLDs rate has continued to increase.[@R12] DALYs from HIV/AIDS are concentrated in sub-Saharan Africa. Adolescents have low rates of HIV testing and poor access to antiretroviral treatment, which might partly explain some of the increases in HIV/AIDS DALYs in this age group.[@R52]

Causes with sharp decreases in DALYs {#S30}
------------------------------------

Since 1990, we have seen exceptional progress in many countries in reducing the burden from communicable diseases, especially vaccine-preventable diseases such as tetanus and measles. Much of this burden came from premature mortality, which has sharply decreased in the past 28 years. However, despite these interventions, DALYs due to these causes remain unnecessarily high in several low, low-middle, and middle SDI countries. Immunisation efforts have been helpful, but progress in immunisation coverage has slowed in the past decade; about 20 million children younger than 1 year, most of them in sub-Saharan Africa and south Asia, did not receive the measles vaccine and the three recommended doses of the diphtheria, tetanus, and pertussis vaccine in 2016.[@R53] Conflict, inadequate investment in national immunisation programmes, and vaccine stock outages were among the reasons for the stalled progress in immunisation coverage.[@R53]

Comparisons with GBD 2016 {#S31}
-------------------------

We have made substantial improvements in the estimation of mortality and life expectancy in GBD 2017 across our publications, including an independent estimation of population, a comprehensive update on fertility, adding a substantial amount of new data (from censuses, Demographic Surveillance Sites, and other sources), improvements to the GBD model life-table system, and enhancements to the modelling framework.[@R13] We made changes to the GBD cause hierarchy, which can restrict comparisons to estimates from previous GBD iterations. For example, we have combined maternal and neonatal conditions at Level 2 of the cause hierarchy in GBD 2017 and reported these causes separately at Level 3 (rather than Level 2). Because of these changes, neonatal disorders now appear for the first time as the first leading cause of DALYs in both 1990 and 2017.

Estimates of DALYs due to congenital birth defects were higher in GBD 2017 than in GBD 2016 for two reasons.[@R9] First, all data sources that captured only a small subset of congenital causes (eg, only congenital heart disease and neural tube defects) were excluded for GBD 2017, leading to increased mortality estimates. Second, for GBD 2017 we implemented an algorithm to empirically identify data sources for registration of birth defects and for administrations (ie, hospital and claims) that had systematic under-reporting by age, sex, and defect. This change led to exclusion of several sources and, in many cases, higher prevalence estimates. The estimated DALYs due to malaria were lower in GBD 2017 than in GBD 2016 because of newly included *Plasmodium* parasite rate survey data and updates to insecticide-treated bednet coverage, which decreased incidence estimates, particularly in Nigeria. The decrease in incidence was in agreement with additional verbal autopsy data for Nigeria, which resulted in a decrease in estimated YLLs and DALYs.

The global age-standardised DALY rate for drug use disorders in GBD 2017 was higher for the most recent decade than in GBD 2016, because of a better fit to the most recent years of cause of death data in the USA and the use of more appropriate covariates, including the prevalence of injecting drug use and an estimate of consumption (measured by import and domestic manufacture of scheduled substances, including opioids, expressed as daily doses per 1000 people per day). Estimates of DALYs due to acute hepatitis overall are very similar to GBD 2016, but our assessments of the relative contribution of different viruses changed. We used clinical administrative data sources to calculate location-specific and age-specific case-fatality ratios for acute hepatitis infection, pairing these ratios with incidence estimates of each virus. Previously all locations were assumed to have identical case-fatality ratios. This resulted in higher estimates of DALYs for acute hepatitis A, and lower DALY estimates for acute hepatitis B, C, and E. Finally, estimated DALYs due to HIV/AIDS among children younger than 5 years have increased in the GBD 2017 study because of methodological improvements. In countries with high-quality vital registration data, incidence among children was adjusted to produce mortality estimates that better align with recorded HIV/AIDS deaths. Additionally, we produced the paediatric estimates of HIV/AIDS mortality using the CD4 progression and CD4-specific mortality rates developed by UNAIDS.[@R54]

Limitations {#S32}
-----------

This study has several limitations. First, the GBD 2017 YLL and YLD analyses had limitations as described in the GBD 2017 cause of death,[@R11] disease and injury,[@R12] and mortality papers.[@R13] Second, we assumed that uncertainty is independent between YLLs and YLDs because little empirical evidence exists to establish this correlation; however, this assumption could result in an under-estimation of the total uncertainty for DALYs. Third, HALE and DALY estimates are influenced by the availability of data for YLL and YLD estimations. Because of time lags in the reporting of health data by countries and their subsequent incorporation into the GBD estimation, recent changes in health states might not have been captured in our estimates. The scarcity of data for a particular location is reflected by wider uncertainty intervals. Fourth, although we have included several sources of uncertainty in our estimations, we have not been able to incorporate uncertainty into the covariates used by cause of death and non-fatal models. Fifth, SDI utility might be restricted in countries with high income inequality. The applicability of SDI could be enhanced in the future by taking into account social heterogeneity within countries. Finally, time trends for specific causes, such as cancer, might be influenced by changes in diagnostic technology, whereas in previous years under-reporting might have occurred when diagnostic tests were done infrequently.

Conclusion {#S33}
----------

Understanding trends in the health status of the global population and changes in the leading causes of disease burden over time is needed to accurately inform policies and set priorities for action. Updating the GBD study on a regular basis provides an opportunity to assess the latest evidence and monitor these trends with time to understand where interventions are having an effect and how much they have affected the disease burden. Our results showed that, globally, enormous improvements in health have occurred over the past 28 years. Nevertheless, large inequalities in HALE, years lived in poor health, and disease burden exist across SDI quintiles and countries, and between sexes. Despite the progress made in reducing the total burden of disease, hundreds of millions of DALYs could still be averted and disparities could be minimised through targeted interventions ranging from the prevention of risk factors and extended vaccine coverage, to universal access to essential health services.
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###### Research in context

Evidence before this study {#S35}
==========================

The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) estimated 333 causes of disability-adjusted life-years (DALYs) for 195 countries and territories from 1990 to 2016. GBD 2016 also provided estimates for life expectancy and healthy life expectancy (HALE) at birth and at age 65 years, by sex, for each location over time. GBD 2016 included analysis of the epidemiological transition as a function of the Socio-demographic Index. The WHO Global Health Estimates has also published estimates of HALE and DALYs, although these estimates largely relied on GBD 2016 results.

Added value of this study {#S36}
=========================

In GBD 2017, we expanded the scope of the study compared with previous iterations to include subnational estimates for five more countries (Ethiopia, Iran, New Zealand, Norway, and Russia) and 19 additional causes. The new causes estimated are invasive non-typhoidal salmonella disease; liver cancer due to non-alcoholic steatohepatitis; cirrhosis due to non-alcoholic steatohepatitis; myelodysplastic, myeloproliferative, and other haemopoietic neoplasms; benign and in-situ intestinal neoplasms; benign and in-situ cervical and uterine neoplasms; other benign and in-situ neoplasms; subarachnoid haemorrhage; non-rheumatic valvular heart disease; non-rheumatic calcific aortic valve disease; non-rheumatic degenerative mitral valve disease; other non-rheumatic valve diseases; gastro-oesophageal reflux disease; type 1 diabetes; type 2 diabetes; chronic kidney disease due to type 1 diabetes; chronic kidney disease due to type 2 diabetes; poisoning by carbon monoxide; and poisoning by other means. In addition to broadening our estimation by cause, location, and time, a substantial amount of new data were added for GBD 2017. For cause-specific non-fatal estimations, we added new data from epidemiological surveillance, disease registries, scientific literature sources, and survey sources. Similarly, for cause-specific fatal estimation, we added new data from verbal autopsy studies, vital registration, and cancer registries. For age-specific all-cause mortality estimations, we added vital registration data, complete birth history sources, summary birth history sources, and sibling history surveys. These improvements are reflected in the summary measures of population health, DALYs and HALE, reported in this paper. We also provided a more detailed assessment for HALE than in previous GBD papers by examining the following: distinguishing the years of life gained over the past 28 years into years spent in good health and in poor health, by sex, for each location; determining which extra years lived were spent in good health and in poor health for females compared with males for each location; and assessing the male--female difference in HALE and years lived in poor health for the period 1990--2017 across Socio-demographic Index (SDI) quintiles. With increasing longevity, such information has relevance for policy development, health systems planning, and resource allocation.

Implications of all the available evidence {#S37}
==========================================

Over the past 28 years, the world has had tremendous gains in life expectancy; however, in many locations simply gaining years of life has not meant living those years in good health. In some locations, a large proportion of those years are spent in poor health. By distinguishing where, among whom, and how many of these additional years of life gained are spent in good health versus poor health, we have more insight to inform policy, planning, and resource prioritisation for improving health and reducing disparities. Our results showed large disparities in health and disease burden by SDI and sex, suggesting that much could be done to narrow these gaps, such as targeted approaches to reduce risk factors and scale up proven cost-effective interventions to decrease the burden of disease and make additional improvements to HALE more equitable. Our results not only provide the most up-to-date evidence, but also serve as a baseline for evaluating the effectiveness of interventions and programmes over time.

![Trends of HALE at birth and years in poor health from birth by SDI quintile and sex, 1990--2017\
HALE=healthy life expectancy. SDI=Socio-demographic Index.](emss-80527-f001){#F1}

![Years of life gained at birth by sex and functional health status for five SDI quintiles, 21 GBD regions, and 28 countries with the largest and smallest proportions of years spent in poor health between 1990 and 2017\
GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. SDI=Socio-demographic Index.](emss-80527-f002){#F2}

![Difference in HALE at birth between males and females by SDI quintile, 1990--2017\
HALE=healthy life expectancy. SDI=Socio-demographic Index.](emss-80527-f003){#F3}

![Extra years of life expected at birth in females compared with males by functional health status for five SDI quintiles, 21 GBD regions, and 28 countries with the largest and smallest percentages of years spent in poor health, 2017\
GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. SDI=Socio-demographic Index.](emss-80527-f004){#F4}

###### DALYs by Level 2 causes by age and sex, for global (A), high SDI (B), high-middle SDI (C), middle SDI (D), low-middle SDI (E), and low SDI (F), 2017

Scales in each panel are different. The early neonatal period is 0--6 days, the late neonatal period is 7--27 days, and the post neonatal period is 28--364 days. DALYs=disability-adjusted life-years. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. SDI=Socio-demographic Index.
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###### Leading 30 Level 3 causes of global DALYs for 1990, 2007, and 2017 with percentage change in number of DALYs and age-standardised DALY rates by sex

Solid lines indicate increases and dashed lines indicate decreases in rank between periods. Significant changes are shown in bold. COPD=chronic obstructive pulmonary disease. DALYs=disability-adjusted life-years.
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![Contribution of YLLs and YLDs to DALYs by age and sex for global (A), high SDI (B), high-middle SDI (C), middle SDI (D), low-middle SDI (E), and low SDI (F), 2017\
The early neonatal period is 0--6 days, the late neonatal period is 7--27 days, and the post neonatal period is 28--364 days. DALYs=disability-adjusted life-years. SDI=Socio-demographic Index. YLDs=years lived with disability. YYLs=years of life lost.](emss-80527-f009){#F7}

![Difference in years between observed and expected HALE at birth on the basis of SDI for females and males, 2017\
ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. HALE=healthy life expectancy. Isl=Islands. LCA=Saint Lucia. SDI=Socio-demographic Index. TTO=Trinidad and Tobago. TLS=Timor-Leste. VCT=Saint Vincent and the Grenadines.](emss-80527-f010){#F8}

###### Life expectancy and HALE at birth for 21 GBD regions and 195 countries and territories, by sex in 1990 and 2017

                                                         Life expectancy at birth   HALE at birth                                                                                                                                   
  ------------------------------------------------------ -------------------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- -----------------------
  **Global**                                             **68·0 (67·8--68·3)**      **75·6 (75·3--75·9)**   **63·2 (62·9--63·4)**   **70·5 (70·1--70·8)**   **58·4 (55·7--60·8)**   **64·8 (61·7--67·4)**   **55·6 (53·5--57·5)**   **61·8 (59·4--64·0)**
                                                                                                                                                                                                                                    
  Low SDI                                                54·8 (54·3--55·4)          67·3 (66·7--67·9)       53·0 (52·4--53·6)       64·5 (63·8--65·1)       46·4 (44·0--48·5)       57·3 (54·5--59·8)       46·1 (44·1--47·9)       56·2 (53·9--58·4)
  Low-middle SDI                                         61·9 (61·5--62·3)          70·1 (69·5--70·7)       59·0 (58·5--59·4)       66·3 (65·7--66·9)       52·6 (50·0--55·0)       59·8 (56·9--62·4)       51·5 (49·3--53·5)       58·0 (55·6--60·1)
  Middle SDI                                             70·0 (69·7--70·3)          77·4 (77·1--77·7)       65·7 (65·3--66·1)       71·7 (71·4--72·1)       60·8 (58·2--63·1)       67·0 (64·1--69·5)       58·4 (56·3--60·2)       63·6 (61·2--65·6)
  High-middle SDI                                        73·1 (72·9--73·4)          79·4 (79·1--79·7)       66·8 (66·5--67·0)       73·3 (73·0--73·7)       63·1 (60·4--65·5)       68·5 (65·4--71·1)       59·0 (56·9--61·0)       64·7 (62·2--66·8)
  High SDI                                               79·3 (79·3--79·3)          83·7 (83·5--83·9)       72·6 (72·5--72·6)       78·5 (78·3--78·6)       67·9 (64·6--70·7)       71·1 (67·6--74·2)       63·8 (61·3--66·0)       68·2 (65·4--70·8)
                                                                                                                                                                                                                                    
  **Central Europe, eastern Europe, and central Asia**   **73·9 (73·8--74·0)**      **77·6 (77·4--77·7)**   **64·8 (64·7--64·9)**   **68·5 (68·3--68·7)**   **63·3 (60·3--65·9)**   **66·3 (63·2--69·1)**   **56·5 (54·2--58·6)**   **59·7 (57·2--62·0)**
                                                                                                                                                                                                                                    
  Central Asia                                           71·8 (71·5--72·0)          74·8 (74·3--75·4)       64·1 (63·7--64·4)       67·4 (66·8--67·9)       61·9 (59·0--64·5)       64·8 (61·9--67·4)       56·3 (54·0--58·3)       59·4 (57·0--61·5)
     Armenia                                             73·3 (72·8--73·8)          78·7 (78·2--79·1)       66·7 (66·2--67·2)       72·4 (72·0--72·8)       63·5 (60·7--66·0)       68·1 (65·0--70·7)       58·3 (55·9--60·5)       63·4 (60·7--65·7)
     Azerbaijan                                          71·2 (70·4--71·9)          74·7 (73·7--75·7)       63·4 (62·6--64·3)       67·2 (66·2--68·2)       61·7 (59·0--64·1)       64·9 (61·9--67·6)       56·0 (53·7--58·1)       59·5 (57·2--61·6)
     Georgia                                             73·9 (73·4--74·4)          77·3 (76·9--77·7)       65·9 (65·2--66·6)       68·4 (68·0--68·8)       64·6 (61·8--67·0)       67·2 (64·3--69·7)       58·4 (56·2--60·4)       60·4 (58·1--62·4)
     Kazakhstan                                          73·3 (73·0--73·5)          76·4 (75·8--77·1)       63·4 (63·1--63·7)       67·5 (66·8--68·2)       62·9 (60·0--65·5)       66·1 (63·2--68·6)       55·5 (53·2--57·5)       59·3 (56·9--61·4)
     Kyrgyzstan                                          70·5 (69·7--71·1)          76·3 (75·9--76·6)       62·0 (61·2--62·8)       69·1 (68·7--69·4)       60·8 (57·8--63·3)       66·0 (63·0--68·5)       54·3 (51·9--56·3)       60·9 (58·5--63·0)
     Mongolia                                            64·0 (63·3--64·7)          73·7 (72·5--74·8)       58·6 (57·9--59·4)       64·5 (63·2--65·9)       55·8 (53·4--58·0)       64·0 (61·0--66·7)       51·7 (49·7--53·7)       56·7 (54·3--59·0)
     Tajikistan                                          69·5 (68·9--70·1)          73·3 (72·1--74·5)       64·5 (63·8--65·1)       67·7 (66·3--68·9)       59·9 (57·2--62·4)       63·5 (60·6--66·1)       56·4 (54·0--58·5)       59·4 (56·8--61·8)
     Turkmenistan                                        69·3 (68·8--69·9)          73·9 (72·7--74·9)       62·6 (62·0--63·1)       66·5 (65·4--67·7)       60·4 (57·8--62·7)       64·5 (61·7--67·1)       55·3 (53·2--57·3)       59·0 (56·6--61·2)
     Uzbekistan                                          72·6 (72·2--72·9)          73·7 (72·2--75·3)       66·0 (65·6--66·4)       67·1 (65·5--68·6)       62·3 (59·3--64·9)       63·9 (60·9--66·8)       57·9 (55·4--60·0)       59·4 (56·8--61·8)
  Central Europe                                         74·9 (74·9--75·0)          80·4 (80·2--80·7)       67·2 (67·1--67·2)       73·6 (73·3--73·9)       64·2 (61·1--66·9)       68·8 (65·5--71·7)       58·3 (55·8--60·5)       63·5 (60·6--66·0)
     Albania                                             77·4 (77·0--77·7)          82·1 (79·9--84·3)       69·8 (69·5--70·2)       74·9 (72·8--77·1)       66·3 (63·0--69·1)       70·5 (67·0--73·9)       60·7 (58·0--63·1)       65·0 (61·8--68·2)
     Bosnia and Herzegovina                              76·6 (76·4--76·8)          79·1 (78·4--79·7)       70·5 (70·4--70·7)       74·3 (73·6--75·0)       65·6 (62·5--68·3)       67·7 (64·5--70·5)       61·1 (58·5--63·4)       63·7 (60·7--66·4)
     Bulgaria                                            75·5 (75·4--75·7)          78·6 (77·9--79·2)       68·2 (68·1--68·3)       71·3 (70·6--72·1)       65·2 (62·2--67·8)       67·7 (64·7--70·5)       59·4 (56·9--61·6)       62·2 (59·5--64·5)
     Croatia                                             76·3 (76·1--76·4)          81·6 (80·9--82·3)       68·7 (68·6--68·9)       75·4 (74·7--76·1)       65·7 (62·8--68·4)       69·9 (66·6--72·8)       59·9 (57·3--62·1)       64·9 (62·0--67·4)
     Czech Republic                                      75·5 (75·4--75·6)          82·0 (81·3--82·6)       67·6 (67·5--67·6)       76·3 (75·6--77·0)       64·7 (61·6--67·4)       69·6 (66·0--72·7)       58·9 (56·3--61·1)       65·1 (61·9--68·0)
     Hungary                                             73·9 (73·8--74·0)          80·2 (79·5--80·9)       65·3 (65·2--65·4)       73·2 (72·4--73·9)       62·9 (59·8--65·7)       68·3 (65·1--71·3)       56·6 (54·2--58·7)       63·1 (60·3--65·6)
     Macedonia                                           74·5 (74·2--74·7)          79·7 (79·2--80·3)       69·6 (69·4--69·8)       73·9 (73·2--74·6)       64·1 (61·2--66·7)       68·4 (65·2--71·3)       60·5 (57·9--62·7)       63·9 (61·1--66·3)
     Montenegro                                          77·5 (77·2--77·8)          78·9 (78·1--79·7)       71·1 (70·8--71·5)       74·1 (72·9--75·2)       66·7 (63·6--69·5)       67·9 (64·7--70·7)       61·8 (59·1--64·2)       64·1 (61·1--66·6)
     Poland                                              75·8 (75·7--75·8)          81·8 (81·2--82·4)       66·8 (66·8--66·9)       74·1 (73·3--74·8)       65·0 (61·9--67·7)       69·9 (66·6--72·9)       58·1 (55·6--60·2)       63·7 (60·7--66·4)
     Romania                                             73·2 (73·1--73·3)          79·0 (78·3--79·6)       66·7 (66·6--66·8)       71·5 (70·8--72·3)       62·6 (59·5--65·2)       67·6 (64·3--70·4)       57·4 (54·8--59·7)       61·9 (59·2--64·4)
     Serbia                                              74·5 (74·3--74·6)          77·9 (77·2--78·5)       67·6 (67·4--67·7)       73·6 (72·9--74·2)       64·0 (60·9--66·5)       66·9 (63·8--69·6)       58·8 (56·4--61·0)       63·7 (60·8--66·2)
     Slovakia                                            75·5 (75·3--75·6)          80·6 (79·9--81·3)       66·7 (66·6--66·8)       74·1 (73·4--74·8)       64·9 (61·8--67·5)       68·9 (65·7--71·8)       57·9 (55·4--60·1)       63·7 (60·7--66·3)
     Slovenia                                            77·8 (77·6--78·0)          84·2 (83·5--85·0)       69·7 (69·6--69·9)       77·9 (77·2--78·7)       66·4 (63·3--69·3)       71·2 (67·5--74·4)       60·1 (57·4--62·5)       66·3 (63·0--69·2)
  Eastern Europe                                         74·6 (74·6--74·7)          77·2 (77·1--77·4)       64·5 (64·5--64·6)       66·5 (66·3--66·7)       63·7 (60·7--66·4)       65·9 (62·7--68·6)       56·3 (54·0--58·4)       58·2 (55·8--60·3)
     Belarus                                             75·7 (75·5--75·9)          78·8 (78·1--79·4)       66·1 (65·8--66·3)       69·0 (68·2--69·7)       64·7 (61·7--67·4)       67·3 (64·1--70·2)       57·7 (55·3--59·9)       60·3 (57·7--62·6)
     Estonia                                             75·0 (74·7--75·2)          82·1 (80·7--83·5)       64·7 (64·5--64·9)       73·6 (72·0--75·3)       64·3 (61·2--66·9)       70·0 (66·5--73·4)       56·5 (54·1--58·7)       63·8 (60·8--66·6)
     Latvia                                              74·7 (74·5--74·9)          79·8 (78·4--81·3)       64·6 (64·4--64·8)       70·1 (68·6--71·7)       63·9 (60·9--66·6)       68·0 (64·6--71·0)       56·3 (53·9--58·5)       60·9 (58·2--63·6)
     Lithuania                                           76·2 (76·0--76·3)          80·2 (79·4--81·0)       66·4 (66·2--66·5)       69·6 (68·7--70·5)       65·2 (62·1--67·8)       68·1 (64·8--71·2)       57·8 (55·4--60·0)       60·4 (57·7--62·8)
     Moldova                                             71·4 (71·2--71·7)          77·4 (77·0--77·9)       64·5 (64·2--64·7)       68·2 (67·8--68·7)       61·1 (58·1--63·6)       66·2 (63·1--69·0)       56·1 (53·6--58·2)       59·6 (57·2--61·8)
     Russia                                              74·6 (74·6--74·6)          77·2 (77·1--77·4)       64·0 (64·0--64·0)       66·8 (66·6--66·9)       63·7 (60·6--66·4)       65·8 (62·6--68·6)       55·9 (53·6--58·0)       58·4 (56·0--60·5)
     Ukraine                                             74·7 (74·5--74·9)          76·5 (75·8--77·2)       65·5 (65·3--65·7)       64·7 (63·9--65·4)       63·7 (60·6--66·4)       65·4 (62·1--68·1)       57·2 (54·8--59·3)       56·7 (54·4--58·8)
                                                                                                                                                                                                                                    
  **High income**                                        **79·4 (79·4--79·4)**      **83·6 (83·4--83·7)**   **72·8 (72·7--72·8)**   **78·4 (78·2--78·6)**   **68·0 (64·7--70·8)**   **71·0 (67·5--74·0)**   **64·0 (61·4--66·1)**   **68·2 (65·3--70·7)**
                                                                                                                                                                                                                                    
  Australasia                                            79·7 (79·6--79·8)          84·4 (83·4--85·4)       73·6 (73·5--73·6)       80·1 (79·1--81·2)       68·0 (64·7--70·9)       71·4 (67·7--74·6)       64·1 (61·4--66·4)       68·9 (65·7--71·8)
     Australia                                           80·0 (79·9--80·1)          84·6 (83·4--85·7)       73·8 (73·7--73·9)       80·2 (78·9--81·5)       68·4 (65·1--71·3)       71·7 (68·0--74·9)       64·3 (61·6--66·7)       69·1 (65·8--72·0)
     New Zealand                                         78·1 (77·9--78·3)          83·6 (83·0--84·2)       72·6 (72·4--72·8)       79·7 (79·0--80·3)       66·3 (62·9--69·3)       70·1 (66·1--73·3)       63·1 (60·2--65·4)       68·0 (64·6--71·0)
  High-income Asia Pacific                               81·0 (81·0--81·1)          86·9 (86·7--87·2)       74·4 (74·4--74·5)       80·8 (80·5--81·0)       70·1 (67·0--72·8)       74·5 (71·0--77·6)       66·3 (63·9--68·3)       71·1 (68·2--73·4)
     Brunei                                              72·1 (71·5--72·8)          77·5 (76·6--78·4)       69·1 (68·5--69·8)       73·3 (72·3--74·4)       62·9 (60·2--65·3)       67·5 (64·5--70·0)       61·4 (59·2--63·4)       65·0 (62·4--67·3)
     Japan                                               82·2 (82·2--82·2)          87·2 (87·0--87·4)       76·2 (76·2--76·2)       81·1 (80·8--81·3)       71·2 (68·0--73·9)       74·6 (71·1--77·8)       68·0 (65·6--70·0)       71·4 (68·6--73·8)
     Singapore                                           78·8 (78·6--79·0)          87·6 (86·9--88·1)       73·5 (73·3--73·7)       81·9 (81·2--82·6)       68·5 (65·5--71·0)       75·8 (72·4--78·7)       65·6 (63·3--67·6)       72·6 (69·8--75·0)
     South Korea                                         76·4 (76·3--76·5)          85·5 (84·9--86·1)       68·0 (67·9--68·1)       79·5 (78·7--80·3)       66·0 (62·9--68·7)       73·5 (70·0--76·5)       60·3 (58·1--62·2)       69·7 (67·0--72·1)
  High-income North America                              79·1 (79·1--79·2)          81·4 (81·1--81·7)       72·3 (72·3--72·3)       76·5 (76·2--76·8)       67·0 (63·6--69·9)       68·2 (64·7--71·3)       62·9 (60·2--65·1)       65·7 (62·7--68·3)
     Canada                                              80·6 (80·5--80·6)          84·0 (83·4--84·6)       74·1 (74·0--74·2)       79·9 (79·2--80·5)       69·0 (65·6--71·8)       71·4 (67·7--74·5)       65·3 (62·7--67·5)       69·6 (66·6--72·3)
     Greenland                                           69·0 (68·4--69·6)          77·2 (76·2--78·0)       62·1 (61·6--62·6)       70·8 (70·3--71·4)       58·5 (55·7--61·1)       65·3 (62·2--68·3)       54·4 (52·2--56·3)       62·2 (59·7--64·3)
     USA                                                 79·0 (79·0--79·0)          81·1 (80·8--81·4)       72·1 (72·1--72·1)       76·1 (75·8--76·4)       66·8 (63·4--69·7)       67·9 (64·3--71·0)       62·6 (59·9--64·9)       65·3 (62·3--67·9)
  Southern Latin America                                 76·2 (76·1--76·2)          80·4 (79·3--81·3)       69·2 (69·1--69·2)       74·5 (73·3--75·5)       65·9 (62·9--68·5)       69·3 (66·2--72·1)       61·1 (58·8--63·2)       65·3 (62·5--67·9)
     Argentina                                           75·9 (75·8--76·0)          79·7 (78·3--81·0)       68·9 (68·9--69·0)       73·6 (72·0--75·0)       65·9 (62·9--68·4)       68·9 (65·7--71·8)       61·0 (58·7--63·0)       64·7 (61·8--67·4)
     Chile                                               76·4 (76·3--76·5)          82·1 (80·8--83·4)       69·9 (69·8--70·0)       77·2 (75·7--78·7)       65·7 (62·6--68·4)       70·2 (66·6--73·3)       61·5 (59·0--63·6)       67·1 (64·1--70·0)
     Uruguay                                             76·8 (76·6--77·0)          80·4 (79·0--81·9)       69·4 (69·2--69·5)       73·5 (72·1--75·0)       66·6 (63·7--69·2)       69·5 (66·4--72·4)       61·5 (59·2--63·5)       64·8 (62·2--67·4)
  Western Europe                                         79·5 (79·5--79·5)          84·2 (83·9--84·5)       73·0 (73·0--73·0)       79·5 (79·2--79·8)       68·2 (65·0--71·0)       71·8 (68·3--74·8)       64·3 (61·8--66·5)       69·4 (66·5--71·9)
     Andorra                                             82·6 (80·8--84·6)          85·1 (83·6--86·7)       76·1 (74·7--77·3)       80·5 (79·4--81·7)       70·6 (67·0--74·1)       72·4 (68·6--75·8)       66·8 (63·9--69·5)       70·1 (67·1--72·8)
     Austria                                             78·9 (78·8--79·0)          84·0 (83·4--84·6)       72·4 (72·3--72·5)       79·4 (78·8--80·1)       67·9 (64·7--70·6)       71·7 (68·2--74·8)       63·9 (61·4--66·0)       69·1 (66·2--71·8)
     Belgium                                             79·3 (79·2--79·4)          83·8 (83·1--84·5)       72·7 (72·6--72·8)       78·9 (78·2--79·5)       67·8 (64·5--70·6)       70·9 (67·3--74·1)       63·9 (61·4--66·1)       68·3 (65·2--71·0)
     Cyprus                                              78·3 (78·1--78·5)          85·2 (84·3--86·0)       73·6 (73·4--73·8)       78·5 (77·4--79·5)       67·2 (64·1--70·0)       72·8 (69·1--76·0)       64·9 (62·5--67·1)       68·8 (65·9--71·4)
     Denmark                                             77·8 (77·6--77·9)          82·7 (81·9--83·4)       72·2 (72·1--72·4)       78·8 (78·1--79·5)       66·9 (63·7--69·5)       70·6 (67·2--73·6)       63·7 (61·2--65·8)       68·6 (65·6--71·3)
     Finland                                             79·1 (78·9--79·3)          84·3 (83·6--84·9)       71·0 (70·9--71·2)       78·5 (77·8--79·2)       67·6 (64·2--70·5)       71·5 (67·9--74·8)       62·2 (59·6--64·4)       68·0 (64·9--70·7)
     France                                              81·1 (81·0--81·1)          85·7 (85·1--86·3)       73·0 (72·9--73·0)       79·8 (79·2--80·4)       69·8 (66·5--72·6)       73·4 (69·9--76·5)       64·7 (62·2--66·8)       70·0 (67·2--72·5)
     Germany                                             78·6 (78·5--78·6)          83·0 (81·8--84·2)       72·1 (72·1--72·2)       78·2 (76·9--79·5)       67·4 (64·2--70·2)       70·8 (67·2--74·1)       63·5 (61·0--65·7)       68·3 (65·2--70·9)
     Greece                                              80·4 (80·3--80·5)          83·6 (83·0--84·2)       74·7 (74·6--74·8)       78·4 (77·8--79·1)       68·9 (65·6--71·8)       71·3 (67·8--74·4)       65·8 (63·3--68·0)       68·6 (65·8--71·1)
     Iceland                                             80·2 (79·8--80·5)          85·9 (85·5--86·4)       75·6 (75·2--75·9)       79·8 (79·4--80·2)       68·5 (65·2--71·4)       73·1 (69·5--76·2)       66·3 (63·7--68·5)       69·6 (66·5--72·2)
     Ireland                                             77·6 (77·4--77·8)          83·7 (82·9--84·4)       72·2 (72·1--72·4)       80·0 (79·3--80·7)       66·7 (63·6--69·5)       71·3 (67·7--74·4)       63·7 (61·2--65·9)       69·4 (66·3--72·0)
     Israel                                              78·9 (78·8--79·1)          84·6 (83·9--85·2)       75·8 (75·6--76·0)       81·3 (80·6--81·9)       67·6 (64·4--70·4)       72·1 (68·6--75·2)       66·4 (63·7--68·7)       70·6 (67·6--73·4)
     Italy                                               80·3 (80·2--80·4)          85·3 (84·7--85·9)       73·7 (73·7--73·8)       80·8 (80·2--81·4)       68·8 (65·6--71·7)       73·0 (69·5--76·1)       65·0 (62·5--67·2)       70·6 (67·7--73·3)
     Luxembourg                                          78·9 (78·6--79·2)          83·3 (82·3--84·2)       71·8 (71·6--72·1)       80·0 (78·9--81·2)       67·0 (63·6--69·9)       70·4 (66·8--73·7)       62·7 (60·1--64·9)       69·0 (65·6--71·9)
     Malta                                               78·8 (78·5--79·0)          83·0 (82·4--83·6)       74·2 (73·9--74·4)       78·9 (78·4--79·5)       67·7 (64·6--70·5)       70·9 (67·4--73·9)       65·3 (62·7--67·5)       68·7 (65·6--71·3)
     Netherlands                                         80·1 (80·0--80·2)          83·1 (82·4--83·7)       73·8 (73·7--73·9)       79·9 (79·2--80·5)       68·4 (65·1--71·3)       70·7 (67·2--73·9)       64·9 (62·4--67·1)       69·6 (66·6--72·2)
     Norway                                              80·0 (79·9--80·1)          84·2 (84·0--84·4)       73·4 (73·3--73·5)       80·5 (80·2--80·7)       68·1 (64·7--71·0)       71·1 (67·4--74·3)       64·0 (61·3--66·4)       69·3 (66·2--72·0)
     Portugal                                            77·6 (77·5--77·7)          84·2 (83·6--84·8)       70·7 (70·5--70·8)       78·5 (77·9--79·2)       66·2 (62·9--69·0)       71·6 (68·0--74·7)       62·1 (59·6--64·2)       68·6 (65·6--71·2)
     Spain                                               80·5 (80·4--80·6)          85·8 (85·3--86·3)       73·5 (73·4--73·5)       80·2 (79·7--80·8)       69·4 (66·3--72·1)       73·6 (70·0--76·7)       65·0 (62·5--67·1)       70·5 (67·7--72·9)
     Sweden                                              80·5 (80·4--80·6)          84·2 (83·7--84·7)       74·9 (74·8--75·1)       80·8 (80·2--81·4)       68·8 (65·4--71·6)       71·4 (67·8--74·6)       66·0 (63·4--68·3)       70·4 (67·4--73·1)
     Switzerland                                         81·1 (81·0--81·3)          85·7 (85·1--86·3)       74·4 (74·3--74·5)       82·1 (81·5--82·8)       69·0 (65·6--72·0)       72·7 (69·0--75·9)       65·1 (62·4--67·4)       71·2 (68·1--74·0)
     UK                                                  78·5 (78·4--78·5)          82·7 (82·6--82·8)       72·9 (72·9--73·0)       79·2 (79·0--79·3)       67·3 (64·0--70·0)       70·0 (66·5--73·1)       64·1 (61·6--66·3)       68·5 (65·5--71·1)
        England                                          78·7 (78·7--78·7)          82·9 (82·8--83·0)       73·2 (73·1--73·2)       79·5 (79·4--79·6)       67·4 (64·2--70·2)       70·1 (66·5--73·2)       64·4 (61·8--66·5)       68·7 (65·6--71·3)
        Northern Ireland                                 77·3 (77·0--77·6)          82·5 (81·5--83·4)       71·5 (71·3--71·7)       78·7 (77·7--79·8)       66·4 (63·3--69·0)       70·3 (67·0--73·5)       63·1 (60·6--65·2)       68·5 (65·5--71·3)
        Scotland                                         76·8 (76·7--77·0)          81·2 (80·3--82·1)       71·2 (71·0--71·3)       76·9 (76·0--78·0)       65·8 (62·7--68·5)       69·3 (66·0--72·2)       62·5 (60·0--64·6)       66·8 (64·0--69·5)
        Wales                                            78·6 (78·4--78·7)          82·5 (81·7--83·2)       72·9 (72·8--73·1)       78·3 (77·5--79·1)       67·3 (64·1--70·1)       70·4 (66·9--73·6)       64·1 (61·5--66·3)       68·1 (65·1--70·7)
                                                                                                                                                                                                                                    
  **Latin America and Caribbean**                        **72·5 (72·3--72·6)**      **78·9 (78·6--79·2)**   **66·2 (66·0--66·4)**   **72·8 (72·4--73·2)**   **62·6 (59·8--65·0)**   **68·3 (65·2--70·8)**   **58·6 (56·3--60·5)**   **64·2 (61·7--66·3)**
                                                                                                                                                                                                                                    
  Andean Latin America                                   70·6 (70·0--71·2)          79·5 (78·4--80·6)       66·7 (66·1--67·3)       76·2 (74·9--77·4)       61·4 (58·8--63·8)       69·2 (66·1--72·0)       58·9 (56·5--60·9)       67·0 (64·3--69·6)
     Bolivia                                             62·1 (60·8--63·3)          74·2 (72·1--76·6)       59·7 (58·5--61·0)       71·3 (68·8--73·9)       54·0 (51·5--56·3)       64·4 (61·2--67·7)       52·6 (50·2--54·6)       62·8 (59·8--65·8)
     Ecuador                                             74·4 (74·1--74·6)          78·7 (77·5--79·9)       69·7 (69·5--70·0)       74·8 (73·3--76·1)       64·8 (62·0--67·3)       68·7 (65·6--71·4)       61·5 (59·0--63·5)       65·8 (63·0--68·2)
     Peru                                                72·2 (71·3--73·2)          81·9 (80·1--83·7)       67·9 (66·9--68·9)       78·7 (76·8--80·8)       62·7 (59·8--65·3)       71·3 (68·1--74·5)       60·0 (57·6--62·2)       69·3 (66·2--72·4)
  Caribbean                                              70·4 (69·9--70·8)          75·4 (74·4--76·4)       66·4 (65·9--66·8)       70·3 (69·3--71·4)       61·2 (58·5--63·6)       65·3 (62·5--67·9)       58·9 (56·7--60·9)       62·2 (59·7--64·5)
     Antigua and Barbuda                                 77·9 (77·2--78·7)          78·7 (78·1--79·4)       70·8 (70·1--71·4)       75·3 (74·4--76·2)       67·3 (64·1--70·2)       68·1 (65·0--70·8)       62·6 (60·1--64·8)       66·4 (63·7--68·7)
     The Bahamas                                         74·7 (74·3--75·1)          76·6 (75·4--77·9)       67·6 (67·2--68·0)       70·8 (69·6--72·1)       65·4 (62·7--67·7)       66·9 (63·9--69·5)       60·5 (58·5--62·3)       63·2 (60·7--65·5)
     Barbados                                            76·1 (75·7--76·5)          78·6 (77·7--79·6)       71·2 (70·8--71·5)       75·5 (74·4--76·6)       66·7 (63·9--69·0)       68·6 (65·5--71·2)       63·8 (61·6--65·7)       67·2 (64·5--69·5)
     Belize                                              73·8 (73·1--74·4)          77·4 (76·9--77·9)       70·3 (69·5--71·0)       71·2 (70·7--71·8)       64·0 (61·0--66·5)       67·0 (64·0--69·5)       62·4 (60·0--64·6)       63·1 (60·6--65·3)
     Bermuda                                             78·3 (77·9--78·6)          85·7 (84·8--86·5)       69·7 (69·3--70·2)       77·1 (76·4--77·6)       68·5 (65·7--70·9)       74·3 (71·0--77·3)       62·5 (60·5--64·4)       68·5 (66·0--70·7)
     Cuba                                                76·8 (76·6--76·9)          80·7 (79·3--82·1)       73·0 (72·9--73·1)       76·2 (74·6--77·7)       66·8 (63·9--69·4)       70·4 (67·4--73·2)       65·3 (63·0--67·2)       67·9 (65·4--70·5)
     Dominica                                            75·3 (74·7--75·7)          75·4 (74·3--76·4)       70·4 (70·0--70·8)       70·4 (69·4--71·4)       65·6 (62·7--68·0)       65·8 (62·9--68·3)       62·7 (60·5--64·8)       62·6 (60·2--64·7)
     Dominican Republic                                  74·4 (73·4--75·4)          76·8 (75·2--78·5)       69·6 (68·4--70·7)       69·8 (67·8--71·9)       64·6 (61·6--67·2)       66·8 (63·6--69·5)       61·5 (59·0--63·8)       62·0 (59·3--64·7)
     Grenada                                             71·6 (71·0--72·1)          75·4 (74·7--76·2)       67·1 (66·6--67·6)       73·0 (72·3--73·6)       62·5 (59·8--64·9)       65·8 (62·9--68·3)       60·0 (57·9--61·9)       64·8 (62·2--66·9)
     Guyana                                              69·0 (68·7--69·4)          72·2 (70·5--73·9)       62·4 (62·0--62·8)       66·4 (64·6--68·2)       59·6 (56·9--62·0)       62·4 (59·3--65·3)       54·9 (52·7--56·9)       58·6 (56·0--60·9)
     Haiti                                               55·0 (53·6--56·5)          66·0 (63·3--68·8)       53·9 (52·3--55·5)       63·8 (61·4--66·4)       47·4 (44·9--49·8)       56·8 (53·6--59·9)       47·3 (44·9--49·5)       55·8 (52·7--58·6)
     Jamaica                                             76·4 (75·7--77·1)          77·5 (75·4--79·4)       73·6 (73·0--74·3)       72·0 (69·8--74·1)       66·6 (63·5--69·0)       67·4 (64·2--70·3)       65·4 (62·9--67·5)       63·9 (61·0--66·6)
     Puerto Rico                                         78·4 (78·2--78·6)          81·6 (80·9--82·3)       70·0 (69·8--70·1)       74·5 (73·7--75·4)       68·6 (65·8--71·1)       70·8 (67·7--73·6)       62·3 (60·0--64·1)       65·8 (63·1--68·1)
     Saint Lucia                                         73·2 (72·8--73·6)          78·1 (77·2--78·9)       67·8 (67·4--68·2)       73·1 (72·2--74·0)       63·7 (61·1--66·2)       67·9 (64·9--70·6)       60·4 (58·3--62·3)       64·9 (62·5--67·0)
     Saint Vincent and the Grenadines                    72·9 (72·4--73·5)          75·4 (74·6--76·3)       69·1 (68·5--69·6)       69·6 (68·9--70·4)       63·5 (60·5--65·9)       65·5 (62·6--68·1)       61·4 (59·2--63·4)       61·7 (59·5--63·9)
     Suriname                                            71·3 (70·5--72·2)          75·3 (74·0--76·6)       66·4 (65·4--67·4)       68·9 (67·2--70·7)       62·1 (59·4--64·5)       65·2 (62·2--68·0)       59·2 (56·9--61·3)       61·2 (58·7--63·7)
     Trinidad and Tobago                                 72·5 (72·1--72·8)          77·6 (74·8--80·3)       67·5 (67·2--67·8)       71·1 (68·4--74·0)       63·0 (60·3--65·4)       67·2 (63·6--70·6)       60·1 (57·9--62·0)       63·0 (59·9--66·0)
     Virgin Islands                                      76·2 (75·1--77·0)          78·8 (77·2--80·1)       69·0 (68·2--69·7)       69·5 (67·9--71·8)       66·9 (64·1--69·4)       69·0 (65·9--71·7)       61·9 (59·7--63·7)       62·2 (59·7--64·9)
  Central Latin America                                  74·0 (73·9--74·2)          79·4 (79·0--79·8)       68·1 (67·9--68·3)       73·3 (72·8--73·8)       64·4 (61·8--66·8)       69·1 (66·1--71·6)       60·6 (58·4--62·4)       65·0 (62·5--67·1)
     Colombia                                            74·8 (74·6--75·0)          82·7 (81·4--83·9)       68·1 (67·9--68·4)       77·4 (75·9--79·0)       65·1 (62·4--67·6)       72·1 (68·9--75·0)       60·7 (58·6--62·5)       68·7 (66·1--71·4)
     Costa Rica                                          78·7 (78·5--79·0)          82·7 (81·9--83·4)       74·4 (74·2--74·6)       76·3 (75·5--77·1)       68·4 (65·4--71·0)       71·9 (68·8--74·4)       66·4 (64·1--68·3)       67·9 (65·2--70·0)
     El Salvador                                         73·6 (73·2--73·9)          78·3 (76·0--80·4)       64·9 (64·5--65·2)       69·3 (66·7--72·0)       64·0 (61·4--66·5)       68·3 (65·0--71·3)       57·2 (55·0--59·2)       61·5 (58·4--64·3)
     Guatemala                                           65·7 (65·3--66·2)          76·0 (74·5--77·4)       60·4 (59·9--60·9)       69·1 (67·4--70·8)       57·1 (54·5--59·3)       66·1 (63·1--69·0)       53·5 (51·4--55·3)       61·2 (58·7--63·7)
     Honduras                                            71·2 (69·6--72·8)          75·0 (72·4--78·2)       66·6 (64·8--68·6)       72·9 (70·2--75·6)       61·7 (58·7--64·3)       65·3 (61·8--68·7)       59·0 (56·4--61·7)       64·6 (61·4--67·7)
     Mexico                                              74·3 (74--74·6·0)          78·5 (78·2--78·8)       68·6 (68·2--68·9)       72·6 (72·3--72·9)       64·7 (62·1--67·0)       68·2 (65·3--70·7)       61·0 (58·9--62·9)       64·2 (61·8--66·3)
     Nicaragua                                           74·1 (73·2--74·9)          80·6 (79·4--82·0)       69·7 (68·6--70·7)       76·9 (75·3--78·4)       63·5 (60·5--66·2)       69·8 (66·6--72·7)       61·2 (58·6--63·4)       67·8 (65·1--70·5)
     Panama                                              78·1 (77·7--78·4)          81·7 (80·9--82·5)       73·8 (73·4--74·1)       77·0 (76·2--77·9)       67·8 (64·8--70·4)       70·9 (67·8--73·6)       65·7 (63·2--67·7)       68·1 (65·4--70·5)
     Venezuela                                           75·1 (75·0--75·2)          79·6 (77·7--81·5)       69·2 (69·1--69·3)       71·2 (68·9--73·7)       65·5 (62·9--67·9)       69·3 (66·0--72·3)       61·8 (59·6--63·6)       63·4 (60·5--66·1)
  Tropical Latin America                                 71·7 (71·4--72·0)          79·1 (78·8--79·3)       64·0 (63·7--64·4)       72·0 (71·8--72·3)       61·2 (58·2--63·8)       67·8 (64·6--70·5)       56·3 (54·0--58·3)       63·1 (60·5--65·3)
     Brazil                                              71·6 (71·2--71·9)          79·1 (78·8--79·3)       63·8 (63·4--64·2)       72·0 (71·7--72·2)       61·1 (58·1--63·7)       67·7 (64·6--70·5)       56·1 (53·9--58·1)       63·1 (60·5--65·3)
     Paraguay                                            76·4 (75·6--77·2)          78·9 (76·8--81·2)       72·3 (71·4--73·0)       73·4 (71·0--76·0)       65·5 (62·3--68·4)       67·9 (64·4--71·0)       63·3 (60·7--65·7)       64·4 (61·1--67·4)
                                                                                                                                                                                                                                    
  **North Africa and Middle East**                       **68·2 (67·9--68·6)**      **76·8 (76·4--77·3)**   **64·5 (64·1--64·9)**   **72·0 (71·5--72·5)**   **57·5 (54·5--60·2)**   **64·8 (61·4--67·7)**   **55·9 (53·5--58·1)**   **62·1 (59·4--64·5)**
                                                                                                                                                                                                                                    
     Afghanistan                                         52·0 (49·9--54·3)          63·2 (60·6--65·8)       53·1 (51·0--55·2)       63·6 (61·3--65·9)       42·9 (40·0--45·9)       52·5 (49·2--56·2)       44·1 (41·1--46·8)       53·6 (50·4--56·5)
     Algeria                                             73·2 (72·3--74·1)          78·5 (77·9--79·1)       70·3 (69·4--71·2)       77·0 (76·4--77·6)       61·9 (58·6--64·9)       66·6 (63·1--69·6)       60·9 (58·2--63·4)       66·4 (63·4--69·0)
     Bahrain                                             71·9 (71·4--72·4)          80·4 (79·5--81·4)       69·4 (69·0--70·0)       78·8 (77·8--79·8)       60·9 (57·8--63·6)       67·6 (64·0--70·9)       60·5 (58·0--62·7)       67·8 (64·7--70·8)
     Egypt                                               66·6 (66·1--67·1)          74·3 (72·9--75·8)       62·6 (62·1--63·0)       68·0 (66·6--69·3)       56·3 (53·3--58·9)       63·0 (59·8--66·0)       54·5 (52·1--56·6)       59·3 (56·7--61·7)
     Iran                                                70·8 (70·1--71·4)          79·4 (79·3--79·5)       65·7 (65·0--66·3)       75·5 (75·4--75·6)       59·6 (56·4--62·4)       66·5 (63·0--69·7)       56·9 (54·5--59·3)       65·0 (62·1--67·5)
     Iraq                                                67·6 (65·8--69·3)          78·8 (78·1--79·6)       64·4 (62·5--66·4)       74·8 (73·9--75·6)       56·6 (53·4--59·7)       65·7 (61·9--69·0)       54·8 (51·9--57·7)       63·3 (60·1--66·2)
     Jordan                                              71·7 (70·3--73·0)          81·1 (79·8--82·3)       70·5 (69·0--71·9)       77·8 (76·3--79·2)       60·9 (57·8--63·7)       68·5 (65·0--71·7)       61·1 (58·3--63·8)       67·1 (63·8--70·0)
     Kuwait                                              77·1 (76·9--77·4)          87·2 (86·7--87·7)       73·3 (73·1--73·6)       80·7 (80·0--81·3)       65·3 (62·0--68·2)       73·1 (69·1--76·6)       63·7 (61·0--66·1)       69·4 (66·1--72·2)
     Lebanon                                             73·4 (72·2--75·0)          80·0 (79·4--80·7)       67·3 (66·1--68·8)       75·8 (75·1--76·4)       62·1 (58·9--65·2)       67·4 (63·9--70·5)       58·3 (55·8--60·7)       65·0 (62·0--67·7)
     Libya                                               73·5 (71·7--75·2)          75·0 (73·3--76·9)       70·8 (69·0--72·6)       71·1 (69·4--73·2)       62·3 (59·0--65·4)       63·5 (60·0--66·7)       61·2 (58·1--63·9)       60·9 (58·1--64·1)
     Morocco                                             66·2 (65·3--67·2)          74·7 (72·7--76·8)       67·1 (66·1--68·1)       73·2 (71·0--75·5)       56·0 (53·1--58·6)       63·3 (59·9--66·7)       57·8 (55·0--60·1)       63·0 (59·7--66·2)
     Oman                                                71·4 (69·2--73·7)          79·4 (78·2--81·2)       66·9 (64·4--69·4)       75·5 (73·3--77·9)       59·6 (55·8--63·1)       66·9 (63·1--70·3)       57·8 (54·7--61·0)       65·0 (61·7--68·5)
     Palestine                                           72·6 (70·7--74·5)          78·0 (77·3--78·9)       68·5 (66·7--70·7)       75·6 (74·7--76·4)       61·1 (57·6--64·3)       65·6 (62·1--68·7)       59·1 (56·0--62·1)       64·6 (61·6--67·4)
     Qatar                                               72·8 (71·2--74·3)          81·7 (79·8--83·5)       70·7 (69·1--72·4)       79·6 (77·7--81·6)       61·7 (58·7--64·6)       68·7 (65·0--72·1)       61·0 (58·0--63·8)       68·1 (64·7--71·5)
     Saudi Arabia                                        73·6 (71·6--75·8)          79·4 (78·0--80·2)       70·3 (68·0--72·5)       75·3 (73·9--76·6)       62·2 (58·8--65·5)       67·8 (64·4--70·7)       61·1 (57·9--64·2)       65·4 (62·7--68·2)
     Sudan                                               59·9 (58·0--61·7)          72·0 (69·5--74·7)       57·4 (55·6--59·1)       68·8 (66·4--71·5)       50·5 (47·3--53·4)       60·9 (57·4--64·3)       49·6 (47·0--52·1)       59·4 (56·2--62·6)
     Syria                                               72·3 (71·2--73·4)          75·0 (74·0--76·3)       67·7 (66·3--69·0)       65·5 (63·8--67·2)       61·2 (58·1--64·0)       63·5 (60·2--66·5)       59·1 (56·4--61·5)       56·7 (54·0--59·3)
     Tunisia                                             74·5 (73·9--75·0)          80·7 (78·5--83·0)       70·8 (70·3--71·5)       76·1 (73·7--78·6)       63·5 (60·4--66·2)       69·0 (65·3--72·2)       61·4 (58·8--63·7)       65·8 (62·5--69·1)
     Turkey                                              72·1 (71·3--72·8)          83·0 (82·0--84·0)       65·6 (64·8--66·3)       75·2 (74·1--76·3)       60·8 (57·5--63·6)       70·3 (66·8--73·6)       57·3 (55·0--59·4)       65·7 (62·9--68·2)
     United Arab Emirates                                73·0 (71·2--75·0)          76·9 (74·7--79·2)       70·2 (68·2--72·4)       71·7 (69·3--74·0)       62·1 (58·7--65·3)       65·6 (62·2--69·0)       60·8 (57·9--63·7)       62·0 (58·8--65·0)
     Yemen                                               59·8 (57·3--62·6)          70·3 (67·6--72·7)       57·5 (55·0--60·1)       66·0 (63·6--68·3)       48·6 (45·0--52·3)       57·8 (54·1--61·7)       48·5 (45·3--51·7)       55·8 (52·6--59·1)
                                                                                                                                                                                                                                    
  **South Asia**                                         **60·3 (59·7--61·0)**      **70·2 (69·7--70·7)**   **59·0 (58·4--59·5)**   **67·9 (67·4--68·4)**   **50·9 (48·2--53·3)**   **59·6 (56·7--62·1)**   **51·5 (49·3--53·4)**   **59·4 (57·1--61·5)**
                                                                                                                                                                                                                                    
     Bangladesh                                          59·5 (58·5--60·6)          74·6 (73·1--76·0)       57·3 (56·4--58·3)       71·8 (70·3--73·3)       50·5 (47·9--52·9)       63·3 (60·1--66·3)       50·4 (48·3--52·3)       62·9 (60·2--65·2)
     Bhutan                                              59·9 (57·8--62·1)          76·0 (73·9--78·1)       60·0 (57·9--62·3)       72·3 (69·8--74·8)       50·6 (47·6--53·7)       64·9 (61·6--68·2)       52·4 (49·6--55·0)       63·5 (60·4--66·4)
     India                                               60·4 (59·6--61·1)          70·2 (69·5--70·8)       58·9 (58·3--59·6)       67·8 (67·2--68·3)       50·8 (48·1--53·2)       59·5 (56·5--62·1)       51·4 (49·2--53·4)       59·3 (56·9--61·4)
     Nepal                                               59·0 (57·3--60·9)          73·3 (71·5--75·1)       57·7 (56·0--59·5)       68·7 (67·2--70·6)       49·7 (47·0--52·4)       62·3 (59·3--65·2)       50·0 (47·3--52·4)       60·1 (57·4--62·6)
     Pakistan                                            61·6 (60·8--62·4)          67·4 (65·1--70·1)       61·7 (60·9--62·6)       66·3 (63·8--69·1)       52·5 (50·0--55·0)       57·8 (54·6--60·9)       54·1 (51·8--56·2)       58·2 (55·3--61·1)
                                                                                                                                                                                                                                    
  **Southeast Asia, east Asia, and Oceania**             **69·9 (69·5--70·3)**      **78·6 (78·2--78·9)**   **65·8 (65·3--66·2)**   **72·9 (72·5--73·3)**   **61·1 (58·7--63·2)**   **68·4 (65·6--70·9)**   **58·8 (56·9--60·5)**   **65·0 (62·7--66·9)**
                                                                                                                                                                                                                                    
  East Asia                                              70·8 (70·3--71·3)          79·9 (79·4--80·3)       67·0 (66·4--67·6)       74·5 (74·0--74·9)       62·0 (59·6--64·1)       69·7 (66·9--72·1)       60·1 (58·2--61·9)       66·6 (64·4--68·5)
     China                                               70·7 (70·1--71·2)          79·9 (79·4--80·4)       66·9 (66·3--67·5)       74·5 (74·1--75·0)       61·9 (59·5--63·9)       69·7 (66·9--72·1)       60·0 (58·1--61·8)       66·6 (64·4--68·6)
     North Korea                                         74·3 (72·1--76·5)          75·0 (72·9--77·2)       68·5 (66·7--70·7)       68·6 (67·1--70·2)       64·7 (61·8--67·6)       65·2 (62·3--68·0)       61·8 (59·2--64·3)       61·6 (59·2--64·0)
     Taiwan (province of China)                          77·3 (77·2--77·4)          83·3 (82·6--83·9)       72·1 (72·1--72·2)       76·8 (76·1--77·5)       67·5 (64·9--69·9)       71·8 (68·7--74·5)       64·9 (62·8--66·7)       68·2 (65·8--70·3)
  Oceania                                                60·7 (58·8--62·6)          63·4 (61·1--65·5)       55·3 (53·5--57·3)       58·2 (55·9--60·6)       52·4 (49·7--54·9)       54·4 (51·4--57·0)       48·9 (46·5--51·2)       51·1 (48·3--53·8)
     American Samoa                                      74·9 (74·2--75·8)          73·8 (72·9--74·8)       67·6 (66·9--68·4)       70·0 (68·5--71·7)       64·4 (61·5--67·0)       63·2 (60·1--66)         59·5 (57·0--61·6)       61·2 (58·5--63·8)
     Federated States of Micronesia                      65·5 (63·4--67·7)          69·6 (67·2--71·7)       61·7 (59·2--64·2)       65·0 (62·8--67·2)       56·8 (53·6--59·7)       59·7 (56·2--62·7)       54·4 (51·5--57·3)       56·9 (54·0--59·5)
     Fiji                                                70·1 (68·7--71·7)          70·4 (68·4--72·5)       65·6 (64·0--67·0)       65·9 (64·2--67·7)       60·7 (57·8--63·3)       60·5 (57·3--63·6)       57·5 (54·9--59·9)       57·9 (55·2--60·3)
     Guam                                                77·0 (76·4--77·5)          76·4 (75·3--77·5)       70·8 (70·3--71·3)       70·2 (69·2--71·3)       66·8 (63·9--69·4)       65·8 (62·6--68·6)       63·1 (60·8--65·1)       61·8 (59·2--64·1)
     Kiribati                                            61·4 (60·0--62·6)          66·3 (63·9--68·9)       55·7 (54·5--57·0)       58·6 (56·2--61·0)       53·0 (50·3--55·4)       56·7 (53·6--59·8)       49·3 (47·2--51·3)       51·4 (48·7--54·1)
     Marshall Islands                                    66·4 (65·7--67·0)          66·8 (64·5--69)         59·9 (59·2--60·6)       62·6 (60·6--64·6)       57·6 (55·0--59·9)       57·7 (54·7--60·7)       53·3 (51·4--55·1)       55·3 (52·7--57·9)
     Northern Mariana Islands                            76·0 (74·3--78·0)          79·2 (78·0--80·2)       72·9 (70·7--74·6)       73·6 (72·3--75·0)       66·0 (63·0--68·9)       68·0 (64·7--71·0)       64·6 (61·8--67·1)       64·6 (61·8--66·9)
     Papua New Guinea                                    57·3 (55·0--59·9)          61·2 (58·6--63·9)       52·0 (49·7--54·5)       56·2 (53·6--59·2)       49·5 (46·7--52·2)       52·6 (49·5--55·3)       46·0 (43·3--48·6)       49·4 (46·4--52·4)
     Samoa                                               73·8 (71·8--75·9)          74·5 (72·9--76·7)       68·1 (66·0--70·2)       71·3 (70·0--72·7)       64·0 (60·7--66·8)       64·0 (61·0--67·0)       60·1 (57·4--62·8)       62·5 (59·8--65·0)
     Solomon Islands                                     63·5 (61·0--65·8)          67·5 (65·4--69·4)       59·9 (57·2--62·5)       64·1 (62·0--66·3)       55·1 (52·1--58·0)       58·0 (54·8--60·9)       53·1 (50·2--55·9)       56·5 (53·7--59·1)
     Tonga                                               72·1 (71·2--73·1)          75·1 (73·3--77·2)       68·3 (67·6--69·1)       68·6 (66·7--70·1)       62·1 (59·2--64·7)       64·3 (61·0--67·5)       60·5 (58·0--62·6)       60·5 (57·7--62·8)
     Vanuatu                                             65·8 (63·1--68·3)          67·8 (65·0--70·2)       59·7 (57·0--62·6)       62·1 (59·2--65·0)       56·5 (53·1--59·7)       57·9 (54·6--60·9)       52·9 (49·8--56·0)       54·9 (51·9--57·8)
  Southeast Asia                                         67·8 (67·4--68·3)          75·8 (75·2--76·3)       62·6 (62·0--63·0)       69·4 (68·9--70·0)       58·9 (56·3--61·1)       65·8 (63·0--68·3)       55·2 (53·1--57·2)       61·5 (59·1--63·5)
     Cambodia                                            59·8 (58·6--61·1)          72·7 (70·6--74·2)       55·3 (54·0--56·6)       66·8 (65·3--68·3)       51·4 (48·7--53·8)       62·6 (59·6--65·5)       48·4 (46·2--50·5)       58·7 (56·1--61·1)
     Indonesia                                           65·4 (64·8--66·0)          73·9 (73·0--74·7)       62·4 (61·8--63·0)       69·2 (68·4--70·1)       56·8 (54·3--58·9)       64·0 (61·2--66·4)       55·0 (52·9--57·0)       61·4 (59·0--63·6)
     Laos                                                54·3 (52·4--56·5)          70·3 (68·3--72·3)       49·6 (47·4--51·7)       65·0 (63·0--67·1)       47·4 (44·6--49·9)       61·3 (58·3--64·2)       44·3 (42·0--46·6)       57·8 (55·2--60·4)
     Malaysia                                            73·7 (73·6--73·8)          77·3 (76·4--78·4)       69·2 (69·1--69·2)       72·4 (71·3--73·5)       64·5 (61·9--66·8)       67·7 (65·0--70·2)       61·6 (59·4--63·5)       64·4 (61·9--66·7)
     Maldives                                            64·6 (64·1--65·0)          83·4 (82·6--84·1)       65·5 (64·9--66·1)       79·9 (79·2--80·6)       55·5 (52·9--57·8)       72·0 (68·7--74·9)       57·6 (55·3--59·7)       70·4 (67·7--72·9)
     Mauritius                                           74·2 (73·9--74·5)          78·1 (77·2--79·0)       66·3 (66·1--66·5)       71·5 (70·6--72·5)       64·3 (61·4--66·8)       67·2 (63·9--70·0)       58·5 (56·2--60·5)       62·5 (59·9--64·8)
     Myanmar                                             58·4 (56·1--60·8)          72·2 (70·3--74·2)       52·5 (50·0--54·9)       64·9 (63·2--66·7)       50·4 (47·7--53·4)       62·4 (59·4--65·4)       46·2 (43·5--48·8)       57·4 (55·1--59·8)
     Philippines                                         71·4 (70·7--72·2)          73·1 (71·2--75·0)       64·6 (63·7--65·6)       66·6 (64·7--68·6)       61·7 (58·9--64·1)       63·5 (60·5--66·2)       56·5 (54·1--58·6)       58·7 (56·1--61·4)
     Sri Lanka                                           74·8 (74·5--75·2)          81·1 (79·6--83·3)       65·6 (65·3--65·9)       73·8 (71·7--76·0)       64·8 (61·8--67·3)       70·6 (67·1--73·9)       58·2 (56·0--60·1)       65·2 (62·2--68·0)
     Seychelles                                          75·6 (75·1--76·1)          77·7 (77·0--78·4)       66·1 (65·7--66·5)       70·1 (69·5--70·7)       66·3 (63·5--68·6)       67·9 (65·1--70·4)       59·3 (57·3--61·1)       62·4 (60·1--64·4)
     Thailand                                            74·3 (73·8--74·8)          82·0 (80·9--83·1)       67·4 (66·7--68·1)       74·3 (72·9--75·9)       64·9 (62·1--67·2)       71·3 (68·2--74·1)       59·6 (57·4--61·7)       65·7 (63·0--68·3)
     Timor-Leste                                         60·7 (58·8--62·9)          73·0 (71·3--74·8)       59·7 (58·0--61·4)       68·8 (67·3--70·7)       52·1 (49·2--55·0)       63·0 (59·8--65·9)       51·3 (48·6--54·0)       59·7 (56·8--62·5)
     Vietnam                                             72·7 (71·4--74·3)          79·2 (77·8--80·9)       64·9 (63·5--66·5)       70·0 (68·3--71·2)       63·1 (60·2--66·0)       69·2 (66·2--72·3)       57·8 (55·2--60·2)       62·4 (60·0--64·6)
                                                                                                                                                                                                                                    
  **Sub-Saharan Africa**                                 **55·7 (55·0--56·3)**      **66·2 (65·4--67·0)**   **51·6 (51·0--52·3)**   **61·7 (60·8--62·4)**   **47·6 (45·2--49·7)**   **56·8 (54·1--59·3)**   **44·8 (42·8--46·7)**   **53·7 (51·3--55·9)**
                                                                                                                                                                                                                                    
  Central sub-Saharan Africa                             54·6 (53·4--56·1)          64·4 (62·7--66·0)       50·1 (48·8--51·4)       60·3 (58·7--62·0)       46·0 (43·3--48·3)       54·7 (51·9--57·4)       43·1 (40·7--45·3)       52·1 (49·2--54·7)
     Angola                                              50·6 (48·5--52·9)          66·7 (64·5--68·9)       45·5 (43·3--47·6)       61·7 (59·7--64·0)       43·0 (40·1--45·7)       56·8 (53·5--59·8)       39·4 (37·0--41·8)       53·3 (50·3--56·3)
     Central African Republic                            50·1 (48·4--51·8)          54·9 (52·0--58·0)       44·6 (42·9--46·3)       49·1 (46·5--51·7)       42·5 (39·9--44·7)       47·0 (43·7--50·2)       38·5 (36·3--40·8)       42·8 (40·1--45·6)
     Congo (Brazzaville)                                 56·2 (54·2--58·1)          62·7 (60·2--65·6)       51·5 (49·4--53·5)       62·6 (60·4--64·8)       48·0 (45·2--50·7)       53·8 (50·7--56·9)       44·6 (42·2--47·2)       54·3 (51·5--57·3)
     Democratic Republic of the Congo                    56·0 (54·1--58·0)          64·3 (62·0--66·7)       51·8 (50·0--53·7)       60·4 (58·2--62·7)       46·9 (43·8--49·7)       54·6 (51·4--57·6)       44·4 (41·8--47·1)       52·0 (48·9--55·2)
     Equatorial Guinea                                   50·8 (48·3--53·5)          66·4 (62·6--70·5)       45·6 (43·0--48·3)       64·3 (61·3--67·1)       43·2 (40·3--46·0)       56·9 (53·1--60·8)       39·5 (36·8--42·1)       55·6 (52·3--58·9)
     Gabon                                               64·0 (62·3--65·7)          72·1 (69·8--74·4)       56·4 (54·8--58·0)       65·1 (63·3--66·7)       54·3 (51·3--57·2)       61·2 (57·7--64·4)       49·0 (46·5--51·4)       56·6 (53·8--59·1)
  Eastern sub-Saharan Africa                             52·8 (52·3--53·4)          67·4 (66·8--68·1)       48·8 (48·0--49·5)       62·5 (61·7--63·3)       45·7 (43·5--47·5)       58·3 (55·6--60·7)       42·6 (40·8--44·4)       54·9 (52·6--57·0)
     Burundi                                             50·5 (48·7--52·4)          63·6 (61·3--65·9)       46·9 (45·0--48·8)       59·7 (57·3--62·2)       44·2 (41·8--46·5)       55·5 (52·7--58·3)       41·7 (39·6--43·9)       52·3 (49·3--55·4)
     Comoros                                             59·4 (57·5--61·6)          70·0 (67·8--72·3)       56·9 (54·9--58·8)       67·1 (65·0--69·2)       51·4 (48·6--54·1)       61·0 (58·0--63·9)       49·6 (47·0--52·0)       58·9 (56·1--61·6)
     Djibouti                                            61·4 (58·8--64·1)          68·9 (65·3--72·0)       58·9 (56·3--61·5)       66·0 (63·1--68·8)       53·7 (50·7--56·7)       60·3 (56·9--63·8)       52·2 (49·2--54·9)       58·5 (55·5--61·5)
     Eritrea                                             43·6 (42·4--44·7)          65·9 (63·4--69·0)       30·6 (29·9--31·4)       59·2 (56·4--61·9)       37·0 (34·8--39·0)       57·0 (53·8--60·4)       26·2 (24·7--27·5)       51·6 (48·7--54·4)
     Ethiopia                                            48·8 (47·8--49·9)          70·4 (69·3--71·5)       45·6 (44·4--46·8)       66·7 (65·6--67·7)       42·2 (40·0--44·1)       60·8 (57·9--63·4)       39·9 (37·8--41·7)       58·5 (55·9--60·8)
     Kenya                                               63·2 (62·4--63·9)          68·8 (67·9--69·5)       60·6 (59·9--61·3)       63·2 (62·4--63·9)       55·0 (52·6--57·3)       59·7 (57·0--62·1)       53·4 (51·1--55·4)       55·7 (53·4--57·7)
     Madagascar                                          57·0 (55·8--58·2)          64·8 (62·3--67·5)       53·9 (52·7--55·1)       62·2 (59·7--64·8)       49·3 (46·9--51·5)       56·3 (53·3--59·3)       47·0 (44·7--48·9)       54·6 (51·7--57·7)
  Malawi                                                 50·5 (48·9--52·0)          66·9 (64·9--69·0)       46·7 (44·9--48·4)       59·6 (57·9--61·5)       43·8 (41·4--45·9)       57·8 (54·7--60·6)       40·8 (38·4--43·0)       52·4 (50·0--54·8)
     Mozambique                                          52·6 (51·3--54·1)          62·0 (59·4--64·5)       48·0 (46·7--49·4)       54·8 (52·7--57·0)       45·3 (42·8--47·5)       53·4 (50·2--56·6)       41·6 (39·4--43·6)       47·9 (45·2--50·4)
     Rwanda                                              51·4 (50·1--52·7)          70·8 (69·1--72·7)       47·4 (46·1--48·7)       65·8 (64·0--67·6)       45·0 (42·9--47·0)       61·3 (58·3--64·2)       42·1 (40·2--44·0)       57·7 (55·1--60·4)
     Somalia                                             52·4 (49·9--55·0)          60·6 (57·7--63·3)       48·0 (45·5--50·5)       56·5 (53·7--59·3)       45·3 (42·5--48·2)       52·7 (49·5--55·6)       42·4 (39·8--45·1)       49·9 (46·7--52·9)
     South Sudan                                         53·5 (50·8--56·3)          61·8 (58·6--65·1)       49·3 (46·6--52·0)       56·9 (53·9--60·0)       44·9 (41·7--47·8)       52·3 (48·5--55·8)       42·4 (39·5--45·2)       49·2 (45·9--52·3)
     Tanzania                                            56·5 (54·9--58·0)          68·9 (67·2--70·6)       53·2 (51·2--55·1)       64·6 (62·9--66·3)       48·8 (46·3--51·1)       59·7 (56·8--62·5)       46·6 (44·1--48·9)       56·8 (54·1--59·3)
     Uganda                                              51·1 (48·8--53·4)          69·2 (67·2--71·1)       44·3 (40·3--48·4)       62·3 (60·5--64·2)       43·7 (40·9--46·6)       59·5 (56·5--62·4)       38·0 (34·4--41·8)       54·5 (52·0--57·0)
     Zambia                                              52·1 (50·2--53·7)          66·3 (64·5--68·3)       49·3 (46·6--51·5)       60·4 (58·5--62·3)       45·3 (42·9--47·6)       57·4 (54·3--60·1)       43·6 (40·8--46·1)       53·1 (50·7--55·4)
  Southern sub-Saharan Africa                            67·9 (67·1--68·6)          68·5 (67·6--69·3)       60·3 (59·3--61·1)       61·5 (60·7--62·2)       57·8 (55·0--60·3)       58·3 (55·4--60·8)       52·6 (50·2--54·6)       53·6 (51·4--55·6)
     Botswana                                            68·8 (66·3--71·3)          71·0 (68·8--72·5)       58·6 (55·2--61·3)       67·0 (64·1--69·2)       58·4 (55·2--61·5)       60·0 (56·8--63·0)       51·0 (47·8--54·0)       57·7 (54·4--60·7)
     Lesotho                                             65·2 (63·5--67·0)          59·3 (56·3--62·7)       56·0 (54·3--57·6)       50·3 (48·1--52·7)       55·3 (52·2--58·1)       50·3 (46·8--53·6)       49·0 (46·6--51·1)       43·9 (41·3--46·4)
     Namibia                                             65·4 (63·9--66·7)          70·7 (67·5--73·5)       58·2 (56·0--59·6)       62·3 (60·3--64·3)       55·8 (53·0--58·4)       60·1 (56·5--63·6)       50·5 (47·9--52·8)       54·2 (51·4--56·8)
     South Africa                                        68·7 (68·1--69·4)          69·7 (68·6--70·6)       61·5 (60·8--62·1)       62·8 (62·0--63·6)       58·4 (55·7--60·9)       59·3 (56·3--61·9)       53·5 (51·3--55·5)       54·7 (52·5--56·8)
     Swaziland (eSwatini)                                66·5 (64·9--68·2)          65·1 (62·1--68·4)       57·9 (56·1--59·7)       54·9 (52·6--57·6)       56·7 (53·9--59·6)       55·1 (51·5--58·5)       50·7 (48·4--53·0)       47·8 (45·1--50·4)
     Zimbabwe                                            64·7 (61·2--67·3)          64·4 (62·1--66·6)       57·5 (52·7--60·7)       58·1 (56·3--60·1)       55·4 (51·9--58·6)       55·1 (52·1--58·1)       50·4 (46·4--53·8)       51·1 (48·6--53·4)
  Western sub-Saharan Africa                             56·2 (55·0--57·4)          65·3 (63·6--66·9)       53·3 (52·0--54·5)       61·7 (60·2--62·9)       47·8 (45·1--50·1)       56·0 (53·0--58·7)       45·9 (43·5--48·1)       53·5 (50·9--56·0)
     Benin                                               57·5 (56·0--58·9)          66·6 (64·2--69·1)       53·0 (51·4--54·4)       62·6 (60·1--65·0)       48·4 (45·5--51·2)       57·2 (54·1--60·5)       45·3 (42·6--47·8)       54·5 (51·5--57·5)
     Burkina Faso                                        52·4 (51·0--53·8)          64·4 (62·6--66·3)       49·1 (47·5--50·8)       58·9 (56·9--61·0)       44·4 (41·8--46·8)       55·4 (52·5--58·2)       41·5 (38·8--44·0)       51·5 (48·8--54·1)
     Cameroon                                            59·2 (58·0--60·4)          65·1 (62·7--67·8)       56·2 (55·0--57·4)       61·0 (58·6--63·5)       50·1 (47·4--52·6)       56·0 (52·6--59·0)       48·1 (45·6--50·3)       53·2 (50·2--56·1)
     Cape Verde                                          73·5 (73·0--74·0)          79·0 (78·2--80·1)       66·4 (66·0--66·9)       72·5 (71·3--73·7)       63·0 (60·0--65·6)       68·1 (65·0--70·9)       58·2 (55·8--60·3)       63·6 (60·9--66·1)
     Chad                                                54·7 (53·3--56·2)          61·6 (59·2--64·2)       52·0 (50·4--53·6)       58·6 (56·4--60·8)       46·2 (43·6--48·7)       52·5 (49·1--55·6)       44·8 (42·5--47·2)       50·7 (47·8--53·4)
     Côte d'Ivoire                                       58·0 (55·5--59·9)          65·3 (62·8--67·7)       52·1 (48·7--54·4)       60·1 (57·8--62·3)       48·9 (45·7--51·7)       56·1 (52·8--59·1)       45·1 (41·5--47·7)       52·6 (49·9--55·3)
     The Gambia                                          62·5 (60·4--64·8)          67·9 (65·6--70·2)       57·8 (55·5--60·2)       63·8 (62·0--65·8)       53·1 (49·9--56·2)       57·9 (54·6--61·0)       50·0 (47·1--53·0)       55·6 (52·9--58·2)
     Ghana                                               60·7 (58·8--62·6)          68·4 (66·7--70·3)       57·8 (55·9--59·8)       62·6 (61·0--64·3)       52·1 (49·2--54·7)       59·3 (56·4--62·1)       50·3 (47·7--52·8)       54·8 (52·0--57·3)
     Guinea                                              52·3 (50·8--53·8)          62·2 (60·3--64·2)       51·6 (50·1--53·0)       59·3 (57·2--61·4)       44·7 (42·2--47·1)       53·8 (50·9--56·4)       44·8 (42·6--46·9)       51·9 (49·1--54·5)
     Guinea-Bissau                                       52·1 (49·9--54·5)          62·6 (60·3--64·9)       45·5 (43·3--47·6)       57·4 (55·1--59·7)       44·6 (41·7--47·4)       53·9 (50·8--56·8)       39·8 (37·5--42·2)       50·2 (47·4--52·8)
     Liberia                                             51·3 (49·5--53·1)          65·1 (63·1--67·4)       46·8 (45·3--48·4)       63·7 (61·5--65·8)       43·4 (40·6--45·8)       54·7 (51·3--57·8)       39·9 (37·6--42·3)       54·0 (50·9--57·3)
     Mali                                                49·5 (48·3--50·6)          63·0 (61·1--64·9)       49·2 (48·0--50·5)       61·0 (58·7--63·2)       42·0 (39·6--44·2)       53·9 (50·9--56·8)       42·1 (39·6--44·2)       52·5 (49·4--55·3)
     Mauritania                                          60·2 (58·7--61·7)          71·0 (68·9--73·0)       59·0 (57·6--60·5)       70·0 (68·0--72·3)       51·8 (49·0--54·0)       61·2 (58·2--64·1)       51·4 (48·9--53·8)       60·7 (57·5--63·7)
     Niger                                               47·4 (45·8--49·0)          63·6 (61·4--66·0)       45·8 (44·3--47·3)       61·1 (58·8--63·5)       40·7 (38·4--43·0)       54·9 (52·2--57·8)       40·0 (37·9--42·1)       53·5 (50·6--56·5)
     Nigeria                                             57·1 (54·5--59·5)          65·8 (62·3--69·1)       54·0 (51·5--56·4)       62·8 (59·7--65·2)       48·5 (45·3--51·6)       56·2 (52·3--59·6)       46·5 (43·6--49·4)       54·0 (50·6--57·2)
     São Tomé and Príncipe                               65·6 (64·3--67·0)          71·8 (70·1--73·8)       62·5 (61·3--63·7)       68·1 (66·5--69·8)       56·5 (53·7--59·0)       62·3 (59·2--65·1)       54·4 (52·0--56·6)       59·6 (56·9--62·3)
     Senegal                                             60·4 (59·0--61·8)          70·0 (68·3--71·9)       56·6 (55·4--57·8)       66·1 (64·5--67·9)       51·5 (48·7--54·1)       60·1 (57·2--62·9)       49·1 (46·6--51·3)       57·7 (54·9--60·3)
     Sierra Leone                                        52·3 (50·4--54·3)          61·4 (59·4--63·7)       48·1 (46·3--50·0)       59·5 (57·2--61·7)       44·7 (41·9--47·2)       52·7 (49·9--55·5)       41·6 (39·3--43·7)       51·5 (48·5--54·3)
     Togo                                                59·3 (57·7--60·9)          67·2 (65·0--69·6)       56·0 (54·3--57·7)       61·4 (59·1--63·8)       50·5 (47·7--53·2)       57·8 (54·6--60·9)       48·6 (46·1--51·0)       53·8 (51·0--56·7)

Data in parentheses are 95% uncertainty intervals. Super-regions, regions, and countries are listed alphabetically. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. HALE=healthy life expectancy. SDI=Socio-demographic Index.

###### Life expectancy and HALE at age 65 years for 21 GBD regions and 195 countries and territories, by sex, in 1990 and 2017

                                                         Life expectancy at age 65 years   HALE at age 65 years                                                                                                                            
  ------------------------------------------------------ --------------------------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- ----------------------- -----------------------
  **Global**                                             **16·2 (16·1--16·2)**             **18·7 (18·6--18·8)**   **13·6 (13·5--13·6)**   **15·9 (15·8--16·0)**   **11·9 (10·8--12·9)**   **13·7 (12·4--14·9)**   **10·3 (9·4--11·0)**    **12·0 (10·9--12·9)**
                                                                                                                                                                                                                                           
  Low SDI                                                12·2 (12·0--12·5)                 14·7 (14·5--15·0)       11·4 (11·1--11·6)       13·7 (13·4--13·9)         8·6 (7·7--9·5)        10·5 (9·5--11·5)          8·3 (7·5--9·1)        10·0 (9·1--10·9)
  Low-middle SDI                                         13·8 (13·6--14·0)                 15·8 (15·6--16·1)       12·6 (12·4--12·8)       14·1 (13·9--14·3)         9·9 (8·9--10·7)       11·4 (10·3--12·5)         9·3 (8·4--10·1)       10·5 (9·5--11·4)
  Middle SDI                                             15·4 (15·3--15·6)                 18·2 (18·0--18·4)       13·8 (13·7--13·9)       15·4 (15·2--15·6)       11·5 (10·5--12·4)       13·5 (12·3--14·6)       10·6 (9·8--11·4)        11·8 (10·8--12·7)
  High-middle SDI                                        15·8 (15·6--15·9)                 18·5 (18·3--18·8)       13·2 (13·0--13·3)       15·6 (15·4--15·9)       11·6 (10·5--12·5)       13·7 (12·4--14·8)       10·0 (9·2--10·8)        11·8 (10·8--12·8)
  High SDI                                               18·7 (18·6--18·7)                 21·9 (21·8--22·0)       14·9 (14·9--14·9)       18·6 (18·5--18·7)       13·9 (12·7--15·1)       16·2 (14·6--17·6)       11·3 (10·3--12·1)       13·8 (12·6--15·0)
                                                                                                                                                                                                                                           
  **Central Europe, eastern Europe, and central Asia**   **15·9 (15·9--15·9)**             **18 (17·9--18·1)**     **12·5 (12·5--12·5)**   **14·0 (14·0--14·1)**   **11·4 (10·2--12·5)**   **12·9 (11·6--14·1)**   **9·0 (8·1--9·9)**      **10·1 (9·1--11·1)**
                                                                                                                                                                                                                                           
  Central Asia                                           16·4 (16·3--16·5)                 16·5 (16·2--16·8)       13·2 (13·1--13·2)       12·8 (12·5--13·0)       12·0 (10·8--13·1)       12·2 (10·9--13·2)         9·8 (8·9--10·6)         9·5 (8·6--10·4)
      Armenia                                            15·7 (15·4--15·9)                 17·3 (17·0--17·6)       13·2 (12·9--13·4)       14·6 (14·4--14·9)       11·4 (10·3--12·5)       12·7 (11·4--13·9)         9·7 (8·7--10·6)       10·8 (9·8--11·8)
      Azerbaijan                                         16·9 (16·6--17·3)                 16·4 (15·8--17·1)       13·6 (13·2--13·9)       11·9 (11·4--12·4)       12·5 (11·4--13·6)       12·1 (10·9--13·4)       10·2 (9·1--11·1)          8·9 (8·0--9·8)
      Georgia                                            16·2 (15·9--16·5)                 16·7 (16·5--17·0)       13·2 (12·9--13·6)       13·1 (12·9--13·3)       12·1 (11·0--13·2)       12·3 (11·1--13·4)       10·0 (9·0--10·8)          9·8 (8·8--10·6)
      Kazakhstan                                         16·5 (16·4--16·5)                 17·0 (16·6--17·4)       12·3 (12·2--12·3)       13·2 (12·9--13·6)       11·8 (10·6--12·9)       12·4 (11·2--13·5)         8·9 (8·0--9·7)          9·7 (8·7--10·6)
      Kyrgyzstan                                         16·0 (15·6--16·4)                 17·0 (16·8--17·3)       12·5 (12·1--12·8)       13·7 (13·5--13·9)       11·7 (10·5--12·8)       12·6 (11·4--13·7)         9·2 (8·3--10·1)       10·3 (9·4--11·2)
      Mongolia                                           13·1 (12·8--13·4)                 16·1 (15·4--16·9)       11·1 (10·8--11·4)       12·1 (11·5--12·8)         9·8 (8·9--10·7)       12·0 (10·7--13·1)         8·4 (7·6--9·1)          9·0 (8·1--9·9)
      Tajikistan                                         16·9 (16·6--17·1)                 17·1 (16·3--17·9)       14·4 (14·3--14·6)       13·9 (13·2--14·6)       12·4 (11·2--13·5)       12·7 (11·4--13·8)       10·8 (9·7--11·7)        10·5 (9·4--11·6)
      Turkmenistan                                       15·4 (15·4--15·5)                 16·4 (15·7--17·1)       12·7 (12·6--12·7)       13·3 (12·8--13·9)       11·5 (10·4--12·5)       12·3 (11·0--13·4)         9·6 (8·7--10·3)       10·1 (9·1--11·0)
      Uzbekistan                                         17·0 (16·9--17·0)                 15·8 (14·8--16·9)       14·2 (14·1--14·2)       12·0 (11·2--12·8)       12·5 (11·3--13·6)       11·7 (10·4--13·0)       10·7 (9·7--11·5)          9·1 (8·1--10·1)
  Central Europe                                         15·9 (15·8--15·9)                 19·0 (18·8--19·2)       12·6 (12·6--12·6)       15·3 (15·2--15·5)       11·2 (10·0--12·3)       13·5 (12·1--14·8)         8·9 (8·0--9·8)        10·8 (9·6--11·9)
      Albania                                            19·3 (19·2--19·5)                 20·6 (18·9--22·4)       13·7 (13·6--13·8)       15·6 (14·4--17·1)       14·1 (12·7--15·4)       15·1 (13·4--17·0)       10·0 (9·1--10·9)        11·4 (10·0--13·0)
      Bosnia and Herzegovina                             16·4 (16·3--16·6)                 17·4 (16·9--17·9)       13·6 (13·6--13·7)       15·1 (14·6--15·5)       11·8 (10·6--12·9)       12·4 (11·1--13·6)         9·8 (8·8--10·7)       10·6 (9·4--11·7)
      Bulgaria                                           16·0 (15·9--16·1)                 18·0 (17·5--18·5)       12·8 (12·7--12·8)       14·2 (13·8--14·7)       11·6 (10·4--12·6)       13·0 (11·7--14·3)         9·2 (8·3--10·1)       10·2 (9·1--11·2)
      Croatia                                            15·9 (15·8--16·0)                 19·3 (18·8--19·8)       12·6 (12·6--12·7)       15·7 (15·3--16·2)       11·4 (10·1--12·5)       13·7 (12·2--15·1)         9·0 (8·0--9·8)        11·1 (9·8--12·2)
      Czech Republic                                     15·3 (15·2--15·4)                 19·8 (19·3--20·3)       11·6 (11·5--11·6)       16·3 (15·9--16·8)       10·6 (9·3--11·7)        13·9 (12·2--15·3)         8·1 (7·2--8·9)        11·2 (9·9--12·5)
      Hungary                                            15·5 (15·4--15·5)                 19·1 (18·6--19·5)       12·1 (12·1--12·1)       15·0 (14·6--15·5)       10·5 (9·3--11·7)        13·4 (11·9--14·8)         8·4 (7·4--9·2)        10·5 (9·3--11·6)
      Macedonia                                          16·3 (16·2--16·5)                 18·8 (18·5--19·2)       13·6 (13·5--13·7)       14·8 (14·3--15·2)       11·7 (10·5--12·8)       13·6 (12·2--14·9)         9·8 (8·8--10·7)       10·6 (9·4--11·6)
      Montenegro                                         17·6 (17·4--17·7)                 17·4 (16·8--18·0)       14·5 (14·4--14·7)       14·8 (14·0--15·5)       12·7 (11·5--14·0)       12·5 (11·2--13·8)       10·5 (9·4--11·5)        10·6 (9·4--11·7)
      Poland                                             16·3 (16·3--16·4)                 20·2 (19·7--20·7)       12·6 (12·6--12·6)       16·0 (15·5--16·4)       11·6 (10·3--12·7)       14·4 (12·8--15·8)         9·0 (8·0--9·8)        11·2 (10--12·5)
      Romania                                            15·2 (15·2--15·2)                 18·2 (17·8--18·7)       13·1 (13·0--13·1)       14·7 (14·3--15·1)       10·8 (9·7--11·9)        13·1 (11·7--14·4)         9·2 (8·2--10·2)       10·4 (9·3--11·5)
      Serbia                                             15·9 (15·8--16·0)                 16·5 (16·0--17·0)       12·4 (12·4--12·5)       14·6 (14·2--15·0)       11·4 (10·2--12·4)       11·8 (10·5--12·9)         8·9 (8·0--9·7)        10·4 (9·3--11·5)
      Slovakia                                           15·8 (15·7--15·9)                 19·0 (18·5--19·5)       12·2 (12·2--12·3)       15·4 (14·9--15·8)       11·2 (10·0--12·3)       13·5 (12·0--14·8)         8·6 (7·6--9·5)        10·7 (9·4--11·8)
      Slovenia                                           17·2 (17·0--17·3)                 21·6 (21·0--22·2)       13·4 (13·3--13·5)       17·5 (17·0--18·0)       12·0 (10·6--13·2)       15·1 (13·3--16·7)         9·3 (8·2--10·3)       12·1 (10·6--13·5)
  Eastern Europe                                         15·9 (15·9--15·9)                 17·7 (17·5--17·8)       12·3 (12·2--12·3)       13·4 (13·2--13·5)       11·4 (10·2--12·4)       12·7 (11·3--13·8)         9·0 (8·1--9·8)          9·8 (8·8--10·6)
      Belarus                                            16·7 (16·6--16·8)                 17·9 (17·5--18·4)       13·2 (13·2--13·2)       13·0 (12·7--13·4)       12·1 (10·9--13·2)       13·0 (11·7--14·2)         9·7 (8·7--10·6)         9·6 (8·6--10·5)
      Estonia                                            15·8 (15·7--16·0)                 20·4 (19·4--21·4)       12·1 (12·0--12·2)       15·9 (15·0--16·9)       11·5 (10·4--12·5)       14·9 (13·3--16·5)         8·8 (7·9--9·6)        11·6 (10·3--12·9)
      Latvia                                             15·9 (15·8--16·0)                 19·0 (18·0--20·0)       12·3 (12·2--12·3)       14·2 (13·4--15·1)       11·4 (10·2--12·5)       13·7 (12·2--15·1)         8·9 (8·0--9·7)        10·3 (9·1--11·4)
      Lithuania                                          16·9 (16·8--17·0)                 19·3 (18·8--19·8)       13·4 (13·3--13·4)       14·3 (13·8--14·7)       12·2 (11·0--13·3)       13·8 (12·3--15·2)         9·8 (8·8--10·6)       10·2 (9·1--11·3)
      Moldova                                            14·9 (14·8--14·9)                 17·9 (17·6--18·2)       12·6 (12·6--12·7)       13·6 (13·4--13·8)       10·8 (9·7--11·7)        13·1 (11·9--14·3)         9·3 (8·3--10·1)       10·1 (9·1--11·0)
      Russia                                             15·9 (15·9--15·9)                 17·7 (17·7--17·8)       12·0 (12·0--12·0)       13·6 (13·6--13·7)       11·3 (10·2--12·4)       12·6 (11·3--13·8)         8·8 (7·9--9·6)          9·9 (8·9--10·8)
      Ukraine                                            15·8 (15·7--15·9)                 17·2 (16·7--17·6)       12·5 (12·4--12·6)       12·5 (12·2--12·9)       11·3 (10·1--12·3)       12·5 (11·2--13·6)         9·2 (8·3--10·0)         9·2 (8·3--10·1)
                                                                                                                                                                                                                                           
  **High income**                                        **18·8 (18·8--18·8)**             **21·9 (21·8--22·0)**   **15·0 (15·0--15·0)**   **18·6 (18·5--18·7)**   **14·1 (12·8--15·2)**   **16·3 (14·7--17·6)**   **11·4 (10·4--12·3)**   **13·9 (12·6--15·0)**
                                                                                                                                                                                                                                           
  Australasia                                            18·9 (18·8--18·9)                 22·2 (21·4--22·9)       15·1 (15·0--15·1)       19·4 (18·7--20·2)       14·0 (12·7--15·2)       16·3 (14·6--17·8)       11·3 (10·2--12·2)       14·3 (12·8--15·7)
      Australia                                          19·0 (18·9--19·1)                 22·3 (21·4--23·2)       15·1 (15·1--15·2)       19·4 (18·6--20·3)       14·2 (12·8--15·3)       16·4 (14·7--17·9)       11·3 (10·3--12·2)       14·4 (12·8--15·7)
      New Zealand                                        18·2 (18·1--18·3)                 21·7 (21·2--22·1)       14·8 (14·6--14·9)       19·2 (18·8--19·7)       13·4 (12·0--14·6)       15·5 (13·8--17·0)       11·0 (9·9--11·9)        13·9 (12·4--15·2)
  High-income Asia Pacific                               19·7 (19·7--19·8)                 24·1 (24·0--24·3)       15·8 (15·8--15·9)       19·5 (19·4--19·7)       15·1 (13·8--16·2)       18·2 (16·6--19·7)       12·3 (11·3--13·1)       14·9 (13·6--16·0)
      Brunei                                             13·8 (13·4--14·2)                 17·8 (17·2--18·4)       12·5 (12·1--12·8)       15·3 (14·4--16·2)       10·3 (9·3--11·2)        13·5 (12·2--14·6)         9·4 (8·5--10·2)       11·6 (10·5--12·8)
      Japan                                              20·3 (20·3--20·3)                 24·4 (24·2--24·6)       16·4 (16·4--16·4)       19·7 (19·5--19·9)       15·6 (14·2--16·7)       18·5 (16·8--19·9)       12·8 (11·8--13·6)       15·1 (13·8--16·2)
      Singapore                                          18·1 (18·0--18·3)                 24·6 (24·1--25·0)       14·7 (14·6--14·8)       20·2 (19·7--20·7)       13·8 (12·6--14·9)       18·8 (17·1--20·2)       11·4 (10·5--12·2)       15·7 (14·4--16·9)
      South Korea                                        16·6 (16·6--16·7)                 22·6 (22·2--23·1)       12·4 (12·4--12·4)       18·5 (18·0--19·0)       12·5 (11·3--13·5)       17·0 (15·4--18·5)         9·4 (8·5--10·1)       13·9 (12·6--15·0)
  High-income North America                              19·2 (19·2--19·2)                 20·8 (20·6--20·9)       15·3 (15·3--15·3)       18·2 (18·0--18·4)       14·1 (12·8--15·3)       14·9 (13·4--16·3)       11·3 (10·2--12·2)       13·1 (11·7--14·3)
      Canada                                             19·6 (19·6--19·7)                 22·1 (21·7--22·6)       15·5 (15·4--15·5)       19·5 (19·0--19·9)       14·8 (13·4--15·9)       16·5 (14·9--17·9)       11·8 (10·7--12·7)       14·6 (13·3--15·9)
      Greenland                                          14·3 (14·0--14·6)                 18·3 (17·6--18·9)       11·6 (11·4--11·8)       14·2 (14·0--15·0)       10·4 (9·4--11·3)        13·4 (12·1--14·6)         8·5 (7·7--9·3)        10·5 (9·5--11·5)
      USA                                                19·1 (19·1--19·1)                 20·6 (20·4--20·8)       15·3 (15·3--15·3)       18·1 (17·9--18·3)       14·1 (12·7--15·3)       14·7 (13·2--16·1)       11·2 (10·2--12·2)       12·9 (11·6--14·1)
  Southern Latin America                                 17·5 (17·5--17·6)                 19·7 (18·9--20·3)       14·0 (14·0--14·0)       16·3 (15·6--16·9)       13·3 (12·1--14·3)       14·9 (13·5--16·2)       10·7 (9·7--11·5)        12·3 (11·1--13·5)
      Argentina                                          17·6 (17·5--17·6)                 19·3 (18·4--20·2)       13·9 (13·9--13·9)       15·7 (14·8--16·5)       13·4 (12·2--14·4)       14·7 (13·3--16·1)       10·6 (9·7--11·4)        11·9 (10·7--13·2)
      Chile                                              17·2 (17·1--17·3)                 20·6 (19·7--21·6)       14·4 (14·4--14·5)       17·9 (17·0--18·9)       12·9 (11·8--14·0)       15·4 (13·9--16·9)       10·9 (9·9--11·8)        13·4 (12·1--14·8)
      Uruguay                                            17·9 (17·8--18·0)                 19·8 (18·9--20·8)       13·9 (13·8--14·0)       15·8 (14·9--16·7)       13·5 (12·3--14·6)       15·0 (13·5--16·4)       10·5 (9·6--11·4)        11·9 (10·7--13·1)
  Western Europe                                         18·5 (18·5--18·5)                 21·9 (21·6--22·1)       14·7 (14·7--14·7)       18·7 (18·5--18·9)       13·9 (12·7--15·0)       16·4 (14·9--17·7)       11·2 (10·3--12·1)       14·1 (12·9--15·2)
      Andorra                                            20·7 (19·4--22·3)                 22·4 (21·3--23·8)       16·6 (15·8--17·2)       19·4 (18·8--20·1)       15·5 (13·8--17·3)       16·8 (15·0--18·5)       12·7 (11·5--13·8)       14·7 (13·4--15·9)
      Austria                                            17·9 (17·8--18·0)                 21·6 (21·1--22·0)       14·5 (14·4--14·6)       18·5 (18·0--18·9)       13·5 (12·3--14·6)       16·1 (14·6--17·5)       11·1 (10·1--11·9)       13·9 (12·6--15·1)
      Belgium                                            18·5 (18·4--18·6)                 21·7 (21·2--22·2)       14·3 (14·2--14·3)       18·3 (17·8--18·7)       13·7 (12·5--14·9)       15·9 (14·4--17·4)       10·8 (9·8--11·6)        13·5 (12·1--14·7)
      Cyprus                                             17·3 (17·2--17·5)                 22·5 (21·8--23·1)       15·0 (14·9--15·1)       17·5 (16·8--18·2)       13·0 (11·8--14·0)       16·8 (15·2--18·3)       11·5 (10·5--12·3)       13·3 (12·0--14·5)
      Denmark                                            17·8 (17·7--17·9)                 20·7 (20·1--21·2)       14·1 (14·0--14·2)       18·0 (17·5--18·4)       13·3 (12·1--14·4)       15·5 (14·0--16·7)       10·8 (9·8--11·6)        13·6 (12·3--14·7)
      Finland                                            17·9 (17·7--18·0)                 21·8 (21·2--22·3)       13·9 (13·8--13·9)       18·2 (17·7--18·7)       13·4 (12·2--14·5)       16·2 (14·7--17·7)       10·5 (9·5--11·3)        13·6 (12·2--14·8)
      France                                             19·9 (19·8--19·9)                 23·5 (23·0--23·9)       15·5 (15·4--15·5)       19·5 (19·1--19·9)       15·1 (13·7--16·3)       17·8 (16·1--19·2)       11·9 (10·9--12·8)       14·9 (13·6--16·1)
      Germany                                            17·7 (17·7--17·8)                 20·8 (19·9--21·7)       14·1 (14·1--14·1)       17·8 (16·9--18·7)       13·3 (12·0--14·3)       15·5 (13·9--17·0)       10·7 (9·7--11·5)        13·4 (12·0--14·6)
      Greece                                             18·9 (18·8--18·9)                 21·3 (20·8--21·8)       15·7 (15·6--15·7)       18·3 (17·9--18·8)       14·2 (13·0--15·3)       16·0 (14·5--17·3)       12·0 (11·0--12·9)       13·8 (12·6--15·0)
      Iceland                                            19·0 (18·8--19·3)                 23·1 (22·7--23·5)       16·1 (15·9--16·3)       18·4 (18·1--18·7)       14·2 (12·9--15·4)       17·2 (15·6--18·6)       12·2 (11·1--13·1)       13·9 (12·5--15·0)
      Ireland                                            16·8 (16·7--17·0)                 21·2 (20·6--21·7)       13·4 (13·3--13·5)       18·7 (18·2--19·2)       12·7 (11·6--13·7)       15·8 (14·3--17·1)       10·2 (9·3--11·0)        14·0 (12·6--15·2)
      Israel                                             18·0 (17·9--18·1)                 21·9 (21·4--22·4)       16·4 (16·3--16·5)       19·9 (19·4--20·4)       13·3 (12·0--14·5)       16·2 (14·6--17·6)       12·3 (11·2--13·3)       14·9 (13·4--16·2)
      Italy                                              19·0 (18·9--19·0)                 22·5 (22·1--23·0)       15·2 (15·2--15·2)       19·2 (18·8--19·6)       14·3 (13·0--15·4)       17·0 (15·5--18·4)       11·6 (10·6--12·5)       14·6 (13·2--15·8)
      Luxembourg                                         18·1 (17·9--18·2)                 20·9 (20·2--21·6)       13·9 (13·8--14·1)       18·8 (18·0--19·6)       13·2 (11·9--14·4)       15·3 (13·8--16·8)       10·4 (9·4--11·2)        13·8 (12·4--15·2)
      Malta                                              17·4 (17·2--17·6)                 20·6 (20·1--21·1)       14·7 (14·5--14·8)       17·9 (17·6--18·3)       13·1 (11·8--14·2)       15·4 (13·9--16·7)       11·1 (10·1--12·0)       13·4 (12·1--14·6)
      Netherlands                                        19·0 (18·9--19·1)                 20·9 (20·5--21·4)       14·4 (14·3--14·4)       18·3 (17·9--18·8)       14·2 (12·9--15·4)       15·6 (14·1--17·0)       10·9 (10·0--11·8)       13·8 (12·5--15·0)
      Norway                                             18·8 (18·7--18·8)                 21·6 (21·4--21·7)       14·7 (14·6--14·7)       19·0 (18·8--19·1)       14·1 (12·7--15·2)       16·0 (14·4--17·3)       11·0 (10·0--11·9)       13·9 (12·6--15·2)
      Portugal                                           17·2 (17·2--17·3)                 21·7 (21·2--22·1)       14·1 (14·0--14·1)       18·3 (17·9--18·8)       12·8 (11·5--13·8)       16·1 (14·5--17·5)       10·6 (9·6--11·4)        13·8 (12·5--15·0)
      Spain                                              19·1 (19·1--19·2)                 23·0 (22·6--23·4)       15·5 (15·5--15·5)       19·1 (18·7--19·5)       14·5 (13·3--15·6)       17·6 (16·0--18·9)       11·9 (10·9--12·8)       14·6 (13·4--15·7)
      Sweden                                             19·1 (19·1--19·2)                 21·5 (21·1--21·9)       15·4 (15·4--15·5)       19·2 (18·8--19·6)       14·4 (13·2--15·6)       16·1 (14·6--17·4)       11·9 (10·8--12·7)       14·5 (13·2--15·7)
      Switzerland                                        19·8 (19·7--19·9)                 22·8 (22·4--23·3)       15·6 (15·5--15·7)       20·2 (19·8--20·7)       14·7 (13·2--15·9)       17·0 (15·4--18·5)       11·8 (10·7--12·7)       15·2 (13·8--16·5)
      UK                                                 17·8 (17·7--17·8)                 20·8 (20·7--20·9)       14·1 (14·0--14·1)       18·5 (18·4--18·6)       13·4 (12·3--14·5)       15·4 (14·0--16·7)       10·8 (9·9--11·6)        13·9 (12·6--15·0)
         England                                         17·9 (17·9--17·9)                 20·9 (20·8--21·0)       14·2 (14·2--14·2)       18·6 (18·6--18·7)       13·6 (12·4--14·6)       15·4 (14·0--16·8)       10·9 (10·0--11·7)       13·9 (12·7--15·1)
         Northern Ireland                                16·9 (16·7--17·1)                 20·7 (19·9--21·4)       13·3 (13·2--13·4)       18·3 (17·7--19·0)       12·8 (11·7--13·8)       15·6 (14·2--16·9)       10·2 (9·3--10·9)        13·8 (12·5--15·1)
         Scotland                                        16·7 (16·6--16·8)                 19·8 (19·2--20·5)       13·2 (13·1--13·2)       17·4 (16·8--18·1)       12·6 (11·5--13·5)       14·9 (13·5--16·2)       10·0 (9·2--10·8)        13·2 (12·0--14·4)
         Wales                                           17·8 (17·7--17·9)                 20·7 (20·1--21·2)       13·9 (13·8--14·0)       18·1 (17·6--18·6)       13·4 (12·2--14·5)       15·6 (14·0--16·9)       10·6 (9·7--11·4)        13·7 (12·4--14·9)
                                                                                                                                                                                                                                           
  **Latin America and Caribbean**                        **17·3 (17·2--17·3)**             **19·7 (19·6--19·9)**   **15·3 (15·3--15·4)**   **17·4 (17·2--17·5)**   **13·0 (11·8--14·0)**   **14·9 (13·6--16·1)**   **11·7 (10·7--12·6)**   **13·3 (12·2--14·3)**
                                                                                                                                                                                                                                           
  Andean Latin America                                   17·8 (17·5--18·1)                 20·2 (19·4--20·9)       16·2 (15·9--16·5)       18·8 (18·0--19·5)       13·5 (12·4--14·6)       15·4 (14·0--16·8)       12·4 (11·3--13·4)       14·4 (13·1--15·7)
      Bolivia                                            13·6 (13·0--14·2)                 16·6 (15·4--18·3)       12·9 (12·4--13·5)       14·9 (13·2--16·7)       10·3 (9·3--11·2)        12·6 (11·2--14·2)         9·7 (8·7--10·7)       11·4 (9·8--13·0)
      Ecuador                                            18·1 (18·0--18·1)                 19·5 (18·7--20·3)       16·4 (16·4--16·5)       18·4 (17·7--19·1)       13·8 (12·6--14·9)       14·9 (13·5--16·3)       12·5 (11·4--13·4)       14·0 (12·6--15·2)
      Peru                                               19·2 (18·6--19·7)                 21·7 (20·4--23·0)       17·2 (16·7--17·8)       20·2 (19·0--21·5)       14·6 (13·3--15·8)       16·7 (15·1--18·4)       13·3 (12·1--14·3)       15·6 (14·0--17·2)
  Caribbean                                              17·1 (16·9--17·2)                 18·9 (18·3--19·4)       15·4 (15·2--15·5)       16·4 (15·9--16·9)       13·1 (12·0--14·1)       14·4 (13·2--15·6)       12·0 (11·0--12·8)       12·7 (11·7--13·8)
      Antigua and Barbuda                                19·0 (18·6--19·5)                 18·5 (18·1--19·1)       14·7 (14·4--15·1)       17·3 (16·8--17·8)       14·6 (13·2--15·8)       14·2 (12·8--15·3)       11·5 (10·5--12·4)       13·4 (12·1--14·4)
      The Bahamas                                        17·9 (17·7--18·1)                 18·5 (17·7--19·3)       14·5 (14·4--14·7)       16·3 (15·7--17·0)       13·8 (12·6--14·8)       14·2 (12·9--15·5)       11·4 (10·5--12·2)       12·8 (11·6--13·9)
      Barbados                                           17·5 (17·3--17·7)                 19·2 (18·6--19·9)       15·0 (14·8--15·1)       17·5 (16·9--18·2)       13·6 (12·5--14·6)       14·8 (13·5--16·0)       11·8 (10·9--12·7)       13·7 (12·5--14·8)
      Belize                                             17·0 (16·6--17·5)                 19·2 (18·9--19·5)       16·3 (15·9--16·7)       17·4 (17·2--17·7)       13·0 (11·8--14·1)       14·6 (13·2--15·7)       12·8 (11·7--13·7)       13·5 (12·4--14·5)
      Bermuda                                            18·3 (18·0--18·6)                 23·1 (22·5--23·8)       13·7 (13·4--14·0)       17·3 (16·8--17·6)       14·1 (12·9--15·2)       17·7 (16·2--19·2)       10·8 (9·9--11·6)        13·4 (12·4--14·5)
      Cuba                                               17·8 (17·7--17·9)                 19·7 (18·7--20·7)       15·9 (15·8--15·9)       17·2 (16·2--18·1)       13·7 (12·5--14·7)       15·1 (13·7--16·5)       12·5 (11·5--13·3)       13·5 (12·3--14·7)
      Dominica                                           17·0 (16·7--17·2)                 17·7 (17·1--18·4)       14·8 (14·6--15·0)       15·4 (15·0--15·9)       13·1 (12·0--14·1)       13·7 (12·5--14·9)       11·6 (10·7--12·4)       12·0 (11·1--13·0))
      Dominican Republic                                 19·6 (19·0--20·2)                 19·3 (18·4--20·3)       18·0 (17·4--18·6)       16·2 (15·2--17·4)       15·0 (13·7--16·2)       14·8 (13·4--16·1)       14 (12·8--15·1)         12·6 (11·4--13·9)
      Grenada                                            15·0 (14·7--15·3)                 16·7 (16·2--17·3)       12·6 (12·4--12·8)       16·9 (16·5--17·3)       11·5 (10·5--12·4)       12·8 (11·7--13·9)         9·9 (9·1--10·7)       13·1 (12·0--14·2)
      Guyana                                             15·1 (15·0--15·3)                 16·2 (15·2--17·2)       12·7 (12·6--12·8)       14·1 (13·2--15·0)       11·5 (10·5--12·4)       12·3 (11·0--13·5)         9·8 (8·9--10·5)       10·9 (9·8--11·9)
      Haiti                                              11·4 (10·6--12·0)                 13·7 (12·3--15·4)       11·6 (10·9--12·3)       13·0 (12·2--14·3)         8·6 (7·7--9·5)        10·4 (9·0--11·8)          8·9 (8·0--9·7)        10·0 (8·9--11·3)
      Jamaica                                            18·1 (17·7--18·6)                 18·5 (17·1--19·8)       16·0 (15·7--16·4)       15·6 (14·5--16·8)       14·0 (12·7--15·1)       14·2 (12·7--15·6)       12·6 (11·6--13·5)       12·2 (10·9--13·5)
      Puerto Rico                                        18·7 (18·6--18·9)                 21·6 (21·1--22·1)       15·9 (15·8--16·0)       18·7 (18·2--19·2)       14·5 (13·3--15·5)       16·5 (15·0--17·8)       12·4 (11·4--13·3)       14·4 (13·1--15·5)
      Saint Lucia                                        16·1 (15·9--16·3)                 18·8 (18·2--19·3)       13·4 (13·2--13·5)       17·0 (16·6--17·5)       12·3 (11·3--13·3)       14·4 (13·1--15·6)       10·5 (9·6--11·2)        13·2 (12·1--14·2)
      Saint Vincent and the Grenadines                   16·2 (15·9--16·5)                 17·4 (16·9--17·9)       14·7 (14·5--14·9)       14·6 (14·3--15·0)       12·4 (11·3--13·4)       13·3 (12·1--14·4)       11·5 (10·5--12·3)       11·3 (10·3--12·2)
      Suriname                                           16·4 (15·9--16·8)                 18·2 (17·4--19·0)       14·7 (14·2--15·1)       15·1 (14·2--16·0)       12·6 (11·5--13·6)       13·8 (12·4--15·1)       11·5 (10·5--12·4)       11·7 (10·5--12·8)
      Trinidad and Tobago                                15·8 (15·6--15·9)                 19·0 (17·3--20·9)       13·4 (13·3--13·5)       15·7 (14·3--17·3)       11·9 (10·9--12·9)       14·4 (12·6--16·2)       10·3 (9·5--11·1)        12·1 (10·6--13·6)
      Virgin Islands                                     17·3 (16·5--17·9)                 18·8 (17·7--19·6)       13·7 (13·4--14·0)       13·5 (12·8--15·4)       13·5 (12·3--14·6)       14·5 (13·1--15·8)       10·8 (10·0--11·6)       10·6 (9·5--12·2)
  Central Latin America                                  17·6 (17·5--17·6)                 19·9 (19·6--20·1)       16·0 (16·0--16·1)       17·8 (17·6--18·1)       13·2 (12·0--14·2)       15·0 (13·7--16·2)       12·3 (11·2--13·2)       13·6 (12·5--14·7)
      Colombia                                           17·5 (17·4--17·5)                 22·1 (21·1--23·0)       16·4 (16·4--16·5)       20·1 (19·2--21·0)       13·2 (12·1--14·3)       16·9 (15·3--18·4)       12·6 (11·6--13·6)       15·5 (14·2--17·0)
      Costa Rica                                         18·8 (18·7--19·0)                 21·5 (20·9--22·0)       16·8 (16·7--16·9)       18·1 (17·6--18·5)       14·2 (12·9--15·4)       16·3 (14·8--17·5)       13·0 (12·0--14·0)       14·0 (12·8--15·0)
      El Salvador                                        18·5 (18·4--18·6)                 19·0 (17·5--20·5)       16·4 (16·4--16·5)       16·6 (15·4--17·8)       14·0 (12·7--15·0)       14·5 (12·8--16·0)       12·6 (11·5--13·5)       12·7 (11·3--14·0)
      Guatemala                                          15·0 (14·9--15·0)                 18·4 (17·5--19·3)       13·8 (13·8--13·9)       16·1 (15·3--16·8)       11·2 (10·2--12·1)       13·8 (12·5--15·2)       10·6 (9·7--11·4)        12·3 (11·2--13·4)
      Honduras                                           18·2 (17·3--19·1)                 17·0 (15·7--19·3)       17·4 (16·4--18·4)       17·0 (15·7--18·4)       13·6 (12·2--14·9)       12·9 (11·3--14·8)       13·3 (12·1--14·6)       13·0 (11·6--14·5)
      Mexico                                             17·6 (17·6--17·6)                 19·1 (18·9--19·2)       16·0 (16·0--16·0)       17·3 (17·1--17·4)       13·2 (12·0--14·2)       14·3 (13·0--15·4)       12·3 (11·2--13·2)       13·1 (12·0--14·2)
      Nicaragua                                          19·1 (18·6--19·6)                 20·6 (19·7--21·5)       18·0 (17·4--18·6)       19·9 (18·9--20·7)       14·2 (12·8--15·4)       15·4 (13·8--16·9)       13·7 (12·4--14·8)       15·2 (13·8--16·6)
      Panama                                             19·3 (19·2--19·5)                 21·6 (21·1--22·2)       17·3 (17·2--17·5)       19·7 (19·2--20·2)       14·6 (13·3--15·8)       16·4 (14·9--17·7)       13·4 (12·2--14·4)       15·1 (13·7--16·3)
      Venezuela                                          17·6 (17·6--17·7)                 20·0 (18·7--21·3)       15·4 (15·4--15·5)       16·9 (15·7--18·1)       13·2 (12·1--14·3)       15·1 (13·5--16·6)       11·9 (10·9--12·7)       13·0 (11·6--14·4)
  Tropical Latin America                                 17·0 (16·9--17·0)                 19·7 (19·6--19·8)       14·5 (14·5--14·5)       16·9 (16·8--16·9)       12·6 (11·4--13·6)       14·8 (13·5--16·0)       11·0 (10·0--11·9)       12·8 (11·7--13·8)
      Brazil                                             16·9 (16·9--17·0)                 19·7 (19·7--19·8)       14·4 (14·4--14·5)       16·9 (16·8--16·9)       12·5 (11·4--13·6)       14·8 (13·5--16·0)       11·0 (10·0--11·8)       12·8 (11·7--13·8)
      Paraguay                                           18·5 (18--19·0)                   19·3 (17·8--20·8)       16·3 (15·8--16·7)       16·5 (15·1--18·0)       13·9 (12·6--15·1)       14·5 (12·9--16·1)       12·4 (11·2--13·4)       12·5 (11·0--14·0)
                                                                                                                                                                                                                                           
  **North Africa and Middle East**                       **15·4 (15·3--15·6)**             **18·6 (18·3--18·9)**   **13·8 (13·6--14·0)**   **15·8 (15·5--16·1)**   **11·0 (9·9--12·1)**    **13·4 (12·0--14·7)**   **10·3 (9·3--11·1)**    **11·7 (10·6--12·7)**
                                                                                                                                                                                                                                           
      Afghanistan                                        10·4 (9·5--11·3)                  12·1 (11·3--13·2)       10·7 (10·0--11·7)       12·5 (12·0--13·2)         7·2 (6·2--8·3)          8·4 (7·3--9·6)          7·8 (6·8--8·8)          9·0 (7·9--10·0)
      Algeria                                            16·9 (16·3--17·4)                 18·9 (18·5--19·3)       15·8 (15·3--16·3)       18·5 (18·1--18·9)       12·1 (10·7--13·3)       13·7 (12·2--15·0)       11·7 (10·5--12·8)       13·6 (12·3--14·9)
      Bahrain                                            13·7 (13·4--14·0)                 18·7 (17·9--19·4)       12·2 (12·0--12·6)       17·7 (17·0--18·4)         9·7 (8·6--10·7)       13·3 (11·8--14·7)         9·0 (8·1--9·8)        12·9 (11·5--14·2)
      Egypt                                              14·7 (14·7--14·7)                 16·2 (15·3--17·2)       11·8 (11·8--11·9)       12·0 (11·3--12·7)       10·5 (9·4--11·5)        11·6 (10·2--12·9)         8·8 (8·0--9·6)          8·9 (8·0--9·8)
      Iran                                               16·3 (16·0--16·6)                 18·6 (18·5--18·6)       15·1 (14·8--15·4)       17·4 (17·3--17·4)       11·9 (10·6--13·0)       13·4 (12·0--14·7)       11·5 (10·5--12·4)       13·0 (11·8--14·1)
      Iraq                                               14·1 (13·1--15·1)                 20·3 (19·8--20·9)       13·2 (12·3--14·2)       20·0 (19·4--20·5)         9·9 (8·7--11·1)       14·3 (12·7--15·8)         9·6 (8·4--10·7)       14·3 (12·7--15·8)
      Jordan                                             15·2 (14·3--16·1)                 19·9 (19·0--20·8)       15·6 (14·7--16·5)       18·2 (17·1--19·2)       11·0 (9·8--12·2)        14·4 (12·8--15·9)       11·6 (10·4--12·9)       13·5 (12·0--14·9)
      Kuwait                                             18·7 (18·5--18·8)                 24·7 (24·3--25·1)       17·9 (17·7--18·0)       20·2 (19·8--20·7)       13·5 (12·0--14·8)       17·7 (15·7--19·4)       13·2 (11·9--14·4)       14·8 (13·3--16·2)
      Lebanon                                            16·6 (15·9--17·6)                 19·0 (18·6--19·5)       13·3 (12·8--14·3)       16·7 (16·1--17·2)       12·0 (10·6--13·3)       13·7 (12·2--15·0)         9·9 (8·9--11·0)       12·3 (11·0--13·4)
      Libya                                              16·8 (15·7--17·9)                 16·6 (15·5--17·9)       15·9 (14·8--16·9)       15·4 (14·4--16·6)       12·0 (10·6--13·4)       11·8 (10·4--13·3)       11·6 (10·2--12·9)       11·2 (9·9--12·7)
      Morocco                                            14·1 (13·6--14·6)                 16·4 (15·1--17·7)       15·4 (14·9--16·0)       15·9 (14·5--17·4)       10·2 (9·0--11·2)        11·9 (10·5--13·5)       11·4 (10·3--12·5)       11·8 (10·2--13·3)
      Oman                                               16·1 (14·8--17·4)                 18·8 (18·2--20·0)       13·2 (11·9--14·7)       16·4 (15·0--18·1)       11·0 (9·4--12·5)        13·1 (11·5--14·7)         9·4 (8·1--10·9)       11·8 (10·3--13·6)
      Palestine                                          16·0 (14·7--17·3)                 17·4 (16·9--18·0)       14·0 (12·9--15·4)       16·6 (15·9--17·3)       11·4 (10·0--13·0)       12·4 (11·0--13·7)       10·4 (9·1--11·9)        12·2 (10·9--13·4)
      Qatar                                              14·2 (13·2--15·3)                 19·9 (18·5--21·4)       13·3 (12·3--14·3)       18·8 (17·5--20·2)         9·9 (8·6--11·1)       14·1 (12·2--15·9)         9·4 (8·1--10·7)       13·5 (11·8--15·2)
      Saudi Arabia                                       17·3 (16·0--18·6)                 19·1 (18·3--19·7)       15·4 (14·1--16·8)       16·6 (15·7--17·1)       12·3 (10·9--13·9)       13·9 (12·5--15·2)       11·4 (10--12·9)         12·3 (11·0--13·5)
      Sudan                                              13·5 (12·6--14·5)                 16·4 (14·9--18·0)       13·0 (12·1--13·8)       14·8 (13·3--16·5)         9·7 (8·4--10·9)       11·8 (10·3--13·4)         9·5 (8·5--10·6)       10·9 (9·4--12·5)
      Syria                                              16·0 (15·4--16·4)                 18·5 (18·0--19·2)       14·2 (13·5--15·0)       15·3 (14·0--16·6)       11·5 (10·4--12·7)       13·4 (11·9--14·7)       10·7 (9·6--11·8)        11·4 (10·1--12·8)
      Tunisia                                            17·0 (16·7--17·3)                 19·4 (17·8--21·2)       15·6 (15·3--15·9)       16·7 (15·2--18·4)       12·4 (11·2--13·5)       14·3 (12·5--16·0)       11·5 (10·4--12·5)       12·4 (10·8--14·0)
      Turkey                                             17·2 (16·7--17·6)                 21·9 (21·2--22·7)       13·9 (13·5--14·3)       16·3 (15·6--17·0)       12·3 (11·0--13·6)       16·0 (14·4--17·6)       10·5 (9·5--11·4)        12·2 (11·0--13·4)
      United Arab Emirates                               14·8 (13·6--16·2)                 16·9 (15·4--18·5)       13·6 (12·5--15·0)       13·8 (12·4--15·3)       10·5 (9·1--12·0)        12·1 (10·6--13·8)       10·0 (8·7--11·3)        10·1 (8·7--11·5)
      Yemen                                              13·2 (11·8--14·7)                 15·6 (14·0--17·0)       12·1 (10·8--13·4)       13·6 (12·5--15·0)         8·8 (7·4--10·2)       10·7 (9·2--12·3)          8·5 (7·3--9·9)          9·7 (8·5--11·1)
                                                                                                                                                                                                                                           
  **South Asia**                                         **13·1 (12·9--13·3)**             **15·2 (15·0--15·4)**   **12·1 (11·9--12·3)**   **14·2 (14·0--14·4)**   **  9·2 (8·2--10·1)**   **10·8 (9·7--11·8)**    **  8·9 (8·0--9·6)**    **10·4 (9·4--11·3)**
                                                                                                                                                                                                                                           
      Bangladesh                                         14·3 (13·9--14·9)                 17·5 (16·6--18·5)       12·5 (12·0--12·9)       16·2 (15·3--17·1)       10·3 (9·2--11·4)        12·5 (11·1--13·9)         9·4 (8·5--10·2)       12·1 (10·9--13·2)
      Bhutan                                             13·5 (12·4--14·5)                 17·9 (16·5--19·3)       13·5 (12·5--14·5)       15·5 (13·7--17·0)         9·7 (8·5--10·9)       13·3 (11·8--14·7)       10·1 (8·9--11·3)        11·8 (10·2--13·3)
      India                                              12·9 (12·6--13·1)                 15·0 (14·8--15·2)       11·7 (11·5--12·0)       13·9 (13·7--14·1)         9·0 (8·0--9·9)        10·6 (9·5--11·6)          8·6 (7·7--9·3)        10·2 (9·3--11·1)
      Nepal                                              12·9 (12·0--13·9)                 16·3 (15·3--17·4)       12·4 (11·6--13·4)       13·3 (12·9--14·5)         9·1 (8·0--10·2)       11·6 (10·5--12·9)         9·1 (8·0--10·1)         9·9 (8·9--11·0)
      Pakistan                                           14·1 (13·7--14·5)                 14·9 (13·5--16·4)       14·1 (13·7--14·6)       14·5 (13·1--15·9)       10·1 (9·0--11·0)        10·6 (9·2--12·2)        10·5 (9·5--11·4)        10·8 (9·5--12·2)
                                                                                                                                                                                                                                           
  **Southeast Asia, east Asia, and Oceania**             **15·0 (14·9--15·2)**             **18·4 (18·1--18·6)**   **13·3 (13·1--13·4)**   **15·4 (15·2--15·7)**   **11·3 (10·3--12·1)**   **13·7 (12·5--14·8)**   **10·3 (9·6--11·0)**    **11·9 (11·0--12·8)**
                                                                                                                                                                                                                                           
  East Asia                                              15·0 (14·8--15·2)                 18·6 (18·3--18·9)       13·3 (13·2--13·5)       15·7 (15·4--16·0)       11·3 (10·4--12·2)       14·0 (12·7--15·1)       10·5 (9·8--11·2)        12·2 (11·3--13·1)
      China                                              15·0 (14·8--15·1)                 18·6 (18·3--18·9)       13·3 (13·2--13·5)       15·7 (15·4--16·0)       11·3 (10·4--12·1)       14·0 (12·7--15·0)       10·5 (9·7--11·2)        12·2 (11·3--13·1)
      North Korea                                        16·5 (15·4--18·0)                 16·7 (15·4--18·1)       13·2 (12·8--14·4)       13·3 (12·9--13·8)       12·3 (11·1--13·7)       12·3 (11·1--13·7)       10·3 (9·5--11·4)        10·3 (9·4--11·1)
      Taiwan (province of China)                         17·0 (16·9--17·1)                 21·3 (20·8--21·8)       15·3 (15·2--15·3)       18·0 (17·6--18·4)       12·7 (11·6--13·7)       15·7 (14·3--17·0)       11·9 (11·0--12·7)       13·6 (12·6--14·7)
  Oceania                                                11·8 (11·4--12·3)                 12·7 (12·1--13·3)       10·4 (10·1--10·8)       11·0 (10·5--11·6)         8·5 (7·6--9·4)          9·0 (8·0--10·0)         7·7 (6·9--8·4)          8·0 (7·2--8·8)
      American Samoa                                     16·4 (15·9--17·1)                 15·9 (15·6--16·4)       13·0 (12·7--13·5)       13·9 (12·9--15·3)       11·8 (10·6--13·0)       11·4 (10·1--12·5)         9·6 (8·7--10·6)       10·2 (9·0--11·6)
      Federated States of Micronesia                     12·7 (12·1--13·6)                 14·3 (13·2--15·0)       11·7 (10·8--12·7)       12·3 (11·8--12·8)         9·3 (8·2--10·3)       10·2 (8·9--11·3)          8·8 (7·7--9·9)          9·1 (8·1--10·0)
      Fiji                                               14·5 (13·6--15·4)                 14·4 (13·3--15·7)       12·6 (11·9--13·3)       12·1 (11·3--13·1)       10·6 (9·4--11·7)        10·4 (9·0--11·8)          9·4 (8·4--10·4)         8·9 (7·9--10·0)
      Guam                                               18·0 (17·6--18·3)                 17·8 (17·1--18·5)       14·3 (14·1--14·6)       15·6 (15·1--16·2)       13·3 (12·0--14·4)       12·9 (11·5--14·2)       11·0 (10·0--11·8)       11·7 (10·5--12·7)
      Kiribati                                           12·0 (11·5--12·5)                 13·0 (12·2--14·3)       10·4 (10·0--10·7)       10·7 (10·1--11·4)         8·7 (7·8--9·6)          9·2 (8·1--10·5)         7·7 (7·0--8·4)          7·8 (6·9--8·7)
      Marshall Islands                                   13·0 (12·8--13·2)                 13·2 (12·3--14·0)       10·3 (10·0--10·6)       11·1 (10·4--12·0)         9·6 (8·7--10·4)         9·6 (8·4--10·7)         7·8 (7·1--8·5)          8·3 (7·4--9·3)
      Northern Mariana Islands                           17·0 (16·2--18·2)                 19·0 (18·2--19·7)       15·6 (14·0--16·4)       15·9 (14·8--16·8)       12·5 (11·2--13·8)       13·8 (12·3--15·2)       11·8 (10·4--13·0)       11·9 (10·5--12·9)
      Papua New Guinea                                   10·5 (10·0--11·2)                 11·6 (10·8--12·3)         9·4 (9·0--10·0)       10·2 (9·6--11·1)          7·5 (6·6--8·3)          8·1 (7·1--9·1)          6·9 (6·2--7·7)          7·5 (6·6--8·3)
      Samoa                                              17·0 (15·9--18·4)                 16·2 (15·3--17·7)       14·3 (13·3--15·2)       14·1 (13·8--14·7)       12·5 (11·0--14·0)       11·7 (10·4--13·2)       10·8 (9·7--11·9)        10·5 (9·5--11·5)
      Solomon Islands                                    12·1 (11·4--12·8)                 13·4 (12·7--14·0)       11·2 (10·4--12·2)       12·1 (11·4--12·8)         8·9 (8·0--9·9)          9·7 (8·6--10·7)         8·5 (7·6--9·5)          9·1 (8·1--10·0)
      Tonga                                              15·0 (14·6--15·5)                 16·6 (15·5--18·0)       13·1 (12·9--13·4)       13·5 (12·7--14·0)       10·9 (9·7--11·9)        11·9 (10·4--13·4)         9·9 (9·0--10·7)       10·1 (9·0--11·0)
      Vanuatu                                            12·8 (12·0--13·6)                 13·4 (12·6--14·4)       10·9 (10·2--11·8)       11·5 (10·6--12·4)         9·3 (8·2--10·3)         9·5 (8·4--10·6)         8·3 (7·4--9·2)          8·6 (7·6--9·5)
  Southeast Asia                                         15·1 (14·8--15·3)                 17·5 (17·2--17·9)       13·0 (12·8--13·2)       14·3 (14·0--14·6)       11·0 (9·9--12·0)        12·9 (11·6--14·0)         9·8 (8·9--10·6)       10·7 (9·8--11·6)
      Cambodia                                           12·4 (11·8--13·1)                 15·9 (14·7--16·8)       11·0 (10·5--11·6)       13·0 (12·7--13·2)         8·8 (7·7--9·8)        11·4 (10·1--12·7)         8·1 (7·2--8·9)          9·6 (8·6--10·4)
      Indonesia                                          14·2 (13·8--14·5)                 16·1 (15·6--16·6)       13·2 (12·9--13·5)       13·4 (13·0--14·0)       10·2 (9·2--11·2)        11·6 (10·5--12·7)         9·8 (8·9--10·7)       10·0 (9·1--11·0)
      Laos                                               11·8 (10·9--13·0)                 15·7 (14·5--16·8)       10·5 (9·7--11·5)        13·2 (12·4--14·3)         8·8 (7·8--10·0)       11·7 (10·4--13·0)         8·1 (7·2--9·0)        10·0 (9·0--11·2)
      Malaysia                                           15·1 (15·0--15·1)                 16·9 (16·2--17·6)       13·3 (13·3--13·3)       14·8 (14·1--15·5)       11·3 (10·3--12·2)       12·6 (11·4--13·8)       10·2 (9·3--11·0)        11·3 (10·3--12·4)
      Maldives                                           12·4 (12·2--12·5)                 21·6 (21·0--22·2)       13·3 (13·2--13·5)       19·2 (18·7--19·7)         8·9 (8·0--9·7)        15·9 (14·3--17·4)       10·0 (9·1--10·8)        14·6 (13·3--15·8)
      Mauritius                                          15·8 (15·6--16·0)                 18·4 (17·8--19·0)       12·3 (12·2--12·4)       15·3 (14·8--15·8)       11·7 (10·6--12·8)       13·4 (12·0--14·7)         9·2 (8·4--10·0)       11·3 (10·2--12·3)
      Myanmar                                            12·5 (11·4--13·7)                 16·3 (15·2--17·6)       10·5 (9·8--11·6)        12·8 (12·5--13·5)         8·8 (7·7--10·1)       11·7 (10·4--13·1)         7·7 (6·7--8·7)          9·5 (8·6--10·3)
      Philippines                                        16·3 (15·9--16·8)                 15·8 (14·6--16·9)       14·3 (13·8--14·7)       12·8 (11·8--13·9)       11·9 (10·7--12·9)       11·5 (10·2--12·8)       10·5 (9·5--11·5)          9·4 (8·3--10·6)
      Sri Lanka                                          17·0 (16·8--17·3)                 19·7 (18·8--21·5)       13·2 (13·0--13·3)       15·8 (14·7--17·0)       12·8 (11·6--13·8)       14·8 (13·2--16·7)       10·0 (9·2--10·8)        12·0 (10·7--13·3)
      Seychelles                                         17·4 (17·0--17·7)                 18·1 (17·7--18·6)       12·6 (12·4--12·8)       14·2 (13·9--14·5)       13·0 (11·8--14·2)       13·5 (12·2--14·7)         9·7 (8·8--10·4)       10·8 (9·8--11·7)
      Thailand                                           17·1 (16·8--17·4)                 21·7 (20·9--22·5)       14·6 (14·3--14·9)       18·5 (17·7--19·4)       12·8 (11·6--13·8)       16·3 (14·8--17·7)       11·0 (10·1--11·9)       14·1 (12·8--15·4)
      Timor-Leste                                        13·4 (12·3--14·5)                 16·3 (15·3--17·3)       13·7 (12·9--14·6)       13·8 (13·0--15·0)         9·5 (8·3--10·8)       11·7 (10·3--13·0)         9·9 (8·8--11·1)       10 ·0 (9·0--11·3)
      Vietnam                                            16·4 (15·7--17·4)                 18·8 (18·0--19·9)       12·7 (12·3--13·3)       13·9 (13·0--14·6)       12·2 (11·0--13·4)       14·0 (12·6--15·5)         9·7 (8·8--10·6)       10·6 (9·6--11·5)
                                                                                                                                                                                                                                           
  **Sub-Saharan Africa**                                 **13·2 (12·9--13·6)**             **15·4 (15·1--15·8)**   **12·1 (11·8--12·4)**   **13·4 (13·1--13·7)**   **9·6 (8·6--10·4)**     **11·3 (10·2--12·4)**   **8·8 (7·9--9·6)**      **9·9 (8·9--10·8)**
                                                                                                                                                                                                                                           
  Central sub-Saharan Africa                             12·2 (11·5--12·8)                 13·9 (12·9--14·8)       10·7 (10·1--11·2)       12·1 (11·6--12·9)         8·5 (7·5--9·5)          9·9 (8·7--11·0)         7·6 (6·7--8·5)          8·7 (7·7--9·8)
      Angola                                             11·6 (10·6--12·8)                 15·0 (13·7--16·3)       10·0 (9·3--11·0)        12·3 (11·7--13·4)         8·4 (7·3--9·5)        10·8 (9·4--12·2)          7·3 (6·4--8·2)          8·9 (7·9--10·1)
      Central African Republic                           10·4 (9·8--11·1)                  11·4 (10·2--13·2)         8·9 (8·6--9·3)          9·7 (9·0--10·6)         7·4 (6·5--8·2)          8·2 (7·0--9·7)          6·3 (5·6--7·0)          7·0 (6·2--7·9)
      Congo (Brazzaville)                                11·0 (10·4--11·7)                 12·8 (11·9--14·4)         9·9 (9·4--10·4)       12·7 (12·1--13·7)         7·8 (6·9--8·7)          9·3 (8·1--10·6)         7·1 (6·3--7·8)          9·2 (8·2--10·3)
      Democratic Republic of the Congo                   12·5 (11·6--13·5)                 13·7 (12·4--15·0)       11·0 (10·2--12·0)       12·1 (11·4--13·3)         8·7 (7·6--9·8)          9·7 (8·5--11·0)         7·8 (6·8--8·9)          8·7 (7·5--10·0)
      Equatorial Guinea                                  10·6 (9·5--11·8)                  15·9 (13·3--18·8)         9·1 (8·5--10·0)       13·7 (12·3--15·3)         7·6 (6·6--8·7)        11·5 (9·5--13·7)          6·6 (5·9--7·5)          9·9 (8·6--11·3)
      Gabon                                              13·5 (12·5--14·4)                 16·3 (14·9--17·8)       10·8 (10·3--11·2)       12·9 (12·5--13·1)         9·6 (8·5--10·8)       11·7 (10·2--13·3)         7·8 (7·0--8·7)          9·4 (8·4--10·2)
  Eastern sub-Saharan Africa                             11·6 (11·4--11·8)                 15·3 (15·0--15·6)       11·1 (10·9--11·3)       13·0 (12·8--13·3)         8·6 (7·7--9·3)        11·4 (10·3--12·3)         8·2 (7·4--8·9)          9·7 (8·8--10·6)
      Burundi                                            10·2 (9·5--11·1)                  13·2 (12·0--14·6)         9·3 (8·8--9·9)        12·0 (11·2--13·2)         7·8 (6·9--8·6)        10·0 (8·8--11·3)          7·0 (6·2--7·7)          9·0 (8·0--10·2)
      Comoros                                            12·4 (11·4--13·5)                 15·2 (13·9--16·5)       11·7 (10·8--12·7)       13·5 (12·6--14·6)         9·2 (8·1--10·3)       11·5 (10·1--12·8)         8·6 (7·5--9·6)        10·1 (8·9--11·3)
      Djibouti                                           13·1 (11·7--14·6)                 15·3 (13·3--17·3)       12·7 (11·4--14·0)       13·4 (12·2--15·0)         9·8 (8·5--11·2)       11·6 (9·9--13·4)          9·6 (8·3--10·9)       10·1 (8·9--11·6)
      Eritrea                                            10·0 (9·4--10·6)                  13·2 (12·2--14·7)         8·0 (7·8--8·3)        11·0 (10·3--12·1)       7·2 (6·4--8·0)            9·8 (8·6--11·2)         5·7 (5·0--6·3)          8·0 (7·1--9·1)
      Ethiopia                                           10·0 (9·6--10·4)                  16·0 (15·4--16·6)         9·5 (9·2--9·8)        14·1 (13·6--14·6)         7·3 (6·5--8·0)        11·9 (10·7--13)           6·9 (6·2--7·6)        10·5 (9·5--11·5)
      Kenya                                              13·9 (13·5--14·2)                 15·9 (15·5--16·3)       13·2 (13·0--13·5)       12·8 (12·5--13·0)       10·4 (9·4--11·2)        11·9 (10·8--12·9)         9·9 (8·9--10·8)         9·5 (8·6--10·3)
      Madagascar                                         12·1 (11·6--12·6)                 13·5 (12·1--15·0)       12·9 (12·3--13·4)       12·6 (11·6--14·0)         9·0 (8·1--9·8)        10·1 (8·8--11·5)          9·6 (8·6--10·5)         9·5 (8·4--10·8)
      Malawi                                             12·1 (11·5--12·7)                 15·8 (14·5--17·0)       11·2 (10·7--11·8)       12·3 (11·8--13·0)         9·0 (8·1--9·9)        11·8 (10·4--13·2)         8·3 (7·4--9·1)          9·1 (8·2--10·0)
      Mozambique                                         12·4 (11·7--13·0)                 14·0 (12·6--15·5)       11·0 (10·5--11·5)       11·2 (10·5--12·0)         9·1 (8·2--10·0)       10·4 (9·0--11·8)          8·0 (7·2--8·9)          8·2 (7·3--9·2)
      Rwanda                                             10·4 (9·8--11·0)                  16·0 (14·9--17·1)         9·5 (9·1--9·9)        13·1 (12·5--14·1)         7·8 (7·0--8·6)        12·1 (10·7--13·4)         7·2 (6·5--7·9)          9·9 (8·9--11·0)
      Somalia                                            10·8 (9·7--12·0)                  12·3 (10·9--13·8)       10·2 (9·2--11·3)        11·4 (10·4--12·7)         8·0 (7·0--9·2)          9·2 (8·0--10·6)         7·6 (6·6--8·7)          8·5 (7·5--9·7)
      South Sudan                                        12·0 (10·8--13·4)                 13·7 (11·9--15·3)       11·0 (9·9--12·2)        12·1 (10·8--13·4)         8·4 (7·2--9·6)          9·5 (8·0--11·0)         7·9 (6·8--9·0)          8·6 (7·3--9·9)
      Tanzania                                           13·1 (12·5--13·9)                 16·0 (15·0--16·8)       12·5 (11·8--13·1)       13·9 (13·0--14·6)         9·8 (8·8--10·7)       12·0 (10·8--13·2)         9·3 (8·3--10·2)       10·4 (9·3--11·5)
      Uganda                                             12·0 (11·3--12·8)                 16·1 (14·9--17·1)       12·1 (11·1--13·4)       12·7 (12·1--13·9)         8·7 (7·7--9·7)        12·0 (10·6--13·3)         8·7 (7·6--10·0)         9·4 (8·5--10·5)
      Zambia                                             11·5 (11·0--12·0)                 14·9 (13·8--16·2)       11·3 (10·8--12·0)       12·4 (12·0--13·2)         8·6 (7·8--9·4)        11·2 (9·8--12·5)          8·5 (7·6--9·4)          9·3 (8·4--10·2)
  Southern sub-Saharan Africa                            17·8 (17·6--18·1)                 17·5 (17·2--17·7)       14·5 (14·3--14·8)       14·0 (13·8--14·2)       12·6 (11·4--13·8)       12·4 (11·2--13·5)       10·5 (9·5--11·5)        10·1 (9·0--11·0)
      Botswana                                           15·8 (14·8--17·0)                 16·3 (15·3--17·1)       11·9 (11·2--12·4)       14·8 (13·5--15·4)       11·2 (10·0--12·5)       11·5 (10·3--12·8)         8·5 (7·6--9·4)        10·5 (9·1--11·8)
      Lesotho                                            14·4 (13·5--15·3)                 13·5 (11·9--15·7)       10·8 (10·3--11·3)       10·0 (9·4--10·7)        10·1 (8·9--11·3)          9·4 (7·9--11·1)         7·8 (6·9--8·5)          7·0 (6·2--7·9)
      Namibia                                            13·9 (13·2--14·7)                 17·7 (16·1--19·2)       11·4 (11·0--11·7)       12·8 (12·4--13·1)         9·8 (8·8--10·9)       12·6 (11·0--14·3)         8·1 (7·2--8·9)          9·1 (8·1--10·0)
      South Africa                                       18·9 (18·6--19·1)                 18·3 (18·1--18·4)       15·7 (15·4--15·9)       14·6 (14·5--14·8)       13·3 (12--14·6)         13·0 (11·7--14·2)       11·3 (10·2--12·4)       10·5 (9·4--11·5)
      Swaziland (eSwatini                                14·0 (13·1--15·0)                 15·1 (13·2--17·2)       10·9 (10·3--11·5)       10·8 (10·1--11·8)         9·9 (8·7--11·1)       10·6 (8·9--12·3)          7·8 (6·9--8·6)          7·6 (6·6--8·5)
      Zimbabwe                                           15·3 (14·5--16·0)                 13·7 (12·5--15·1)       12·3 (11·6--13·3)       11·6 (10·7--12·3)       10·9 (9·8--12·1)          9·8 (8·5--11·1)         9·0 (8·0--10·1)         8·4 (7·4--9·3)
  Western sub-Saharan Africa                             13·6 (12·9--14·4)                 15·3 (14·4--16·2)       12·8 (12·1--13·5)       13·9 (13·2--14·5)         9·8 (8·7--10·8)       11·2 (9·9--12·4)          9·3 (8·2--10·2)       10·2 (9·1--11·2)
      Benin                                              13·5 (12·8--14·3)                 14·9 (13·5--16·3)       12·0 (11·4--12·6)       13·3 (12·1--14·4)         9·6 (8·5--10·7)       10·9 (9·5--12·4)          8·7 (7·6--9·7)          9·8 (8·5--11·1)
      Burkina Faso                                       12·5 (11·9--13·1)                 14·3 (13·4--15·3)       11·7 (11·1--12·3)       12·5 (11·7--13·3)         8·9 (7·9--9·9)        10·6 (9·4--11·7)          8·3 (7·2--9·2)          9·2 (8·2--10·3)
      Cameroon                                           12·9 (12·3--13·6)                 14·8 (13·2--16·3)       12·1 (11·6--12·7)       12·8 (11·7--14·1)         9·2 (8·2--10·2)       10·9 (9·4--12·3)          8·8 (7·8--9·6)          9·5 (8·2--10·7)
      Cape Verde                                         18·8 (18·5--19·1)                 19·7 (19·4--20·4)       16·1 (15·9--16·3)       17·4 (16·8--18·1)       14·0 (12·6--15·1)       14·8 (13·4--16·1)       12·2 (11·1--13·1)       13·2 (11·9--14·4)
      Chad                                               13·0 (12·4--13·7)                 13·8 (12·6--15·0)       12·2 (11·6--12·9)       12·8 (11·8--13·7)         9·3 (8·3--10·4)         9·9 (8·6--11·2)         8·8 (7·8--9·8)          9·3 (8·2--10·4)
      Côte d'Ivoire                                      13·4 (12·6--14·2)                 14·7 (13·4--16·0)       11·7 (11·0--12·5)       12·9 (11·8--13·9)         9·3 (8·1--10·4)       10·7 (9·4--12·2)          8·3 (7·3--9·3)          9·5 (8·3--10·6)
      The Gambia                                         13·6 (12·5--14·9)                 14·5 (13·2--15·8)       12·0 (10·9--13·2)       12·7 (12·3--13·3)         9·9 (8·7--11·2)       10·6 (9·2--12·0)          8·9 (7·8--10·1)         9·5 (8·5--10·4)
      Ghana                                              13·3 (12·3--14·4)                 15·2 (14·1--16·3)       12·6 (11·7--13·6)       12·4 (12·0--13·1)         9·8 (8·7--11·0)       11·3 (10·1--12·6)         9·3 (8·2--10·4)         9·3 (8·3--10·2)
      Guinea                                             12·4 (11·8--13·0)                 13·1 (12·1--14·2)       12·8 (12·2--13·4)       12·2 (11·4--13·2)         9·0 (8·1--10·0)         9·7 (8·6--10·8)         9·4 (8·6--10·3)         9·1 (8·0--10·2)
      Guinea-Bissau                                      11·3 (10·4--12·5)                 13·0 (11·8--14·5)         9·6 (8·9--10·5)       11·4 (10·6--12·1)         8·2 (7·1--9·3)          9·5 (8·2--10·7)         7·0 (6·1--7·9)          8·4 (7·4--9·3)
      Liberia                                            12·6 (11·7--13·5)                 14·1 (12·8--15·5)       12·5 (11·7--13·3)       13·7 (12·6--14·6)         8·7 (7·6--9·8)        10·0 (8·6--11·3)          8·9 (7·7--10)           9·8 (8·6--11·1)
      Mali                                               11·5 (11·0--12·0)                 14·5 (13·4--15·6)       11·8 (11·3--12·3)       14·1 (13·3--15·2)         8·2 (7·2--9·0)        10·5 (9·2--11·8)          8·4 (7·5--9·3)        10·3 (9·0--11·4)
      Mauritania                                         12·2 (11·5--13·0)                 15·5 (14·3--16·7)       12·4 (11·8--13·2)       15·1 (14·1--16·6)         8·8 (7·8--9·7)        11·3 (9·9--12·7)          9·0 (8·1--10·0)       11·0 (9·6--12·5)
      Niger                                              12·6 (11·9--13·3)                 14·2 (13·1--15·5)       12·0 (11·4--12·6)       13·4 (12·5--14·4)         9·3 (8·2--10·2)       10·5 (9·4--11·8)          8·8 (7·9--9·8)        10·0 (8·8--11·1)
      Nigeria                                            14·3 (12·8--15·9)                 16·4 (14·3--18·8)       13·5 (12·1--15·0)       15·2 (13·5--16·4)       10·3 (8·9--11·8)        12·0 (10·0--13·8)         9·8 (8·5--11·3)       11·1 (9·5--12·5)
      São Tomé and Príncipe                              15·9 (15·2--16·6)                 15·3 (14·3--16·6)       14·3 (13·7--14·9)       13·6 (13·0--14·4)       11·7 (10·5--12·8)       11·4 (10·2--12·8)       10·6 (9·6--11·6)        10·1 (9·1--11·2)
      Senegal                                            13·5 (12·9--14·2)                 15·3 (14·2--16·3)       12·3 (11·7--12·9)       13·3 (12·5--14·2)         9·8 (8·7--10·9)       11·2 (9·9--12·4)          9·0 (8·0--9·9)          9·8 (8·6--10·9)
      Sierra Leone                                       13·2 (12·2--14·2)                 13·3 (12·2--14·5)       11·6 (10·8--12·4)       13·0 (12·1--13·9)         9·6 (8·5--10·7)         9·7 (8·5--10·9)         8·4 (7·5--9·3)          9·5 (8·2--10·6)
      Togo                                               13·2 (12·4--14·1)                 15·1 (13·7--16·5)       12·2 (11·5--13·0)       12·5 (11·7--13·6)         9·6 (8·5--10·7)       11·1 (9·7--12·6)          9·0 (8·0--10·0)         9·3 (8·2--10·4)

Data in parentheses are 95% uncertainty intervals. Super-regions, regions, and countries are listed alphabetically. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. HALE=healthy life expectancy. SDI=Socio-demographic Index.

###### Global all-age DALYs and age-standardised DALY rates in 2017 with percentage changes between 2007 and 2017 for all causes, by sex

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                        All-age DALYs (thousands)      Age-standardised DALY rate (per 100 000)                                                                                                                                                                                                                                                                                                                                                                                                            
  ----------------------------------------------------------------------------------------------------- ------------------------------ ------------------------------------------ ------------------------------ ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------ ---------------------------- ---------------------------- ---------------------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------
  **All causes**                                                                                        **1 340 000**\                 **1 160 000**\                             **2 500 000**\                 **  −1·4%**\                                           **  −1·6%**\                                           **  −1·5%**\                                           **  35 834·3**\              **  29 934·6**\              **  32 796·9**\              ** −15·9%**\                                           ** −16·7%**\                                           ** −16·2%**\
                                                                                                        **(1 240 000 to 1 460 000)**   **(1 040 000 to 1 290 000)**               **(2 290 000 to 2 740 000)**   **(−3·0 to 0·1)**                                      **(−3·5 to 0·2)**                                      **(−3·1 to 0·1)**                                      **(33 218·6 to 38 740·3)**   **(26 981·7 to 33 211·3)**   **(30 041·9 to 35 849·3)**   **(−17·2 to −14·6)**[\*](#TFN4){ref-type="table-fn"}   **(−18·3 to −15·1)**[\*](#TFN4){ref-type="table-fn"}   **(−17·6 to −14·8)**[\*](#TFN4){ref-type="table-fn"}

  **Communicable, maternal, neonatal, and nutritional diseases**                                        **   362 000**\                **   334 000**\                            **   696 000**\                **−25·8%**\                                            **−27·0%**\                                            **−26·4%**\                                            **  10 106·6**\              **     9601·9**\             **     9853·3**\             ** −31·5%**\                                           ** −32·9%**\                                           ** −32·2%**\
                                                                                                        **(345 000 to 384 000)**       **(314 000 to 357 000)**                   **(660 000 to 740 000)**       **(−27·9 to −23·6)**[\*](#TFN4){ref-type="table-fn"}   **(−29·1 to −24·8)**[\*](#TFN4){ref-type="table-fn"}   **(−28·4 to −24·3)**[\*](#TFN4){ref-type="table-fn"}   **(9630·6 to 10 695·2)**     **(9073·8 to 10 240·7)**     **(9349·7 to 10 459·3)**     **(−33·4 to −29·4)**[\*](#TFN4){ref-type="table-fn"}   **(−34·8 to −30·9)**[\*](#TFN4){ref-type="table-fn"}   **(−34·0 to −30·3)**[\*](#TFN4){ref-type="table-fn"}

  **    HIV/AIDS and sexually transmitted infections**                                                  **     35 100**\               **     30 800**\                           **     65 900**\               **−40·4%**\                                            **−50·0%**\                                            **−45·3%**\                                            **       918·3**\            **       828·2**\            **       874·1**\            ** −46·1%**\                                           ** −54·7%**\                                           ** −50·5%**\
                                                                                                        **(30 900 to 40 400)**         **(27 700 to 34 400)**                     **(58 700 to 74 700)**         **(−43·4 to −37·0)**[\*](#TFN4){ref-type="table-fn"}   **(−52·7 to −46·9)**[\*](#TFN4){ref-type="table-fn"}   **(−48·0 to −42·0)**[\*](#TFN4){ref-type="table-fn"}   **(799·5 to 1074·4)**        **(735·9 to 937·9)**         **(767·5 to 1006·2)**        **(−49·3 to −42·5)**[\*](#TFN4){ref-type="table-fn"}   **(−57·4 to −51·6)**[\*](#TFN4){ref-type="table-fn"}   **(−53·4 to −47·1)**[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      HIV/AIDS                                                                                               28 300\                        26 100\                                    54 400\                   −44·8%\                                                −53·9%\                                                −49·6%\                                                       724·0\                       686·1\                       704·8\                 −51·1%\                                                −58·8%\                                                −55·2%\
                                                                                                        (26 700 to 30 200)             (24 300 to 28 000)                         (51 200 to 57 700)             (−46·6 to −42·5)[\*](#TFN4){ref-type="table-fn"}       (−55·8 to −51·6)[\*](#TFN4){ref-type="table-fn"}       (−51·3 to −47·4)[\*](#TFN4){ref-type="table-fn"}       (683·0 to 771·1)             (638·2 to 735·8)             (662·6 to 747·9)             (−52·6 to −49·0)[\*](#TFN4){ref-type="table-fn"}       (−60·6 to −56·8)[\*](#TFN4){ref-type="table-fn"}       (−56·8 to −53·3)[\*](#TFN4){ref-type="table-fn"}

         HIV/AIDS and drug-susceptible tuberculosis co-infection                                                5810\                          5260\                                   11 100\                   −51·9%\                                                −57·8%\                                                −54·9%\                                                       150·0\                       140·2\                       145·1\                 −57·2%\                                                −62·3%\                                                −59·8%\
                                                                                                        (4180 to 7430)                 (3760 to 6760)                             (7940 to 14 200)               (−55·0 to −48·0)[\*](#TFN4){ref-type="table-fn"}       (−60·8 to −53·9)[\*](#TFN4){ref-type="table-fn"}       (−57·9 to −51·0)[\*](#TFN4){ref-type="table-fn"}       (108·3 to 191·6)             (100·6 to 179·4)             (104·4 to 185·3)             (−59·9 to −53·7)[\*](#TFN4){ref-type="table-fn"}       (−65·0 to −58·9)[\*](#TFN4){ref-type="table-fn"}       (−62·5 to −56·3)[\*](#TFN4){ref-type="table-fn"}

         HIV/AIDS and multidrug-resistant tuberculosis without extensive drug resistance co-infection             674\                           589\                                     1260\                  −48·9%\                                                −54·2%\                                                −51·5%\                                                         17·4\                        15·8\                        16·6\                −54·4%\                                                −58·9%\                                                −56·6%\
                                                                                                        (405 to 1020)                  (347 to 905)                               (755 to 1920)                  (−62·9 to −29·4)[\*](#TFN4){ref-type="table-fn"}       (−68·1 to −36·0)[\*](#TFN4){ref-type="table-fn"}       (−65·6 to −32·9)[\*](#TFN4){ref-type="table-fn"}       (10·5 to 26·5)               (9·3 to 24·2)                (9·9 to 25·3)                (−67·0 to −37·1)[\*](#TFN4){ref-type="table-fn"}       (−71·4 to −42·4)[\*](#TFN4){ref-type="table-fn"}       (−69·1 to −40·1)[\*](#TFN4){ref-type="table-fn"}

         HIV/AIDS and extensively drug-resistant tuberculosis co-infection                                       39·3\                          23·9\                                      63·3\                   −8·1%\                                               −13·5%\                                                −10·2%\                                                           1·0\                         0·6\                         0·8\               −19·0%\                                                −23·3%\                                                −20·7%\
                                                                                                        (23·8 to 58·0)                 (14·9 to 35·3)                             (38·8 to 93·3)                 (−25·0 to 13·5)                                        (−32·8 to 10·9)                                        (−28·3 to 11·9)                                        (0·6 to 1·5)                 (0·4 to 0·9)                 (0·5 to 1·2)                 (−33·9 to −0·1)[\*](#TFN4){ref-type="table-fn"}        (−40·4 to −1·7)[\*](#TFN4){ref-type="table-fn"}        (−36·7 to −1·1)[\*](#TFN4){ref-type="table-fn"}

         HIV/AIDS resulting in other diseases                                                                21 800\                        20 200\                                    42 100\                   −42·4%\                                                −52·8%\                                                −47·9%\                                                       555·5\                       529·5\                       542·3\                 −49·0%\                                                −57·8%\                                                −53·7%\
                                                                                                        (19 500 to 24 300)             (18 000 to 22 600)                         (37 800 to 46 700)             (−45·1 to −39·2)[\*](#TFN4){ref-type="table-fn"}       (−55·5 to −49·8)[\*](#TFN4){ref-type="table-fn"}       (−50·5 to −44·9)[\*](#TFN4){ref-type="table-fn"}       (497·5 to 618·1)             (469·3 to 591·4)             (487·0 to 603·1)             (−51·3 to −46·1)[\*](#TFN4){ref-type="table-fn"}       (−60·2 to −55·2)[\*](#TFN4){ref-type="table-fn"}       (−56·1 to −51·1)[\*](#TFN4){ref-type="table-fn"}

      Sexually transmitted infections excluding HIV                                                             6740\                          4730\                                   11 500\                   −10·4%\                                                  −6·8%\                                                 −8·9%\                                                      194·3\                       142·1\                       169·3\                 −13·8%\                                                −11·7%\                                                −13·0%\
                                                                                                        (2970 to 12 200)               (2350 to 8070)                             (5320 to 20 200)               (−18·2 to −1·8)[\*](#TFN4){ref-type="table-fn"}        (−14·2 to 1·2)                                         (−16·1 to −1·0)[\*](#TFN4){ref-type="table-fn"}        (84·5 to 355)                (67·7 to 246·7)              (76·7 to 300·4)              (−21·2 to −5·7)[\*](#TFN4){ref-type="table-fn"}        (−18·4 to −4·7)[\*](#TFN4){ref-type="table-fn"}        (−20·1 to −5·5)[\*](#TFN4){ref-type="table-fn"}

         Syphilis                                                                                               6160\                          3750\                                      9910\                  −11·9%\                                                −10·4%\                                                −11·3%\                                                       179·6\                       117·3\                       149·5\                 −14·8%\                                                −13·4%\                                                −14·3%\
                                                                                                        (2430 to 11 600)               (1460 to 7060)                             (3930 to 18 700)               (−19·7 to −2·9)[\*](#TFN4){ref-type="table-fn"}        (−18·5 to −1·7)[\*](#TFN4){ref-type="table-fn"}        (−19·1 to −2·9)[\*](#TFN4){ref-type="table-fn"}        (70·8 to 339)                (45·6 to 221·1)              (59·1 to 283·2)              (−22·3 to −6·1)[\*](#TFN4){ref-type="table-fn"}        (−21·2 to −5·0)[\*](#TFN4){ref-type="table-fn"}        (−21·8 to −6·2)[\*](#TFN4){ref-type="table-fn"}

         Chlamydial infection                                                                                     192\                           163\                                       355\                     7·9%\                                                  8·3%\                                                  8·1%\                                                         4·8\                         4·1\                         4·5\                 −2·6%\                                                 −3·5%\                                                 −3·0%\
                                                                                                        (112 to 336)                   (107 to 266)                               (219 to 606)                   (4·0 to 11·6)[\*](#TFN4){ref-type="table-fn"}          (4·8 to 11·3)[\*](#TFN4){ref-type="table-fn"}          (5·1 to 10·5)[\*](#TFN4){ref-type="table-fn"}          (2·8 to 8·5)                 (2·7 to 6·8)                 (2·8 to 7·7)                 (−5·9 to 0·7)                                          (−7·0 to −0·9)[\*](#TFN4){ref-type="table-fn"}         (−5·9 to −0·8)[\*](#TFN4){ref-type="table-fn"}

         Gonococcal infection                                                                                     135\                           168\                                       303\                    11·2%\                                                −0·3%\                                                   4·5%\                                                         3·5\                         4·2\                        3·9\                    2·2%\                                              −12·0%\                                                  −6·1%\
                                                                                                        (77·5 to 244)                  (132 to 229)                               (216 to 468)                   (7·2 to 16·0)[\*](#TFN4){ref-type="table-fn"}          (−5·7 to 5·5)                                          (0·1 to 8·6)[\*](#TFN4){ref-type="table-fn"}           (2·0 to 6·2)                 (3·3 to 5·8)                 (2·7 to 6·0)                 (−1·5 to 6·5)                                          (−17·4 to −6·2)[\*](#TFN4){ref-type="table-fn"}        (−10·7 to −2·1)[\*](#TFN4){ref-type="table-fn"}

         Trichomoniasis                                                                                          7·04\                           236\                                       243\                   16·2%\                                                 16·0%\                                                 16·0%\                                                          0·2\                         6·0\                         3·1\                   1·7%\                                                  2·3%\                                                  2·2%\
                                                                                                        (2·77 to 14·8)                 (94·7 to 508)                              (97·6 to 524)                  (12·8 to 19·5)[\*](#TFN4){ref-type="table-fn"}         (14·2 to 17·7)[\*](#TFN4){ref-type="table-fn"}         (14·2 to 17·7)[\*](#TFN4){ref-type="table-fn"}         (0·1 to 0·4)                 (2·4 to 12·9)                (1·2 to 6·6)                 (−1·0 to 4·3)                                          (1·2 to 3·4)[\*](#TFN4){ref-type="table-fn"}           (1·1 to 3·2)[\*](#TFN4){ref-type="table-fn"}

         Genital herpes                                                                                          98·4\                           149\                                       247\                   21·2%\                                                 18·9%\                                                 19·8%\                                                          2·5\                         3·7\                         3·1\                   2·6%\                                                  0·9%\                                                  1·5%\
                                                                                                        (32·0 to 235)                  (48·0 to 357)                              (79·8 to 594)                  (19·3 to 22·5)[\*](#TFN4){ref-type="table-fn"}         (17·0 to 20·4)[\*](#TFN4){ref-type="table-fn"}         (18·1 to 21·0)[\*](#TFN4){ref-type="table-fn"}         (0·8 to 5·9)                 (1·2 to 8·8)                 (1·0 to 7·4)                 (1·7 to 3·5)[\*](#TFN4){ref-type="table-fn"}           (−0·1 to 1·9)                                          (0·9 to 2·3)[\*](#TFN4){ref-type="table-fn"}

         Other sexually transmitted infections                                                                    147\                           269\                                       416\                     8·0%\                                                  8·2%\                                                  8·1%\                                                         3·7\                         6·8\                         5·3\                 −1·0%\                                                 −3·5%\                                                 −2·6%\
                                                                                                        (86·7 to 258)                  (189 to 399)                               (276 to 659)                   (5·3 to 11·1)[\*](#TFN4){ref-type="table-fn"}          (5·2 to 11·0)[\*](#TFN4){ref-type="table-fn"}          (5·9 to 10·1)[\*](#TFN4){ref-type="table-fn"}          (2·2 to 6·6)                 (4·8 to 10·2)                (3·5 to 8·4)                 (−3·5 to 1·7)                                          (−6·6 to −0·8)[\*](#TFN4){ref-type="table-fn"}         (−5·0 to −0·7)[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **    Respiratory infections and tuberculosis**                                                       **     88 800**\               **     71 100**\                           **   160 000**\                **−22·1%**\                                            **−24·0%**\                                            **−22·9%**\                                            **     2434·0**\             **     2002·9**\             **     2209·6**\             ** −30·7%**\                                           ** −32·1%**\                                           ** −31·4%**\
                                                                                                        **(84 000 to 94 100)**         **(66 900 to 75 600)**                     **(152 000 to 168 000)**       **(−25·2 to −18·5)**[\*](#TFN4){ref-type="table-fn"}   **(−27·4 to −20·4)**[\*](#TFN4){ref-type="table-fn"}   **(−25·6 to −19·9)**[\*](#TFN4){ref-type="table-fn"}   **(2298·0 to 2579·8)**       **(1881·7 to 2134·1)**       **(2095·9 to 2327·9)**       **(−33·5 to −27·5)**[\*](#TFN4){ref-type="table-fn"}   **(−35·3 to −28·8)**[\*](#TFN4){ref-type="table-fn"}   **(−33·9 to −28·6)**[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Tuberculosis                                                                                           28 000\                        17 000\                                    45 000\                   −19·1%\                                                −20·6%\                                                −19·7%\                                                       714·5\                       437·3\                       572·8\                 −32·0%\                                                −32·2%\                                                −32·0%\
                                                                                                        (26 400 to 29 700)             (16 100 to 18 200)                         (42 800 to 47 300)             (−23·4 to −15·2)[\*](#TFN4){ref-type="table-fn"}       (−24·6 to −13·1)[\*](#TFN4){ref-type="table-fn"}       (−22·7 to −16·0)[\*](#TFN4){ref-type="table-fn"}       (672·6 to 759·4)             (412·6 to 467·3)             (544·0 to 602·4)             (−35·5 to −28·7)[\*](#TFN4){ref-type="table-fn"}       (−35·5 to −25·8)[\*](#TFN4){ref-type="table-fn"}       (−34·5 to −28·9)[\*](#TFN4){ref-type="table-fn"}

         Latent tuberculosis infection                                                                                0\                             0\                                         0\                     ··                                                     ··                                                     ··                                                          0\                           0\                           0\                       ··                                                     ··                                                     ··
                                                                                                        (0 to 0)                       (0 to 0)                                   (0 to 0)                                                                                                                                                                                            (0 to 0)                     (0 to 0)                     (0 to 0)                                                                                                                                   

         Drug-susceptible tuberculosis                                                                       24 800\                        15 100\                                    39 900\                   −19·4%\                                                −21·4%\                                                −20·2%\                                                       632·9\                       389·1\                       508·2\                 −32·2%\                                                −32·9%\                                                −32·4%\
                                                                                                        (22 600 to 26 900)             (13 700 to 16 500)                         (36 400 to 43 100)             (−25·7 to −13·5)[\*](#TFN4){ref-type="table-fn"}       (−28·2 to −13·0)[\*](#TFN4){ref-type="table-fn"}       (−26·0 to −14·4)[\*](#TFN4){ref-type="table-fn"}       (576·3 to 686·5)             (354·0 to 424·5)             (463·4 to 548·7)             (−37·4 to −27·4)[\*](#TFN4){ref-type="table-fn"}       (−38·4 to −25·6)[\*](#TFN4){ref-type="table-fn"}       (−37·2 to −27·6)[\*](#TFN4){ref-type="table-fn"}

         Multidrug-resistant tuberculosis without extensive drug resistance                                     2910\                          1740\                                      4650\                  −18·3%\                                                −15·0%\                                                −17·1%\                                                         74·0\                        44·6\                        59·0\                −31·3%\                                                −27·3%\                                                −29·8%\
                                                                                                        (1710 to 4530)                 (971 to 2780)                              (2660 to 7220)                 (−49·4 to 25·3)                                        (−49·6 to 33·5)                                        (−49·1 to 27·5)                                        (43·5 to 115·1)              (25·3 to 70·5)               (34·0 to 91·4)               (−57·4 to 4·8)                                         (−56·5 to 13·6)                                        (−56·6 to 7·6)

         Extensively drug-resistant tuberculosis                                                                  304\                           143\                                       447\                     2·0%\                                                15·8%\                                                   6·0%\                                                         7·7\                         3·6\                         5·6\               −14·4%\                                                  −1·6%\                                               −10·7%\
                                                                                                        (219 to 416)                   (92·7 to 211)                              (311 to 626)                   (−23·9 to 38·3)                                        (−20·7 to 69·3)                                        (−22·7 to 45·8)                                        (5·5 to 10·5)                (2·3 to 5·3)                 (3·9 to 7·8)                 (−36·2 to 16·1)                                        (−32·3 to 43·4)                                        (−34·8 to 22·8)

      Lower respiratory infections                                                                           56 600\                        49 900\                                  106 000\                    −24·9%\                                                −26·8%\                                                −25·8%\                                                     1605·9\                      1453·6\                      1523·9\                  −31·4%\                                                −33·6%\                                                −32·5%\
                                                                                                        (52 800 to 60 400)             (46 600 to 53 000)                         (100 000 to 112 000)           (−29·1 to −20·4)[\*](#TFN4){ref-type="table-fn"}       (−30·7 to −22·6)[\*](#TFN4){ref-type="table-fn"}       (−29·1 to −22·1)[\*](#TFN4){ref-type="table-fn"}       (1498·2 to 1716·6)           (1354·5 to 1547·7)           (1433 to 1610·4)             (−35·3 to −27·4)[\*](#TFN4){ref-type="table-fn"}       (−37·3 to −29·7)[\*](#TFN4){ref-type="table-fn"}       (−35·6 to −29·1)[\*](#TFN4){ref-type="table-fn"}

      Upper respiratory infections                                                                              3200\                          3140\                                      6340\                      5·5%\                                                  6·8%\                                                  6·1%\                                                       84·5\                        84·7\                        84·6\                  −5·2%\                                                 −4·2%\                                                 −4·7%\
                                                                                                        (1930 to 4960)                 (1910 to 4880)                             (3870 to 9820)                 (−1·7 to 10·4)                                         (0·7 to 10·7)[\*](#TFN4){ref-type="table-fn"}          (0·7 to 9·9)[\*](#TFN4){ref-type="table-fn"}           (51·1 to 131·1)              (51·4 to 131·0)              (51·7 to 130·7)              (−11·5 to −0·8)[\*](#TFN4){ref-type="table-fn"}        (−9·5 to −0·5)[\*](#TFN4){ref-type="table-fn"}         (−9·7 to −1·4)[\*](#TFN4){ref-type="table-fn"}

      Otitis media                                                                                              1090\                            992\                                     2080\                      1·7%\                                                  2·3%\                                                  2·0%\                                                       29·1\                        27·3\                        28·2\                  −6·9%\                                                 −6·8%\                                                 −6·8%\
                                                                                                        (668 to 1730)                  (608 to 1560)                              (1280 to 3290)                 (−2·9 to 5·5)                                          (−2·2 to 5·9)                                          (−1·6 to 4·8)                                          (17·8 to 46·2)               (16·7 to 43·2)               (17·3 to 44·7)               (−11·1 to −3·5)[\*](#TFN4){ref-type="table-fn"}        (−10·9 to −3·6)[\*](#TFN4){ref-type="table-fn"}        (−10·2 to −4·4)[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      **Enteric infections**                                                                                 **49 100**\                    **46 100**\                                **95 200**\               **−27·0%**\                                            **−27·0%**\                                            **−27·0%**\                                                 **1377·7**\                  **1319·4**\                  **1350·2**\              **−33·2%**\                                            **−34·3%**\                                            **−33·6%**\
                                                                                                        **(41 400 to 61 500)**         **(38 700 to 57 600)**                     **(83 900 to 112 000)**        **(−35·6 to −16·6)**[\*](#TFN4){ref-type="table-fn"}   **(−33·1 to −18·7)**[\*](#TFN4){ref-type="table-fn"}   **(−32·5 to −20·5)**[\*](#TFN4){ref-type="table-fn"}   **(1165·5 to 1708·6)**       **(1127·4 to 1605·6)**       **(1195·2 to 1579·1)**       **(−40·8 to −23·6)**[\*](#TFN4){ref-type="table-fn"}   **(−39·8 to −27·0)**[\*](#TFN4){ref-type="table-fn"}   **(−38·7 to −27·9)**[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Diarrhoeal diseases                                                                                    41 400\                        39 600\                                    81 000\                   −27·7%\                                                −27·8%\                                                −27·8%\                                                     1166·8\                      1128·4\                      1149\                    −34·0%\                                                −35·5%\                                                −34·7%\
                                                                                                        (33 900 to 53 400)             (32 100 to 50 200)                         (70 100 to 97 200)             (−37·5 to −15·6)[\*](#TFN4){ref-type="table-fn"}       (−35·0 to −18·1)[\*](#TFN4){ref-type="table-fn"}       (−33·8 to −20·3)[\*](#TFN4){ref-type="table-fn"}       (958·5 to 1491·2)            (932·6 to 1406·7)            (1005·2 to 1359·9)           (−42·8 to −22·8)[\*](#TFN4){ref-type="table-fn"}       (−41·8 to −27·1)[\*](#TFN4){ref-type="table-fn"}       (−40·1 to −28·1)[\*](#TFN4){ref-type="table-fn"}

      Typhoid and paratyphoid                                                                                   5350\                          4450\                                      9800\                  −25·4%\                                                −21·9%\                                                −23·8%\                                                       146·6\                       128·8\                       137·9\                 −30·0%\                                                −27·0%\                                                −28·7%\
                                                                                                        (3070 to 8560)                 (2530 to 7300)                             (5580 to 15 800)               (−30·4 to −20·8)[\*](#TFN4){ref-type="table-fn"}       (−27·7 to −17·0)[\*](#TFN4){ref-type="table-fn"}       (−29·3 to −19·4)[\*](#TFN4){ref-type="table-fn"}       (84·1 to 235·4)              (72·5 to 211·4)              (78·4 to 223·3)              (−35·0 to −25·6)[\*](#TFN4){ref-type="table-fn"}       (−32·6 to −22·3)[\*](#TFN4){ref-type="table-fn"}       (−33·9 to −24·4)[\*](#TFN4){ref-type="table-fn"}

         Typhoid fever                                                                                          4620\                          3820\                                      8440\                  −26·6%\                                                −23·7%\                                                −25·3%\                                                       126·6\                       110·5\                       118·8\                 −31·2%\                                                −28·7%\                                                −30·1%\
                                                                                                        (2590 to 7330)                 (2140 to 6220)                             (4730 to 13 500)               (−32·2 to −21·9)[\*](#TFN4){ref-type="table-fn"}       (−30·4 to −18·7)[\*](#TFN4){ref-type="table-fn"}       (−31·0 to −20·8)[\*](#TFN4){ref-type="table-fn"}       (71·2 to 202·5)              (61·9 to 180·5)              (66·9 to 190·4)              (−36·6 to −26·5)[\*](#TFN4){ref-type="table-fn"}       (−35·0 to −23·9)[\*](#TFN4){ref-type="table-fn"}       (−35·6 to −25·8)[\*](#TFN4){ref-type="table-fn"}

         Paratyphoid fever                                                                                        730\                           633\                                     1360\                  −16·3%\                                                  −9·3%\                                               −13·2%\                                                         20·0\                        18·3\                        19·1\                −21·5%\                                                −15·1%\                                                −18·7%\
                                                                                                        (336 to 1400)                  (287 to 1220)                              (633 to 2630)                  (−25·7 to −5·7)[\*](#TFN4){ref-type="table-fn"}        (−20·3 to 2·5)                                         (−21·2 to −3·8)[\*](#TFN4){ref-type="table-fn"}        (9·1 to 38·3)                (8·3 to 35·2)                (8·9 to 36·7)                (−30·4 to −11·6)[\*](#TFN4){ref-type="table-fn"}       (−25·6 to −3·8)[\*](#TFN4){ref-type="table-fn"}        (−26·5 to −9·8)[\*](#TFN4){ref-type="table-fn"}

      Invasive non-typhoidal salmonella disease                                                                 2240\                          2020\                                      4260\                  −16·0%\                                                −18·5%\                                                −17·2%\                                                         63·0\                        60·3\                        61·7\                −21·4%\                                                −23·8%\                                                −22·6%\
                                                                                                        (1240 to 3850)                 (1150 to 3500)                             (2380 to 7380)                 (−25·9 to −3·1)[\*](#TFN4){ref-type="table-fn"}        (−27·7 to −8·1)[\*](#TFN4){ref-type="table-fn"}        (−25·7 to −6·8)[\*](#TFN4){ref-type="table-fn"}        (34·9 to 108·8)              (34·0 to 104·8)              (34·7 to 107·6)              (−31·0 to −9·1)[\*](#TFN4){ref-type="table-fn"}        (−32·6 to −13·9)[\*](#TFN4){ref-type="table-fn"}       (−30·7 to −12·5)[\*](#TFN4){ref-type="table-fn"}

      Other intestinal infectious diseases                                                                       45·5\                          59·9\                                       105\                 −43·0%\                                                −44%\                                                  −43·6%\                                                           1·3\                         1·8\                         1·5\               −46·4%\                                                −47·3%\                                                −46·9%\
                                                                                                        (26·6 to 87·5)                 (33·5 to 120)                              (68·7 to 172)                  (−75·3 to 37·9)                                        (−77·7 to 38·8)                                        (−71·4 to 11·5)                                        (0·7 to 2·5)                 (1·0 to 3·7)                 (1·0 to 2·5)                 (−76·8 to 30·8)                                        (−79·2 to 32·5)                                        (−73·5 to 5·7)

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **    Neglected tropical diseases and malaria**                                                       **     33 300**\               **     29 000**\                           **     62 300**\               **−29·5%**\                                            **−30·0%**\                                            **−29·7%**\                                            **       917·6**\            **       836·2**\            **       877·6**\            ** −35·2%**\                                           ** −36·2%**\                                           ** −35·7%**\
                                                                                                        **(25 900 to 43 000)**         **(22 300 to 36 900)**                     **(48 600 to 79 900)**         **(−37·2 to −21·1)**[\*](#TFN4){ref-type="table-fn"}   **(−38·0 to −21·3)**[\*](#TFN4){ref-type="table-fn"}   **(−37·2 to −21·2)**[\*](#TFN4){ref-type="table-fn"}   **(710·8 to 1192·3)**        **(636·3 to 1073·7)**        **(679·5 to 1129·2)**        **(−42·5 to −27·4)**[\*](#TFN4){ref-type="table-fn"}   **(−43·7 to −28·0)**[\*](#TFN4){ref-type="table-fn"}   **(−42·7 to −27·7)**[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Malaria                                                                                                24 000\                        21 100\                                    45 000\                   −33·0%\                                                −35·4%\                                                −34·2%\                                                       672·3\                       626·4\                       649·8\                 −37·7%\                                                −40·2%\                                                −38·9%\
                                                                                                        (16 800 to 32 800)             (14 800 to 28 400)                         (31 700 to 61 000)             (−42·5 to −22·3)[\*](#TFN4){ref-type="table-fn"}       (−44·9 to −25·4)[\*](#TFN4){ref-type="table-fn"}       (−43·1 to −23·5)[\*](#TFN4){ref-type="table-fn"}       (468·6 to 924·1)             (437·9 to 848·8)             (457·1 to 878·7)             (−46·8 to −27·6)[\*](#TFN4){ref-type="table-fn"}       (−49·2 to −30·7)[\*](#TFN4){ref-type="table-fn"}       (−47·4 to −28·8)[\*](#TFN4){ref-type="table-fn"}

      Chagas disease                                                                                              138\                             94\                                      232\                   −3·6%\                                                 −1·4%\                                                 −2·8%\                                                          3·6\                         2·2\                         2·9\               −24·0%\                                                −22·7%\                                                −23·4%\
                                                                                                        (125 to 156)                   (84·1 to 107)                              (210 to 261)                   (−8·8 to 4·6)                                          (−5·9 to 4·6)                                          (−6·8 to 4·1)                                          (3·2 to 4·0)                 (2·0 to 2·6)                 (2·6 to 3·2)                 (−28·1 to −17·7)[\*](#TFN4){ref-type="table-fn"}       (−26·2 to −18·0)[\*](#TFN4){ref-type="table-fn"}       (−26·6 to −18·0)[\*](#TFN4){ref-type="table-fn"}

      Leishmaniasis                                                                                               442\                           332\                                       774\                 −55·4%\                                                −46·5%\                                                −52%\                                                           11·9\                          9·2\                       10·6\                −59·0%\                                                −52·1%\                                                −56·3%\
                                                                                                        (89·4 to 1700)                 (109 to 1030)                              (199 to 2720)                  (−68·9 to 28·3)                                        (−67·3 to 36·1)                                        (−68·2 to 32·5)                                        (2·3 to 46·7)                (2·8 to 29·6)                (2·6 to 38·2)                (−71·0 to 12·7)                                        (−69·9 to 20·1)                                        (−70·6 to 16·5)

         Visceral leishmaniasis                                                                                   326\                           184\                                       511\                 −63·9%\                                                −63·8%\                                                −63·9%\                                                           8·9\                         5·4\                         7·2\               −66·3%\                                                −66·1%\                                                −66·2%\
                                                                                                        (0·657 to 1570)                (0·355 to 878)                             (1·02 to 2440)                 (−85·7 to −41·3)[\*](#TFN4){ref-type="table-fn"}       (−81·6 to −36·5)[\*](#TFN4){ref-type="table-fn"}       (−84·5 to −40·0)[\*](#TFN4){ref-type="table-fn"}       (0 to 43·3)                  (0 to 25·8)                  (0 to 34·7)                  (−87·4 to −46·2)[\*](#TFN4){ref-type="table-fn"}       (−83·1 to −41·3)[\*](#TFN4){ref-type="table-fn"}       (−86·0 to −44·3)[\*](#TFN4){ref-type="table-fn"}

         Cutaneous and mucocutaneous leishmaniasis                                                                116\                           148\                                       264\                   30·5%\                                                 32·3%\                                                 31·5%\                                                          3·0\                         3·8\                         3·4\                 14·4%\                                                 15·8%\                                                 15·3%\
                                                                                                        (74·8 to 171)                  (96·6 to 216)                              (172 to 389)                   (20·3 to 43·1)[\*](#TFN4){ref-type="table-fn"}         (22·0 to 45·5)[\*](#TFN4){ref-type="table-fn"}         (21·2 to 44·2)[\*](#TFN4){ref-type="table-fn"}         (1·9 to 4·4)                 (2·5 to 5·5)                 (2·2 to 5·0)                 (4·6 to 26·4)[\*](#TFN4){ref-type="table-fn"}          (5·8 to 28·1)[\*](#TFN4){ref-type="table-fn"}          (5·2 to 27·4)[\*](#TFN4){ref-type="table-fn"}

      African trypanosomiasis                                                                                       41·5\                          37·5\                                      79·0\              −80·7%\                                                −80·8%\                                                −80·7%\                                                           1·1\                         1·0\                         1·1\               −82·3%\                                                −82·3%\                                                −82·3%\
                                                                                                        (7·46 to 160)                  (7·06 to 142)                              (15·4 to 287)                  (−95·9 to −22·4)[\*](#TFN4){ref-type="table-fn"}       (−95·8 to −30·1)[\*](#TFN4){ref-type="table-fn"}       (−95·6 to −27·3)[\*](#TFN4){ref-type="table-fn"}       (0·2 to 4·2)                 (0·2 to 3·8)                 (0·2 to 3·9)                 (−96·3 to −30·8)[\*](#TFN4){ref-type="table-fn"}       (−96·2 to −33·5)[\*](#TFN4){ref-type="table-fn"}       (−95·9 to −33·4)[\*](#TFN4){ref-type="table-fn"}

      Schistosomiasis                                                                                             693\                           738\                                     1430\                  −19·3%\                                                −19·8%\                                                −19·6%\                                                         17·7\                        18·9\                        18·3\                −29·3%\                                                −29·5%\                                                −29·4%\
                                                                                                        (427 to 1180)                  (447 to 1250)                              (876 to 2440)                  (−21·9 to −15·7)[\*](#TFN4){ref-type="table-fn"}       (−22·5 to −17·1)[\*](#TFN4){ref-type="table-fn"}       (−21·6 to −17·3)[\*](#TFN4){ref-type="table-fn"}       (10·9 to 30·0)               (11·5 to 31·9)               (11·2 to 30·9)               (−31·8 to −26·2)[\*](#TFN4){ref-type="table-fn"}       (−32·1 to −27·1)[\*](#TFN4){ref-type="table-fn"}       (−31·4 to −27·4)[\*](#TFN4){ref-type="table-fn"}

      Cysticercosis                                                                                               671\                           937\                                     1610\                      3·7%\                                                10·5%\                                                   7·6%\                                                       17·1\                        23·1\                        20·1\                −13·0%\                                                  −7·3%\                                                 −9·8%\
                                                                                                        (440 to 928)                   (618 to 1300)                              (1050 to 2230)                 (−1·7 to 8·8)                                          (5·5 to 15·1)[\*](#TFN4){ref-type="table-fn"}          (2·4 to 12·0)[\*](#TFN4){ref-type="table-fn"}          (11·2 to 23·5)               (15·2 to 32·1)               (13·2 to 27·8)               (−17·5 to −8·9)[\*](#TFN4){ref-type="table-fn"}        (−11·7 to −3·5)[\*](#TFN4){ref-type="table-fn"}        (−14·0 to −6·1)[\*](#TFN4){ref-type="table-fn"}

      Cystic echinococcosis                                                                                         46·8\                          53·4\                                    100\                 −22·7%\                                                −17·7%\                                                −20·1%\                                                           1·2\                         1·4\                         1·3\               −32·5%\                                                −29·4%\                                                −30·8%\
                                                                                                        (32·0 to 65·0)                 (37·2 to 73·4)                             (72·8 to 139)                  (−46·2 to 7·7)                                         (−39 to 7·2)                                           (−36·7 to 0·6)                                         (0·8 to 1·7)                 (1·0 to 1·9)                 (1·0 to 1·8)                 (−53·1 to −6·3)[\*](#TFN4){ref-type="table-fn"}        (−48·1 to −7·5)[\*](#TFN4){ref-type="table-fn"}        (−45·2 to −13·2)[\*](#TFN4){ref-type="table-fn"}

      Lymphatic filariasis                                                                                      1110\                            258\                                     1360\                  −40·8%\                                                −13·2%\                                                −37·0%\                                                         28·1\                          6·6\                       17·4\                −48·1%\                                                −24·2%\                                                −44·8%\
                                                                                                        (569 to 1830)                  (151 to 394)                               (752 to 2160)                  (−52·3 to −30·0)[\*](#TFN4){ref-type="table-fn"}       (−16·7 to −9·8)[\*](#TFN4){ref-type="table-fn"}        (−48·7 to −26·4)[\*](#TFN4){ref-type="table-fn"}       (14·4 to 46·4)               (3·9 to 10·0)                (9·6 to 27·5)                (−58·2 to −38·6)[\*](#TFN4){ref-type="table-fn"}       (−27·5 to −21·2)[\*](#TFN4){ref-type="table-fn"}       (−54·7 to −35·5)[\*](#TFN4){ref-type="table-fn"}

      Onchocerciasis                                                                                              719\                           624\                                     1340\                      3·2%\                                                  4·7%\                                                  3·9%\                                                       18·5\                        16·2\                        17·3\                  −8·6%\                                                 −7·3%\                                                 −8·0%\
                                                                                                        (346 to 1270)                  (299 to 1130)                              (639 to 2370)                  (−15·4 to 19·2)                                        (−16·0 to 21·7)                                        (−15·1 to 19·9)                                        (8·9 to 32·7)                (7·6 to 29·3)                (8·2 to 30·5)                (−26·0 to 6·0)                                         (−26·6 to 8·3)                                         (−25·8 to 6·7)

      Trachoma                                                                                                    122\                           181\                                       303\                   −0·7%\                                                 −8·5%\                                                 −5·5%\                                                          3·4\                         4·2\                         3·8\               −25·6%\                                                −30·1%\                                                −28·2%\
                                                                                                        (80·3 to 174)                  (120 to 253)                               (202 to 425)                   (−11·7 to 10·5)                                        (−16·5 to −0·8)[\*](#TFN4){ref-type="table-fn"}        (−13·1 to 2·0)                                         (2·2 to 4·8)                 (2·8 to 5·9)                 (2·6 to 5·4)                 (−33·6 to −17·3)[\*](#TFN4){ref-type="table-fn"}       (−35·9 to −24·1)[\*](#TFN4){ref-type="table-fn"}       (−33·8 to −22·5)[\*](#TFN4){ref-type="table-fn"}

      Dengue                                                                                                    1530\                          1390\                                      2920\                    39·9%\                                                 42·1%\                                                 40·9%\                                                        41·1\                        38\                          39·6\                  26·1%\                                                 26·3%\                                                 26·2%\
                                                                                                        (754 to 2110)                  (651 to 1930)                              (1630 to 3970)                 (4·2 to 73·1)[\*](#TFN4){ref-type="table-fn"}          (4 to 79·5)[\*](#TFN4){ref-type="table-fn"}            (13·9 to 67·9)[\*](#TFN4){ref-type="table-fn"}         (20·2 to 56·2)               (17·6 to 52·8)               (22·0 to 53·3)               (−6·1 to 56·2)                                         (−8·0 to 60·3)                                         (2·2 to 49·5)[\*](#TFN4){ref-type="table-fn"}

      Yellow fever                                                                                                222\                             92·3\                                    314\                 −16·9%\                                                −13·5%\                                                −16·0%\                                                           6·0\                         2·6\                         4·3\               −22·3%\                                                −19·1%\                                                −21·3%\
                                                                                                        (45·9 to 632)                  (18·7 to 267)                              (67·2 to 900)                  (−33·2 to 4·4)                                         (−31·2 to 8·6)                                         (−28·9 to 0)[\*](#TFN4){ref-type="table-fn"}           (1·2 to 17·0)                (0·5 to 7·6)                 (0·9 to 12·4)                (−37·9 to −1·8)[\*](#TFN4){ref-type="table-fn"}        (−35·6 to 2·3)                                         (−33·6 to −5·9)[\*](#TFN4){ref-type="table-fn"}

      Rabies                                                                                                      441\                           193\                                       634\                 −49·9%\                                                −54·8%\                                                −51·5%\                                                         11·7\                          5·3\                         8·6\               −54·4%\                                                −59·5%\                                                −56·2%\
                                                                                                        (356 to 598)                   (98·0 to 287)                              (504 to 836)                   (−60·1 to −33·9)[\*](#TFN4){ref-type="table-fn"}       (−70·4 to −34·7)[\*](#TFN4){ref-type="table-fn"}       (−61·3 to −38·9)[\*](#TFN4){ref-type="table-fn"}       (9·4 to 16·1)                (2·7 to 8·1)                 (6·8 to 11·5)                (−63·8 to −39·4)[\*](#TFN4){ref-type="table-fn"}       (−73·7 to −40·8)[\*](#TFN4){ref-type="table-fn"}       (−65·1 to −44·3)[\*](#TFN4){ref-type="table-fn"}

      Intestinal nematode infections                                                                              907\                         1010\                                      1920\                  −32·4%\                                                −32·2%\                                                −32·3%\                                                         24·2\                        27·8\                        25·9\                −38·3%\                                                −38·2%\                                                −38·3%\
                                                                                                        (569 to 1410)                  (632 to 1560)                              (1200 to 2980)                 (−38·3 to −27·2)[\*](#TFN4){ref-type="table-fn"}       (−37·8 to −26·9)[\*](#TFN4){ref-type="table-fn"}       (−37·1 to −27·7)[\*](#TFN4){ref-type="table-fn"}       (15·3 to 37·5)               (17·5 to 42·6)               (16·4 to 40·1)               (−43·7 to −33·3)[\*](#TFN4){ref-type="table-fn"}       (−43·6 to −33·2)[\*](#TFN4){ref-type="table-fn"}       (−42·7 to −33·9)[\*](#TFN4){ref-type="table-fn"}

         Ascariasis                                                                                               427\                           434\                                       861\                 −37·8%\                                                −37·2%\                                                −37·5%\                                                         11·6\                        12·3\                        12·0\                −42·7%\                                                −42·4%\                                                −42·6%\
                                                                                                        (284 to 641)                   (284 to 661)                               (569 to 1290)                  (−46·7 to −28·4)[\*](#TFN4){ref-type="table-fn"}       (−46·2 to −27·1)[\*](#TFN4){ref-type="table-fn"}       (−45·0 to −29·7)[\*](#TFN4){ref-type="table-fn"}       (7·7 to 17·3)                (8·1 to 18·6)                (8·0 to 17·8)                (−51·0 to −33·7)[\*](#TFN4){ref-type="table-fn"}       (−50·9 to −32·6)[\*](#TFN4){ref-type="table-fn"}       (−49·5 to −35·3)[\*](#TFN4){ref-type="table-fn"}

         Trichuriasis                                                                                             107\                           106\                                       213\                 −23·1%\                                                −23·0%\                                                −23·1%\                                                           2·8\                         2·8\                         2·8\               −29·3%\                                                −29·2%\                                                −29·3%\
                                                                                                        (59·8 to 178)                  (59·6 to 177)                              (120 to 354)                   (−29·4 to −16·0)[\*](#TFN4){ref-type="table-fn"}       (−29·3 to −15·7)[\*](#TFN4){ref-type="table-fn"}       (−29·3 to −15·8)[\*](#TFN4){ref-type="table-fn"}       (1·6 to 4·6)                 (1·6 to 4·7)                 (1·6 to 4·7)                 (−35·1 to −22·7)[\*](#TFN4){ref-type="table-fn"}       (−35·0 to −22·5)[\*](#TFN4){ref-type="table-fn"}       (−35·0 to −22·5)[\*](#TFN4){ref-type="table-fn"}

         Hookworm disease                                                                                         373\                           472\                                       845\                 −27·8%\                                                −28·9%\                                                −28·5%\                                                           9·8\                       12·6\                        11·2\                −34·7%\                                                −35·5%\                                                −35·2%\
                                                                                                        (218 to 603)                   (289 to 740)                               (510 to 1340)                  (−33·3 to −22·0)[\*](#TFN4){ref-type="table-fn"}       (−34·6 to −23·2)[\*](#TFN4){ref-type="table-fn"}       (−34·0 to −22·7)[\*](#TFN4){ref-type="table-fn"}       (5·7 to 15·8)                (7·7 to 19·8)                (6·7 to 17·8)                (−39·7 to −29·3)[\*](#TFN4){ref-type="table-fn"}       (−40·6 to −30·3)[\*](#TFN4){ref-type="table-fn"}       (−40·2 to −30·0)[\*](#TFN4){ref-type="table-fn"}

      Food-borne trematodiases                                                                                  1110\                            763\                                     1870\                      4·3%\                                                15·0%\                                                   8·5%\                                                       27·7\                        19\                          23·4\                  −9·4%\                                                 −1·0%\                                                 −6·2%\
                                                                                                        (627 to 1890)                  (432 to 1280)                              (1070 to 3150)                 (0·9 to 8·0)[\*](#TFN4){ref-type="table-fn"}           (9·8 to 20·2)[\*](#TFN4){ref-type="table-fn"}          (4·8 to 12·0)[\*](#TFN4){ref-type="table-fn"}          (15·7 to 47·1)               (10·7 to 31·9)               (13·4 to 39·3)               (−12·4 to −6·5)[\*](#TFN4){ref-type="table-fn"}        (−5·3 to 3·2)                                          (−9·1 to −3·5)[\*](#TFN4){ref-type="table-fn"}

      Leprosy                                                                                                       22·1\                            9·46\                                    31·5\                −2·2%\                                                   1·0%\                                                −1·3%\                                                          0·6\                         0·2\                         0·4\               −21·2%\                                                −18·8%\                                                −20·4%\
                                                                                                        (15·0 to 31·0)                 (6·35 to 13·3)                             (21·5 to 44·6)                 (−5·2 to 0·8)                                          (−2·7 to 4·8)                                          (−3·7 to 1·1)                                          (0·4 to 0·8)                 (0·2 to 0·3)                 (0·3 to 0·6)                 (−23·6 to −18·9)[\*](#TFN4){ref-type="table-fn"}       (−21·9 to −15·9)[\*](#TFN4){ref-type="table-fn"}       (−22·4 to −18·5)[\*](#TFN4){ref-type="table-fn"}

      Ebola virus disease                                                                                             0·319\                         0·184\                                     0·503\           −97·5%\                                                −98·6%\                                                −98·1%\                                                           0\                           0\                           0\                 −97·7%\                                                −98·7%\                                                −98·2%\
                                                                                                        (0·238 to 0·361)               (0·161 to 0·210)                           (0·459 to 0·552)               (−97·8 to −97·2)[\*](#TFN4){ref-type="table-fn"}       (−98·8 to −98·4)[\*](#TFN4){ref-type="table-fn"}       (−98·3 to −97·9)[\*](#TFN4){ref-type="table-fn"}       (0 to 0)                     (0 to 0)                     (0 to 0)                     (−98·0 to −97·4)[\*](#TFN4){ref-type="table-fn"}       (−98·9 to −98·5)[\*](#TFN4){ref-type="table-fn"}       (−98·4 to −98·0)[\*](#TFN4){ref-type="table-fn"}

      Zika virus disease                                                                                              1·13\                          1·12\                                      2·24\                  ··                                                     ··                                                     ··                                                          0\                           0\                           0\                       ··                                                     ··                                                     ··
                                                                                                        (0·657 to 2·09)                (0·529 to 2·71)                            (1·27 to 4·66)                                                                                                                                                                                      (0 to 0·1)                   (0 to 0·1)                   (0 to 0·1)                                                                                                                                 

      Guinea worm disease                                                                                             0·000249\                      0·000301\                                  0·000550\        −99·5%\                                                −99·5%\                                                −99·5%\                                                           0\                           0\                           0\                 −99·6%\                                                −99·5%\                                                −99·5%\
                                                                                                        (0·000133 to 0·000398)         (0·000161 to 0·000482)                     (0·000294 to 0·000883)         (−99·7 to −99·3)[\*](#TFN4){ref-type="table-fn"}       (−99·6 to −99·2)[\*](#TFN4){ref-type="table-fn"}       (−99·6 to −99·3)[\*](#TFN4){ref-type="table-fn"}       (0 to 0)                     (0 to 0)                     (0 to 0)                     (−99·7 to −99·4)[\*](#TFN4){ref-type="table-fn"}       (−99·7 to −99·3)[\*](#TFN4){ref-type="table-fn"}       (−99·7 to −99·3)[\*](#TFN4){ref-type="table-fn"}

      Other neglected tropical diseases                                                                         1130\                          1200\                                      2340\                    −2·6%\                                                 −2·6%\                                                 −2·6%\                                                        31·6\                        34·0\                        32·8\                  −9·7%\                                               −10·5%\                                                −10·1%\
                                                                                                        (743 to 2330)                  (794 to 2070)                              (1560 to 4190)                 (−13·5 to 9·7)                                         (−8·6 to 4·8)                                          (−9·5 to 5·6)                                          (20·7 to 65·7)               (22·5 to 60·8)               (21·8 to 60·1)               (−20·1 to 1·9)                                         (−16·5 to −2·9)[\*](#TFN4){ref-type="table-fn"}        (−16·7 to −2·3)[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      **Other infectious diseases**                                                                          **29 500**\                    **27 500**\                                **57 100**\               **−30·8%**\                                            **−32·1%**\                                            **−31·4%**\                                                   **824·0**\                   **810·9**\                   **816·8**\             **−35·9%**\                                            **−37·3%**\                                            **−36·6%**\
                                                                                                        **(25 200 to 34 700)**         **(23 200 to 32 600)**                     **(48 800 to 67 300)**         **(−37·5 to −23·1)**[\*](#TFN4){ref-type="table-fn"}   **(−38·7 to −24·3)**[\*](#TFN4){ref-type="table-fn"}   **(−37·8 to −23·8)**[\*](#TFN4){ref-type="table-fn"}   **(703·3 to 971·5)**         **(677·3 to 966·3)**         **(693·8 to 970·0)**         **(−42·2 to −28·7)**[\*](#TFN4){ref-type="table-fn"}   **(−43·5 to −29·9)**[\*](#TFN4){ref-type="table-fn"}   **(−42·6 to −29·5)**[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Meningitis                                                                                             10 900\                           9430\                                   20 400\                   −23·3%\                                                −25·6%\                                                −24·4%\                                                       306·8\                       278·6\                       293\                   −28·4%\                                                −30·8%\                                                −29·6%\
                                                                                                        (9460 to 12 700)               (7810 to 11 100)                           (17 800 to 23 400)             (−31·0 to −12·2)[\*](#TFN4){ref-type="table-fn"}       (−32·7 to −15·3)[\*](#TFN4){ref-type="table-fn"}       (−30·6 to −15·3)[\*](#TFN4){ref-type="table-fn"}       (264·8 to 356·4)             (232·0 to 327·4)             (254·3 to 337·3)             (−35·6 to −17·9)[\*](#TFN4){ref-type="table-fn"}       (−37·7 to −21·0)[\*](#TFN4){ref-type="table-fn"}       (−35·5 to −21·1)[\*](#TFN4){ref-type="table-fn"}

         Pneumococcal meningitis                                                                                1770\                          1310\                                      3080\                  −18·5%\                                                −20·3%\                                                −19·2%\                                                         49·4\                        38·0\                        43·9\                −24·2%\                                                −26·3%\                                                −25·1%\
                                                                                                        (1480 to 2130)                 (1080 to 1560)                             (2640 to 3600)                 (−27·9 to −4·6)[\*](#TFN4){ref-type="table-fn"}        (−27·8 to −10·3)[\*](#TFN4){ref-type="table-fn"}       (−26·5 to −8·9)[\*](#TFN4){ref-type="table-fn"}        (41·1 to 59·6)               (31·3 to 45·3)               (37·5 to 51·4)               (−33·1 to −11·3)[\*](#TFN4){ref-type="table-fn"}       (−33·5 to −16·7)[\*](#TFN4){ref-type="table-fn"}       (−32·1 to −15·1)[\*](#TFN4){ref-type="table-fn"}

         H *influenzae* type B meningitis                                                                       2530\                          2460\                                      4990\                  −39·5%\                                                −41·6%\                                                −40·6%\                                                         70·9\                        72·6\                        71·6\                −43·8%\                                                −45·9%\                                                −44·9%\
                                                                                                        (2110 to 3140)                 (2070 to 3010)                             (4310 to 5890)                 (−46·2 to −31·0)[\*](#TFN4){ref-type="table-fn"}       (−48 to −33·1)[\*](#TFN4){ref-type="table-fn"}         (−46·1 to −33·3)[\*](#TFN4){ref-type="table-fn"}       (59·0 to 88·1)               (60·7 to 88·6)               (61·6 to 85)                 (−50·0 to −35·6)[\*](#TFN4){ref-type="table-fn"}       (−52·0 to −37·8)[\*](#TFN4){ref-type="table-fn"}       (−50·1 to −38·0)[\*](#TFN4){ref-type="table-fn"}

         Meningococcal infection                                                                                1280\                          1000\                                      2280\                  −33·5%\                                                −34·7%\                                                −34·0%\                                                         36·2\                        30·1\                        33·2\                −37·5%\                                                −38·9%\                                                −38·1%\
                                                                                                        (1050 to 1550)                 (819 to 1200)                              (1920 to 2720)                 (−41·4 to −22·0)[\*](#TFN4){ref-type="table-fn"}       (−41·7 to −24·7)[\*](#TFN4){ref-type="table-fn"}       (−40·3 to −25·6)[\*](#TFN4){ref-type="table-fn"}       (29·6 to 44·2)               (24·3 to 36·1)               (27·8 to 39·7)               (−45·0 to −26·4)[\*](#TFN4){ref-type="table-fn"}       (−45·5 to −29·4)[\*](#TFN4){ref-type="table-fn"}       (−44·1 to −30·0)[\*](#TFN4){ref-type="table-fn"}

         Other meningitis                                                                                       5360\                          4660\                                   10 000\                   −10·5%\                                                −11·9%\                                                −11·1%\                                                       150·4\                       137·9\                       144·2\                 −16·3%\                                                −17·8%\                                                −17·0%\
                                                                                                        (4570 to 6270)                 (3810 to 5480)                             (8600 to 11 500)               (−19·7 to 3·3)                                         (−20·8 to 0·8)                                         (−18·5 to 0·6)                                         (128·2 to 175·7)             (112·6 to 162·9)             (123·6 to 166·2)             (−25·1 to −3·1)[\*](#TFN4){ref-type="table-fn"}        (−26·3 to −5·6)[\*](#TFN4){ref-type="table-fn"}        (−24·2 to −5·9)[\*](#TFN4){ref-type="table-fn"}

      Encephalitis                                                                                              2620\                          2490\                                      5110\                  −12·4%\                                                  −8·4%\                                               −10·5%\                                                         71·6\                        70·2\                        70·8\                −20·4%\                                                −17·5%\                                                −18·9%\
                                                                                                        (2310 to 3030)                 (2220 to 2810)                             (4540 to 5760)                 (−27·6 to 4·5)                                         (−24·1 to 8·3)                                         (−25·5 to 4·7)                                         (63·0 to 82·3)               (62·0 to 79·2)               (62·8 to 79·3)               (−34·4 to −5·1)[\*](#TFN4){ref-type="table-fn"}        (−32·3 to −2·3)[\*](#TFN4){ref-type="table-fn"}        (−32·9 to −5·2)[\*](#TFN4){ref-type="table-fn"}

      Diphtheria                                                                                                  155\                           143\                                       299\                 −21·9%\                                                −26·1%\                                                −23·9%\                                                           4·4\                         4·4\                         4·4\               −26·3%\                                                −30·4%\                                                −28·3%\
                                                                                                        (80·2 to 331)                  (74·1 to 291)                              (182 to 510)                   (−63·8 to 75·5)                                        (−65·7 to 71·5)                                        (−56·7 to 38·7)                                        (2·3 to 9·5)                 (2·3 to 8·9)                 (2·7 to 7·6)                 (−66·2 to 66·6)                                        (−67·9 to 62·6)                                        (−59·5 to 31·4)

      Whooping cough                                                                                            3540\                          4440\                                      7980\                  −24·1%\                                                −22·5%\                                                −23·2%\                                                       102·5\                       137·4\                       119·3\                 −27·7%\                                                −26·4%\                                                −27·0%\
                                                                                                        (1790 to 6340)                 (2250 to 7740)                             (4020 to 14 100)               (−54·8 to 33·4)                                        (−54·3 to 35·1)                                        (−54·5 to 35·0)                                        (51·9 to 183·6)              (69·6 to 239·7)              (60·1 to 210·7)              (−56·9 to 27·1)                                        (−56·6 to 28·3)                                        (−56·8 to 28·4)

      Tetanus                                                                                                   1400\                          1050\                                      2450\                  −58·1%\                                                −60·9%\                                                −59·3%\                                                         38·9\                        31·3\                        35·2\                −61·0%\                                                −63·4%\                                                −62·1%\
                                                                                                        (955 to 1930)                  (753 to 1410)                              (1740 to 3200)                 (−70·2 to −37·9)[\*](#TFN4){ref-type="table-fn"}       (−72·2 to −42·0)[\*](#TFN4){ref-type="table-fn"}       (−69·9 to −43·5)[\*](#TFN4){ref-type="table-fn"}       (26·6 to 54·3)               (22·5 to 42·2)               (25 to 46·4)                 (−72·2 to −42)[\*](#TFN4){ref-type="table-fn"}         (−74·1 to −45·6)[\*](#TFN4){ref-type="table-fn"}       (−72·1 to −47)[\*](#TFN4){ref-type="table-fn"}

      Measles                                                                                                   4080\                          4080\                                      8160\                  −56·5%\                                                −57·2%\                                                −56·8%\                                                       117·7\                       125·6\                       121·5\                 −58·8%\                                                −59·5%\                                                −59·1%\
                                                                                                        (1460 to 8860)                 (1480 to 8710)                             (2950 to 17 600)               (−61·9 to −50·6)[\*](#TFN4){ref-type="table-fn"}       (−62·6 to −51·6)[\*](#TFN4){ref-type="table-fn"}       (−61·8 to −51·7)[\*](#TFN4){ref-type="table-fn"}       (42·1 to 255·6)              (45·7 to 268·5)              (44·0 to 261·7)              (−63·9 to −53·2)[\*](#TFN4){ref-type="table-fn"}       (−64·7 to −54·2)[\*](#TFN4){ref-type="table-fn"}       (−63·8 to −54·3)[\*](#TFN4){ref-type="table-fn"}

      Varicella and herpes zoster                                                                                 559\                           586\                                     1140\                  −15·8%\                                                −12·3%\                                                −14·0%\                                                         15·5\                        16·5\                        16·0\                −24·1%\                                                −21·6%\                                                −22·8%\
                                                                                                        (476 to 656)                   (495 to 690)                               (985 to 1320)                  (−25·9 to −4·3)[\*](#TFN4){ref-type="table-fn"}        (−23·2 to −1·6)[\*](#TFN4){ref-type="table-fn"}        (−22·4 to −5·6)[\*](#TFN4){ref-type="table-fn"}        (13·3 to 18·1)               (14·0 to 19·3)               (13·9 to 18·4)               (−33·0 to −13·7)[\*](#TFN4){ref-type="table-fn"}       (−31·6 to −11·5)[\*](#TFN4){ref-type="table-fn"}       (−30·2 to −15·5)[\*](#TFN4){ref-type="table-fn"}

      Acute hepatitis                                                                                           3240\                          2750\                                      5990\                  −18·9%\                                                −21·0%\                                                −19·8%\                                                         84·2\                        74·2\                        78·9\                −29·0%\                                                −30·1%\                                                −29·5%\
                                                                                                        (2150 to 3940)                 (1970 to 3390)                             (4580 to 6900)                 (−25·9 to −5·0)[\*](#TFN4){ref-type="table-fn"}        (−29·2 to −12·3)[\*](#TFN4){ref-type="table-fn"}       (−25·6 to −12·7)[\*](#TFN4){ref-type="table-fn"}       (55·8 to 102·9)              (52·5 to 92·2)               (60·1 to 91·2)               (−35·1 to −16)[\*](#TFN4){ref-type="table-fn"}         (−37·5 to −22·4)[\*](#TFN4){ref-type="table-fn"}       (−34·8 to −23·1)[\*](#TFN4){ref-type="table-fn"}

         Acute hepatitis A                                                                                        697\                           801\                                     1500\                  −31·6%\                                                −32·7%\                                                −32·2%\                                                         18·8\                        23·1\                        20·9\                −36·9%\                                                −37·5%\                                                −37·2%\
                                                                                                        (465 to 949)                   (565 to 1050)                              (1130 to 1870)                 (−42·8 to −10·4)[\*](#TFN4){ref-type="table-fn"}       (−44·1 to −19·5)[\*](#TFN4){ref-type="table-fn"}       (−40·9 to −21·1)[\*](#TFN4){ref-type="table-fn"}       (12·6 to 25·4)               (16·3 to 30·4)               (15·7 to 26·2)               (−47·4 to −16·2)[\*](#TFN4){ref-type="table-fn"}       (−48·6 to −24·5)[\*](#TFN4){ref-type="table-fn"}       (−45·5 to −26·3)[\*](#TFN4){ref-type="table-fn"}

         Acute hepatitis B                                                                                      2050\                          1470\                                      3530\                  −11·2%\                                                −10·5%\                                                −10·9%\                                                         52·4\                        38·0\                        45·1\                −24·7%\                                                −24·0%\                                                −24·5%\
                                                                                                        (1370 to 2460)                 (1040 to 1810)                             (2620 to 4120)                 (−20·0 to 1·6)                                         (−21·0 to 1·4)                                         (−18·2 to −2·0)[\*](#TFN4){ref-type="table-fn"}        (34·8 to 63·0)               (26·7 to 46·7)               (33·3 to 53·0)               (−32·1 to −13·9)[\*](#TFN4){ref-type="table-fn"}       (−33·0 to −13·7)[\*](#TFN4){ref-type="table-fn"}       (−30·4 to −17·0)[\*](#TFN4){ref-type="table-fn"}

         Acute hepatitis C                                                                                        106\                           122\                                       228\                 −30·5%\                                                −29·9%\                                                −30·2%\                                                           3·0\                         3·7\                         3·3\               −35·1%\                                                −34·6%\                                                −34·8%\
                                                                                                        (54 to 187)                    (64·9 to 207)                              (124 to 383)                   (−44·8 to −1·8)[\*](#TFN4){ref-type="table-fn"}        (−44·3 to −9·9)[\*](#TFN4){ref-type="table-fn"}        (−42·2 to −14·7)[\*](#TFN4){ref-type="table-fn"}       (1·5 to 5·3)                 (1·9 to 6·2)                 (1·8 to 5·6)                 (−48·3 to −7·0)[\*](#TFN4){ref-type="table-fn"}        (−48·4 to −15·3)[\*](#TFN4){ref-type="table-fn"}       (−46·4 to −20·3)[\*](#TFN4){ref-type="table-fn"}

         Acute hepatitis E                                                                                        382\                           356\                                       739\                 −24·5%\                                                −24·6%\                                                −24·6%\                                                           9·9\                         9·5\                         9·7\               −31·2%\                                                −30·9%\                                                −31·1%\
                                                                                                        (226 to 507)                   (247 to 459)                               (517 to 935)                   (−36·5 to −10·1)[\*](#TFN4){ref-type="table-fn"}       (−38·9 to −9·6)[\*](#TFN4){ref-type="table-fn"}        (−34·1 to −13·6)[\*](#TFN4){ref-type="table-fn"}       (5·9 to 13·1)                (6·6 to 12·3)                (6·8 to 12·2)                (−41·6 to −18·4)[\*](#TFN4){ref-type="table-fn"}       (−43·9 to −17·5)[\*](#TFN4){ref-type="table-fn"}       (−39·5 to −21·2)[\*](#TFN4){ref-type="table-fn"}

      Other unspecified infectious diseases                                                                     2990\                          2580\                                      5570\                    −6·3%\                                               −10·5%\                                                  −8·3%\                                                        82·5\                        72·7\                        77·6\                −14·1%\                                                −18·8%\                                                −16·4%\
                                                                                                        (2240 to 3420)                 (1980 to 3060)                             (4300 to 6430)                 (−13·2 to 4·5)                                         (−15·7 to −5·8)[\*](#TFN4){ref-type="table-fn"}        (−13·2 to −2·7)[\*](#TFN4){ref-type="table-fn"}        (61·4 to 94·3)               (55·3 to 85·8)               (59·3 to 89·5)               (−20·6 to −4·3)[\*](#TFN4){ref-type="table-fn"}        (−23·7 to −14·4)[\*](#TFN4){ref-type="table-fn"}       (−21 to −11·2)[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **    Maternal and neonatal disorders**                                                               **   103 000**\                **     94 500**\                           **   198 000**\                **−20·1%**\                                            **−19·0%**\                                            **−19·6%**\                                            **     2979·1**\             **     2839·4**\             **     2916·4**\             ** −22·9%**\                                           ** −22·9%**\                                           ** −22·9%**\
                                                                                                        **(97 100 to 109 000)**        **(89 300 to 100 000)**                    **(187 000 to 209 000)**       **(−23·3 to −16·5)**[\*](#TFN4){ref-type="table-fn"}   **(−22·1 to −15·9)**[\*](#TFN4){ref-type="table-fn"}   **(−22·5 to −16·5)**[\*](#TFN4){ref-type="table-fn"}   **(2808·2 to 3151·8)**       **(2691·4 to 3000·0)**       **(2761·0 to 3077·1)**       **(−26·1 to −19·4)**[\*](#TFN4){ref-type="table-fn"}   **(−25·8 to −19·8)**[\*](#TFN4){ref-type="table-fn"}   **(−25·8 to −19·9)**[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Maternal disorders                                                                                               ··                   11 800\                                    11 800\                         ··                                               −24·1%\                                                −24·1%\                                                             ··                     305·5\                       151·2\                       ··                                               −30·3%\                                                −30·5%\
                                                                                                                                       (11 000 to 12 800)                         (11 000 to 12 800)                                                                    (−28·3 to −19·9)[\*](#TFN4){ref-type="table-fn"}       (−28·3 to −19·9)[\*](#TFN4){ref-type="table-fn"}                                    (284·3 to 330·6)             (140·7 to 163·6)                                                                    (−34·1 to −26·3)[\*](#TFN4){ref-type="table-fn"}       (−34·3 to −26·5)[\*](#TFN4){ref-type="table-fn"}

         Maternal haemorrhage                                                                                          ··                      2230\                                      2230\                        ··                                               −52·4%\                                                −52·4%\                                                             ··                       57·8\                        28·6\                      ··                                               −56·3%\                                                −56·4%\
                                                                                                                                       (1910 to 2610)                             (1910 to 2610)                                                                        (−59·5 to −44·3)[\*](#TFN4){ref-type="table-fn"}       (−59·5 to −44·3)[\*](#TFN4){ref-type="table-fn"}                                    (49·6 to 67·4)               (24·5 to 33·4)                                                                      (−62·8 to −48·9)[\*](#TFN4){ref-type="table-fn"}       (−62·8 to −49·1)[\*](#TFN4){ref-type="table-fn"}

         Maternal sepsis and other pregnancy-related infections                                                        ··                      1250\                                      1250\                        ··                                               −27·8%\                                                −27·8%\                                                             ··                       32·5\                        16·1\                      ··                                               −33·4%\                                                −33·6%\
                                                                                                                                       (1080 to 1480)                             (1080 to 1480)                                                                        (−39·6 to −15·1)[\*](#TFN4){ref-type="table-fn"}       (−39·6 to −15·1)[\*](#TFN4){ref-type="table-fn"}                                    (27·8 to 38·4)               (13·8 to 19·0)                                                                      (−43·7 to −21·8)[\*](#TFN4){ref-type="table-fn"}       (−43·9 to −21·9)[\*](#TFN4){ref-type="table-fn"}

         Maternal hypertensive disorders                                                                               ··                      1870\                                      1870\                        ··                                                 −6·2%\                                                 −6·2%\                                                            ··                       48·9\                        24·2\                      ··                                               −13·0%\                                                −13·3%\
                                                                                                                                       (1620 to 2190)                             (1620 to 2190)                                                                        (−21·4 to 9·8)                                         (−21·4 to 9·8)                                                                      (42·2 to 57·1)               (20·9 to 28·2)                                                                      (−27·2 to 1·9)                                         (−27·5 to 1·6)

         Maternal obstructed labour and uterine rupture                                                                ··                      1120\                                      1120\                        ··                                               −16·1%\                                                −16·1%\                                                             ··                       28·8\                        14·3\                      ··                                               −23·7%\                                                −23·9%\
                                                                                                                                       (901 to 1380)                              (901 to 1380)                                                                         (−29·9 to −2·6)[\*](#TFN4){ref-type="table-fn"}        (−29·9 to −2·6)[\*](#TFN4){ref-type="table-fn"}                                     (23·2 to 35·6)               (11·5 to 17·6)                                                                      (−36·1 to −11·2)[\*](#TFN4){ref-type="table-fn"}       (−36·3 to −11·5)[\*](#TFN4){ref-type="table-fn"}

         Maternal abortive outcome                                                                                     ··                        982\                                       982\                       ··                                                 −8·7%\                                                 −8·7%\                                                            ··                       25·3\                        12·5\                      ··                                               −16·4%\                                                −16·6%\
                                                                                                                                       (827 to 1180)                              (827 to 1180)                                                                         (−23·9 to 8·8)                                         (−23·9 to 8·8)                                                                      (21·3 to 30·5)               (10·5 to 15·1)                                                                      (−30·2 to −0·5)[\*](#TFN4){ref-type="table-fn"}        (−30·3 to −0·7)[\*](#TFN4){ref-type="table-fn"}

         Ectopic pregnancy                                                                                             ··                        606\                                       606\                       ··                                               −12·8%\                                                −12·8%\                                                             ··                       15·7\                          7·8\                     ··                                               −19·6%\                                                −19·8%\
                                                                                                                                       (424 to 896)                               (424 to 896)                                                                          (−42·8 to 26·4)                                        (−42·8 to 26·4)                                                                     (11·0 to 23·4)               (5·4 to 11·6)                                                                       (−46·9 to 17·3)                                        (−47·1 to 16·9)

         Indirect maternal deaths                                                                                      ··                      1930\                                      1930\                        ··                                                 −6·1%\                                                 −6·1%\                                                            ··                       50·1\                        24·8\                      ··                                               −13·6%\                                                −13·9%\
                                                                                                                                       (1690 to 2220)                             (1690 to 2220)                                                                        (−19·2 to 6·8)                                         (−19·2 to 6·8)                                                                      (43·9 to 57·5)               (21·7 to 28·5)                                                                      (−25·5 to −2·0)[\*](#TFN4){ref-type="table-fn"}        (−25·8 to −2·3)[\*](#TFN4){ref-type="table-fn"}

         Late maternal deaths                                                                                          ··                        195\                                       195\                       ··                                                 −2·0%\                                                 −2·0%\                                                            ··                         5·1\                         2·5\                     ··                                                 −9·8%\                                               −10·1%\
                                                                                                                                       (152 to 251)                               (152 to 251)                                                                          (−8·2 to 4·1)                                          (−8·2 to 4·1)                                                                       (4·0 to 6·5)                 (2·0 to 3·2)                                                                        (−15·1 to −4·3)[\*](#TFN4){ref-type="table-fn"}        (−15·4 to −4·5)[\*](#TFN4){ref-type="table-fn"}

         Maternal deaths aggravated by HIV/AIDS                                                                        ··                          84·4\                                      84·4\                    ··                                               −26·7%\                                                −26·7%\                                                             ··                         2·2\                         1·1\                     ··                                               −34·1%\                                                −34·2%\
                                                                                                                                       (53·0 to 114)                              (53·0 to 114)                                                                         (−33·6 to −19·2)[\*](#TFN4){ref-type="table-fn"}       (−33·6 to −19·2)[\*](#TFN4){ref-type="table-fn"}                                    (1·4 to 2·9)                 (0·7 to 1·4)                                                                        (−40·4 to −27·3)[\*](#TFN4){ref-type="table-fn"}       (−40·6 to −27·5)[\*](#TFN4){ref-type="table-fn"}

         Other maternal disorders                                                                                      ··                      1520\                                      1520\                        ··                                                 −8·0%\                                                 −8·0%\                                                            ··                       39·2\                        19·4\                      ··                                               −15·5%\                                                −15·7%\
                                                                                                                                       (1280 to 1810)                             (1280 to 1810)                                                                        (−24·7 to 10·9)                                        (−24·7 to 10·9)                                                                     (33·0 to 46·7)               (16·4 to 23·1)                                                                      (−30·5 to 1·5)                                         (−30·7 to 1·3)

      Neonatal disorders                                                                                   103 000\                         82 700\                                  186 000\                    −20·1%\                                                −18·2%\                                                −19·3%\                                                     2979·1\                      2533·9\                      2765·2\                  −22·9%\                                                −21·9%\                                                −22·5%\
                                                                                                        (97 100 to 109 000)            (77 800 to 88 200)                         (175 000 to 197 000)           (−23·3 to −16·5)[\*](#TFN4){ref-type="table-fn"}       (−21·7 to −14·6)[\*](#TFN4){ref-type="table-fn"}       (−22·4 to −15·9)[\*](#TFN4){ref-type="table-fn"}       (2808·2 to 3151·8)           (2389·9 to 2691·1)           (2611·8 to 2922·7)           (−26·1 to −19·4)[\*](#TFN4){ref-type="table-fn"}       (−25·2 to −18·4)[\*](#TFN4){ref-type="table-fn"}       (−25·5 to −19·2)[\*](#TFN4){ref-type="table-fn"}

         Neonatal preterm birth                                                                              38 400\                        31 800\                                    70 200\                   −20·9%\                                                −18·7%\                                                −19·9%\                                                     1109·6\                        966·4\                    1041·2\                   −23·8%\                                                −22·7%\                                                −23·3%\
                                                                                                        (35 200 to 42 800)             (28 500 to 36 000)                         (64 400 to 77 200)             (−26·6 to −15·1)[\*](#TFN4){ref-type="table-fn"}       (−24·7 to −12·4)[\*](#TFN4){ref-type="table-fn"}       (−25·3 to −14·4)[\*](#TFN4){ref-type="table-fn"}       (1019·0 to 1236·1)           (871·4 to 1090·2)            (958·9 to 1138·5)            (−29·2 to −18·3)[\*](#TFN4){ref-type="table-fn"}       (−28·4 to −17·0)[\*](#TFN4){ref-type="table-fn"}       (−28·4 to −18·3)[\*](#TFN4){ref-type="table-fn"}

         Neonatal encephalopathy due to birth asphyxia and trauma                                            32 200\                        24 300\                                    56 500\                   −19·7%\                                                −18·4%\                                                −19·1%\                                                       928·1\                       742·9\                       838·9\                 −22·7%\                                                −22·2%\                                                −22·5%\
                                                                                                        (28 300 to 36 200)             (21 200 to 27 700)                         (50 200 to 63 100)             (−27·1 to −11·6)[\*](#TFN4){ref-type="table-fn"}       (−25·6 to −11·3)[\*](#TFN4){ref-type="table-fn"}       (−25·0 to −12·4)[\*](#TFN4){ref-type="table-fn"}       (817·0 to 1038·6)            (644·7 to 836·9)             (746·3 to 930·9)             (−29·8 to −14·9)[\*](#TFN4){ref-type="table-fn"}       (−29·0 to −15·4)[\*](#TFN4){ref-type="table-fn"}       (−28·0 to −16·4)[\*](#TFN4){ref-type="table-fn"}

         Neonatal sepsis and other neonatal infections                                                       11 900\                        10 100\                                    22 000\                   −10·5%\                                                  −3·2%\                                                 −7·3%\                                                      343·3\                       306·1\                       325·4\                 −14·1%\                                                  −7·8%\                                               −11·3%\
                                                                                                        (10 100 to 14 600)             (7820 to 13 700)                           (18 900 to 28 000)             (−20·2 to 0·8)                                         (−14·6 to 7·0)                                         (−15·3 to 1·5)                                         (291·8 to 416·1)             (241·7 to 420·6)             (281·2 to 417·5)             (−23·4 to −3·1)[\*](#TFN4){ref-type="table-fn"}        (−18·9 to 1·8)                                         (−19·0 to −2·7)[\*](#TFN4){ref-type="table-fn"}

         Haemolytic disease and other neonatal jaundice                                                         2890\                          2300\                                      5190\                  −31·9%\                                                −32·1%\                                                −32·0%\                                                         83·3\                        70·4\                        77·1\                −34·5%\                                                −35·3%\                                                −34·9%\
                                                                                                        (2480 to 3300)                 (1970 to 2660)                             (4610 to 5790)                 (−41·3 to −21·1)[\*](#TFN4){ref-type="table-fn"}       (−42·3 to −18·4)[\*](#TFN4){ref-type="table-fn"}       (−39·7 to −22·9)[\*](#TFN4){ref-type="table-fn"}       (71·5 to 95·2)               (60·1 to 81·8)               (68·4 to 86·0)               (−43·6 to −24·2)[\*](#TFN4){ref-type="table-fn"}       (−45·1 to −21·8)[\*](#TFN4){ref-type="table-fn"}       (−42·3 to −26·0)[\*](#TFN4){ref-type="table-fn"}

         Other neonatal disorders                                                                            17 600\                        14 300\                                    31 800\                   −22·3%\                                                −23·0%\                                                −22·6%\                                                       514·8\                       448·2\                       482·6\                 −24·4%\                                                −25·3%\                                                −24·8%\
                                                                                                        (13 900 to 19 800)             (12 200 to 16 000)                         (27 100 to 34 800)             (−30·3 to −12·3)[\*](#TFN4){ref-type="table-fn"}       (−31·3 to −13·2)[\*](#TFN4){ref-type="table-fn"}       (−28·7 to −14·7)[\*](#TFN4){ref-type="table-fn"}       (407·8 to 579·1)             (384·7 to 503·4)             (410·4 to 527·5)             (−32·2 to −14·7)[\*](#TFN4){ref-type="table-fn"}       (−33·3 to −15·8)[\*](#TFN4){ref-type="table-fn"}       (−30·6 to −17·1)[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **    Nutritional deficiencies**                                                                      **     23 600**\               **     34 400**\                           **     58 000**\               **−21·1%**\                                            **−14·0%**\                                            **−17·0%**\                                            **       655·9**\            **       964·9**\            **       808·7**\            ** −27·3%**\                                           ** −22·0%**\                                           ** −24·3%**\
                                                                                                        **(17 900 to 30 700)**         **(26 000 to 45 600)**                     **(44 300 to 76 900)**         **(−27·5 to −14·0)**[\*](#TFN4){ref-type="table-fn"}   **(−17·6 to −10·5)**[\*](#TFN4){ref-type="table-fn"}   **(−21·4 to −12·6)**[\*](#TFN4){ref-type="table-fn"}   **(499·1 to 849·1)**         **(731·6 to 1268·5)**        **(619·2 to 1065·8)**        **(−33·2 to −20·8)**[\*](#TFN4){ref-type="table-fn"}   **(−25·4 to −18·7)**[\*](#TFN4){ref-type="table-fn"}   **(−28·3 to −20·3)**[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Protein-energy malnutrition                                                                               7770\                          8430\                                   16 200\                   −36·5%\                                                −28·6%\                                                −32·7%\                                                       222·6\                       254·9\                       238·0\                 −40·7%\                                                −33·5%\                                                −37·2%\
                                                                                                        (6790 to 9010)                 (7490 to 9310)                             (14 500 to 18 000)             (−43·9 to −22·8)[\*](#TFN4){ref-type="table-fn"}       (−34·8 to −22·5)[\*](#TFN4){ref-type="table-fn"}       (−38·3 to −24·7)[\*](#TFN4){ref-type="table-fn"}       (194·7 to 258·2)             (225·6 to 281·7)             (212·7 to 264·8)             (−47·6 to −27·8)[\*](#TFN4){ref-type="table-fn"}       (−39·3 to −27·7)[\*](#TFN4){ref-type="table-fn"}       (−42·5 to −29·7)[\*](#TFN4){ref-type="table-fn"}

      Iodine deficiency                                                                                           886\                         1170\                                      2060\                    −6·9%\                                                 −7·0%\                                                 −6·9%\                                                        22·8\                        30·8\                        26·7\                −17·6%\                                                −17·2%\                                                −17·4%\
                                                                                                        (542 to 1370)                  (705 to 1870)                              (1250 to 3260)                 (−10·6 to −4·0)[\*](#TFN4){ref-type="table-fn"}        (−10·1 to −4·0)[\*](#TFN4){ref-type="table-fn"}        (−10·1 to −4·3)[\*](#TFN4){ref-type="table-fn"}        (14·0 to 35·4)               (18·5 to 48·9)               (16·2 to 42·3)               (−20·8 to −14·9)[\*](#TFN4){ref-type="table-fn"}       (−20·2 to −14·3)[\*](#TFN4){ref-type="table-fn"}       (−20·1 to −14·9)[\*](#TFN4){ref-type="table-fn"}

      Dietary iron deficiency                                                                                10 700\                        19 300\                                    30 000\                     −5·6%\                                                 −5·0%\                                                 −5·2%\                                                      291·9\                       514·3\                       403·0\                 −13·7%\                                                −14·6%\                                                −14·3%\
                                                                                                        (7040 to 15 800)               (13 000 to 27 800)                         (20 300 to 43 600)             (−11·3 to 0·3)                                         (−8·0 to −2·1)[\*](#TFN4){ref-type="table-fn"}         (−8·3 to −1·9)[\*](#TFN4){ref-type="table-fn"}         (191·3 to 428·4)             (345·7 to 740·8)             (272·4 to 586·6)             (−18·8 to −8·1)[\*](#TFN4){ref-type="table-fn"}        (−17·3 to −12·0)[\*](#TFN4){ref-type="table-fn"}       (−17·2 to −11·4)[\*](#TFN4){ref-type="table-fn"}

      Other nutritional deficiencies                                                                              561\                           885\                                     1450\                  −32·3%\                                                −21·7%\                                                −26·2%\                                                         15·3\                        23·8\                        19·5\                −40·7%\                                                −32·7%\                                                −35·9%\
                                                                                                        (479 to 693)                   (751 to 1020)                              (1250 to 1640)                 (−40·1 to −14·3)[\*](#TFN4){ref-type="table-fn"}       (−30·7 to −12·7)[\*](#TFN4){ref-type="table-fn"}       (−33·4 to −17·7)[\*](#TFN4){ref-type="table-fn"}       (13·1 to 18·9)               (20·0 to 27·7)               (16·8 to 22·3)               (−47·5 to −25·0)[\*](#TFN4){ref-type="table-fn"}       (−40·8 to −24·8)[\*](#TFN4){ref-type="table-fn"}       (−42·3 to −28·5)[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Non-communicable diseases**                                                                         **   811 000**\                **   740 000**\                            **1 550 000**\                 **  15·7%**\                                           **  16·4%**\                                           **  16·0%**\                                           **  21 329·9**\              **  18 204·5**\              **  19 676·5**\              **   −6·2%**\                                          **   −5·0%**\                                          **   −5·6%**\
                                                                                                        **(732 000 to 902 000)**       **(649 000 to 844 000)**                   **(1 380 000 to 1 750 000)**   **(14·5 to 16·9)**[\*](#TFN4){ref-type="table-fn"}     **(15·3 to 17·4)**[\*](#TFN4){ref-type="table-fn"}     **(15·1 to 16·9)**[\*](#TFN4){ref-type="table-fn"}     **(19 298·6 to 23 679·8)**   **(15 923·1 to 20 796·3)**   **(17 509·8 to 22 177·9)**   **(−7·4 to −5·2)**[\*](#TFN4){ref-type="table-fn"}     **(−6·1 to −4·1)**[\*](#TFN4){ref-type="table-fn"}     **(−6·6 to −4·8)**[\*](#TFN4){ref-type="table-fn"}

  **    Neoplasms**                                                                                     **   131 000**\                **   102 000**\                            **   234 000**\                **  20·2%**\                                           **  20·2%**\                                           **  20·2%**\                                           **     3417·7**\             **     2454·6**\             **     2900·9**\             **   −5·7%**\                                          **   −4·5%**\                                          **   −5·1%**\
                                                                                                        **(128 000 to 135 000)**       **(99 300 to 105 000)**                    **(229 000 to 238 000)**       **(17·8 to 22·6)**[\*](#TFN4){ref-type="table-fn"}     **(17·2 to 23·1)**[\*](#TFN4){ref-type="table-fn"}     **(18·3 to 22·0)**[\*](#TFN4){ref-type="table-fn"}     **(3337·7 to 3497·3)**       **(2386·7 to 2517·4)**       **(2842·8 to 2957)**         **(−7·6 to −3·9)**[\*](#TFN4){ref-type="table-fn"}     **(−7·0 to −2·3)**[\*](#TFN4){ref-type="table-fn"}     **(−6·6 to −3·7)**[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Lip and oral cavity cancer                                                                                3490\                          1770\                                      5250\                    27·3%\                                                 38·4%\                                                 30·8%\                                                        87·6\                        42·2\                        64·2\                    0·4%\                                                  9·5%\                                                  3·2%\
                                                                                                        (3240 to 3680)                 (1660 to 1880)                             (4980 to 5500)                 (18·3 to 34·2)[\*](#TFN4){ref-type="table-fn"}         (30·6 to 47·1)[\*](#TFN4){ref-type="table-fn"}         (24·1 to 36·6)[\*](#TFN4){ref-type="table-fn"}         (81·5 to 92·4)               (39·6 to 45·0)               (60·9 to 67·2)               (−6·6 to 5·8)                                          (3·3 to 16·5)[\*](#TFN4){ref-type="table-fn"}          (−2·0 to 7·7)

      Nasopharynx cancer                                                                                        1520\                            563\                                     2090\                    19·0%\                                                 16·9%\                                                 18·4%\                                                        38·0\                        13·6\                        25·4\                  −4·7%\                                                 −5·5%\                                                 −4·9%\
                                                                                                        (1440 to 1610)                 (539 to 589)                               (2000 to 2170)                 (13·2 to 25·4)[\*](#TFN4){ref-type="table-fn"}         (11·2 to 23·7)[\*](#TFN4){ref-type="table-fn"}         (14·0 to 23·1)[\*](#TFN4){ref-type="table-fn"}         (36·0 to 40·1)               (13·0 to 14·2)               (24·4 to 26·5)               (−9·2 to 0·4)                                          (−10·1 to −0·2)[\*](#TFN4){ref-type="table-fn"}        (−8·5 to −1·2)[\*](#TFN4){ref-type="table-fn"}

      Other pharynx cancer                                                                                      2340\                            927\                                     3260\                    34·5%\                                                 40·2%\                                                 36·1%\                                                        58·2\                        22·1\                        39·6\                    5·4%\                                                10·5%\                                                   6·6%\
                                                                                                        (1940 to 2540)                 (859 to 990)                               (2820 to 3460)                 (20·6 to 47·1)[\*](#TFN4){ref-type="table-fn"}         (30·1 to 49·4)[\*](#TFN4){ref-type="table-fn"}         (25·6 to 44·3)[\*](#TFN4){ref-type="table-fn"}         (48·3 to 63·4)               (20·4 to 23·6)               (34·3 to 42·0)               (−5·6 to 15·1)                                         (2·4 to 17·8)[\*](#TFN4){ref-type="table-fn"}          (−1·6 to 12·9)

      Oesophageal cancer                                                                                        7190\                          2590\                                      9780\                    11·2%\                                                   3·4%\                                                  9·0%\                                                     184·3\                         61·0\                      119·9\                 −14·5%\                                                −20·3%\                                                −16·2%\
                                                                                                        (6960 to 7420)                 (2480 to 2690)                             (9530 to 10 000)               (7·2 to 15·2)[\*](#TFN4){ref-type="table-fn"}          (−1·7 to 8·3)                                          (5·9 to 12·2)[\*](#TFN4){ref-type="table-fn"}          (178·3 to 190·1)             (58·5 to 63·4)               (116·9 to 123·0)             (−17·5 to −11·4)[\*](#TFN4){ref-type="table-fn"}       (−24·2 to −16·6)[\*](#TFN4){ref-type="table-fn"}       (−18·5 to −13·7)[\*](#TFN4){ref-type="table-fn"}

      Stomach cancer                                                                                         12 200\                           6880\                                   19 100\                       5·6%\                                                  4·5%\                                                  5·2%\                                                     317·8\                       163·0\                       235·9\                 −18·5%\                                                −18·1%\                                                −18·4%\
                                                                                                        (11 900 to 12 600)             (6680 to 7080)                             (18 700 to 19 600)             (2·4 to 9·2)[\*](#TFN4){ref-type="table-fn"}           (0·8 to 8·0)[\*](#TFN4){ref-type="table-fn"}           (2·8 to 7·8)[\*](#TFN4){ref-type="table-fn"}           (308·7 to 327·9)             (158·3 to 167·8)             (231·1 to 241·3)             (−20·9 to −15·8)[\*](#TFN4){ref-type="table-fn"}       (−21·1 to −15·4)[\*](#TFN4){ref-type="table-fn"}       (−20·2 to −16·3)[\*](#TFN4){ref-type="table-fn"}

      Colon and rectum cancer                                                                                10 700\                           8330\                                   19 000\                     26·9%\                                                 21·6%\                                                 24·5%\                                                      280·3\                       196·3\                       235·7\                   −2·6%\                                                 −6·0%\                                                 −4·1%\
                                                                                                        (10 200 to 11 000)             (8060 to 8580)                             (18 500 to 19 500)             (20·9 to 31·5)[\*](#TFN4){ref-type="table-fn"}         (15·9 to 26·0)[\*](#TFN4){ref-type="table-fn"}         (20·0 to 28·3)[\*](#TFN4){ref-type="table-fn"}         (269 to 290·5)               (189·9 to 202·2)             (229·7 to 242·0)             (−7·1 to 0·8)                                          (−10·4 to −2·6)[\*](#TFN4){ref-type="table-fn"}        (−7·5 to −1·2)[\*](#TFN4){ref-type="table-fn"}

      Liver cancer                                                                                           15 200\                           5530\                                   20 800\                     22·9%\                                                 17·6%\                                                 21·4%\                                                      382·9\                       130·9\                       253·6\                   −3·0%\                                                 −8·2%\                                                 −4·5%\
                                                                                                        (14 300 to 16 300)             (5320 to 5750)                             (19 900 to 21 800)             (16·8 to 31·8)[\*](#TFN4){ref-type="table-fn"}         (12·0 to 25·0)[\*](#TFN4){ref-type="table-fn"}         (17·3 to 27·5)[\*](#TFN4){ref-type="table-fn"}         (360·9 to 408·8)             (125·9 to 136·2)             (243·2 to 266·2)             (−7·7 to 4·0)                                          (−12·5 to −2·5)[\*](#TFN4){ref-type="table-fn"}        (−7·8 to 0·2)

         Liver cancer due to hepatitis B                                                                        7580\                          1970\                                      9550\                    16·4%\                                                   9·2%\                                                14·9%\                                                      187·3\                         47·0\                      115·8\                   −6·7%\                                               −13·1%\                                                  −8·2%\
                                                                                                        (7030 to 8270)                 (1840 to 2110)                             (8920 to 10 300)               (10·2 to 26·6)[\*](#TFN4){ref-type="table-fn"}         (2·6 to 17·3)[\*](#TFN4){ref-type="table-fn"}          (9·9 to 22·1)[\*](#TFN4){ref-type="table-fn"}          (173·8 to 204·4)             (43·8 to 50·4)               (108·3 to 124·4)             (−11·6 to 1·3)                                         (−18·4 to −6·7)[\*](#TFN4){ref-type="table-fn"}        (−12·1 to −2·5)[\*](#TFN4){ref-type="table-fn"}

         Liver cancer due to hepatitis C                                                                        3160\                          1800\                                      4960\                    29·5%\                                                 23·0%\                                                 27·1%\                                                        81·5\                        42·1\                        61·1\                  −1·0%\                                                 −6·1%\                                                 −2·9%\
                                                                                                        (2880 to 3450)                 (1690 to 1910)                             (4600 to 5330)                 (23·6 to 36·8)[\*](#TFN4){ref-type="table-fn"}         (18·0 to 29·5)[\*](#TFN4){ref-type="table-fn"}         (23·4 to 31·7)[\*](#TFN4){ref-type="table-fn"}         (74·7 to 88·7)               (39·6 to 44·7)               (56·9 to 65·6)               (−5·4 to 4·6)                                          (−9·9 to −1·1)[\*](#TFN4){ref-type="table-fn"}         (−5·7 to 0·6)

         Liver cancer due to alcohol use                                                                        2490\                            589\                                     3080\                    29·0%\                                                 23·6%\                                                 27·9%\                                                        63·2\                        13·9\                        37·6\                  0·4%\                                                  −4·2%\                                                 −0·5%\
                                                                                                        (2160 to 2910)                 (514 to 688)                               (2680 to 3590)                 (22·0 to 36·7)[\*](#TFN4){ref-type="table-fn"}         (18·4 to 30·0)[\*](#TFN4){ref-type="table-fn"}         (22·5 to 34·0)[\*](#TFN4){ref-type="table-fn"}         (55·2 to 73·3)               (12·1 to 16·2)               (32·9 to 43·8)               (−4·6 to 6·0)                                          (−8·2 to 0·7)                                          (−4·4 to 4·0)

         Liver cancer due to NASH                                                                                 956\                           505\                                     1460\                    40·7%\                                                 31·6%\                                                 37·4%\                                                        24·6\                        11·9\                        18·0\                    9·1%\                                                  1·6%\                                                  6·4%\
                                                                                                        (842 to 1070)                  (451 to 560)                               (1300 to 1620)                 (33·5 to 49·8)[\*](#TFN4){ref-type="table-fn"}         (25·4 to 39·2)[\*](#TFN4){ref-type="table-fn"}         (32·8 to 42·9)[\*](#TFN4){ref-type="table-fn"}         (21·8 to 27·6)               (10·6 to 13·2)               (16·1 to 20·0)               (3·7 to 16·1)[\*](#TFN4){ref-type="table-fn"}          (−3·1 to 7·3)                                          (3·0 to 10·6)[\*](#TFN4){ref-type="table-fn"}

         Liver cancer due to other causes                                                                       1050\                            670\                                     1720\                    24·9%\                                                 16·0%\                                                 21·3%\                                                        26·3\                        16·0\                        21·1\                    0·1%\                                                −8·1%\                                                 −3·3%\
                                                                                                        (930 to 1200)                  (607 to 743)                               (1540 to 1920)                 (17·6 to 34)[\*](#TFN4){ref-type="table-fn"}           (9·6 to 24·5)[\*](#TFN4){ref-type="table-fn"}          (16·2 to 27·7)[\*](#TFN4){ref-type="table-fn"}         (23·3 to 29·7)               (14·5 to 17·7)               (19·0 to 23·5)               (−5·3 to 7·2)                                          (−13 to −1·5)[\*](#TFN4){ref-type="table-fn"}          (−7·0 to 1·5)

      Gallbladder and biliary tract cancer                                                                      1460\                          2020\                                      3480\                    21·9%\                                                 22·0%\                                                 22·0%\                                                        38·7\                        47·5\                        43·2\                  −6·9%\                                                 −6·4%\                                                 −6·7%\
                                                                                                        (1220 to 1620)                 (1710 to 2160)                             (3040 to 3710)                 (15·8 to 27·9)[\*](#TFN4){ref-type="table-fn"}         (16·7 to 27·2)[\*](#TFN4){ref-type="table-fn"}         (18·0 to 26·4)[\*](#TFN4){ref-type="table-fn"}         (32·2 to 42·9)               (40·2 to 50·7)               (37·7 to 46·1)               (−11·4 to −2·5)[\*](#TFN4){ref-type="table-fn"}        (−10·5 to −2·4)[\*](#TFN4){ref-type="table-fn"}        (−9·8 to −3·4)[\*](#TFN4){ref-type="table-fn"}

      Pancreatic cancer                                                                                         4990\                          4090\                                      9080\                    33·6%\                                                 38·6%\                                                 35·8%\                                                      129·4\                         96·1\                      112·2\                     2·6%\                                                  6·0%\                                                  4·0%\
                                                                                                        (4830 to 5140)                 (4000 to 4190)                             (8890 to 9260)                 (28·1 to 38·1)[\*](#TFN4){ref-type="table-fn"}         (35·7 to 41·4)[\*](#TFN4){ref-type="table-fn"}         (32·5 to 38·6)[\*](#TFN4){ref-type="table-fn"}         (125·4 to 133·2)             (94·0 to 98·4)               (110·0 to 114·4)             (−1·5 to 6·0)                                          (3·8 to 8·1)[\*](#TFN4){ref-type="table-fn"}           (1·5 to 6·1)[\*](#TFN4){ref-type="table-fn"}

      Larynx cancer                                                                                             2730\                            547\                                     3280\                    16·9%\                                                 22·5%\                                                 17·8%\                                                       69·0\                        13·0\                        39·9\                   −9·6%\                                                 −4·0%\                                                 −8·8%\
                                                                                                        (2650 to 2820)                 (523 to 570)                               (3190 to 3380)                 (13·2 to 20·8)[\*](#TFN4){ref-type="table-fn"}         (17·1 to 28·0)[\*](#TFN4){ref-type="table-fn"}         (14·4 to 21·4)[\*](#TFN4){ref-type="table-fn"}         (66·9 to 71·1)               (12·4 to 13·5)               (38·8 to 41·0)               (−12·3 to −6·6)[\*](#TFN4){ref-type="table-fn"}        (−8·2 to 0·3)                                          (−11·3 to −6)[\*](#TFN4){ref-type="table-fn"}

      Tracheal, bronchus, and lung cancer                                                                    28 400\                        12 600\                                    40 900\                     22·3%\                                                 31·7%\                                                 25·0%\                                                      734·1\                       295·7\                       503·1\                   −6·4%\                                                   1·4%\                                                −4·0%\
                                                                                                        (27 500 to 29 200)             (12 200 to 13 000)                         (40 000 to 41 900)             (18·0 to 26·0)[\*](#TFN4){ref-type="table-fn"}         (27·5 to 35·9)[\*](#TFN4){ref-type="table-fn"}         (21·9 to 27·8)[\*](#TFN4){ref-type="table-fn"}         (712 to 754·8)               (286·6 to 305·2)             (491·9 to 514·3)             (−9·6 to −3·5)[\*](#TFN4){ref-type="table-fn"}         (−1·8 to 4·6)                                          (−6·4 to −1·9)[\*](#TFN4){ref-type="table-fn"}

      Malignant skin melanoma                                                                                     905\                           749\                                     1650\                    17·3%\                                                 17·3%\                                                 17·3%\                                                        23·3\                        17·9\                        20·5\                  −6·2%\                                                 −6·2%\                                                 −6·3%\
                                                                                                        (603 to 1130)                  (584 to 966)                               (1330 to 1940)                 (9·6 to 22·9)[\*](#TFN4){ref-type="table-fn"}          (11·1 to 25·5)[\*](#TFN4){ref-type="table-fn"}         (14·0 to 21·0)[\*](#TFN4){ref-type="table-fn"}         (15·4 to 28·9)               (14·0 to 23·1)               (16·5 to 24·0)               (−12·0 to −1·6)[\*](#TFN4){ref-type="table-fn"}        (−11·0 to 0·8)                                         (−8·9 to −3)[\*](#TFN4){ref-type="table-fn"}

      Non-melanoma skin cancer                                                                                    929\                           400\                                     1330\                    28·4%\                                                 34·4%\                                                 30·1%\                                                        24·9\                          9·4\                       16·6\                  −1·5%\                                                   3·7%\                                                  0·3%\
                                                                                                        (883 to 976)                   (380 to 426)                               (1270 to 1400)                 (25·3 to 30·9)[\*](#TFN4){ref-type="table-fn"}         (27·7 to 40·1)[\*](#TFN4){ref-type="table-fn"}         (26·5 to 32·8)[\*](#TFN4){ref-type="table-fn"}         (23·6 to 26·2)               (9·0 to 10·0)                (15·9 to 17·5)               (−3·8 to 0·4)                                          (−1·4 to 8·1)                                          (−2·3 to 2·4)

         Non-melanoma skin cancer (squamous-cell carcinoma)                                                       928\                           399\                                     1330\                    28·4%\                                                 34·5%\                                                 30·1%\                                                        24·8\                          9·4\                       16·6\                  −1·5%\                                                   3·7%\                                                  0·3%\
                                                                                                        (883 to 975)                   (379 to 424)                               (1270 to 1390)                 (25·3 to 30·9)[\*](#TFN4){ref-type="table-fn"}         (27·7 to 40·2)[\*](#TFN4){ref-type="table-fn"}         (26·5 to 32·8)[\*](#TFN4){ref-type="table-fn"}         (23·6 to 26·1)               (8·9 to 10·0)                (15·9 to 17·5)               (−3·8 to 0·4)                                          (−1·4 to 8·1)                                          (−2·3 to 2·4)

         Non-melanoma skin cancer (basal-cell carcinoma)                                                              1·35\                          1·12\                                      2·47\              32·6%\                                                 28·6%\                                                 30·8%\                                                          0\                           0\                           0\                   −1·5%\                                                 −1·5%\                                                 −1·0%\
                                                                                                        (0·512 to 2·86)                (0·433 to 2·33)                            (0·945 to 5·20)                (24·7 to 39·4)[\*](#TFN4){ref-type="table-fn"}         (20·0 to 35·8)[\*](#TFN4){ref-type="table-fn"}         (23·1 to 37·0)[\*](#TFN4){ref-type="table-fn"}         (0 to 0·1)                   (0 to 0·1)                   (0 to 0·1)                   (−7·3 to 3·4)                                          (−7·6 to 3·5)                                          (−6·4 to 3·2)

      Breast cancer                                                                                               285\                      17 400\                                    17 700\                     39·0%\                                                 24·4%\                                                 24·6%\                                                          7·3\                     414·7\                       216·3\                     7·9%\                                                −1·4%\                                                 −1·2%\
                                                                                                        (273 to 299)                   (16 600 to 18 400)                         (16 900 to 18 700)             (31·5 to 46·1)[\*](#TFN4){ref-type="table-fn"}         (17·8 to 29·1)[\*](#TFN4){ref-type="table-fn"}         (18·1 to 29·3)[\*](#TFN4){ref-type="table-fn"}         (7·0 to 7·6)                 (395·5 to 437·6)             (206·4 to 228·1)             (2·3 to 13·2)[\*](#TFN4){ref-type="table-fn"}          (−6·5 to 2·4)                                          (−6·3 to 2·5)

      Cervical cancer                                                                                                  ··                      8060\                                      8060\                        ··                                                 15·2%\                                                 15·2%\                                                            ··                     193·0\                         98·2\                      ··                                                 −7·1%\                                                 −7·0%\
                                                                                                                                       (7530 to 8400)                             (7530 to 8400)                                                                        (9·5 to 19·2)[\*](#TFN4){ref-type="table-fn"}          (9·5 to 19·2)[\*](#TFN4){ref-type="table-fn"}                                       (180·2 to 201·2)             (91·7 to 102·4)                                                                     (−11·8 to −3·9)[\*](#TFN4){ref-type="table-fn"}        (−11·6 to −3·8)[\*](#TFN4){ref-type="table-fn"}

      Uterine cancer                                                                                                   ··                      2140\                                      2140\                        ··                                                 16·6%\                                                 16·6%\                                                            ··                       50·5\                        26·3\                      ··                                                 −9·8%\                                                 −9·8%\
                                                                                                                                       (2060 to 2230)                             (2060 to 2230)                                                                        (13·3 to 20·8)[\*](#TFN4){ref-type="table-fn"}         (13·3 to 20·8)[\*](#TFN4){ref-type="table-fn"}                                      (48·5 to 52·5)               (25·2 to 27·3)                                                                      (−12·4 to −6·7)[\*](#TFN4){ref-type="table-fn"}        (−12·4 to −6·7)[\*](#TFN4){ref-type="table-fn"}

      Ovarian cancer                                                                                                   ··                      4670\                                      4670\                        ··                                               29%\                                                     29·0%\                                                            ··                     110·9\                         57·1\                      ··                                                   1·3%\                                                  1·2%\
                                                                                                                                       (4530 to 4830)                             (4530 to 4830)                                                                        (24·7 to 33·1)[\*](#TFN4){ref-type="table-fn"}         (24·7 to 33·1)[\*](#TFN4){ref-type="table-fn"}                                      (107·5 to 114·6)             (55·4 to 59·0)                                                                      (−2·0 to 4·5)                                          (−2·1 to 4·3)

      Prostate cancer                                                                                           7060\                                 ··                                  7060\                    29·7%\                                                     ··                                                 29·7%\                                                      201·3\                             ··                       90·0\                  −4·4%\                                                     ··                                                 −2·6%\
                                                                                                        (6050 to 8350)                                                            (6050 to 8350)                 (26·3 to 36·3)[\*](#TFN4){ref-type="table-fn"}                                                                (26·3 to 36·3)[\*](#TFN4){ref-type="table-fn"}         (171·7 to 237·1)                                          (77·2 to 106·6)              (−6·8 to 0·6)                                                                                                 (−5·1 to 2·4)

      Testicular cancer                                                                                           375\                                ··                                    375\                     2·7%\                                                    ··                                                   2·7%\                                                         9·5\                           ··                         4·7\                 −9·4%\                                                     ··                                                 −9·2%\
                                                                                                        (356 to 398)                                                              (356 to 398)                   (−1·4 to 8·0)                                                                                                 (−1·4 to 8·0)                                          (9·0 to 10·1)                                             (4·5 to 5·0)                 (−13·0 to −4·7)[\*](#TFN4){ref-type="table-fn"}                                                               (−12·9 to −4·5)[\*](#TFN4){ref-type="table-fn"}

      Kidney cancer                                                                                             2170\                          1120\                                      3280\                    25·3%\                                                 19·2%\                                                 23·2%\                                                        56·5\                        27·2\                        41·1\                  −1·9%\                                                 −5·7%\                                                 −3·2%\
                                                                                                        (2030 to 2240)                 (1030 to 1160)                             (3090 to 3390)                 (20·3 to 29·6)[\*](#TFN4){ref-type="table-fn"}         (11·8 to 25·7)[\*](#TFN4){ref-type="table-fn"}         (18·5 to 27·3)[\*](#TFN4){ref-type="table-fn"}         (53·0 to 58·5)               (25·0 to 28·3)               (38·7 to 42·5)               (−5·7 to 1·4)                                          (−11·5 to −0·3)[\*](#TFN4){ref-type="table-fn"}        (−6·9 to 0·1)

      Bladder cancer                                                                                            2710\                            889\                                     3600\                    24·2%\                                                 20·6%\                                                 23·3%\                                                        74·2\                        20·9\                        45·3\                  −6·5%\                                                 −7·7%\                                                 −6·4%\
                                                                                                        (2600 to 2870)                 (854 to 924)                               (3480 to 3770)                 (21·1 to 27·3)[\*](#TFN4){ref-type="table-fn"}         (14·3 to 26·1)[\*](#TFN4){ref-type="table-fn"}         (20·6 to 26·0)[\*](#TFN4){ref-type="table-fn"}         (71·2 to 78·7)               (20·1 to 21·7)               (43·7 to 47·4)               (−8·8 to −4·2)[\*](#TFN4){ref-type="table-fn"}         (−12·5 to −3·4)[\*](#TFN4){ref-type="table-fn"}        (−8·4 to −4·3)[\*](#TFN4){ref-type="table-fn"}

      Brain and nervous system cancer                                                                           5030\                          3720\                                      8740\                    24·2%\                                                 12·4%\                                                 18·9%\                                                      129·4\                         95·0\                      111·9\                     5·0%\                                                −5·3%\                                                   0·4%\
                                                                                                        (4200 to 5740)                 (2690 to 4210)                             (7650 to 9550)                 (16·8 to 33·9)[\*](#TFN4){ref-type="table-fn"}         (−3·8 to 31·5)                                         (12·3 to 25·1)[\*](#TFN4){ref-type="table-fn"}         (108·3 to 147·9)             (68·6 to 107·9)              (97·8 to 122·5)              (−1·2 to 13·3)                                         (−19·1 to 11·1)                                        (−5·3 to 5·7)

      Thyroid cancer                                                                                              468\                           665\                                     1130\                    30·3%\                                                 19·6%\                                                 23·8%\                                                        12·1\                        16·0\                        14·1\                    3·7%\                                                −3·8%\                                                 −0·9%\
                                                                                                        (444 to 493)                   (618 to 747)                               (1070 to 1230)                 (21·6 to 36·6)[\*](#TFN4){ref-type="table-fn"}         (12·6 to 27·0)[\*](#TFN4){ref-type="table-fn"}         (18·6 to 29·6)[\*](#TFN4){ref-type="table-fn"}         (11·5 to 12·7)               (14·9 to 18·0)               (13·3 to 15·3)               (−3·1 to 8·6)                                          (−9·6 to 2·4)                                          (−5·1 to 3·8)

      Mesothelioma                                                                                                478\                           193\                                       671\                   23·0%\                                                 16·7%\                                                 21·1%\                                                        12·5\                          4·6\                         8·3\                 −4·9%\                                                 −7·0%\                                                 −5·3%\
                                                                                                        (462 to 494)                   (181 to 208)                               (648 to 693)                   (15·9 to 29·0)[\*](#TFN4){ref-type="table-fn"}         (7·0 to 25·5)[\*](#TFN4){ref-type="table-fn"}          (13·9 to 27·4)[\*](#TFN4){ref-type="table-fn"}         (12·1 to 12·9)               (4·3 to 5·0)                 (8·0 to 8·6)                 (−10·2 to −0·4)[\*](#TFN4){ref-type="table-fn"}        (−14·2 to −0·6)[\*](#TFN4){ref-type="table-fn"}        (−10·7 to −0·7)[\*](#TFN4){ref-type="table-fn"}

      Hodgkin lymphoma                                                                                            871\                           508\                                     1380\                    −6·0%\                                                 −1·8%\                                                 −4·5%\                                                        22·5\                        13·1\                        17·8\                −18·3%\                                                −13·1%\                                                −16·6%\
                                                                                                        (705 to 1090)                  (400 to 606)                               (1160 to 1620)                 (−9·6 to −2·3)[\*](#TFN4){ref-type="table-fn"}         (−7·7 to 4·4)                                          (−8·0 to −1·1)[\*](#TFN4){ref-type="table-fn"}         (18·1 to 28·2)               (10·3 to 15·6)               (14·9 to 20·9)               (−21·5 to −15·1)[\*](#TFN4){ref-type="table-fn"}       (−18·4 to −7·1)[\*](#TFN4){ref-type="table-fn"}        (−19·5 to −13·4)[\*](#TFN4){ref-type="table-fn"}

      Non-Hodgkin lymphoma                                                                                      4260\                          2760\                                      7020\                    23·2%\                                                 21·5%\                                                 22·5%\                                                      111·1\                         68·5\                        89·3\                    1·2%\                                                −0·7%\                                                   0·4%\
                                                                                                        (4070 to 4420)                 (2670 to 2860)                             (6790 to 7230)                 (12·7 to 28·8)[\*](#TFN4){ref-type="table-fn"}         (14·5 to 27·8)[\*](#TFN4){ref-type="table-fn"}         (16·2 to 27·3)[\*](#TFN4){ref-type="table-fn"}         (106·2 to 115·4)             (66·1 to 71·2)               (86·1 to 92·2)               (−7·2 to 5·8)                                          (−6·6 to 4·7)                                          (−4·9 to 4·6)

      Multiple myeloma                                                                                          1240\                          1080\                                      2330\                    32·4%\                                                 29·3%\                                                 30·9%\                                                        32·4\                        25·5\                        28·8\                    1·7%\                                                −0·5%\                                                   0·7%\
                                                                                                        (1090 to 1460)                 (1030 to 1240)                             (2180 to 2610)                 (23·6 to 38·6)[\*](#TFN4){ref-type="table-fn"}         (23·9 to 34·6)[\*](#TFN4){ref-type="table-fn"}         (26·1 to 35·0)[\*](#TFN4){ref-type="table-fn"}         (28·2 to 37·9)               (24·3 to 29·2)               (26·9 to 32·2)               (−4·8 to 6·3)                                          (−4·5 to 3·6)                                          (−2·9 to 3·8)

      Leukaemia                                                                                                 6820\                          5150\                                   12 000\                       4·3%\                                                  0·6%\                                                  2·7%\                                                     181·0\                       134·2\                       156·8\                 −10·4%\                                                −13·5%\                                                −11·7%\
                                                                                                        (6010 to 7300)                 (4420 to 5630)                             (10 700 to 12 800)             (0·4 to 9·0)[\*](#TFN4){ref-type="table-fn"}           (−8·4 to 6·0)                                          (−3·3 to 6·6)                                          (159·4 to 194·1)             (115·0 to 147·3)             (140·8 to 168·1)             (−13·9 to −6·5)[\*](#TFN4){ref-type="table-fn"}        (−21·6 to −8·5)[\*](#TFN4){ref-type="table-fn"}        (−17 to −8·3)[\*](#TFN4){ref-type="table-fn"}

         Acute lymphoid leukaemia                                                                               1580\                          1130\                                      2700\                      4·2%\                                                  7·8%\                                                  5·6%\                                                       42·2\                        31·1\                        36·7\                  −5·7%\                                                 −2·3%\                                                 −4·4%\
                                                                                                        (1360 to 1740)                 (923 to 1310)                              (2380 to 2990)                 (−6·1 to 19·1)                                         (−13·8 to 18·0)                                        (−8·2 to 15·9)                                         (36·2 to 46·7)               (25·5 to 36·4)               (32·2 to 40·7)               (−15·3 to 7·9)                                         (−22·5 to 7·4)                                         (−17·4 to 5·0)

         Chronic lymphoid leukaemia                                                                               436\                           273\                                       709\                   20·5%\                                                 20·4%\                                                 20·5%\                                                        11·8\                          6·5\                         8·9\                 −8·4%\                                                 −7·1%\                                                 −7·7%\
                                                                                                        (401 to 473)                   (245 to 296)                               (667 to 755)                   (15·0 to 26·7)[\*](#TFN4){ref-type="table-fn"}         (15·9 to 24·7)[\*](#TFN4){ref-type="table-fn"}         (16·4 to 24·5)[\*](#TFN4){ref-type="table-fn"}         (10·9 to 12·8)               (5·8 to 7·0)                 (8·4 to 9·5)                 (−12·5 to −3·7)[\*](#TFN4){ref-type="table-fn"}        (−10·6 to −3·7)[\*](#TFN4){ref-type="table-fn"}        (−10·8 to −4·6)[\*](#TFN4){ref-type="table-fn"}

         Acute myeloid leukaemia                                                                                1870\                          1350\                                      3220\                    20·5%\                                                 10·9%\                                                 16·3%\                                                        49·2\                        34·5\                        41·7\                    1·9%\                                                −5·9%\                                                 −1·4%\
                                                                                                        (1590 to 2020)                 (1180 to 1520)                             (2890 to 3440)                 (11·1 to 29·1)[\*](#TFN4){ref-type="table-fn"}         (−6·1 to 19·9)                                         (4·5 to 24·6)[\*](#TFN4){ref-type="table-fn"}          (41·7 to 53·1)               (30·0 to 39·1)               (37·3 to 44·5)               (−5·8 to 9·1)                                          (−20·6 to 2·1)                                         (−11·2 to 5·8)

         Chronic myeloid leukaemia                                                                                347\                           308\                                       655\                   −1·8%\                                                 −1·4%\                                                 −1·6%\                                                          9·0\                         7·5\                         8·2\               −20·3%\                                                −19·0%\                                                −19·6%\
                                                                                                        (309 to 383)                   (259 to 358)                               (595 to 713)                   (−6·1 to 3·1)                                          (−7·5 to 3·6)                                          (−5·0 to 1·7)                                          (8·0 to 9·9)                 (6·3 to 8·7)                 (7·4 to 8·9)                 (−23·7 to −16·4)[\*](#TFN4){ref-type="table-fn"}       (−23·9 to −14·8)[\*](#TFN4){ref-type="table-fn"}       (−22·4 to −17·0)[\*](#TFN4){ref-type="table-fn"}

         Other leukaemia                                                                                          2590\                        2090\                                      4690\                    −6·0%\                                                 −9·7%\                                                 −7·7%\                                                        68·8\                        54·6\                        61·4\                −18·9%\                                                −22·3%\                                                −20·5%\
                                                                                                        (2190 to 2920)                 (1700 to 2320)                             (4040 to 5120)                 (−11·4 to 1·5)                                         (−19·9 to −2·4)[\*](#TFN4){ref-type="table-fn"}        (−14·2 to −1·4)[\*](#TFN4){ref-type="table-fn"}        (58·1 to 77·3)               (44·1 to 60·7)               (53·0 to 67·0)               (−23·4 to −12·6)[\*](#TFN4){ref-type="table-fn"}       (−31·4 to −15·8)[\*](#TFN4){ref-type="table-fn"}       (−26·1 to −15·1)[\*](#TFN4){ref-type="table-fn"}

      Other malignant cancers                                                                                   6300\                          5570\                                   11 900\                     21·1%\                                                 23·1%\                                                 22·0%\                                                      165·0\                       142·4\                       153·2\                     2·0%\                                                  3·7%\                                                  2·7%\
                                                                                                        (5620 to 6650)                 (5090 to 5960)                             (11 000 to 12 400)             (14·3 to 27·3)[\*](#TFN4){ref-type="table-fn"}         (17·0 to 28·8)[\*](#TFN4){ref-type="table-fn"}         (15·8 to 27·0)[\*](#TFN4){ref-type="table-fn"}         (147·5 to 174·4)             (129·9 to 152·7)             (142·0 to 160·8)             (−3·7 to 7·1)                                          (−1·8 to 9·0)                                          (−2·5 to 7·0)

      Other neoplasms                                                                                           1290\                          1190\                                      2480\                    35·6%\                                                 30·2%\                                                 33·0%\                                                        34·5\                        29·4\                        31·8\                    9·5%\                                                  6·0%\                                                  7·9%\
                                                                                                        (963 to 1690)                  (926 to 1540)                              (2080 to 2980)                 (23·6 to 50·5)[\*](#TFN4){ref-type="table-fn"}         (20·3 to 43·3)[\*](#TFN4){ref-type="table-fn"}         (26·1 to 42·4)[\*](#TFN4){ref-type="table-fn"}         (25·4 to 45·1)               (23·1 to 38·1)               (26·6 to 38·2)               (−0·4 to 21·8)                                         (−2·3 to 17·3)                                         (2·1 to 16·2)[\*](#TFN4){ref-type="table-fn"}

         Myelodysplastic, myeloproliferative, and other haemopoietic neoplasms                                  1180\                          1060\                                      2240\                    36·2%\                                                 31·3%\                                                 33·9%\                                                        31·6\                        26·0\                        28·6\                    8·7%\                                                  5·4%\                                                  7·2%\
                                                                                                        (876 to 1550)                  (823 to 1380)                              (1880 to 2720)                 (23·8 to 51·8)[\*](#TFN4){ref-type="table-fn"}         (22·3 to 44·4)[\*](#TFN4){ref-type="table-fn"}         (26·8 to 43·1)[\*](#TFN4){ref-type="table-fn"}         (23·2 to 41·4)               (20·3 to 33·8)               (23·9 to 34·6)               (−1·4 to 21·4)                                         (−2·4 to 16·6)                                         (1·4 to 15·3)[\*](#TFN4){ref-type="table-fn"}

         Benign and in-situ intestinal neoplasms                                                                      0\                             0\                                         0\                     -                                                      -                                                      -                                                           0\                           0\                           0\                     -                                                      -                                                      -
                                                                                                        (0 to 0)                       (0 to 0)                                   (0 to 0)                                                                                                                                                                                            (0 to 0)                     (0 to 0)                     (0 to 0)                                                                                                                                   

         Benign and in-situ cervical and uterine neoplasms                                                             -                             0\                                         0\                     -                                                      -                                                      -                                                           -                            0\                           0\                     -                                                      -                                                      -
                                                                                                                                       (0 to 0)                                   (0 to 0)                                                                                                                                                                                                                         (0 to 0)                     (0 to 0)                                                                                                                                   

         Other benign and in-situ neoplasms                                                                       111\                           126\                                       237\                   29·1%\                                                 21·5%\                                                 25·0%\                                                          2·9\                         3·4\                         3·2\                 18·7%\                                                 10·6%\                                                 14·3%\
                                                                                                        (77·4 to 148)                  (89·7 to 150)                              (186 to 278)                   (18·4 to 45·4)[\*](#TFN4){ref-type="table-fn"}         (5·6 to 39·3)[\*](#TFN4){ref-type="table-fn"}          (12·7 to 38·6)[\*](#TFN4){ref-type="table-fn"}         (2·0 to 3·9)                 (2·4 to 4·1)                 (2·5 to 3·7)                 (8·9 to 33·9)[\*](#TFN4){ref-type="table-fn"}          (−4·1 to 26·8)                                         (3·0 to 27·0)[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **    Cardiovascular diseases**                                                                       **   210 000**\                **   156 000**\                            **   366 000**\                **  17·1%**\                                           **  15·4%**\                                           **  16·4%**\                                           **     5588·6**\             **     3680·1**\             **     4597·9**\             **   −9·3%**\                                          ** −10·8%**\                                           **   −9·9%**\
                                                                                                        **(204 000 to 216 000)**       **(150 000 to 162 000)**                   **(355 000 to 377 000)**       **(15·3 to 19·0)[\*](#TFN4){ref-type="table-fn"}**     **(13·5 to 17·5)[\*](#TFN4){ref-type="table-fn"}**     **(15·0 to 17·8)[\*](#TFN4){ref-type="table-fn"}**     **(5428·4 to 5743·1)**       **(3541·4 to 3821·0)**       **(4463·7 to 4734·2)**       **(−10·7 to −7·8)[\*](#TFN4){ref-type="table-fn"}**    **(−12·4 to −9·3)[\*](#TFN4){ref-type="table-fn"}**    **(−11·0 to −8·8)[\*](#TFN4){ref-type="table-fn"}**

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Rheumatic heart disease                                                                                   4110\                          5280\                                      9390\                    −9·2%\                                                 −3·1%\                                                 −5·9%\                                                      106·9\                       130·3\                       118·7\                 −23·8%\                                                −19·6%\                                                −21·5%\
                                                                                                        (3710 to 4630)                 (4710 to 5950)                             (8580 to 10 300)               (−14·6 to −4·0)[\*](#TFN4){ref-type="table-fn"}        (−8·6 to 2·4)                                          (−10·6 to −2·2)[\*](#TFN4){ref-type="table-fn"}        (96·7 to 120·0)              (116·1 to 147·3)             (108·5 to 130·7)             (−28·3 to −19·5)[\*](#TFN4){ref-type="table-fn"}       (−24·3 to −14·9)[\*](#TFN4){ref-type="table-fn"}       (−25·4 to −18·2)[\*](#TFN4){ref-type="table-fn"}

      Ischaemic heart disease                                                                              105 000\                         65 300\                                  170 000\                      17·8%\                                                 17·0%\                                                 17·5%\                                                    2776\                        1534·3\                      2132·1\                    −9·2%\                                               −10·4%\                                                  −9·7%\
                                                                                                        (103 000 to 108 000)           (63 300 to 67 200)                         (167 000 to 174 000)           (15·7 to 20·0)[\*](#TFN4){ref-type="table-fn"}         (14·6 to 19·4)[\*](#TFN4){ref-type="table-fn"}         (15·7 to 19·2)[\*](#TFN4){ref-type="table-fn"}         (2715·3 to 2843·4)           (1487·3 to 1580·5)           (2093·7 to 2179·8)           (−10·8 to −7·6)[\*](#TFN4){ref-type="table-fn"}        (−12·3 to −8·6)[\*](#TFN4){ref-type="table-fn"}        (−11·0 to −8·4)[\*](#TFN4){ref-type="table-fn"}

      Stroke                                                                                                 72 200\                        59 900\                                  132 000\                      17·4%\                                                 13·6%\                                                 15·7%\                                                    1924·7\                      1412·1\                      1657·2\                    −9·9%\                                               −12·5%\                                                −11·0%\
                                                                                                        (69 400 to 75 000)             (56 700 to 63 000)                         (126 000 to 137 000)           (14·6 to 20·1)[\*](#TFN4){ref-type="table-fn"}         (10·9 to 16·4)[\*](#TFN4){ref-type="table-fn"}         (13·5 to 17·7)[\*](#TFN4){ref-type="table-fn"}         (1848·8 to 1998·4)           (1336·8 to 1485·8)           (1587·4 to 1723·8)           (−11·9 to −7·9)[\*](#TFN4){ref-type="table-fn"}        (−14·6 to −10·4)[\*](#TFN4){ref-type="table-fn"}       (−12·6 to −9·4)[\*](#TFN4){ref-type="table-fn"}

         Ischaemic stroke                                                                                    28 500\                        26 700\                                    55 100\                     28·6%\                                                 20·8%\                                                 24·7%\                                                      790·0\                       625·2\                       702·8\                   −3·7%\                                                 −8·1%\                                                 −5·8%\
                                                                                                        (26 400 to 30 600)             (24 400 to 29 000)                         (50 900 to 59 400)             (25·0 to 32·2)[\*](#TFN4){ref-type="table-fn"}         (17·3 to 24·2)[\*](#TFN4){ref-type="table-fn"}         (21·8 to 27·5)[\*](#TFN4){ref-type="table-fn"}         (732·7 to 846·5)             (570·9 to 679·3)             (649·5 to 756·5)             (−6·3 to −1·0)[\*](#TFN4){ref-type="table-fn"}         (−10·8 to −5·6)[\*](#TFN4){ref-type="table-fn"}        (−8·0 to −3·7)[\*](#TFN4){ref-type="table-fn"}

         Intracerebral haemorrhage                                                                           37 400\                        27 200\                                    64 500\                     10·7%\                                                   7·9%\                                                  9·5%\                                                     971·6\                       641·7\                       800·3\                 −14·5%\                                                −16·4%\                                                −15·2%\
                                                                                                        (35 900 to 38 900)             (25 900 to 28 500)                         (62 300 to 66 600)             (7·5 to 14·2)[\*](#TFN4){ref-type="table-fn"}          (4·4 to 11·6)[\*](#TFN4){ref-type="table-fn"}          (6·7 to 12·0)[\*](#TFN4){ref-type="table-fn"}          (933·9 to 1011·4)            (611·1 to 673·3)             (773·3 to 826·1)             (−16·9 to −11·8)[\*](#TFN4){ref-type="table-fn"}       (−19·1 to −13·6)[\*](#TFN4){ref-type="table-fn"}       (−17·4 to −13·3)[\*](#TFN4){ref-type="table-fn"}

         Subarachnoid haemorrhage                                                                               6350\                          6060\                                   12 400\                     13·4%\                                                 10·9%\                                                 12·2%\                                                      163·1\                       145·2\                       154·1\                   −8·8%\                                               −12·0%\                                                −10·4%\
                                                                                                        (5680 to 7240)                 (5610 to 6780)                             (11 600 to 13 700)             (7·6 to 24·3)[\*](#TFN4){ref-type="table-fn"}          (7·1 to 14·7)[\*](#TFN4){ref-type="table-fn"}          (8·5 to 17·3)[\*](#TFN4){ref-type="table-fn"}          (145·8 to 185·9)             (134·5 to 162·8)             (143·7 to 170·1)             (−13·7 to −0·5)[\*](#TFN4){ref-type="table-fn"}        (−15·0 to −9·0)[\*](#TFN4){ref-type="table-fn"}        (−13·3 to −6·4)[\*](#TFN4){ref-type="table-fn"}

      Hypertensive heart disease                                                                                7880\                          8660\                                   16 500\                     39·5%\                                                 32·2%\                                                 35·6%\                                                      214·6\                       203·2\                       209·4\                     7·0%\                                                  0·9%\                                                  3·7%\
                                                                                                        (5500 to 8620)                 (6730 to 9560)                             (12 700 to 17 900)             (19·4 to 51·3)[\*](#TFN4){ref-type="table-fn"}         (19·7 to 45·7)[\*](#TFN4){ref-type="table-fn"}         (20·5 to 46·6)[\*](#TFN4){ref-type="table-fn"}         (149·8 to 234·1)             (158·1 to 224·5)             (160·5 to 226·3)             (−8·7 to 15·5)                                         (−8·4 to 10·8)                                         (−7·9 to 11·8)

      Non-rheumatic valvular heart disease                                                                      1270\                          1260\                                      2530\                    23·6%\                                                 23·7%\                                                 23·6%\                                                        36·0\                        29·6\                        32·7\                  −5·0%\                                                 −5·6%\                                                 −5·5%\
                                                                                                        (1130 to 1400)                 (1100 to 1420)                             (2290 to 2770)                 (19·2 to 27·7)[\*](#TFN4){ref-type="table-fn"}         (19·3 to 28)[\*](#TFN4){ref-type="table-fn"}           (20·6 to 26·5)[\*](#TFN4){ref-type="table-fn"}         (31·6 to 39·7)               (26·0 to 33·5)               (29·5 to 36·0)               (−8·2 to −1·8)[\*](#TFN4){ref-type="table-fn"}         (−8·4 to −2·2)[\*](#TFN4){ref-type="table-fn"}         (−7·5 to −3·2)[\*](#TFN4){ref-type="table-fn"}

         Non-rheumatic calcific aortic valve disease                                                              793\                           720\                                     1510\                    32·1%\                                                 30·5%\                                                 31·3%\                                                        22·9\                        16·8\                        19·8\                  −0·3%\                                                 −2·5%\                                                 −1·5%\
                                                                                                        (682 to 873)                   (595 to 818)                               (1340 to 1650)                 (26·1 to 36·8)[\*](#TFN4){ref-type="table-fn"}         (23·7 to 36·1)[\*](#TFN4){ref-type="table-fn"}         (26·4 to 35·6)[\*](#TFN4){ref-type="table-fn"}         (19·5 to 25·1)               (14·0 to 19·1)               (17·5 to 21·5)               (−4·3 to 3·2)                                          (−6·7 to 1·2)                                          (−4·7 to 1·4)

         Non-rheumatic degenerative mitral valve disease                                                          408\                           466\                                       874\                   12·5%\                                                 16·4%\                                                 14·6%\                                                        11·2\                        11·1\                        11·2\                −12·1%\                                                  −9·1%\                                               −10·7%\
                                                                                                        (340 to 480)                   (381 to 577)                               (748 to 1010)                  (7·0 to 19·9)[\*](#TFN4){ref-type="table-fn"}          (10·8 to 22·3)[\*](#TFN4){ref-type="table-fn"}         (9·8 to 19·8)[\*](#TFN4){ref-type="table-fn"}          (9·4 to 13·2)                (9·1 to 13·7)                (9·5 to 12·9)                (−16·1 to −6·3)[\*](#TFN4){ref-type="table-fn"}        (−13·0 to −4·7)[\*](#TFN4){ref-type="table-fn"}        (−14·3 to −6·7)[\*](#TFN4){ref-type="table-fn"}

         Other non-rheumatic valve diseases                                                                         71·5\                          70·6\                                    142\                     7·2%\                                                  9·7%\                                                  8·5%\                                                         1·9\                         1·7\                         1·8\               −13·3%\                                                −11·0%\                                                −12·2%\
                                                                                                        (46·3 to 103)                  (48·9 to 102)                              (109 to 190)                   (−4·1 to 29·7)                                         (−1·3 to 32·3)                                         (−1·8 to 27·8)                                         (1·2 to 2·8)                 (1·2 to 2·5)                 (1·4 to 2·4)                 (−23·3 to 7·0)                                         (−20·1 to 7·4)                                         (−21·0 to 4·7)

      Cardiomyopathy and myocarditis                                                                            6530\                          3720\                                   10 200\                     −3·6%\                                                 −4·2%\                                                 −3·8%\                                                      168·8\                         92·8\                      130·3\                 −19·9%\                                                −21·5%\                                                −20·6%\
                                                                                                        (5880 to 7020)                 (3490 to 4010)                             (9500 to 10 900)               (−9·6 to 12·4)                                         (−7·1 to −0·2)[\*](#TFN4){ref-type="table-fn"}         (−8·1 to 6·4)                                          (152·5 to 181·2)             (86·9 to 100·2)              (121·0 to 138·8)             (−24·7 to −6·8)[\*](#TFN4){ref-type="table-fn"}        (−23·8 to −18·4)[\*](#TFN4){ref-type="table-fn"}       (−24·1 to −12·5)[\*](#TFN4){ref-type="table-fn"}

         Myocarditis                                                                                              745\                           646\                                     1390\                      6·2%\                                                −4·3%\                                                   1·0%\                                                       19·9\                        16·7\                        18·3\                −9·3%\                                                 −19·1%\                                                −14·2%\
                                                                                                        (625 to 894)                   (561 to 723)                               (1220 to 1560)                 (−2·2 to 17·6)                                         (−10·6 to 5·0)                                         (−5·3 to 8·3)                                          (16·7 to 23·7)               (14·5 to 18·7)               (16·1 to 20·4)               (−16·7 to 0·6)                                         (−24·5 to −11·2)[\*](#TFN4){ref-type="table-fn"}       (−19·6 to −7·2)[\*](#TFN4){ref-type="table-fn"}

         Alcoholic cardiomyopathy                                                                               2330\                            660\                                     2990\                  −26·9%\                                                −37·1%\                                                −29·4%\                                                         57·6\                        15·9\                        36·4\                −39·7%\                                                −49·0%\                                                −42·2%\
                                                                                                        (1990 to 2530)                 (610 to 750)                               (2720 to 3210)                 (−32 to −0·2)[\*](#TFN4){ref-type="table-fn"}          (−40 to −31·7)[\*](#TFN4){ref-type="table-fn"}         (−33·5 to −11·1)[\*](#TFN4){ref-type="table-fn"}       (49·2 to 62·7)               (14·6 to 18·0)               (33·2 to 39·1)               (−43·9 to −18·2)[\*](#TFN4){ref-type="table-fn"}       (−51·3 to −44·6)[\*](#TFN4){ref-type="table-fn"}       (−45·5 to −27·5)[\*](#TFN4){ref-type="table-fn"}

         Other cardiomyopathy                                                                                   3450\                          2420\                                      5870\                    19·7%\                                                 11·7%\                                                 16·3%\                                                        91·4\                        60·3\                        75·6\                  −2·2%\                                                 −9·5%\                                                 −5·3%\
                                                                                                        (3050 to 3800)                 (2160 to 2640)                             (5290 to 6390)                 (12·7 to 25·7)[\*](#TFN4){ref-type="table-fn"}         (7·6 to 17·6)[\*](#TFN4){ref-type="table-fn"}          (11·6 to 20·3)[\*](#TFN4){ref-type="table-fn"}         (81·2 to 100·1)              (53·8 to 65·9)               (68·3 to 82·1)               (−7·6 to 2·7)                                          (−12·7 to −5·2)[\*](#TFN4){ref-type="table-fn"}        (−8·9 to −2·1)[\*](#TFN4){ref-type="table-fn"}

      Atrial fibrillation and flutter                                                                           2850\                          3120\                                      5980\                    36·0%\                                                 35·8%\                                                 35·9%\                                                        84·0\                        72·7\                        78·0\                  −0·1%\                                                   1·1%\                                                  0·5%\
                                                                                                        (2360 to 3460)                 (2690 to 3640)                             (5040 to 7090)                 (33·1 to 38·5)[\*](#TFN4){ref-type="table-fn"}         (34·1 to 37·9)[\*](#TFN4){ref-type="table-fn"}         (34·3 to 37·8)[\*](#TFN4){ref-type="table-fn"}         (70·0 to 101·4)              (62·6 to 84·9)               (66·1 to 92·0)               (−2·2 to 1·6)                                          (−0·1 to 2·6)                                          (−0·5 to 1·7)

      Aortic aneurysm                                                                                           2090\                            949\                                     3040\                    17·9%\                                                 21·6%\                                                 19·0%\                                                        56·0\                        22·3\                        38·2\                  −9·9%\                                                 −6·6%\                                                 −8·5%\
                                                                                                        (1950 to 2250)                 (907 to 1050)                              (2880 to 3190)                 (12·9 to 23·6)[\*](#TFN4){ref-type="table-fn"}         (16·2 to 25·9)[\*](#TFN4){ref-type="table-fn"}         (14·5 to 23·6)[\*](#TFN4){ref-type="table-fn"}         (52·3 to 60·2)               (21·4 to 24·7)               (36·2 to 40·0)               (−13·6 to −5·7)[\*](#TFN4){ref-type="table-fn"}        (−10·6 to −3·2)[\*](#TFN4){ref-type="table-fn"}        (−11·9 to −5·1)[\*](#TFN4){ref-type="table-fn"}

      Peripheral vascular disease                                                                                 759\                           674\                                     1430\                    40·6%\                                                 39·8%\                                                 40·2%\                                                        21·4\                        15·7\                        18·4\                    4·1%\                                                  4·1%\                                                  4·1%\
                                                                                                        (513 to 1190)                  (395 to 1150)                              (970 to 2130)                  (22·7 to 52·9)[\*](#TFN4){ref-type="table-fn"}         (23·3 to 55·6)[\*](#TFN4){ref-type="table-fn"}         (25·9 to 53·5)[\*](#TFN4){ref-type="table-fn"}         (14·4 to 33·9)               (9·2 to 26·7)                (12·5 to 27·6)               (−9·0 to 13·4)                                         (−8·1 to 15·4)                                         (−6·5 to 13·9)

      Endocarditis                                                                                              1160\                          1070\                                      2230\                    20·6%\                                                 13·6%\                                                 17·1%\                                                        30·8\                        27·3\                        29·0\                    0·8%\                                                −5·2%\                                                 −2·3%\
                                                                                                        (1090 to 1230)                 (920 to 1220)                              (2080 to 2420)                 (11·0 to 26·2)[\*](#TFN4){ref-type="table-fn"}         (5·9 to 20·5)[\*](#TFN4){ref-type="table-fn"}          (9·3 to 22·3)[\*](#TFN4){ref-type="table-fn"}          (28·9 to 32·7)               (23·5 to 31·1)               (27·1 to 31·7)               (−6·7 to 5·2)                                          (−11·4 to 0·6)                                         (−8·6 to 2·0)

      Other cardiovascular and circulatory diseases                                                             6420\                          5730\                                   12 200\                     15·3%\                                                 17·1%\                                                 16·2%\                                                      169·4\                       139·8\                       153·8\                   −7·5%\                                                 −5·8%\                                                 −6·7%\
                                                                                                        (5620 to 7410)                 (4950 to 6750)                             (10 600 to 14 000)             (12·3 to 18·4)[\*](#TFN4){ref-type="table-fn"}         (14·2 to 21·3)[\*](#TFN4){ref-type="table-fn"}         (13·6 to 18·6)[\*](#TFN4){ref-type="table-fn"}         (148·6 to 195·5)             (120·4 to 163·9)             (134·7 to 176·5)             (−9·9 to −5·2)[\*](#TFN4){ref-type="table-fn"}         (−8·2 to −2·6)[\*](#TFN4){ref-type="table-fn"}         (−8·7 to −5·0)[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **    Chronic respiratory diseases**                                                                  **     58 600**\               **     53 700**\                           **   112 000**\                **  10·7%**\                                           **  18·9%**\                                           **  14·5%**\                                           **     1586·3**\             **     1293·2**\             **     1422·9**\             ** −14·2%**\                                           **   −6·0%**\                                          ** −10·2%**\
                                                                                                        **(54 900 to 62 300)**         **(49 000 to 57 900)**                     **(105 000 to 120 000)**       **(8·5 to 13·3)**[\*](#TFN4){ref-type="table-fn"}      **(14·8 to 23·6)**[\*](#TFN4){ref-type="table-fn"}     **(12·3 to 17·2)**[\*](#TFN4){ref-type="table-fn"}     **(1489·1 to 1681·7)**       **(1178·8 to 1399·0)**       **(1326·6 to 1517·2)**       **(−16·1 to −12·1)**[\*](#TFN4){ref-type="table-fn"}   **(−9·2 to −2·4)**[\*](#TFN4){ref-type="table-fn"}     **(−12·0 to −8·1)**[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Chronic obstructive pulmonary disease                                                                  43 300\                        38 300\                                    81 600\                     13·5%\                                                 21·2%\                                                 17·0%\                                                    1181·3\                        906·4\                     1028·8\                  −14·1%\                                                  −6·3%\                                               −10·3%\
                                                                                                        (40 100 to 46 100)             (34 900 to 41 400)                         (76 000 to 86 800)             (10·3 to 16·9)[\*](#TFN4){ref-type="table-fn"}         (14·9 to 26·5)[\*](#TFN4){ref-type="table-fn"}         (13·7 to 20·0)[\*](#TFN4){ref-type="table-fn"}         (1097·1 to 1255·3)           (824·1 to 979·9)             (960·4 to 1092·5)            (−16·4 to −11·5)[\*](#TFN4){ref-type="table-fn"}       (−11·1 to −2·3)[\*](#TFN4){ref-type="table-fn"}        (−12·9 to −8·0)[\*](#TFN4){ref-type="table-fn"}

      Pneumoconiosis                                                                                              453\                             54·1\                                    507\                   10·4%\                                                 11·8%\                                                 10·6%\                                                        12·1\                          1·3\                         6·3\               −15·6%\                                                −12·3%\                                                −14·4%\
                                                                                                        (421 to 489)                   (45·7 to 63·1)                             (472 to 548)                   (4·3 to 17·1)[\*](#TFN4){ref-type="table-fn"}          (0·1 to 22·4)[\*](#TFN4){ref-type="table-fn"}          (5·2 to 16·6)[\*](#TFN4){ref-type="table-fn"}          (11·2 to 13·0)               (1·1 to 1·5)                 (5·9 to 6·8)                 (−20·1 to −10·7)[\*](#TFN4){ref-type="table-fn"}       (−21·5 to −4·1)[\*](#TFN4){ref-type="table-fn"}        (−18·6 to −9·8)[\*](#TFN4){ref-type="table-fn"}

         Silicosis                                                                                                247\                             13·3\                                    261\                   13·0%\                                                 17·8%\                                                 13·2%\                                                          6·5\                         0·3\                         3·2\               −13·6%\                                                  −7·6%\                                               −12·3%\
                                                                                                        (220 to 272)                   (8·66 to 17·0)                             (233 to 286)                   (0·3 to 24·2)[\*](#TFN4){ref-type="table-fn"}          (6·0 to 31·2)[\*](#TFN4){ref-type="table-fn"}          (1·2 to 24·1)[\*](#TFN4){ref-type="table-fn"}          (5·8 to 7·2)                 (0·2 to 0·4)                 (2·9 to 3·5)                 (−23·1 to −5·1)[\*](#TFN4){ref-type="table-fn"}        (−17·0 to 3·0)                                         (−21·6 to −3·9)[\*](#TFN4){ref-type="table-fn"}

         Asbestosis                                                                                                 57·3\                          11·7\                                      69·1\                20·2%\                                                 14·7%\                                                 19·2%\                                                          1·6\                         0·3\                         0·9\                 −9·1%\                                               −10·5%\                                                  −8·5%\
                                                                                                        (41·7 to 67·9)                 (8·38 to 15·0)                             (52·2 to 81·4)                 (12·3 to 31·3)[\*](#TFN4){ref-type="table-fn"}         (0·8 to 32·0)[\*](#TFN4){ref-type="table-fn"}          (11·8 to 30·4)[\*](#TFN4){ref-type="table-fn"}         (1·2 to 1·9)                 (0·2 to 0·4)                 (0·7 to 1·0)                 (−14·9 to −0·7)[\*](#TFN4){ref-type="table-fn"}        (−21·3 to 3·4)                                         (−14·1 to 0·3)

         Coal worker pneumoconiosis                                                                                 74·6\                            6·24\                                    80·8\                −0·6%\                                                   9·0%\                                                  0·1%\                                                         2·0\                         0·1\                         1·0\               −24·3%\                                                −14·8%\                                                −23%\
                                                                                                        (63 to 92·9)                   (4·00 to 8·12)                             (69·0 to 100)                  (−10·0 to 12·9)                                        (−2·8 to 27·2)                                         (−8·8 to 12·9)                                         (1·7 to 2·5)                 (0·1 to 0·2)                 (0·9 to 1·3)                 (−31·2 to −14·5)[\*](#TFN4){ref-type="table-fn"}       (−24·0 to −0·6)[\*](#TFN4){ref-type="table-fn"}        (−29·8 to −13·3)[\*](#TFN4){ref-type="table-fn"}

         Other pneumoconiosis                                                                                       74·1\                          22·8\                                      96·9\                  7·4%\                                                  8·1%\                                                  7·6%\                                                         2·0\                         0·5\                         1·2\               −16·6%\                                                −15·0%\                                                −15·9%\
                                                                                                        (61·6 to 94·6)                 (17·6 to 28·8)                             (81·8 to 117)                  (−1·2 to 22·6)                                         (−3·9 to 19·7)                                         (0·6 to 20·5)[\*](#TFN4){ref-type="table-fn"}          (1·6 to 2·5)                 (0·4 to 0·7)                 (1·0 to 1·5)                 (−23·4 to −4·8)[\*](#TFN4){ref-type="table-fn"}        (−24·6 to −5·9)[\*](#TFN4){ref-type="table-fn"}        (−21·4 to −5·5)[\*](#TFN4){ref-type="table-fn"}

      Asthma                                                                                                 11 000\                        11 700\                                    22 800\                     −2·7%\                                                   9·7%\                                                  3·3%\                                                     290·1\                       297·4\                       293·3\                 −19·3%\                                                  −8·2%\                                               −13·7%\
                                                                                                        (8470 to 14 100)               (9050 to 14 800)                           (18 100 to 28 300)             (−8·9 to 4·8)                                          (4·3 to 17·0)[\*](#TFN4){ref-type="table-fn"}          (−1·1 to 9·0)                                          (223·0 to 371·5)             (229·0 to 376·2)             (232·4 to 365·2)             (−25·5 to −10·8)[\*](#TFN4){ref-type="table-fn"}       (−13·6 to −0·9)[\*](#TFN4){ref-type="table-fn"}        (−18·2 to −7·9)[\*](#TFN4){ref-type="table-fn"}

      Interstitial lung disease and pulmonary sarcoidosis                                                       1840\                          1530\                                      3360\                    40·6%\                                                 39·5%\                                                 40·1%\                                                        49·8\                        36·2\                        42·3\                    7·9%\                                                  8·3%\                                                  8·3%\
                                                                                                        (1490 to 2390)                 (1160 to 2000)                             (2770 to 4080)                 (25·8 to 49·7)[\*](#TFN4){ref-type="table-fn"}         (25·2 to 53·3)[\*](#TFN4){ref-type="table-fn"}         (31·5 to 47·8)[\*](#TFN4){ref-type="table-fn"}         (40·1 to 64·4)               (27·5 to 47·5)               (34·8 to 51·4)               (−3·0 to 14·7)                                         (−2·6 to 19·1)                                         (1·8 to 14·3)[\*](#TFN4){ref-type="table-fn"}

      Other chronic respiratory diseases                                                                        2070\                          2010\                                      4080\                    14·8%\                                                 21·3%\                                                 17·9%\                                                        53·0\                        51·9\                        52·1\                  −1·7%\                                                   6·0%\                                                  2·0%\
                                                                                                        (1820 to 2360)                 (1740 to 2280)                             (3600 to 4560)                 (9·5 to 22·0)[\*](#TFN4){ref-type="table-fn"}          (14·8 to 29·3)[\*](#TFN4){ref-type="table-fn"}         (13·2 to 24·5)[\*](#TFN4){ref-type="table-fn"}         (46·6 to 60·4)               (44·7 to 58·9)               (46·1 to 58·2)               (−6·3 to 4·3)                                          (0·1 to 13·5)[\*](#TFN4){ref-type="table-fn"}          (−2·2 to 7·8)

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **    Digestive diseases**                                                                            **     52 800**\               **     32 500**\                           **     85 300**\               **    9·9%**\                                          **  10·9%**\                                           **  10·3%**\                                           **     1346·7**\             **       803·1**\            **     1070·8**\             **   −9·6%**\                                          **   −8·9%**\                                          **   −9·4%**\
                                                                                                        **(48 500 to 58 200)**         **(29 100 to 36 800)**                     **(78 000 to 94 500)**         **(6·7 to 16·1)**[\*](#TFN4){ref-type="table-fn"}      **(8·1 to 14·4)**[\*](#TFN4){ref-type="table-fn"}      **(7·5 to 14·3)**[\*](#TFN4){ref-type="table-fn"}      **(1237·4 to 1486·3)**       **(717·1 to 911·3)**         **(979·3 to 1187·9)**        **(−12·2 to −4·5)**[\*](#TFN4){ref-type="table-fn"}    **(−11·5 to −6·0)**[\*](#TFN4){ref-type="table-fn"}    **(−11·7 to −6·0)**[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Cirrhosis and other chronic liver diseases                                                             28 800\                        12 600\                                    41 400\                       9·9%\                                                  9·4%\                                                  9·8%\                                                     719·3\                       307·6\                       510·7\                 −10·2%\                                                −11·2%\                                                −10·6%\
                                                                                                        (27 300 to 31 400)             (11 900 to 14 700)                         (39 600 to 45 100)             (4·3 to 16·4)[\*](#TFN4){ref-type="table-fn"}          (2·9 to 15·5)[\*](#TFN4){ref-type="table-fn"}          (4·5 to 15·2)[\*](#TFN4){ref-type="table-fn"}          (683·0 to 784·9)             (288·5 to 359·6)             (487·6 to 557·1)             (−14·8 to −4·9)[\*](#TFN4){ref-type="table-fn"}        (−16·5 to −6·3)[\*](#TFN4){ref-type="table-fn"}        (−14·9 to −6·3)[\*](#TFN4){ref-type="table-fn"}

         Cirrhosis and other chronic liver diseases due to hepatitis B                                          9190\                          3020\                                   12 200\                       4·5%\                                                  3·9%\                                                  4·3%\                                                     229·5\                         72·9\                      150·1\                 −14·3%\                                                −15·8%\                                                −14·7%\
                                                                                                        (8310 to 10 500)               (2700 to 3600)                             (11 100 to 13 900)             (−2·3 to 11·9)                                         (−4·3 to 13·3)                                         (−2·2 to 11·4)                                         (208·0 to 261·6)             (65·0 to 86·8)               (136·2 to 170·3)             (−20 to −8·2)[\*](#TFN4){ref-type="table-fn"}          (−22·4 to −8·4)[\*](#TFN4){ref-type="table-fn"}        (−20·0 to −8·9)[\*](#TFN4){ref-type="table-fn"}

         Cirrhosis and other chronic liver diseases due to hepatitis C                                          7160\                          3250\                                   10 400\                     13·0%\                                                 13·1%\                                                 13·0%\                                                      178·1\                         77·8\                      127·2\                   −8·5%\                                                 −9·6%\                                                 −8·9%\
                                                                                                        (6450 to 8000)                 (2950 to 3700)                             (9470 to 11 600)               (7·5 to 19·1)[\*](#TFN4){ref-type="table-fn"}          (6·0 to 20·0)[\*](#TFN4){ref-type="table-fn"}          (7·7 to 18·1)[\*](#TFN4){ref-type="table-fn"}          (160·8 to 198·8)             (70·7 to 88·4)               (115·9 to 141·8)             (−12·9 to −3·7)[\*](#TFN4){ref-type="table-fn"}        (−15·2 to −4·4)[\*](#TFN4){ref-type="table-fn"}        (−13·1 to −4·9)[\*](#TFN4){ref-type="table-fn"}

         Cirrhosis and other chronic liver diseases due to alcohol use                                          7660\                          2530\                                   10 200\                     13·0%\                                                 13·3%\                                                 13·1%\                                                      189·6\                         60·2\                      123·9\                   −8·8%\                                               −10·3%\                                                  −9·3%\
                                                                                                        (6980 to 8450)                 (2290 to 2980)                             (9310 to 11 300)               (7·8 to 19·0)[\*](#TFN4){ref-type="table-fn"}          (7·2 to 22·4)[\*](#TFN4){ref-type="table-fn"}          (8·1 to 18·9)[\*](#TFN4){ref-type="table-fn"}          (173·1 to 209·1)             (54·5 to 70·8)               (113·2 to 138·1)             (−13·2 to −4)[\*](#TFN4){ref-type="table-fn"}          (−15·2 to −3·3)[\*](#TFN4){ref-type="table-fn"}        (−13·4 to −4·8)[\*](#TFN4){ref-type="table-fn"}

         Cirrhosis due to NASH                                                                                  2110\                          1330\                                      3430\                    24·3%\                                                 21·9%\                                                 23·4%\                                                        52·2\                        31·6\                        41·8\                  −0·6%\                                                 −4·1%\                                                 −2·0%\
                                                                                                        (1920 to 2310)                 (1220 to 1470)                             (3150 to 3740)                 (18·4 to 30·1)[\*](#TFN4){ref-type="table-fn"}         (15·4 to 27·6)[\*](#TFN4){ref-type="table-fn"}         (17·8 to 28·3)[\*](#TFN4){ref-type="table-fn"}         (47·8 to 57·3)               (29·0 to 35·0)               (38·5 to 45·5)               (−5·2 to 4·2)                                          (−9·2 to 0·3)                                          (−6·4 to 1·9)

         Cirrhosis and other chronic liver diseases due to other causes                                         2660\                          2500\                                      5160\                      3·6%\                                                  2·5%\                                                  3·1%\                                                       70·0\                        65·2\                        67·7\                −10·5%\                                                −11·8%\                                                −11·1%\
                                                                                                        (2370 to 3000)                 (2220 to 2960)                             (4650 to 5760)                 (−3·7 to 13·8)                                         (−4·5 to 11·5)                                         (−3·0 to 11·2)                                         (62·7 to 78·6)               (57·7 to 77·8)               (61·1 to 75·4)               (−16·8 to −1·6)[\*](#TFN4){ref-type="table-fn"}        (−18·2 to −3·9)[\*](#TFN4){ref-type="table-fn"}        (−16·5 to −3·9)[\*](#TFN4){ref-type="table-fn"}

      Upper digestive system diseases                                                                        10 200\                           9640\                                   19 800\                       7·4%\                                                12·7%\                                                   9·9%\                                                     261·0\                       237·4\                       248·7\                 −11·5%\                                                  −6·6%\                                                 −9·1%\
                                                                                                        (7880 to 13 400)               (7080 to 13 200)                           (15 100 to 26 600)             (2·3 to 12·3)[\*](#TFN4){ref-type="table-fn"}          (9·4 to 15·7)[\*](#TFN4){ref-type="table-fn"}          (6·0 to 13·4)[\*](#TFN4){ref-type="table-fn"}          (202·6 to 342·2)             (173·6 to 324·9)             (189·1 to 333·3)             (−16·1 to −7·2)[\*](#TFN4){ref-type="table-fn"}        (−9·7 to −3·8)[\*](#TFN4){ref-type="table-fn"}         (−12·7 to −5·9)[\*](#TFN4){ref-type="table-fn"}

         Peptic ulcer disease                                                                                   3740\                          2610\                                      6350\                    −7·2%\                                                   0·7%\                                                −4·1%\                                                        96·9\                        63·2\                        79·6\                −25·4%\                                                −19·1%\                                                −22·9%\
                                                                                                        (3440 to 4200)                 (2270 to 2910)                             (5900 to 6870)                 (−12·8 to −1·0)[\*](#TFN4){ref-type="table-fn"}        (−4·3 to 6·9)                                          (−8·5 to 0·9)                                          (89·1 to 108·9)              (55·0 to 70·7)               (73·9 to 86·2)               (−29·9 to −20·5)[\*](#TFN4){ref-type="table-fn"}       (−23·2 to −14·1)[\*](#TFN4){ref-type="table-fn"}       (−26·5 to −18·9)[\*](#TFN4){ref-type="table-fn"}

         Gastritis and duodenitis                                                                               3470\                          4000\                                      7470\                    16·4%\                                                 15·7%\                                                 16·1%\                                                        89·1\                        99·7\                        94·3\                  −2·0%\                                                 −2·7%\                                                 −2·3%\
                                                                                                        (2500 to 4700)                 (2750 to 5550)                             (5240 to 10 200)               (11·8 to 21·0)[\*](#TFN4){ref-type="table-fn"}         (12·8 to 18·7)[\*](#TFN4){ref-type="table-fn"}         (13·0 to 19·1)[\*](#TFN4){ref-type="table-fn"}         (64·1 to 120·1)              (68·4 to 138·5)              (66·4 to 129·1)              (−6·0 to 1·9)                                          (−5·3 to −0·3)[\*](#TFN4){ref-type="table-fn"}         (−5·1 to 0·4)

         Gastro-oesophageal reflux disease                                                                      2980\                          3040\                                      6010\                    20·3%\                                                 21·0%\                                                 20·7%\                                                        75·1\                        74·5\                        74·8\                    1·2%\                                                  1·4%\                                                  1·3%\
                                                                                                        (1590 to 5020)                 (1630 to 5150)                             (3220 to 10 200)               (18·6 to 22·2)[\*](#TFN4){ref-type="table-fn"}         (19·3 to 22·8)[\*](#TFN4){ref-type="table-fn"}         (19·1 to 22·3)[\*](#TFN4){ref-type="table-fn"}         (40·1 to 126·9)              (40·1 to 126·9)              (40·1 to 126·9)              (0·1 to 2·3)[\*](#TFN4){ref-type="table-fn"}           (0·4 to 2·4)[\*](#TFN4){ref-type="table-fn"}           (0·6 to 2·0)[\*](#TFN4){ref-type="table-fn"}

      Appendicitis                                                                                                910\                           947\                                     1860\                    −7·3%\                                                 −6·2%\                                                 −6·7%\                                                        23·9\                        25·0\                        24·4\                −19%\                                                  −17·3%\                                                −18·1%\
                                                                                                        (813 to 1030)                  (799 to 1050)                              (1680 to 2020)                 (−16·6 to 3·8)                                         (−14·3 to 2·8)                                         (−14·1 to 1·6)                                         (21·4 to 27)                 (21·1 to 27·7)               (22·0 to 26·5)               (−27·1 to −9·5)[\*](#TFN4){ref-type="table-fn"}        (−24·8 to −9·0)[\*](#TFN4){ref-type="table-fn"}        (−24·7 to −10·6)[\*](#TFN4){ref-type="table-fn"}

      Paralytic ileus and intestinal obstruction                                                                4080\                          3210\                                      7290\                      5·9%\                                                  7·4%\                                                  6·6%\                                                     110·7\                         84·9\                        97·6\                  −8·9%\                                                 −8·2%\                                                 −8·6%\
                                                                                                        (3230 to 4700)                 (2350 to 3650)                             (5910 to 8030)                 (−4·9 to 17·8)                                         (−3·2 to 18·7)                                         (−2·9 to 15·5)                                         (88·4 to 127·2)              (62·3 to 96·2)               (79·4 to 107·4)              (−18·0 to 1·0)                                         (−17·1 to 1·5)                                         (−16·7 to −0·8)[\*](#TFN4){ref-type="table-fn"}

      Inguinal, femoral, and abdominal hernia                                                                   2490\                            989\                                     3480\                    13·3%\                                                 15·2%\                                                 13·9%\                                                        65·5\                        25·0\                        44·8\                  −5·3%\                                                 −4·4%\                                                 −5·0%\
                                                                                                        (1860 to 3230)                 (753 to 1250)                              (2610 to 4480)                 (10·1 to 16·7)[\*](#TFN4){ref-type="table-fn"}         (11·9 to 19·7)[\*](#TFN4){ref-type="table-fn"}         (11·0 to 16·8)[\*](#TFN4){ref-type="table-fn"}         (49·1 to 84·6)               (18·9 to 31·8)               (33·6 to 57·5)               (−8·0 to −2·6)[\*](#TFN4){ref-type="table-fn"}         (−7·2 to −1·1)[\*](#TFN4){ref-type="table-fn"}         (−7·3 to −2·7)[\*](#TFN4){ref-type="table-fn"}

      Inflammatory bowel disease                                                                                  885\                           964\                                     1850\                    16·8%\                                                 15·8%\                                                 16·3%\                                                        23·0\                        23·5\                        23·2\                  −5·0%\                                                 −6·2%\                                                 −5·6%\
                                                                                                        (741 to 1050)                  (751 to 1180)                              (1510 to 2230)                 (8·4 to 23·2)[\*](#TFN4){ref-type="table-fn"}          (8·3 to 21·0)[\*](#TFN4){ref-type="table-fn"}          (8·8 to 21·4)[\*](#TFN4){ref-type="table-fn"}          (19·3 to 27·2)               (18·3 to 28·6)               (19·1 to 27·8)               (−11·5 to 0·1)                                         (−12·2 to −2·1)[\*](#TFN4){ref-type="table-fn"}        (−11·5 to −1·9)[\*](#TFN4){ref-type="table-fn"}

      Vascular intestinal disorders                                                                               806\                           791\                                     1600\                    16·9%\                                                 18·6%\                                                 17·7%\                                                        21·9\                        18·6\                        20·4\                −10·1%\                                                  −9·4%\                                                 −9·9%\
                                                                                                        (742 to 866)                   (688 to 869)                               (1460 to 1700)                 (9·5 to 28·2)[\*](#TFN4){ref-type="table-fn"}          (12·1 to 24·5)[\*](#TFN4){ref-type="table-fn"}         (11·0 to 24·8)[\*](#TFN4){ref-type="table-fn"}         (20·2 to 23·6)               (16·1 to 20·5)               (18·7 to 21·6)               (−15·6 to −2·3)[\*](#TFN4){ref-type="table-fn"}        (−14·4 to −4·9)[\*](#TFN4){ref-type="table-fn"}        (−15·0 to −4·9)[\*](#TFN4){ref-type="table-fn"}

      Gallbladder and biliary diseases                                                                            940\                         1070\                                      2010\                    22·5%\                                                 15·3%\                                                 18·6%\                                                        25·7\                        25·8\                        25·7\                  −3·8%\                                                 −9·2%\                                                 −6·8%\
                                                                                                        (882 to 1040)                  (933 to 1140)                              (1890 to 2130)                 (15·6 to 31·7)[\*](#TFN4){ref-type="table-fn"}         (9·9 to 23·9)[\*](#TFN4){ref-type="table-fn"}          (13·6 to 25·3)[\*](#TFN4){ref-type="table-fn"}         (24·2 to 28·4)               (22·4 to 27·7)               (24·1 to 27·2)               (−8·9 to 3·0)                                          (−13·6 to −2·3)[\*](#TFN4){ref-type="table-fn"}        (−10·8 to −1·7)[\*](#TFN4){ref-type="table-fn"}

      Pancreatitis                                                                                              2210\                          1050\                                      3250\                    14·7%\                                                 15·9%\                                                 15·1%\                                                        55·6\                        25·3\                        40·3\                  −5·2%\                                                 −6·9%\                                                 −5·9%\
                                                                                                        (1950 to 2470)                 (831 to 1210)                              (2890 to 3610)                 (7·4 to 21·7)[\*](#TFN4){ref-type="table-fn"}          (8·8 to 22·6)[\*](#TFN4){ref-type="table-fn"}          (10·6 to 20·5)[\*](#TFN4){ref-type="table-fn"}         (49·2 to 62·2)               (20·0 to 29·3)               (35·9 to 44·7)               (−11 to 0·5)                                           (−12·5 to −1·5)[\*](#TFN4){ref-type="table-fn"}        (−9·5 to −1·6)[\*](#TFN4){ref-type="table-fn"}

      Other digestive diseases                                                                                  1510\                          1210\                                      2720\                    22·3%\                                                 18·8%\                                                 20·7%\                                                        40·2\                        30·0\                        35·0\                  −0·4%\                                                 −3·7%\                                                 −1·9%\
                                                                                                        (1300 to 1750)                 (1050 to 1380)                             (2380 to 3110)                 (11·7 to 34·6)[\*](#TFN4){ref-type="table-fn"}         (12·2 to 26·9)[\*](#TFN4){ref-type="table-fn"}         (12·9 to 28·4)[\*](#TFN4){ref-type="table-fn"}         (34·7 to 46·3)               (26·0 to 34·4)               (30·7 to 40·0)               (−8·3 to 9·2)                                          (−9·2 to 3·1)                                          (−8·2

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **    Neurological disorders**                                                                        **     46 300**\               **     64 900**\                           **   111 000**\                **  20·5%**\                                           **  20·6%**\                                           **  20·5%**\                                           **     1275·1**\             **     1606·9**\             **     1444·4**\             **   −0·1%**\                                          **   −0·2%**\                                          **   −0·2%**\
                                                                                                        **(37 200 to 57 200)**         **(51 100 to 81 400)**                     **(88 500 to 139 000)**        **(18·4 to 23·3)**[\*](#TFN4){ref-type="table-fn"}     **(18·9 to 22·4)**[\*](#TFN4){ref-type="table-fn"}     **(18·8 to 22·6)**[\*](#TFN4){ref-type="table-fn"}     **(1036·4 to 1554·8)**       **(1256·7 to 2030·1)**       **(1154 to 1792·7)**         **(−1·9 to 2·0)**                                      **(−1·5 to 1·2)**                                      **(−1·6 to 1·4)**

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Alzheimer's disease and other dementias                                                                11 700\                        18 900\                                    30 500\                     41·8%\                                                 36·1%\                                                 38·3%\                                                      376·8\                       436·2\                       412·6\                     0·5%\                                                −0·9%\                                                 −0·6%\
                                                                                                        (10 900 to 12 500)             (17 600 to 20 200)                         (28 500 to 32 600)             (38·0 to 44·4)[\*](#TFN4){ref-type="table-fn"}         (32·8 to 38·2)[\*](#TFN4){ref-type="table-fn"}         (36·0 to 40·1)[\*](#TFN4){ref-type="table-fn"}         (352·1 to 404·4)             (407·7 to 466·2)             (385·7 to 440·3)             (−2·0 to 2·1)                                          (−3·2 to 0·6)                                          (−2·2 to 0·6)

      Parkinson's disease                                                                                       3190\                          2390\                                      5580\                     36·1%\                                                 31·0%\                                                 33·9%\                                                      94·0\                        55·9\                        72·5\                     0·2%\                                                −0·7%\                                                   0·4%\
                                                                                                        (2940 to 3500)                 (2200 to 2630)                             (5150 to 6080)                 (31·2 to 39·3)[\*](#TFN4){ref-type="table-fn"}         (26·5 to 34·0)[\*](#TFN4){ref-type="table-fn"}         (29·7 to 36·4)[\*](#TFN4){ref-type="table-fn"}         (86·7 to 103·1)              (51·3 to 61·3)               (66·9 to 79·0)               (−3·4 to 2·5)                                          (−4·0 to 1·6)                                          (−2·7 to 2·3)

      Epilepsy                                                                                                  7910\                          6880\                                   14 800\                       4·3%\                                                  7·7%\                                                  5·8%\                                                     208·1\                       183·5\                       195·8\                   −6·4%\                                                 −3·8%\                                                 −5·2%\
                                                                                                        (6200 to 10 100)               (5220 to 8960)                             (11 400 to 19 000)             (−3·3 to 15·0)                                         (−1 to 18·2)                                           (−2·0 to 15·9)                                         (162·8 to 266·7)             (139·3 to 239·7)             (151·4 to 251·8)             (−13·2 to 3·2)                                         (−11·4 to 5·4)                                         (−12·2 to 3·7)

      Multiple sclerosis                                                                                          408\                           677\                                     1080\                    17·9%\                                                 17·4%\                                                 17·6%\                                                        10·1\                        16·3\                        13·3\                  −3·8%\                                                 −4·5%\                                                 −4·2%\
                                                                                                        (354 to 459)                   (579 to 781)                               (943 to 1240)                  (9·3 to 21·6)[\*](#TFN4){ref-type="table-fn"}          (11·1 to 22·3)[\*](#TFN4){ref-type="table-fn"}         (10·2 to 21·9)[\*](#TFN4){ref-type="table-fn"}         (8·8 to 11·4)                (14·0 to 18·9)               (11·5 to 15·2)               (−10·3 to −0·8)[\*](#TFN4){ref-type="table-fn"}        (−9·1 to −0·4)[\*](#TFN4){ref-type="table-fn"}         (−9·8 to −0·6)[\*](#TFN4){ref-type="table-fn"}

      Motor neuron disease                                                                                        508\                           371\                                       879\                   27·9%\                                                 26·1%\                                                 27·2%\                                                        13·1\                          9·0\                       11·0\                    1·4%\                                                −1·0%\                                                   0·3%\
                                                                                                        (481 to 556)                   (345 to 407)                               (841 to 966)                   (21 to 31·9)[\*](#TFN4){ref-type="table-fn"}           (20·0 to 31·1)[\*](#TFN4){ref-type="table-fn"}         (22·9 to 30·9)[\*](#TFN4){ref-type="table-fn"}         (12·4 to 14·3)               (8·3 to 9·8)                 (10·5 to 12·0)               (−3·8 to 4·5)                                          (−5·8 to 2·9)                                          (−3·1 to 3·3)

      Headache disorders                                                                                     20 500\                        33 900\                                    54 300\                     15·5%\                                                 15·3%\                                                 15·4%\                                                      516·5\                       857·0\                       686·5\                     1·5%\                                                  0·7%\                                                  1·0%\
                                                                                                        (13 400 to 29 300)             (22 200 to 48 100)                         (35 600 to 76 800)             (14·5 to 16·5)[\*](#TFN4){ref-type="table-fn"}         (14·4 to 16·2)[\*](#TFN4){ref-type="table-fn"}         (14·6 to 16·2)[\*](#TFN4){ref-type="table-fn"}         (338 to 738·7)               (561·5 to 1217·0)            (448·7 to 970·5)             (0·8 to 2·3)[\*](#TFN4){ref-type="table-fn"}           (0·1 to 1·3)[\*](#TFN4){ref-type="table-fn"}           (0·5 to 1·5)[\*](#TFN4){ref-type="table-fn"}

         Migraine                                                                                            17 300\                        29 900\                                    47 200\                     15·5%\                                                 15·2%\                                                 15·3%\                                                      437·7\                       756·5\                       596·8\                     1·7%\                                                  0·8%\                                                  1·1%\
                                                                                                        (10 900 to 25 500)             (19 000 to 42 900)                         (30 000 to 68 700)             (14·4 to 16·7)[\*](#TFN4){ref-type="table-fn"}         (14·2 to 16·2)[\*](#TFN4){ref-type="table-fn"}         (14·5 to 16·2)[\*](#TFN4){ref-type="table-fn"}         (273·7 to 645·5)             (480·9 to 1088·1)            (378·2 to 866)               (0·9 to 2·6)[\*](#TFN4){ref-type="table-fn"}           (0·1 to 1·5)[\*](#TFN4){ref-type="table-fn"}           (0·6 to 1·7)[\*](#TFN4){ref-type="table-fn"}

         Tension-type headache                                                                                  3110\                          3990\                                      7100\                    15·3%\                                                 15·8%\                                                 15·6%\                                                        78·8\                      100·5\                         89·7\                    0·5%\                                                  0·1%\                                                  0·3%\
                                                                                                        (1740 to 5000)                 (2270 to 6230)                             (4040 to 11 200)               (14·1 to 16·7)[\*](#TFN4){ref-type="table-fn"}         (14·6 to 17·2)[\*](#TFN4){ref-type="table-fn"}         (14·5 to 16·9)[\*](#TFN4){ref-type="table-fn"}         (44·4 to 126·9)              (57·2 to 157·6)              (51·0 to 142·2)              (0 to 1·0)                                             (−0·4 to 0·6)                                          (−0·1

      Other neurological disorders                                                                              2130\                          1830\                                      3970\                    19·1%\                                                 22·4%\                                                 20·6%\                                                        56·4\                        49·1\                        52·7\                    6·3%\                                                  8·2%\                                                  7·2%\
                                                                                                        (1780 to 2570)                 (1480 to 2300)                             (3270 to 4850)                 (10·1 to 28·5)[\*](#TFN4){ref-type="table-fn"}         (11·4 to 32·8)[\*](#TFN4){ref-type="table-fn"}         (12·5 to 29·7)[\*](#TFN4){ref-type="table-fn"}         (47·3 to 68)                 (39·2 to 61·9)               (43·3 to 64·7)               (−1·9 to 14·6)                                         (−1·6 to 17·6)                                         (−0·3 to 15·3)

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **    Mental disorders**                                                                              **     56 200**\               **     66 500**\                           **   123 000**\                **  13·4%**\                                           **  13·6%**\                                           **  13·5%**\                                           **     1435·0**\             **     1681·8**\             **     1560·4**\             **   −0·6%**\                                          **   −1·5%**\                                          **   −1·1%**\
                                                                                                        **(41 800 to 72 700)**         **(49 700 to 85 700)**                     **(91 600 to 158 000)**        **(12·7 to 14·0)**[\*](#TFN4){ref-type="table-fn"}     **(12·9 to 14·4)**[\*](#TFN4){ref-type="table-fn"}     **(12·9 to 14·1)**[\*](#TFN4){ref-type="table-fn"}     **(1065·8 to 1856·2)**       **(1255·2 to 2169·0)**       **(1165·1 to 2010·5)**       **(−1·1 to −0·2)**[\*](#TFN4){ref-type="table-fn"}     **(−2·1 to −1·0)**[\*](#TFN4){ref-type="table-fn"}     **(−1·5 to −0·7)**[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Schizophrenia                                                                                             6510\                          6140\                                   12 700\                     16·7%\                                                 17·7%\                                                 17·2%\                                                      161·6\                       151·3\                       156·4\                   −0·4%\                                                 −0·2%\                                                 −0·3%\
                                                                                                        (4860 to 8020)                 (4610 to 7540)                             (9480 to 15 600)               (15·4 to 18·2)[\*](#TFN4){ref-type="table-fn"}         (16·3 to 19·2)[\*](#TFN4){ref-type="table-fn"}         (16·1 to 18·3)[\*](#TFN4){ref-type="table-fn"}         (120·5 to 198·9)             (113·2 to 185·8)             (117·1 to 192·3)             (−1·4 to 0·6)                                          (−1·3 to 0·9)                                          (−1·1 to 0·4)

      Depressive disorders                                                                                   16 800\                        26 300\                                    43 100\                     14·8%\                                                 14·1%\                                                 14·3%\                                                      425·1\                       653·5\                       540·5\                   −1·9%\                                                 −3·1%\                                                 −2·6%\
                                                                                                        (11 900 to 22 900)             (18 700 to 35 900)                         (30 500 to 58 900)             (13·5 to 16·2)[\*](#TFN4){ref-type="table-fn"}         (12·8 to 15·5)[\*](#TFN4){ref-type="table-fn"}         (13·1 to 15·6)[\*](#TFN4){ref-type="table-fn"}         (300·8 to 579·9)             (462·2 to 892·4)             (382·4 to 737·8)             (−2·8 to −1·0)[\*](#TFN4){ref-type="table-fn"}         (−4·1 to −2·1)[\*](#TFN4){ref-type="table-fn"}         (−3·5 to −1·8)[\*](#TFN4){ref-type="table-fn"}

         Major depressive disorder                                                                           12 700\                        20 100\                                    32 800\                     13·2%\                                                 12·2%\                                                 12·6%\                                                      323·6\                       500·9\                       413·0\                   −2·7%\                                                 −4·2%\                                                 −3·6%\
                                                                                                        (8910 to 17 300)               (14 200 to 27 000)                         (23 100 to 44 300)             (11·8 to 14·6)[\*](#TFN4){ref-type="table-fn"}         (10·7 to 13·7)[\*](#TFN4){ref-type="table-fn"}         (11·3 to 14·0)[\*](#TFN4){ref-type="table-fn"}         (225·9 to 439·5)             (352·5 to 676·7)             (289·8 to 558·9)             (−3·8 to −1·8)[\*](#TFN4){ref-type="table-fn"}         (−5·3 to −3·1)[\*](#TFN4){ref-type="table-fn"}         (−4·6 to −2·7)[\*](#TFN4){ref-type="table-fn"}

         Dysthymia                                                                                              4030\                          6220\                                   10 300\                     20·2%\                                                 20·6%\                                                 20·4%\                                                      101·5\                       152·7\                       127·4\                     1·0%\                                                  0·6%\                                                  0·8%\
                                                                                                        (2690 to 5880)                 (4180 to 9090)                             (6880 to 15 000)               (17·4 to 23·2)[\*](#TFN4){ref-type="table-fn"}         (17·7 to 23·5)[\*](#TFN4){ref-type="table-fn"}         (18·2 to 22·6)[\*](#TFN4){ref-type="table-fn"}         (67·9 to 148·0)              (102·4 to 222·6)             (85·4 to 185·6)              (−1·0 to 3·0)                                          (−1·4 to 2·8)                                          (−0·8 to 2·3)

      Bipolar disorder                                                                                          4490\                          4810\                                      9290\                    15·3%\                                                 15·2%\                                                 15·2%\                                                      113·4\                       121·6\                       117·5\                     1·5%\                                                  0·9%\                                                  1·2%\
                                                                                                        (2820 to 6630)                 (3030 to 7100)                             (5870 to 13 700)               (14·0 to 16·8)[\*](#TFN4){ref-type="table-fn"}         (13·8 to 16·7)[\*](#TFN4){ref-type="table-fn"}         (14·0 to 16·6)[\*](#TFN4){ref-type="table-fn"}         (71·3 to 167·4)              (76·8 to 179·5)              (74·1 to 173·5)              (0·7 to 2·3)[\*](#TFN4){ref-type="table-fn"}           (0·1 to 1·8)[\*](#TFN4){ref-type="table-fn"}           (0·6 to 1·8)[\*](#TFN4){ref-type="table-fn"}

      Anxiety disorders                                                                                      10 200\                        17 000\                                    27 100\                     13·6%\                                                 12·4%\                                                 12·8%\                                                      259·2\                       431·9\                       345·7\                     0%\                                                  −1·9%\                                                 −1·2%\
                                                                                                        (7200 to 13 500)               (12 000 to 22 500)                         (19 200 to 36 100)             (12·2 to 15·1)[\*](#TFN4){ref-type="table-fn"}         (11·0 to 13·8)[\*](#TFN4){ref-type="table-fn"}         (11·7 to 14·0)[\*](#TFN4){ref-type="table-fn"}         (183·1 to 343·3)             (306·8 to 575·5)             (245·6 to 459·7)             (−1·1 to 1·1)                                          (−2·9 to −0·7)[\*](#TFN4){ref-type="table-fn"}         (−2·0 to −0·4)[\*](#TFN4){ref-type="table-fn"}

      Eating disorders                                                                                          1050\                          2320\                                      3370\                    20·7%\                                                 18·2%\                                                 18·9%\                                                        26·7\                        60·5\                        43·4\                  10·7%\                                                   8·9%\                                                  9·4%\
                                                                                                        (662 to 1530)                  (1500 to 3370)                             (2170 to 4890)                 (18·4 to 22·9)[\*](#TFN4){ref-type="table-fn"}         (16·4 to 19·8)[\*](#TFN4){ref-type="table-fn"}         (17·3 to 20·5)[\*](#TFN4){ref-type="table-fn"}         (16·8 to 39·1)               (39·2 to 87·6)               (27·9 to 62·9)               (8·8 to 12·4)[\*](#TFN4){ref-type="table-fn"}          (7·6 to 10·3)[\*](#TFN4){ref-type="table-fn"}          (8·2 to 10·5)[\*](#TFN4){ref-type="table-fn"}

         Anorexia nervosa                                                                                         143\                           585\                                       728\                   13·8%\                                                 13·4%\                                                 13·5%\                                                          3·7\                       15·5\                          9·5\                   6·7%\                                                  6·2%\                                                  6·1%\
                                                                                                        (87·8 to 215)                  (365 to 864)                               (454 to 1080)                  (9·4 to 18·2)[\*](#TFN4){ref-type="table-fn"}          (10·8 to 16·0)[\*](#TFN4){ref-type="table-fn"}         (11·1 to 15·7)[\*](#TFN4){ref-type="table-fn"}         (2·3 to 5·6)                 (9·6 to 22·8)                (5·9 to 14·1)                (3·0 to 10·6)[\*](#TFN4){ref-type="table-fn"}          (3·9 to 8·5)[\*](#TFN4){ref-type="table-fn"}           (4·2 to 8·1)[\*](#TFN4){ref-type="table-fn"}

         Bulimia nervosa                                                                                          904\                         1740\                                      2640\                    21·9%\                                                 19·8%\                                                 20·5%\                                                        22·9\                        45·0\                        33·8\                  11·4%\                                                   9·9%\                                                10·3%\
                                                                                                        (559 to 1340)                  (1100 to 2620)                             (1660 to 3940)                 (19·3 to 24·3)[\*](#TFN4){ref-type="table-fn"}         (17·8 to 21·9)[\*](#TFN4){ref-type="table-fn"}         (18·7 to 22·1)[\*](#TFN4){ref-type="table-fn"}         (14·2 to 33·9)               (28·6 to 67·8)               (21·3 to 50·5)               (9·3 to 13·2)[\*](#TFN4){ref-type="table-fn"}          (8·4 to 11·4)[\*](#TFN4){ref-type="table-fn"}          (9·0 to 11·6)[\*](#TFN4){ref-type="table-fn"}

      Autism spectrum disorders                                                                                 3590\                          1140\                                      4730\                    11·1%\                                                 12·4%\                                                 11·4%\                                                        94\                          30·4\                        62·4\                  −0·6%\                                                   0·5%\                                                −0·3%\
                                                                                                        (2460 to 4940)                 (771 to 1570)                              (3240 to 6520)                 (10·4 to 11·9)[\*](#TFN4){ref-type="table-fn"}         (11·3 to 13·6)[\*](#TFN4){ref-type="table-fn"}         (10·8 to 12·1)[\*](#TFN4){ref-type="table-fn"}         (64·4 to 129·2)              (20·5 to 41·9)               (42·7 to 86·0)               (−1·2 to 0·1)                                          (−0·5 to 1·6)                                          (−0·8 to 0·3)

      Attention-deficit/hyperactivity disorder                                                                    627\                           262\                                       889\                     6·6%\                                                  7·7%\                                                  6·9%\                                                       16·5\                          7·1\                       11·9\                  −0·8%\                                                   0%\                                                  −0·6%\
                                                                                                        (383 to 996)                   (158 to 416)                               (543 to 1410)                  (4·4 to 8·6)[\*](#TFN4){ref-type="table-fn"}           (5·3 to 10·0)[\*](#TFN4){ref-type="table-fn"}          (5·2 to 8·5)[\*](#TFN4){ref-type="table-fn"}           (10·0 to 26·2)               (4·3 to 11·3)                (7·3 to 18·9)                (−2·9 to 1·1)                                          (−2·2 to 2·2)                                          (−2·1 to 0·8)

      Conduct disorder                                                                                          4190\                          2250\                                      6450\                      4·1%\                                                  6·3%\                                                  4·8%\                                                     113·8\                         64·9\                        90·0\                    1·7%\                                                  3·7%\                                                  2·4%\
                                                                                                        (2520 to 6630)                 (1330 to 3650)                             (3870 to 10 300)               (1·9 to 6·1)[\*](#TFN4){ref-type="table-fn"}           (4·0 to 8·7)[\*](#TFN4){ref-type="table-fn"}           (3·1 to 6·5)[\*](#TFN4){ref-type="table-fn"}           (68·5 to 179·9)              (38·2 to 105·5)              (54·0 to 143·9)              (−0·4 to 3·6)                                          (1·4 to 5·8)[\*](#TFN4){ref-type="table-fn"}           (0·9 to 3·8)[\*](#TFN4){ref-type="table-fn"}

      Idiopathic developmental intellectual disability                                                          2200\                          1840\                                      4050\                      0·6%\                                                −0·6%\                                                   0%\                                                         58·0\                        50·4\                        54·2\                  −8·4%\                                                 −9·1%\                                                 −8·7%\
                                                                                                        (1060 to 3740)                 (901 to 3080)                              (1940 to 6860)                 (−2·0 to 2·0)                                          (−3·9 to 1·3)                                          (−2·8 to 1·5)                                          (28·0 to 98·6)               (24·7 to 84·1)               (26·1 to 91·9)               (−10·6 to −7·1)[\*](#TFN4){ref-type="table-fn"}        (−12·0 to −7·5)[\*](#TFN4){ref-type="table-fn"}        (−11·1 to −7·5)[\*](#TFN4){ref-type="table-fn"}

      Other mental disorders                                                                                    6640\                          4470\                                   11 100\                     17·2%\                                                 18·2%\                                                 17·6%\                                                      166·8\                       110·3\                       138·4\                   −0·1%\                                                   0·1%\                                                  0%\
                                                                                                        (4330 to 9180)                 (3010 to 6140)                             (7360 to 15 300)               (16·5 to 18·0)[\*](#TFN4){ref-type="table-fn"}         (17·3 to 19·1)[\*](#TFN4){ref-type="table-fn"}         (17·0 to 18·3)[\*](#TFN4){ref-type="table-fn"}         (108·9 to 230·4)             (74·2 to 151·5)              (91·6 to 191)                (−0·7 to 0·5)                                          (−0·6 to 0·8)                                          (−0·4 to 0·5)

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **    Substance use disorders**                                                                       **     31 900**\               **     12 800**\                           **     44 700**\               **  15·9%**\                                           **  20·8%**\                                           **  17·3%**\                                           **       797·5**\            **       320·9**\            **       559·2**\            **     0·9%**\                                         **     5·8%**\                                         **     2·3%**\
                                                                                                        **(25 900 to 38 400)**         **(9930 to 15 700)**                       **(35 900 to 54 100)**         **(13·5 to 18·1)**[\*](#TFN4){ref-type="table-fn"}     **(18·9 to 23·3)**[\*](#TFN4){ref-type="table-fn"}     **(15·2 to 19·3)**[\*](#TFN4){ref-type="table-fn"}     **(645·9 to 960·9)**         **(248·9 to 395·7)**         **(448·2 to 677·9)**         **(−1·3 to 2·9)**                                      **(4·2 to 8·0)**[\*](#TFN4){ref-type="table-fn"}       **(0·5 to 4·0)**[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Alcohol use disorders                                                                                  13 300\                           4170\                                   17 500\                       3·8%\                                                  9·4%\                                                  5·0%\                                                     329·7\                       104·0\                       216·4\                 −11·4%\                                                  −5·9%\                                               −10·2%\
                                                                                                        (10 900 to 16 200)             (3140 to 5420)                             (14 100 to 21 600)             (0·8 to 6·1)[\*](#TFN4){ref-type="table-fn"}           (6·0 to 15·3)[\*](#TFN4){ref-type="table-fn"}          (2·4 to 7·4)[\*](#TFN4){ref-type="table-fn"}           (269·2 to 401·9)             (78·1 to 134·8)              (174·1 to 268·5)             (−14·1 to −9·3)[\*](#TFN4){ref-type="table-fn"}        (−9·1 to −0·8)[\*](#TFN4){ref-type="table-fn"}         (−12·7 to −8·1)[\*](#TFN4){ref-type="table-fn"}

      Drug use disorders                                                                                     18 600\                           8590\                                   27 200\                     26·6%\                                                 27·3%\                                                 26·8%\                                                      467·7\                       217·0\                       342·8\                   11·9%\                                                 12·4%\                                                 12·1%\
                                                                                                        (14 500 to 22 900)             (6660 to 10 700)                           (21 100 to 33 600)             (23·5 to 29·9)[\*](#TFN4){ref-type="table-fn"}         (24·3 to 30·7)[\*](#TFN4){ref-type="table-fn"}         (24·2 to 29·6)[\*](#TFN4){ref-type="table-fn"}         (364·7 to 576·6)             (168·1 to 270·9)             (266·4 to 424·1)             (9·3 to 14·7)[\*](#TFN4){ref-type="table-fn"}          (10·1 to 15·2)[\*](#TFN4){ref-type="table-fn"}         (9·9 to 14·5)[\*](#TFN4){ref-type="table-fn"}

         Opioid use disorders                                                                                14 800\                           6640\                                   21 500\                     31·2%\                                                 29·8%\                                                 30·8%\                                                      372·9\                       167·4\                       270·5\                   15·6%\                                                 14·4%\                                                 15·3%\
                                                                                                        (11 300 to 18 700)             (4960 to 8460)                             (16 300 to 27 100)             (27·6 to 34·9)[\*](#TFN4){ref-type="table-fn"}         (25·3 to 35·0)[\*](#TFN4){ref-type="table-fn"}         (27·5 to 34·4)[\*](#TFN4){ref-type="table-fn"}         (282·9 to 468·1)             (124·8 to 214·1)             (204·4 to 342·2)             (12·3 to 18·9)[\*](#TFN4){ref-type="table-fn"}         (10·7 to 18·5)[\*](#TFN4){ref-type="table-fn"}         (12·4 to 18·3)[\*](#TFN4){ref-type="table-fn"}

         Cocaine use disorders                                                                                    698\                           293\                                       992\                   17·2%\                                                 23·4%\                                                 19·0%\                                                        17·6\                          7·4\                       12·5\                    3·3%\                                                  8·7%\                                                  4·9%\
                                                                                                        (531 to 900)                   (215 to 391)                               (747 to 1290)                  (13·2 to 21·2)[\*](#TFN4){ref-type="table-fn"}         (14·9 to 35·6)[\*](#TFN4){ref-type="table-fn"}         (15·5 to 24·2)[\*](#TFN4){ref-type="table-fn"}         (13·3 to 22·7)               (5·4 to 9·9)                 (9·4 to 16·3)                (−0·2 to 6·7)                                          (1·4 to 19·3)[\*](#TFN4){ref-type="table-fn"}          (1·9 to 9·3)[\*](#TFN4){ref-type="table-fn"}

         Amphetamine use disorders                                                                                785\                           399\                                     1180\                      4·0%\                                                  8·5%\                                                  5·5%\                                                       20·1\                        10·4\                        15·3\                  −4·1%\                                                   0·6%\                                                −2·5%\
                                                                                                        (501 to 1150)                  (253 to 593)                               (757 to 1740)                  (−0·4 to 8·4)                                          (2·7 to 16·7)[\*](#TFN4){ref-type="table-fn"}          (1·5 to 9·4)[\*](#TFN4){ref-type="table-fn"}           (12·7 to 29·5)               (6·5 to 15·5)                (9·7 to 22·6)                (−8·2 to −0·5)[\*](#TFN4){ref-type="table-fn"}         (−4·4 to 7·4)                                          (−6·2 to 0·4)

         Cannabis use disorders                                                                                   343\                           174\                                       518\                     5·4%\                                                  2·6%\                                                  4·4%\                                                         8·8\              4·5\                         6·7\                            −2·8%\                                                 −5·6%\                                                 −3·7%\
                                                                                                        (217 to 510)                   (110 to 257)                               (329 to 766)                   (2·7 to 8·3)[\*](#TFN4){ref-type="table-fn"}           (−0·1 to 5·4)                                          (2·2 to 6·6)[\*](#TFN4){ref-type="table-fn"}           (5·6 to 13·1)                (2·9 to 6·7)                 (4·2 to 9·9)                 (−5·4 to −0·2)[\*](#TFN4){ref-type="table-fn"}         (−8·0 to −3·3)[\*](#TFN4){ref-type="table-fn"}         (−5·7 to −1·7)[\*](#TFN4){ref-type="table-fn"}

         Other drug use disorders                                                                               1920\                          1090\                                      3010\                    12·9%\                                                 26·5%\                                                 17·5%\                                                        48·5\                        27·2\                        37·9\                  −0·1%\                                                 10·4%\                                                   3·5%\
                                                                                                        (1630 to 2260)                 (908 to 1300)                              (2550 to 3540)                 (8·1 to 17·1)[\*](#TFN4){ref-type="table-fn"}          (14·5 to 41·6)[\*](#TFN4){ref-type="table-fn"}         (10·9 to 24·1)[\*](#TFN4){ref-type="table-fn"}         (41·0 to 57·2)               (22·6 to 32·6)               (32·1 to 44·7)               (−4·5 to 3·3)                                          (0·1 to 22·9)[\*](#TFN4){ref-type="table-fn"}          (−2·2 to 8·9)

      **Diabetes and kidney diseases**                                                                  **     54 000**\               **     50 000**\                           **   104 000**\                **  27·1%**\                                           **  26·6%**\                                           **  26·9%**\                                           **     1399·8**\             **     1197·7**\             **     1294·2**\             **     1·0%**\                                         **     0·3%**\                                         **     0·8%**\
                                                                                                        **(46 900 to 62 700)**         **(43 100 to 58 000)**                     **(90 100 to 121 000)**        **(24·6 to 29·7)**[\*](#TFN4){ref-type="table-fn"}     **(24·1 to 29·2)**[\*](#TFN4){ref-type="table-fn"}     **(24·7 to 29·2)**[\*](#TFN4){ref-type="table-fn"}     **(1218·1 to 1617·7)**       **(1033·3 to 1390·8)**       **(1122·0 to 1496·7)**       **(−0·9 to 3·0)**                                      **(−1·7 to 2·4)**                                      **(−1·0 to 2·6)**

      Diabetes mellitus                                                                                      35 000\                        32 900\                                    67 900\                     30·4%\                                                 29·5%\                                                 30·0%\                                                      898·7\                       782·9\                       839\                       2·9%\                                                  1·9%\                                                  2·5%\
                                                                                                        (28 500 to 42 700)             (26 800 to 39 900)                         (55 400 to 82 600)             (27·1 to 34·1)[\*](#TFN4){ref-type="table-fn"}         (26·4 to 32·9)[\*](#TFN4){ref-type="table-fn"}         (26·9 to 33·3)[\*](#TFN4){ref-type="table-fn"}         (733·5 to 1095·5)            (638·0 to 951·0)             (685·1 to 1020·0)            (0·2 to 5·7)[\*](#TFN4){ref-type="table-fn"}           (−0·7 to 4·6)                                          (0 to 5·1)[\*](#TFN4){ref-type="table-fn"}

         Type 1 diabetes mellitus                                                                               5270\                          5180\                                   10 400\                     13·7%\                                                   9·3%\                                                11·5%\                                                      133·6\                       125·3\                       129·4\                   −7·7%\                                               −11·9%\                                                  −9·8%\
                                                                                                        (4760 to 5820)                 (4640 to 5700)                             (9790 to 11 100)               (9·5 to 18·3)[\*](#TFN4){ref-type="table-fn"}          (4·0 to 14)[\*](#TFN4){ref-type="table-fn"}            (7·9 to 14·5)[\*](#TFN4){ref-type="table-fn"}          (120·6 to 147·8)             (112·6 to 138·1)             (121·3 to 137·6)             (−11·4 to −4·0)[\*](#TFN4){ref-type="table-fn"}        (−16·2 to −7·9)[\*](#TFN4){ref-type="table-fn"}        (−12·8 to −7·2)[\*](#TFN4){ref-type="table-fn"}

         Type 2 diabetes mellitus                                                                              29 700\                      27 700\                                    57 400\                     33·9%\                                                 34·2%\                                                 34·0%\                                                      765·2\                       657·5\                       709·6\                     5·0%\                                                  5·0%\                                                  5·1%\
                                                                                                        (23 200 to 37 200)             (21 900 to 34 500)                         (45 000 to 71 900)             (30·0 to 38·2)[\*](#TFN4){ref-type="table-fn"}         (30·3 to 38·4)[\*](#TFN4){ref-type="table-fn"}         (30·3 to 38·1)[\*](#TFN4){ref-type="table-fn"}         (599·9 to 955·7)             (518·1 to 820·8)             (557·2 to 888·3)             (1·9 to 8·2)[\*](#TFN4){ref-type="table-fn"}           (2·1 to 8·3)[\*](#TFN4){ref-type="table-fn"}           (2·3 to 8·1)[\*](#TFN4){ref-type="table-fn"}

      Chronic kidney disease                                                                                 18 900\                        16 900\                                    35 800\                     21·9%\                                                 21·5%\                                                 21·7%\                                                      496·3\                       411·5\                       451·3\                   −2·0%\                                                 −2·4%\                                                 −2·1%\
                                                                                                        (17 700 to 20 000)             (15 800 to 18 100)                         (33 700 to 38 000)             (18·6 to 24·7)[\*](#TFN4){ref-type="table-fn"}         (18·7 to 24·1)[\*](#TFN4){ref-type="table-fn"}         (19·2 to 23·9)[\*](#TFN4){ref-type="table-fn"}         (465·5 to 524·8)             (384·8 to 439·6)             (424·9 to 478·3)             (−4·6 to 0·2)                                          (−4·6 to −0·3)[\*](#TFN4){ref-type="table-fn"}         (−4·0 to −0·4)[\*](#TFN4){ref-type="table-fn"}

         Chronic kidney disease due to type 1 diabetes mellitus                                                 1590\                          1300\                                      2890\                    18·5%\                                                 17·7%\                                                 18·2%\                                                        39·1\                        31·3\                        35·2\                  −1·9%\                                                 −3·4%\                                                 −2·6%\
                                                                                                        (1280 to 1950)                 (1060 to 1560)                             (2370 to 3500)                 (13·4 to 23·2)[\*](#TFN4){ref-type="table-fn"}         (13·3 to 22·2)[\*](#TFN4){ref-type="table-fn"}         (14·3 to 22·3)[\*](#TFN4){ref-type="table-fn"}         (31·6 to 48·0)               (25·7 to 37·7)               (28·9 to 42·6)               (−5·5 to 1·4)                                          (−6·3 to −0·4)[\*](#TFN4){ref-type="table-fn"}         (−5·1 to −0·3)[\*](#TFN4){ref-type="table-fn"}

  Chronic kidney disease due to type 2 diabetes mellitus                                                        4280\                          3840\                                      8120\                    34·2%\                                                 34·4%\                                                 34·3%\                                                      112·7\                         90·2\                      100·9\                     2·0%\                                                  2·4%\                                                  2·3%\
                                                                                                        (3700 to 4900)                 (3380 to 4340)                             (7120 to 9250)                 (29·0 to 38·1)[\*](#TFN4){ref-type="table-fn"}         (31·2 to 37·6)[\*](#TFN4){ref-type="table-fn"}         (30·9 to 37·2)[\*](#TFN4){ref-type="table-fn"}         (97·7 to 128·8)              (79·2 to 102·0)              (88·4 to 114·8)              (−1·9 to 4·6)                                          (0·1 to 4·8)[\*](#TFN4){ref-type="table-fn"}           (−0·2 to 4·2)

         Chronic kidney disease due to hypertension                                                             4050\                          3300\                                      7350\                    32·4%\                                                 32·3%\                                                 32·3%\                                                      110·2\                         78·0\                        92·7\                    1·4%\                                                  2·3%\                                                  2·1%\
                                                                                                        (3520 to 4550)                 (2900 to 3710)                             (6450 to 8220)                 (27·5 to 36·2)[\*](#TFN4){ref-type="table-fn"}         (29·1 to 35·2)[\*](#TFN4){ref-type="table-fn"}         (29·0 to 35·0)[\*](#TFN4){ref-type="table-fn"}         (96·2 to 123·3)              (68·6 to 87·7)               (81·7 to 103·7)              (−2·1 to 4·0)                                          (−0·1 to 4·5)                                          (−0·3 to 4·1)

         Chronic kidney disease due to glomerulonephritis                                                       3570\                          3040\                                      6600\                    14·7%\                                                 12·9%\                                                 13·8%\                                                        92·3\                        75·9\                        83·7\                  −3·6%\                                                 −5·4%\                                                 −4·4%\
                                                                                                        (3160 to 4020)                 (2680 to 3420)                             (5860 to 7420)                 (11·3 to 18·0)[\*](#TFN4){ref-type="table-fn"}         (9·4 to 16·4)[\*](#TFN4){ref-type="table-fn"}          (11·0 to 17·0)[\*](#TFN4){ref-type="table-fn"}         (81·9 to 103·7)              (67·1 to 84·9)               (74·4 to 93·7)               (−5·9 to −1·4)[\*](#TFN4){ref-type="table-fn"}         (−7·9 to −3)[\*](#TFN4){ref-type="table-fn"}           (−6·3 to −2·4)[\*](#TFN4){ref-type="table-fn"}

         Chronic kidney disease due to other and unspecified causes                                             5390\                          5470\                                   10 900\                     12·6%\                                                 14·0%\                                                 13·3%\                                                      142·1\                       136·1\                       138·8\                   −6·3%\                                                 −5·9%\                                                 −6·0%\
                                                                                                        (4780 to 6060)                 (4800 to 6270)                             (9660 to 12 200)               (9·2 to 16·1)[\*](#TFN4){ref-type="table-fn"}          (10·7 to 17·3)[\*](#TFN4){ref-type="table-fn"}         (10·4 to 16·2)[\*](#TFN4){ref-type="table-fn"}         (126·4 to 159·3)             (119·7 to 155·0)             (123·7 to 155·9)             (−8·5 to −3·8)[\*](#TFN4){ref-type="table-fn"}         (−8·4 to −3·4)[\*](#TFN4){ref-type="table-fn"}         (−8·0 to −4·1)[\*](#TFN4){ref-type="table-fn"}

      Acute glomerulonephritis                                                                                    180\                           130\                                       311\                   −3·9%\                                                 −7·6%\                                                 −5·5%\                                                          4·7\                         3·3\                         4·0\               −19·2%\                                                −23·0%\                                                −20·9%\
                                                                                                        (165 to 201)                   (117 to 145)                               (285 to 339)                   (−10·5 to 7·0)                                         (−13·0 to 0·5)                                         (−10·3 to 2·2)                                         (4·3 to 5·3)                 (2·9 to 3·7)                 (3·6 to 4·3)                 (−24·8 to −10·5)[\*](#TFN4){ref-type="table-fn"}       (−27·5 to −16·3)[\*](#TFN4){ref-type="table-fn"}       (−25·0 to −15·0)[\*](#TFN4){ref-type="table-fn"}

      **Skin and subcutaneous diseases**                                                                **     20 900**\               **     23 200**\                           **     44 100**\               **  13·7%**\                                           **  13·7%**\                                           **  13·7%**\                                           **       553·3**\            **       618·0**\            **       585**\              **     0·9%**\                                         **     0·7%**\                                         **     0·8%**\
                                                                                                        **(14 200 to 30 700)**         **(15 800 to 33 500)**                     **(29 900 to 64 200)**         **(12·9 to 15·1)**[\*](#TFN4){ref-type="table-fn"}     **(13·0 to 14·9)**[\*](#TFN4){ref-type="table-fn"}     **(13·0 to 14·7)**[\*](#TFN4){ref-type="table-fn"}     **(375·4 to 812·0)**         **(418·6 to 893·5)**         **(396·2 to 851·8)**         **(0·2 to 2·1)**[\*](#TFN4){ref-type="table-fn"}       **(0·1 to 1·5)**[\*](#TFN4){ref-type="table-fn"}       **(0·2 to 1·6)**[\*](#TFN4){ref-type="table-fn"}

      Dermatitis                                                                                                5100\                          6020\                                   11 100\                     12·3%\                                                 11·9%\                                                 12·1%\                                                      136·5\                       164·7\                       150·3\                     1·4%\                                                  0·9%\                                                  1·1%\
                                                                                                        (2980 to 8140)                 (3510 to 9590)                             (6480 to 17 700)               (11·3 to 13·3)[\*](#TFN4){ref-type="table-fn"}         (11·1 to 12·8)[\*](#TFN4){ref-type="table-fn"}         (11·3 to 12·8)[\*](#TFN4){ref-type="table-fn"}         (79·3 to 217·8)              (94·8 to 263·5)              (87·0 to 240·3)              (0·5 to 2·4)[\*](#TFN4){ref-type="table-fn"}           (0 to 1·7)[\*](#TFN4){ref-type="table-fn"}             (0·4 to 1·8)[\*](#TFN4){ref-type="table-fn"}

         Atopic dermatitis                                                                                      4100\                          4900\                                      9000\                    11·9%\                                                 11·4%\                                                 11·6%\                                                      110·7\                       136·4\                       123·3\                     2·0%\                                                  1·4%\                                                  1·7%\
                                                                                                        (2220 to 6820)                 (2670 to 8160)                             (4890 to 15 000)               (10·8 to 13·0)[\*](#TFN4){ref-type="table-fn"}         (10·4 to 12·4)[\*](#TFN4){ref-type="table-fn"}         (10·8 to 12·5)[\*](#TFN4){ref-type="table-fn"}         (59·8 to 184·4)              (74·0 to 227·2)              (66·8 to 205·2)              (0·9 to 3·2)[\*](#TFN4){ref-type="table-fn"}           (0·5 to 2·4)[\*](#TFN4){ref-type="table-fn"}           (0·9 to 2·6)[\*](#TFN4){ref-type="table-fn"}

         Contact dermatitis                                                                                       937\                         1050\                                      1990\                    14·4%\                                                 14·4%\                                                 14·4%\                                                        24·0\                        26·6\                        25·3\                  −0·8%\                                                 −1·3%\                                                 −1·1%\
                                                                                                        (618 to 1390)                  (692 to 1560)                              (1300 to 2950)                 (12·3 to 16·4)[\*](#TFN4){ref-type="table-fn"}         (12·5 to 16·3)[\*](#TFN4){ref-type="table-fn"}         (12·6 to 16·2)[\*](#TFN4){ref-type="table-fn"}         (15·8 to 35·6)               (17·4 to 39·4)               (16·6 to 37·4)               (−1·7 to 0·1)                                          (−2·2 to −0·5)[\*](#TFN4){ref-type="table-fn"}         (−1·7 to −0·5)[\*](#TFN4){ref-type="table-fn"}

         Seborrhoeic dermatitis                                                                                     69·0\                          66·6\                                    136\                     8·9%\                                                  7·8%\                                                  8·4%\                                                         1·8\                         1·7\                         1·7\                 −6·7%\                                                 −7·5%\                                                 −7·1%\
                                                                                                        (39·8 to 110)                  (38·3 to 105)                              (78·1 to 215)                  (6·7 to 11·2)[\*](#TFN4){ref-type="table-fn"}          (5·6 to 10·1)[\*](#TFN4){ref-type="table-fn"}          (6·6 to 10·3)[\*](#TFN4){ref-type="table-fn"}          (1·0 to 2·8)                 (1·0 to 2·7)                 (1·0 to 2·7)                 (−8·3 to −5·1)[\*](#TFN4){ref-type="table-fn"}         (−9·0 to −5·9)[\*](#TFN4){ref-type="table-fn"}         (−8·3 to −5·8)[\*](#TFN4){ref-type="table-fn"}

      Psoriasis                                                                                                 2710\                          2860\                                      5570\                    21·2%\                                                 20·9%\                                                 21·1%\                                                        68·7\                        71·4\                        70·0\                    2·5%\                                                  2·1%\                                                  2·3%\
                                                                                                        (1920 to 3590)                 (2030 to 3770)                             (3960 to 7350)                 (20·2 to 22·4)[\*](#TFN4){ref-type="table-fn"}         (19·8 to 22·0)[\*](#TFN4){ref-type="table-fn"}         (20·3 to 21·9)[\*](#TFN4){ref-type="table-fn"}         (48·7 to 90·9)               (50·7 to 94·2)               (49·7 to 92·5)               (1·7 to 3·4)[\*](#TFN4){ref-type="table-fn"}           (1·2 to 3·0)[\*](#TFN4){ref-type="table-fn"}           (1·6 to 2·9)[\*](#TFN4){ref-type="table-fn"}

      Bacterial skin diseases                                                                                   1160\                          1110\                                      2270\                    24·2%\                                                 26·9%\                                                 25·5\                                                         31·1\                        29·1\                        30·0\                    4·6%\                                                  7·2%\                                                  6·0%\
                                                                                                        (700 to 1590)                  (636 to 1540)                              (1560 to 2900)                 (13·4 to 39·3)[\*](#TFN4){ref-type="table-fn"}         (17·9 to 42·0)[\*](#TFN4){ref-type="table-fn"}         (17·8 to 34·9)[\*](#TFN4){ref-type="table-fn"}         (18·7 to 42·9)               (16·6 to 40·7)               (20·6 to 38·2)               (−4·5 to 18·1)                                         (−1·0 to 20·4)                                         (−0·5 to 14·5)

         Cellulitis                                                                                               321\                           278\                                       598\                   34·4%\                                                 30·1%\                                                 32·4%\                                                          8·4\                         7·0\                         7·7\                 12·4%\                                                   7·5%\                                                10·0%\
                                                                                                        (178 to 465)                   (155 to 393)                               (377 to 760)                   (22·9 to 48·1)[\*](#TFN4){ref-type="table-fn"}         (15·8 to 46·6)[\*](#TFN4){ref-type="table-fn"}         (26·4 to 41·1)[\*](#TFN4){ref-type="table-fn"}         (4·7 to 12·3)                (3·9 to 9·8)                 (4·9 to 9·8)                 (2·7 to 24·4)[\*](#TFN4){ref-type="table-fn"}          (−3·7 to 21·6)                                         (5·1 to 17·4)[\*](#TFN4){ref-type="table-fn"}

         Pyoderma                                                                                                 843\                           833\                                     1680\                    20·6%\                                                 25·9%\                                                 23·2%\                                                        22·7\                        22·1\                        22·3\                    2·0%\                                                  7·1%\                                                  4·7%\
                                                                                                        (489 to 1170)                  (441 to 1190)                              (1110 to 2200)                 (9·4 to 37·5)[\*](#TFN4){ref-type="table-fn"}          (16·3 to 41·7)[\*](#TFN4){ref-type="table-fn"}         (14·5 to 34·3)[\*](#TFN4){ref-type="table-fn"}         (13·1 to 31·5)               (11·7 to 31·9)               (14·8 to 29·4)               (−7·5 to 17·2)                                         (−1·8 to 21·3)                                         (−2·7 to 14·7)

      Scabies                                                                                                   2260\                          2270\                                      4530\                      6·4%\                                                  6·7%\                                                  6·6%\                                                       59·4\                        60·6\                        60·0\                  −3·2%\                                                 −3·1%\                                                 −3·1%\
                                                                                                        (1250 to 3700)                 (1260 to 3700)                             (2510 to 7410)                 (5·0 to 7·9)[\*](#TFN4){ref-type="table-fn"}           (5·3 to 8·2)[\*](#TFN4){ref-type="table-fn"}           (5·3 to 8·0)[\*](#TFN4){ref-type="table-fn"}           (32·9 to 96·8)               (33·5 to 98·8)               (33·2 to 97·8)               (−3·8 to −2·5)[\*](#TFN4){ref-type="table-fn"}         (−3·7 to −2·5)[\*](#TFN4){ref-type="table-fn"}         (−3·6 to −2·6)[\*](#TFN4){ref-type="table-fn"}

      Fungal skin diseases                                                                                      2100\                          2050\                                      4150\                      9·8%\                                                12·1%\                                                 10·9%\                                                        56·5\                        53·2\                        54·9\                  −4·6%\                                                 −4·1%\                                                 −4·4%\
                                                                                                        (832 to 4370)                  (819 to 4260)                              (1650 to 8630)                 (8·1 to 11·5)[\*](#TFN4){ref-type="table-fn"}          (10·4 to 13·7)[\*](#TFN4){ref-type="table-fn"}         (9·2 to 12·5)[\*](#TFN4){ref-type="table-fn"}          (22·4 to 117·4)              (21·2 to 110·5)              (21·8 to 114·2)              (−5·6 to −3·6)[\*](#TFN4){ref-type="table-fn"}         (−5·1 to −3·1)[\*](#TFN4){ref-type="table-fn"}         (−5·4 to −3·4)[\*](#TFN4){ref-type="table-fn"}

      Viral skin diseases                                                                                       1940\                          2090\                                      4030\                      7·1%\                                                  5·9%\                                                  6·4%\                                                       52·9\                        59·0\                        56·0\                  −1·0%\                                                 −2·5%\                                                 −1·8%\
                                                                                                        (1250 to 2880)                 (1350 to 3110)                             (2600 to 6000)                 (6·4 to 7·7)[\*](#TFN4){ref-type="table-fn"}           (5·3 to 6·4)[\*](#TFN4){ref-type="table-fn"}           (6·0 to 6·9)[\*](#TFN4){ref-type="table-fn"}           (33·9 to 78·5)               (38·0 to 87·7)               (36·0 to 83·2)               (−1·5 to −0·4)[\*](#TFN4){ref-type="table-fn"}         (−3·0 to −2·0)[\*](#TFN4){ref-type="table-fn"}         (−2·2 to −1·4)[\*](#TFN4){ref-type="table-fn"}

      Acne vulgaris                                                                                             1150\                          1400\                                      2550\                    17·3%\                                                 15·3%\                                                 16·2%\                                                        30·0\                        37·9\                        33·9\                  12·8%\                                                 10·2%\                                                 11·4%\
                                                                                                        (677 to 1830)                  (841 to 2230)                              (1520 to 4060)                 (15·8 to 18·9)[\*](#TFN4){ref-type="table-fn"}         (14·1 to 16·6)[\*](#TFN4){ref-type="table-fn"}         (15·2 to 17·2)[\*](#TFN4){ref-type="table-fn"}         (17·7 to 47·9)               (22·7 to 60·5)               (20·2 to 54·1)               (11·3 to 14·6)[\*](#TFN4){ref-type="table-fn"}         (9·0 to 11·6)[\*](#TFN4){ref-type="table-fn"}          (10·3 to 12·5)[\*](#TFN4){ref-type="table-fn"}

      Alopecia areata                                                                                             241\                           282\                                       523\                   12·8%\                                                 12·7%\                                                 12·7%\                                                          6·1\                         7·1\                         6·6\                 −0·6%\                                                 −2·2%\                                                 −1·5%\
                                                                                                        (154 to 358)                   (181 to 418)                               (335 to 775)                   (11·3 to 14·2)[\*](#TFN4){ref-type="table-fn"}         (11·4 to 14·0)[\*](#TFN4){ref-type="table-fn"}         (11·8 to 13·8)[\*](#TFN4){ref-type="table-fn"}         (3·9 to 9·1)                 (4·6 to 10·6)                (4·2 to 9·8)                 (−1·9 to 0·7)                                          (−3·3 to −1·2)[\*](#TFN4){ref-type="table-fn"}         (−2·3 to −0·6)[\*](#TFN4){ref-type="table-fn"}

      Pruritus                                                                                                    331\                           424\                                       756\                   19·3%\                                                 18·6%\                                                 18·9%\                                                          8·6\                       10·7\                          9·7\                   2·2%\                                                  1·2%\                                                  1·6%\
                                                                                                        (156 to 632)                   (200 to 801)                               (356 to 1430)                  (17·7 to 20·9)[\*](#TFN4){ref-type="table-fn"}         (17·1 to 20·2)[\*](#TFN4){ref-type="table-fn"}         (17·5 to 20·4)[\*](#TFN4){ref-type="table-fn"}         (4·0 to 16·1)                (5·0 to 20·2)                (4·5 to 18·2)                (1·6 to 2·8)[\*](#TFN4){ref-type="table-fn"}           (0·6 to 1·7)[\*](#TFN4){ref-type="table-fn"}           (1·2 to 2·0)[\*](#TFN4){ref-type="table-fn"}

      Urticaria                                                                                                 2190\                          2830\                                      5010\                    10·8%\                                                 10·8%\                                                 10·8%\                                                        58·4\                        77·2\                        67·7\                    0·6%\                                                  0·1%\                                                  0·3%\
                                                                                                        (1450 to 3090)                 (1880 to 3970)                             (3320 to 7050)                 (9·6 to 12·1)[\*](#TFN4){ref-type="table-fn"}          (9·6 to 12·0)[\*](#TFN4){ref-type="table-fn"}          (9·8 to 11·9)[\*](#TFN4){ref-type="table-fn"}          (38·6 to 82·5)               (51·1 to 109·0)              (44·8 to 95·4)               (−0·2 to 1·5)                                          (−0·5 to 0·8)                                          (−0·2 to 0·8)

      Decubitus ulcer                                                                                             238\                           265\                                       503\                   26·2%\                                                 28·1%\                                                 27·2%\                                                          6·7\                         6·3\                         6·5\                 −2·3%\                                                 −0·8%\                                                 −1·6%\
                                                                                                        (169 to 357)                   (184 to 371)                               (379 to 661)                   (18·8 to 41·0)[\*](#TFN4){ref-type="table-fn"}         (21·7 to 35·5)[\*](#TFN4){ref-type="table-fn"}         (21·5 to 37·7)[\*](#TFN4){ref-type="table-fn"}         (4·7 to 10·1)                (4·4 to 8·9)                 (4·9 to 8·6)                 (−8·2 to 9·4)                                          (−5·9 to 5·6)                                          (−6·0 to 7·1)

      Other skin and subcutaneous diseases                                                                      1470\                          1640\                                      3110\                    25·8%\                                                 25·0%\                                                 25·4%\                                                        38·4\                        40·7\                        39·5\                    4·5%\                                                  3·9%\                                                  4·2%\
                                                                                                        (736 to 2680)                  (819 to 2970)                              (1560 to 5650)                 (25·0 to 26·5)[\*](#TFN4){ref-type="table-fn"}         (24·2 to 26·0)[\*](#TFN4){ref-type="table-fn"}         (24·8 to 26·0)[\*](#TFN4){ref-type="table-fn"}         (19·3 to 69·9)               (20·4 to 73·9)               (19·8 to 71·9)               (3·9 to 5·0)[\*](#TFN4){ref-type="table-fn"}           (3·3 to 4·7)[\*](#TFN4){ref-type="table-fn"}           (3·8 to 4·7)[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **    Sense organ diseases**                                                                          **     31 700**\               **     34 800**\                           **     66 600**\               **  23·9%**\                                           **  24·2%**\                                           **  24·1%**\                                           **       843·1**\            **       841·0**\            **       842·2**\            **   −0·9%**\                                          **   −0·9%**\                                          **   −0·9%**\
                                                                                                        **(21 300 to 45 700)**         **(23 500 to 49 900)**                     **(44 700 to 95 700)**         **(23·1 to 24·9)[\*](#TFN4){ref-type="table-fn"}**     **(23·4 to 25·0)[\*](#TFN4){ref-type="table-fn"}**     **(23·4 to 24·8)[\*](#TFN4){ref-type="table-fn"}**     **(568·7 to 1205·8)**        **(567·7 to 1206·4)**        **(566·6 to 1206·5)**        **(−1·7 to −0·3)[\*](#TFN4){ref-type="table-fn"}**     **(−1·6 to −0·2)[\*](#TFN4){ref-type="table-fn"}**     **(−1·5 to −0·3)[\*](#TFN4){ref-type="table-fn"}**

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Blindness and vision impairment                                                                        13 500\                        16 400\                                    29 900\                     23·6%\                                                 22·6%\                                                 23·1%\                                                      356·2\                       395·7\                       376·6\                   −1·5%\                                                 −2·1%\                                                 −1·8%\
                                                                                                        (9060 to 20 000)               (11 100 to 24 100)                         (20 300 to 44 000)             (22·4 to 24·8)[\*](#TFN4){ref-type="table-fn"}         (21·6 to 23·5)[\*](#TFN4){ref-type="table-fn"}         (22·0 to 24)[\*](#TFN4){ref-type="table-fn"}           (240·0 to 523·0)             (267·6 to 583·1)             (255·6 to 555)               (−2·4 to −0·6)[\*](#TFN4){ref-type="table-fn"}         (−3 to −1·2)[\*](#TFN4){ref-type="table-fn"}           (−2·7 to −0·9)[\*](#TFN4){ref-type="table-fn"}

         Glaucoma                                                                                                 342\                           344\                                       686\                   28·8%\                                                 27·1%\                                                 27·9%\                                                          9·4\                         8·0\                         8·6\                 −4·7%\                                                 −4·8%\                                                 −4·7%\
                                                                                                        (230 to 474)                   (233 to 478)                               (463 to 949)                   (27·0 to 30·8)[\*](#TFN4){ref-type="table-fn"}         (25·1 to 28·9)[\*](#TFN4){ref-type="table-fn"}         (26·4 to 29·4)[\*](#TFN4){ref-type="table-fn"}         (6·3 to 12·9)                (5·4 to 11·2)                (5·8 to 12·0)                (−6·1 to −3·4)[\*](#TFN4){ref-type="table-fn"}         (−6·3 to −3·3)[\*](#TFN4){ref-type="table-fn"}         (−5·8 to −3·6)[\*](#TFN4){ref-type="table-fn"}

         Cataract                                                                                               3350\                          4650\                                      8010\                    31·3%\                                                 28·4%\                                                 29·6%\                                                        93·2\                      109·0\                       101·8\                   −1·7%\                                                 −2·3%\                                                 −2·0%\
                                                                                                        (2340 to 4540)                 (3250 to 6270)                             (5580 to 10 800)               (28·5 to 34·1)[\*](#TFN4){ref-type="table-fn"}         (26·5 to 30·2)[\*](#TFN4){ref-type="table-fn"}         (27·4 to 31·7)[\*](#TFN4){ref-type="table-fn"}         (65·1 to 126·4)              (76 to 147)                  (70·9 to 137·7)              (−3·7 to 0·2)                                          (−3·7 to −0·9)[\*](#TFN4){ref-type="table-fn"}         (−3·6 to −0·5)[\*](#TFN4){ref-type="table-fn"}

         Age-related macular degeneration                                                                         223\                           308\                                       531\                   34·1%\                                                 28·3%\                                                 30·7%\                                                          6·3\                         7·2\                         6·8\                 −1·4%\                                                 −4·8%\                                                 −3·7%\
                                                                                                        (153 to 307)                   (210 to 422)                               (364 to 729)                   (31·3 to 37·1)[\*](#TFN4){ref-type="table-fn"}         (26·2 to 30·6)[\*](#TFN4){ref-type="table-fn"}         (28·6 to 32·9)[\*](#TFN4){ref-type="table-fn"}         (4·3 to 8·6)                 (4·9 to 9·8)                 (4·6 to 9·3)                 (−3·2 to 0·6)                                          (−6·5 to −3·1)[\*](#TFN4){ref-type="table-fn"}         (−5·3 to −2·1)[\*](#TFN4){ref-type="table-fn"}

         Refraction disorders                                                                                   3980\                          4000\                                      7980\                    17·0%\                                                 13·7%\                                                 15·3%\                                                      103·8\                       100·7\                       102·2\                   −1·5%\                                                 −4·6%\                                                 −3·1%\
                                                                                                        (2650 to 5780)                 (2700 to 5720)                             (5350 to 11 500)               (15·0 to 19·0)[\*](#TFN4){ref-type="table-fn"}         (12·0 to 15·2)[\*](#TFN4){ref-type="table-fn"}         (13·6 to 17·0)[\*](#TFN4){ref-type="table-fn"}         (68·9 to 150·7)              (67·6 to 144·2)              (68·2 to 147·3)              (−2·9 to −0·1)[\*](#TFN4){ref-type="table-fn"}         (−5·7 to −3·6)[\*](#TFN4){ref-type="table-fn"}         (−4·2 to −1·9)[\*](#TFN4){ref-type="table-fn"}

         Near vision loss                                                                                       4260\                          5540\                                      9800\                    23·7%\                                                 25·4%\                                                 24·6%\                                                      108·3\                       133·7\                       121·0\                   −0·7%\                                                   1·4%\                                                  0·5%\
                                                                                                        (2030 to 7790)                 (2640 to 10 100)                           (4670 to 17 900)               (22·9 to 24·5)[\*](#TFN4){ref-type="table-fn"}         (24·6 to 26·1)[\*](#TFN4){ref-type="table-fn"}         (24 to 25·2)[\*](#TFN4){ref-type="table-fn"}           (51·7 to 198·2)              (63·6 to 244·5)              (57·7 to 221·3)              (−1·2 to −0·2)[\*](#TFN4){ref-type="table-fn"}         (0·9 to 1·9)[\*](#TFN4){ref-type="table-fn"}           (0·1 to 0·9)[\*](#TFN4){ref-type="table-fn"}

         Other vision loss                                                                                      1350\                          1540\                                      2890\                    22·9%\                                                 19·5%\                                                 21·0%\                                                        35·3\                        37·1\                        36·3\                  −2·1%\                                                 −5·0%\                                                 −3·7%\
                                                                                                        (941 to 1810)                  (1070 to 2070)                             (2010 to 3880)                 (20·9 to 24·7)[\*](#TFN4){ref-type="table-fn"}         (17·8 to 21·1)[\*](#TFN4){ref-type="table-fn"}         (19·4 to 22·6)[\*](#TFN4){ref-type="table-fn"}         (24·6 to 47·5)               (25·8 to 49·9)               (25·3 to 48·9)               (−3·5 to −0·8)[\*](#TFN4){ref-type="table-fn"}         (−6·1 to −3·9)[\*](#TFN4){ref-type="table-fn"}         (−4·8 to −2·6)[\*](#TFN4){ref-type="table-fn"}

      Age-related and other hearing loss                                                                     17 200\                        17 100\                                    34 200\                     24·2%\                                                 25·7%\                                                 24·9%\                                                      458·7\                       411·6\                       434·6\                   −0·7%\                                                   0·2%\                                                −0·2%\
                                                                                                        (11 500 to 24 500)             (11 600 to 24 200)                         (23 200 to 48 700)             (22·8 to 25·6)[\*](#TFN4){ref-type="table-fn"}         (24·4 to 27·1)[\*](#TFN4){ref-type="table-fn"}         (23·9 to 26·0)[\*](#TFN4){ref-type="table-fn"}         (311·5 to 650·0)             (279·5 to 583·7)             (295·4 to 616·1)             (−1·8 to 0·4)                                          (−0·9 to 1·2)                                          (−1·0 to 0·5)

      Other sense organ diseases                                                                                1070\                          1380\                                      2450\                    24·9%\                                                 25·0%\                                                 25·0%\                                                        28·1\                        33·7\                        31·0\                    1·1%\                                                  0·8%\                                                  0·9%\
                                                                                                        (665 to 1570)                  (854 to 2010)                              (1520 to 3570)                 (23·9 to 26·0)[\*](#TFN4){ref-type="table-fn"}         (24·1 to 26)[\*](#TFN4){ref-type="table-fn"}           (24·2 to 25·8)[\*](#TFN4){ref-type="table-fn"}         (17·5 to 41·2)               (20·9 to 49·0)               (19·2 to 45·2)               (0·4 to 1·8)[\*](#TFN4){ref-type="table-fn"}           (0·1 to 1·5)[\*](#TFN4){ref-type="table-fn"}           (0·4 to 1·4)[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **    Musculoskeletal disorders**                                                                     **     60 800**\               **     77 900**\                           **   139 000**\                **  19·5%**\                                           **  20·2%**\                                           **  19·9%**\                                           **     1538·9**\             **     1894·7**\             **     1720·5**\             **     −1%**\                                          **   −1·2%**\                                          **   −1·1%**\
                                                                                                        **(44 700 to 80 400)**         **(57 500 to 103 000)**                    **(102 000 to 183 000)**       **(18·3 to 20·7)[\*](#TFN4){ref-type="table-fn"}**     **(19 to 21·6)[\*](#TFN4){ref-type="table-fn"}**       **(18·8 to 21·2)[\*](#TFN4){ref-type="table-fn"}**     **(1134·0 to 2023·2)**       **(1398·6 to 2491·4)**       **(1264·4 to 2259·2)**       **(−1·7 to −0·4)[\*](#TFN4){ref-type="table-fn"}**     **(−1·9 to −0·5)[\*](#TFN4){ref-type="table-fn"}**     **(−1·7 to −0·5)[\*](#TFN4){ref-type="table-fn"}**

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Rheumatoid arthritis                                                                                        977\                         2510\                                      3490\                    26·1%\                                                 30·6%\                                                 29·3%\                                                        25·4\                        60·1\                        43·3\                  −0·6%\                                                   3·4%\                                                  2·3%\
                                                                                                        (750 to 1220)                  (1910 to 3180)                             (2660 to 4410)                 (22·9 to 28·9)[\*](#TFN4){ref-type="table-fn"}         (26·3 to 34·1)[\*](#TFN4){ref-type="table-fn"}         (26·0 to 32·1)[\*](#TFN4){ref-type="table-fn"}         (19·6 to 31·5)               (45·5 to 76·0)               (33·0 to 54·5)               (−3·5 to 1·7)                                          (0·1 to 6·2)[\*](#TFN4){ref-type="table-fn"}           (−0·5 to 4·6)

      Osteoarthritis                                                                                            3840\                          5760\                                      9600\                    32·0%\                                                 31·0%\                                                 31·4%\                                                      100·0\                       135·6\                       118·8\                     1·6%\                                                  0·8%\                                                  1·0%\
                                                                                                        (1930 to 7680)                 (2880 to 11 500)                           (4810 to 19 100)               (31·0 to 33·0)[\*](#TFN4){ref-type="table-fn"}         (30·3 to 31·8)[\*](#TFN4){ref-type="table-fn"}         (30·7 to 32·1)[\*](#TFN4){ref-type="table-fn"}         (50·3 to 199·1)              (67·7 to 269·7)              (59·5 to 236·2)              (0·9 to 2·3)[\*](#TFN4){ref-type="table-fn"}           (0·2 to 1·4)[\*](#TFN4){ref-type="table-fn"}           (0·5 to 1·6)[\*](#TFN4){ref-type="table-fn"}

      Low back pain                                                                                          29 500\                        35 500\                                    64 900\                     17·8%\                                                 17·3%\                                                 17·5%\                                                      748·2\                       869·1\                       810·3\                   −1·3%\                                                 −2·7%\                                                 −2·1%\
                                                                                                        (21 000 to 40 000)             (25 400 to 47 700)                         (46 500 to 87 400)             (16·5 to 19·3)[\*](#TFN4){ref-type="table-fn"}         (15·8 to 18·8)[\*](#TFN4){ref-type="table-fn"}         (16·2 to 19·0)[\*](#TFN4){ref-type="table-fn"}         (537·6 to 1008·5)            (624·5 to 1164·5)            (582·4 to 1089·1)            (−1·9 to −0·7)[\*](#TFN4){ref-type="table-fn"}         (−3·3 to −2·2)[\*](#TFN4){ref-type="table-fn"}         (−2·6 to −1·6)[\*](#TFN4){ref-type="table-fn"}

      Neck pain                                                                                              12 200\                        16 400\                                    28 600\                     22·3%\                                                 20·8%\                                                 21·4%\                                                      307·4\                       395·1\                       352·0\                     0·4%\                                                −1·5%\                                                 −0·7%\
                                                                                                        (8540 to 17 200)               (11 400 to 22 900)                         (20 000 to 40 200)             (20·1 to 24·3)[\*](#TFN4){ref-type="table-fn"}         (18·4 to 23·7)[\*](#TFN4){ref-type="table-fn"}         (19·5 to 23·6)[\*](#TFN4){ref-type="table-fn"}         (215·7 to 430·8)             (275·9 to 551·8)             (245·6 to 493·3)             (−0·8 to 1·5)                                          (−3·0 to 0·2)                                          (−1·6 to 0·5)

      Gout                                                                                                        953\                           332\                                     1280\                    30·2%\                                                 32·9%\                                                 30·9%\                                                        24·6\                          7·8\                       15·9\                    2·4%\                                                  3·1%\                                                  2·7%\
                                                                                                        (641 to 1300)                  (226 to 451)                               (867 to 1770)                  (28·2 to 32·2)[\*](#TFN4){ref-type="table-fn"}         (30·5 to 35·3)[\*](#TFN4){ref-type="table-fn"}         (29·2 to 32·6)[\*](#TFN4){ref-type="table-fn"}         (16·6 to 33·8)               (5·3 to 10·7)                (10·7 to 21·8)               (1·1 to 3·7)[\*](#TFN4){ref-type="table-fn"}           (1·3 to 4·9)[\*](#TFN4){ref-type="table-fn"}           (1·6 to 3·7)[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **    Other musculoskeletal disorders**                                                               **     13 300**\               **     17 500**\                           **     30 800**\               **  16·6%**\                                           **  21·0%**\                                           **  19·1%**\                                           **       333·3**\            **       427·0**\            **       380·2**\            **   −2·7%**\                                          **     0·9%**\                                         **   −0·7%**\
                                                                                                        **(9130 to 18 400)**           **(12 400 to 23 600)**                     **(21 500 to 42 000)**         **(13·2 to 19·8)[\*](#TFN4){ref-type="table-fn"}**     **(17·7 to 24·4)[\*](#TFN4){ref-type="table-fn"}**     **(15·8 to 22·3)[\*](#TFN4){ref-type="table-fn"}**     **(229·5 to 459·1)**         **(303·1 to 577·3)**         **(266·2 to 520·3)**         **(−5·2 to −0·4)[\*](#TFN4){ref-type="table-fn"}**     **(−1·6 to 3·2)**                                      **(−3·0 to 1·4)**

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Other non-communicable diseases                                                                        56 000\                        65 900\                                  122 000\                      −3·8%\                                                   0·3%\                                                −1·6%\                                                    1547·8\                      1812·4\                      1678·1\                  −12·8%\                                                −10·3%\                                                −11·5%\
                                                                                                        (48 900 to 64 900)             (54 700 to 79 500)                         (104 000 to 144 000)           (−10·8 to 0·6)                                         (−3·7 to 3·3)                                          (−6·1 to 1·6)                                          (1362·6 to 1778·5)           (1524·5 to 2156·7)           (1450·0 to 1961·2)           (−18·8 to −9·3)[\*](#TFN4){ref-type="table-fn"}        (−13·4 to −7·9)[\*](#TFN4){ref-type="table-fn"}        (−15·4 to −8·9)[\*](#TFN4){ref-type="table-fn"}

      Congenital anomalies                                                                                   32 300\                        28 600\                                    60 900\                   −12·1%\                                                  −9·6%\                                               −10·9%\                                                       917·1\                       859·6\                       889·0\                 −16·7%\                                                −14·8%\                                                −15·8%\
                                                                                                        (29 800 to 35 300)             (26 400 to 30 700)                         (56 400 to 65 400)             (−21·3 to −7·0)[\*](#TFN4){ref-type="table-fn"}        (−14·8 to −5·7)[\*](#TFN4){ref-type="table-fn"}        (−17·3 to −7·1)[\*](#TFN4){ref-type="table-fn"}        (847·3 to 999·7)             (795·0 to 920·4)             (827·6 to 951·5)             (−25·3 to −12)[\*](#TFN4){ref-type="table-fn"}         (−19·6 to −11)[\*](#TFN4){ref-type="table-fn"}         (−21·8 to −12·3)[\*](#TFN4){ref-type="table-fn"}

         Neural tube defects                                                                                    3140\                          3030\                                      6170\                  −11·2%\                                                  −9·0%\                                               −10·2%\                                                         90·1\                        92·7\                        91·3\                −15·3%\                                                −13·6%\                                                −14·5%\
                                                                                                        (2380 to 4350)                 (2280 to 4150)                             (4840 to 8170)                 (−27·1 to 1·4)                                         (−22·0 to 4·9)                                         (−21·3 to 0·9)                                         (68·3 to 125·1)              (69·7 to 127·2)              (71·7 to 121·2)              (−30·4 to −3·2)[\*](#TFN4){ref-type="table-fn"}        (−26·0 to −0·2)[\*](#TFN4){ref-type="table-fn"}        (−25·1 to −4·0)[\*](#TFN4){ref-type="table-fn"}

         Congenital heart anomalies                                                                          11 500\                        10 700\                                    22 200\                   −19·1%\                                                −17·6%\                                                −18·4%\                                                       332·1\                       328·0\                       330·0\                 −22·5%\                                                −21·3%\                                                −21·9%\
                                                                                                        (9480 to 14 000)               (8260 to 12 600)                           (18 400 to 26 300)             (−27·9 to −9·6)[\*](#TFN4){ref-type="table-fn"}        (−23·4 to −10·1)[\*](#TFN4){ref-type="table-fn"}       (−24·8 to −10·3)[\*](#TFN4){ref-type="table-fn"}       (272·0 to 404·0)             (253·0 to 388·2)             (272·3 to 390·8)             (−30·9 to −13·4)[\*](#TFN4){ref-type="table-fn"}       (−26·9 to −14·2)[\*](#TFN4){ref-type="table-fn"}       (−28·1 to −14·3)[\*](#TFN4){ref-type="table-fn"}

         Orofacial clefts                                                                                         352\                           300\                                       652\                   21·9%\                                               −21·8%\                                                −21·9%\                                                           9·8\                         8·7\                         9·3\               −27·2%\                                                −28·3%\                                                −27·7%\
                                                                                                        (194 to 657)                   (187 to 599)                               (411 to 1110)                  (−37·7 to −4·3)[\*](#TFN4){ref-type="table-fn"}        (−38·2 to −5·6)[\*](#TFN4){ref-type="table-fn"}        (−35·2 to −8·1)[\*](#TFN4){ref-type="table-fn"}        (5·3 to 18·7)                (5·3 to 18·2)                (5·8 to 16·2)                (−41·8 to −10·0)[\*](#TFN4){ref-type="table-fn"}       (−42·6 to −13·9)[\*](#TFN4){ref-type="table-fn"}       (−39·9 to −15·4)[\*](#TFN4){ref-type="table-fn"}

         Down syndrome                                                                                          1240\                            989\                                     2230\                    −1·5%\                                                   2·6%\                                                  0·3%\                                                       34·8\                        29·0\                        32·0\                  −7·8%\                                                 −4·6%\                                                 −6·4%\
                                                                                                        (963 to 1790)                  (755 to 1520)                              (1760 to 3040)                 (−12·1 to 14·2)                                        (−9·0 to 16·7)                                         (−9·2 to 13·6)                                         (26·7 to 50·5)               (21·9 to 45·3)               (24·9 to 43·9)               (−17·4 to 6·7)                                         (−15·3 to 8·3)                                         (−15·1 to 5·9)

         Turner syndrome                                                                                               ··                          10·1\                                   10·1\                       ··                                                   9·1%\                                                  9·1%\                                                          ··                          0·3\                         0·1\                     ··                                                   1·0%\                                                  0·9%\
                                                                                                                                       (5·02 to 16·5)                             (5·02 to 16·5)                                                                        (7·3 to 10·9)[\*](#TFN4){ref-type="table-fn"}          (7·3 to 10·9)[\*](#TFN4){ref-type="table-fn"}                                       (0·1 to 0·5)                 (0·1 to 0·2)                                                                        (−0·6 to 2·6)                                          (−0·7 to 2·5)

         Klinefelter syndrome                                                                                         5·16\                           ··                                   5·16\                     7·4%\                                                    ··                                                   7·4%\                                                         0·1\                           ··                         0·1\                 −1·9%\                                                    ··                                                  −1·7%\
                                                                                                        (2·43 to 9·74)                                                            (2·43 to 9·74)                 (4·3 to 10·7)[\*](#TFN4){ref-type="table-fn"}                                                                 (4·3 to 10·7)[\*](#TFN4){ref-type="table-fn"}          (0·1 to 0·3)                                              (0 to 0·1)                   (−4·7 to 1·0)                                                                                                 (−4·5 to 1·1)

         Other chromosomal abnormalities                                                                          928\                         1170\                                      2100\                    10·2%\                                                   6·1%\                                                  7·9%\                                                       26·0\                        35·2\                        30·4\                    3·7%\                                                  0·2%\                                                  1·7%\
                                                                                                        (654 to 1380)                  (769 to 2010)                              (1510 to 2840)                 (−2·8 to 22·0)                                         (−7·2 to 19·3)                                         (−1·9 to 18·2)                                         (18·3 to 38·8)               (22·6 to 61·2)               (21·8 to 41·3)               (−8·1 to 14·5)                                         (−11·8 to 12·6)                                        (−7·2 to 11·4)

         Congenital musculoskeletal and limb anomalies                                                          2890\                          2650\                                      5530\                      8·6%\                                                  9·0%\                                                  8·8%\                                                       76·8\                        71·6\                        74·2\                  −2·3%\                                                 −2·7%\                                                 −2·5%\
                                                                                                        (2030 to 3790)                 (1850 to 3510)                             (3880 to 7270)                 (4·1 to 11·8)[\*](#TFN4){ref-type="table-fn"}          (4·2 to 12·8)[\*](#TFN4){ref-type="table-fn"}          (4·8 to 11·1)[\*](#TFN4){ref-type="table-fn"}          (54·5 to 100·5)              (50·4 to 94·3)               (52·6 to 97·2)               (−5·9 to 0·3)                                          (−6·7 to 0·4)                                          (−5·6 to −0·5)[\*](#TFN4){ref-type="table-fn"}

         Urogenital congenital anomalies                                                                          687\                           560\                                     1250\                    −4·9%\                                                 −3·9%\                                                 −4·5%\                                                        19·7\                        16·9\                        18·3\                  −9·1%\                                                 −9·1%\                                                 −9·1%\
                                                                                                        (459 to 879)                   (411 to 698)                               (926 to 1500)                  (−15·5 to 8·5)                                         (−13·3 to 7·3)                                         (−13·2 to 6·1)                                         (13·0 to 25·3)               (12·3 to 21·0)               (13·6 to 22·1)               (−19·1 to 3·5)                                         (−18·1 to 1·8)                                         (−17·2 to 0·8)

         Digestive congenital anomalies                                                                         2970\                          2220\                                      5190\                  −16·1%\                                                  −9·5%\                                               −13·4%\                                                         85·3\                        67·5\                        76·7\                −20·0%\                                                −14·1%\                                                −17·6%\
                                                                                                        (2190 to 3960)                 (1440 to 3300)                             (3990 to 7050)                 (−30·4 to −4·8)[\*](#TFN4){ref-type="table-fn"}        (−17·8 to 1·3)                                         (−24·5 to −4·0)[\*](#TFN4){ref-type="table-fn"}        (62·6 to 113·9)              (43·1 to 101·0)              (58·7 to 104·6)              (−33·4 to −9·1)[\*](#TFN4){ref-type="table-fn"}        (−21·9 to −4·1)[\*](#TFN4){ref-type="table-fn"}        (−28·1 to −8·9)[\*](#TFN4){ref-type="table-fn"}

         Other congenital anomalies                                                                             8570\                          6980\                                   15 500\                     −9·7%\                                                 −5·8%\                                                 −8·0%\                                                      242·4\                       209·8\                       226·5\                 −14·5%\                                                −11·0%\                                                −13·0%\
                                                                                                        (6620 to 10 500)               (5170 to 8960)                             (12 000 to 19 200)             (−17·9 to 1·5)                                         (−14·8 to 5·0)                                         (−15·8 to 2·7)                                         (186·3 to 297·7)             (155·1 to 270·2)             (174·1 to 279·7)             (−22·1 to −4·1)[\*](#TFN4){ref-type="table-fn"}        (−19·4 to −1·0)[\*](#TFN4){ref-type="table-fn"}        (−20·4 to −3·3)[\*](#TFN4){ref-type="table-fn"}

      Urinary diseases and male infertility                                                                     6080\                          3310\                                      9390\                    21·8%\                                                 24·5%\                                                 22·8%\                                                      162·2\                         82·7\                      119·9\                   −2·7%\                                                   2·3%\                                                −0·8%\
                                                                                                        (5080 to 7320)                 (3140 to 3480)                             (8260 to 10 700)               (18·1 to 25·1)[\*](#TFN4){ref-type="table-fn"}         (18 to 28·2)[\*](#TFN4){ref-type="table-fn"}           (18·9 to 25·6)[\*](#TFN4){ref-type="table-fn"}         (136 to 194·8)               (78·4 to 87·1)               (105·9 to 136·8)             (−5·3 to −0·2)[\*](#TFN4){ref-type="table-fn"}         (−3·3 to 5·4)                                          (−3·9 to 1·6)

         Urinary tract infections                                                                               2120\                          2570\                                      4700\                    24·5%\                                                 36·4%\                                                 30·8%\                                                        57·8\                        63·8\                        60·7\                    2·3%\                                                11·3%\                                                   7·0%\
                                                                                                        (1970 to 2410)                 (2410 to 2830)                             (4430 to 5190)                 (17·7 to 31·7)[\*](#TFN4){ref-type="table-fn"}         (28·5 to 44·1)[\*](#TFN4){ref-type="table-fn"}         (24·2 to 37·8)[\*](#TFN4){ref-type="table-fn"}         (53·8 to 65·4)               (59·5 to 70·5)               (57·2 to 67·2)               (−3·0 to 7·9)                                          (4·8 to 17·6)[\*](#TFN4){ref-type="table-fn"}          (1·6 to 12·6)[\*](#TFN4){ref-type="table-fn"}

         Urolithiasis                                                                                             281\                           205\                                       486\                   15·9%\                                                 23·7%\                                                 19·1%\                                                          7·3\                         4·9\                         6·0\                 −7·0%\                                                 −0·2%\                                                 −4·1%\
                                                                                                        (227 to 346)                   (165 to 252)                               (397 to 591)                   (9·5 to 25·0)[\*](#TFN4){ref-type="table-fn"}          (18·2 to 34·5)[\*](#TFN4){ref-type="table-fn"}         (13·6 to 28)[\*](#TFN4){ref-type="table-fn"}           (5·9 to 8·9)                 (4·0 to 6·1)                 (4·9 to 7·3)                 (−12·3 to 0·3)                                         (−4·6 to 8·2)                                          (−8·5 to 3·0)

         Benign prostatic hyperplasia                                                                           2430\                                 ··                                  2430\                    32·0%\                                                     ··                                                 32·0%\                                                        63·7\                            ··                       29·9\                  −0·7%\                                                    ··                                                  −0·2%\
                                                                                                        (1560 to 3460)                                                            (1560 to 3460)                 (30·7 to 33·3)[\*](#TFN4){ref-type="table-fn"}                                                                (30·7 to 33·3)[\*](#TFN4){ref-type="table-fn"}         (40·9 to 90·7)                                            (19·2 to 42·5)               (−1·6 to 0·3)                                                                                                 (−1·1 to 0·8)

         Male infertility                                                                                         181\                                ··                                    181\                   17·0%\                                                     ··                                                 17·0%\                                                          4·6\                           ··                         2·3\                   6·7%\                                                   ··                                                    6·9%\
                                                                                                        (74·8 to 374)                                                             (74·8 to 374)                  (13·7 to 20·1)[\*](#TFN4){ref-type="table-fn"}                                                                (13·7 to 20·1)[\*](#TFN4){ref-type="table-fn"}         (1·9 to 9·5)                                              (1·0 to 4·8)                 (3·9 to 9·4)[\*](#TFN4){ref-type="table-fn"}                                                                  (4·1 to 9·7)[\*](#TFN4){ref-type="table-fn"}

         Other urinary diseases                                                                                 1080\                            526\                                     1600\                      1·7%\                                              −12·4%\                                                  −3·4%\                                                        28·9\                        13·9\                        21·0\                −15·0%\                                                −24·8%\                                                −18·4%\
                                                                                                        (903 to 1240)                  (346 to 654)                               (1290 to 1790)                 (−6·3 to 11·6)                                         (−23·3 to −3·3)[\*](#TFN4){ref-type="table-fn"}        (−9·4 to 5·1)                                          (24·3 to 33·4)               (9·2 to 17·4)                (16·9 to 23·6)               (−21·4 to −7·3)[\*](#TFN4){ref-type="table-fn"}        (−33·4 to −17·3)[\*](#TFN4){ref-type="table-fn"}       (−23·1 to −11·5)[\*](#TFN4){ref-type="table-fn"}

      Gynaecological diseases                                                                                          ··                   11 900\                                    11 900\                         ··                                                 10·2%\                                                 10·2%\                                                           ··                      299·4\                       148·8\                       ··                                                 −2·4%\                                                 −2·5%\
                                                                                                                                       (8210 to 16 600)                           (8210 to 16 600)                                                                      (9·0 to 11·6)[\*](#TFN4){ref-type="table-fn"}          (9·0 to 11·6)[\*](#TFN4){ref-type="table-fn"}                                       (206·4 to 415·8)             (102·6 to 206·6)                                                                    (−3·3 to −1·4)[\*](#TFN4){ref-type="table-fn"}         (−3·4 to −1·4)[\*](#TFN4){ref-type="table-fn"}

         Uterine fibroids                                                                                              ··                      1550\                                      1550\                        ··                                                   8·3%\                                                  8·3%\                                                          ··                        37·7\                        18·9\                      ··                                                 −8·2%\                                                 −7·9%\
                                                                                                                                       (947 to 2460)                              (947 to 2460)                                                                         (4·5 to 11·9)[\*](#TFN4){ref-type="table-fn"}          (4·5 to 11·9)[\*](#TFN4){ref-type="table-fn"}                                       (23·1 to 59·9)               (11·5 to 30·0)                                                                      (−11·4 to −5·2)[\*](#TFN4){ref-type="table-fn"}        (−11·1 to −5·0)[\*](#TFN4){ref-type="table-fn"}

         Polycystic ovarian syndrome                                                                                   ··                        460\                                       460\                       ··                                                 13·1%\                                                 13·1%\                                                           ··                        11·7\                          5·8\                     ··                                                   2·0%\                                                  1·8%\
                                                                                                                                       (204 to 886)                               (204 to 886)                                                                          (12·1 to 14·0)[\*](#TFN4){ref-type="table-fn"}         (12·1 to 14·0)[\*](#TFN4){ref-type="table-fn"}                                      (5·2 to 22·7)                (2·6 to 11·2)                                                                       (1·1 to 2·8)[\*](#TFN4){ref-type="table-fn"}           (1·0 to 2·7)[\*](#TFN4){ref-type="table-fn"}

         Female infertility                                                                                            ··                        343\                                       343\                       ··                                                 27·5%\                                                 27·5%\                                                           ··                          8·8\                         4·4\                     ··                                                 16·7%\                                                 16·5%\
                                                                                                                                       (129 to 723)                               (129 to 723)                                                                          (22·2 to 32·7)[\*](#TFN4){ref-type="table-fn"}         (22·2 to 32·7)[\*](#TFN4){ref-type="table-fn"}                                      (3·3 to 18·5)                (1·7 to 9·2)                                                                        (12·2 to 21·1)[\*](#TFN4){ref-type="table-fn"}         (12·0 to 20·8)[\*](#TFN4){ref-type="table-fn"}

         Endometriosis                                                                                                 ··                      4130\                                      4130\                        ··                                                   9·2%\                                                  9·2%\                                                          ··                      103·9\                         51·6\                      ··                                                 −2·9%\                                                 −3·0%\
                                                                                                                                       (2760 to 5950)                             (2760 to 5950)                                                                        (7·9 to 10·5)[\*](#TFN4){ref-type="table-fn"}          (7·9 to 10·5)[\*](#TFN4){ref-type="table-fn"}                                       (69·5 to 149·1)              (34·5 to 74)                                                                        (−3·8 to −1·9)[\*](#TFN4){ref-type="table-fn"}         (−3·9 to −2·0)[\*](#TFN4){ref-type="table-fn"}

         Genital prolapse                                                                                              ··                        352\                                       352\                       ··                                                 18·6%\                                                 18·6%\                                                           ··                          8·4\                         4·3\                     ··                                                 −4·5%\                                                 −4·7%\
                                                                                                                                       (173 to 652)                               (173 to 652)                                                                          (16·0 to 20·4)[\*](#TFN4){ref-type="table-fn"}         (16·0 to 20·4)[\*](#TFN4){ref-type="table-fn"}                                      (4·1 to 15·6)                (2·1 to 8·0)                                                                        (−6·7 to −3·4)[\*](#TFN4){ref-type="table-fn"}         (−6·9 to −3·5)[\*](#TFN4){ref-type="table-fn"}

         Premenstrual syndrome                                                                                         ··                      3930\                                      3930\                        ··                                                   8·8%\                                                  8·8%\                                                          ··                      100·0\                         49·5\                      ··                                                 −2·1%\                                                 −2·2%\
                                                                                                                                       (2530 to 5900)                             (2530 to 5900)                                                                        (7·2 to 10·1)[\*](#TFN4){ref-type="table-fn"}          (7·2 to 10·1)[\*](#TFN4){ref-type="table-fn"}                                       (64·5 to 150·1)              (31·9 to 74·3)                                                                      (−3·5 to −0·9)[\*](#TFN4){ref-type="table-fn"}         (−3·6 to −1·0)[\*](#TFN4){ref-type="table-fn"}

         Other gynaecological diseases                                                                                 ··                      1150\                                      1150\                        ··                                                 13·5%\                                                 13·5%\                                                           ··                        28·9\                        14·4\                      ··                                                   0·2%\                                                  0·2%\
                                                                                                                                       (830 to 1580)                              (830 to 1580)                                                                         (10·1 to 16·6)[\*](#TFN4){ref-type="table-fn"}         (10·1 to 16·6)[\*](#TFN4){ref-type="table-fn"}                                      (20·8 to 39·6)               (10·3 to 19·7)                                                                      (−2·8 to 3·0)                                          (−2·8 to 3·0)

      Haemoglobinopathies and haemolytic anaemias                                                               4350\                          5800\                                   10 100\                     −1·0%\                                                 −5·6%\                                                 −3·7%\                                                      117·9\                       156·6\                       137·1\                 −10·5%\                                                −15·3%\                                                −13·2%\
                                                                                                        (3040 to 6130)                 (4510 to 7370)                             (7740 to 13 300)               (−9·7 to 7·3)                                          (−10·3 to 0·2)                                         (−9·3 to 2·3)                                          (82·4 to 165·8)              (122·3 to 198·9)             (104·6 to 179·3)             (−18·6 to −2·8)[\*](#TFN4){ref-type="table-fn"}        (−19·8 to −9·8)[\*](#TFN4){ref-type="table-fn"}        (−18·5 to −7·6)[\*](#TFN4){ref-type="table-fn"}

         Thalassaemias                                                                                            308\                           274\                                       582\                 −21·1%\                                                −28·0%\                                                −24·5%\                                                           8·7\                         8·2\                         8·4\               −25%\                                                  −32·0%\                                                −28·5%\
                                                                                                        (239 to 367)                   (221 to 338)                               (491 to 683)                   (−33·6 to −6·2)[\*](#TFN4){ref-type="table-fn"}        (−36·5 to −13·4)[\*](#TFN4){ref-type="table-fn"}       (−33·5 to −13·4)[\*](#TFN4){ref-type="table-fn"}       (6·8 to 10·4)                (6·6 to 10·1)                (7·1 to 9·9)                 (−37·2 to −10·7)[\*](#TFN4){ref-type="table-fn"}       (−40·2 to −18·0)[\*](#TFN4){ref-type="table-fn"}       (−37·2 to −17·8)[\*](#TFN4){ref-type="table-fn"}

         Thalassaemias trait                                                                                      477\                         1430\                                      1910\                  −13·8%\                                                −11·5%\                                                −12·1%\                                                         12·8\                        37·2\                        25\                  −22·6%\                                                −21·4%\                                                −21·6%\
                                                                                                        (306 to 722)                   (968 to 2070)                              (1280 to 2780)                 (−20·0 to −7·0)[\*](#TFN4){ref-type="table-fn"}        (−16 to −6·8)[\*](#TFN4){ref-type="table-fn"}          (−16·1 to −7·7)[\*](#TFN4){ref-type="table-fn"}        (8·2 to 19·3)                (25·1 to 53·8)               (16·8 to 36·4)               (−28·1 to −16·8)[\*](#TFN4){ref-type="table-fn"}       (−25·4 to −17·3)[\*](#TFN4){ref-type="table-fn"}       (−25·1 to −18·0)[\*](#TFN4){ref-type="table-fn"}

         Sickle cell disorders                                                                                  1580\                          1470\                                      3050\                      8·2%\                                                −1·9%\                                                   3·1%\                                                       43·5\                        42·9\                        43·2\                    2·2%\                                                −8·1%\                                                 −3·0%\
                                                                                                        (865 to 2640)                  (1050 to 2090)                             (2000 to 4200)                 (−11·4 to 23·1)                                        (−15·7 to 19·2)                                        (−11·6 to 16·9)                                        (23·8 to 72·8)               (30·6 to 61·2)               (28·3 to 59·4)               (−16·6 to 16·6)                                        (−21·4 to 12·7)                                        (−16·9 to 10·6)

         Sickle cell trait                                                                                        362\                           841\                                     1200\                    −5·1%\                                                   0·4%\                                                −1·3%\                                                          9·8\                       22·8\                        16·3\                −13·4%\                                                  −8·8%\                                               −10·3%\
                                                                                                        (237 to 534)                   (567 to 1200)                              (812 to 1730)                  (−13·0 to 3·5)                                         (−3·4 to 4·4)                                          (−5·1 to 2·9)                                          (6·4 to 14·6)                (15·4 to 32·5)               (11·0 to 23·4)               (−20·4 to −5·4)[\*](#TFN4){ref-type="table-fn"}        (−12·3 to −5·2)[\*](#TFN4){ref-type="table-fn"}        (−13·9 to −6·4)[\*](#TFN4){ref-type="table-fn"}

         G6PD deficiency                                                                                          485\                           232\                                       717\                     6·6%\                                                −0·3%\                                                   4·3%\                                                       12·3\                          5·9\                         9·1\                 −7·8%\                                               −13·0%\                                                  −9·6%\
                                                                                                        (330 to 655)                   (187 to 289)                               (546 to 920)                   (−2·1 to 16·1)                                         (−5·6 to 8·2)                                          (−2·2 to 11·9)                                         (8·4 to 16·6)                (4·8 to 7·4)                 (7·0 to 11·7)                (−14·3 to −0·5)[\*](#TFN4){ref-type="table-fn"}        (−17·7 to −5·4)[\*](#TFN4){ref-type="table-fn"}        (−14·7 to −3·5)[\*](#TFN4){ref-type="table-fn"}

         G6PD trait                                                                                                   0\                      0·416\                                     0·416\                        ··                                                   3·0%\                                                  3·0%\                                                         0\                           0\                           0\                       ··                                                 −8·1%\                                                 −8·1%\
                                                                                                        (0 to 0)                       (0·281 to 0·580)                           (0·281 to 0·580)                                                                      (−1·7 to 7·8)                                          (−1·7 to 7·8)                                          (0 to 0)                     (0 to 0)                     (0 to 0)                                                                            (−12·1 to −3·9)[\*](#TFN4){ref-type="table-fn"}        (−12·2 to −3·9)[\*](#TFN4){ref-type="table-fn"}

         Other haemoglobinopathies and haemolytic anaemias                                                      1140\                          1550\                                      2680\                    −1·2%\                                                 −1·6%\                                                 −1·4%\                                                        30·7\                        39·4\                        35·0\                −15·3%\                                                −15·9%\                                                −15·6%\
                                                                                                        (845 to 1550)                  (1180 to 2060)                             (2030 to 3580)                 (−5·5 to 3·8)                                          (−4·1 to 1·0)                                          (−3·8 to 1·4)                                          (22·9 to 41·6)               (29·9 to 52·8)               (26·4 to 46·7)               (−19·2 to −11)[\*](#TFN4){ref-type="table-fn"}         (−18·4 to −13·6)[\*](#TFN4){ref-type="table-fn"}       (−18·1 to −12·9)[\*](#TFN4){ref-type="table-fn"}

      Endocrine, metabolic, blood, and immune disorders                                                         3310\                          4410\                                      7720\                    10·3%\                                                   5·1%\                                                  7·3%\                                                       89·1\                      115·1\                       101·8\                   −4·7%\                                                 −9·0%\                                                 −7·2%\
                                                                                                        (2750 to 3820)                 (3610 to 5350)                             (6500 to 9080)                 (3·9 to 15·5)[\*](#TFN4){ref-type="table-fn"}          (1·6 to 8·5)[\*](#TFN4){ref-type="table-fn"}           (3·0 to 11·1)[\*](#TFN4){ref-type="table-fn"}          (73·8 to 102·7)              (94·0 to 140·0)              (85·9 to 120·0)              (−9·8 to −0·5)[\*](#TFN4){ref-type="table-fn"}         (−11·8 to −6·0)[\*](#TFN4){ref-type="table-fn"}        (−10·7 to −4·1)[\*](#TFN4){ref-type="table-fn"}

      Oral disorders                                                                                            7860\                       10 400\                                    18 300\                     20·5%\                                                 22·1%\                                                 21·4%\                                                      202·1\                       253·7\                       228·8\                   −1·8%\                                                 −0·9%\                                                 −1·3%\
                                                                                                        (4620 to 12 300)               (6390 to 16 000)                           (11 000 to 28 300)             (19·6 to 21·4)[\*](#TFN4){ref-type="table-fn"}         (21·2 to 23·0)[\*](#TFN4){ref-type="table-fn"}         (20·5 to 22·3)[\*](#TFN4){ref-type="table-fn"}         (119·1 to 315·7)             (154·8 to 388·5)             (137·5 to 353·7)             (−2·6 to −1·1)[\*](#TFN4){ref-type="table-fn"}         (−1·6 to −0·2)[\*](#TFN4){ref-type="table-fn"}         (−2·0 to −0·6)[\*](#TFN4){ref-type="table-fn"}

         Caries of deciduous teeth                                                                                  72·4\                          66·5\                                    139\                     4·6%\                                                  5·1%\                                                  4·9%\                                                         2·1\                         2·0\                         2·0\                 −2·2%\                                                 −2·0%\                                                 −2·1%\
                                                                                                        (30·9 to 145)                  (28·5 to 133)                              (59·4 to 278)                  (2·7 to 6·3)[\*](#TFN4){ref-type="table-fn"}           (3·0 to 6·9)[\*](#TFN4){ref-type="table-fn"}           (3·1 to 6·3)[\*](#TFN4){ref-type="table-fn"}           (0·9 to 4·1)                 (0·9 to 4·0)                 (0·9 to 4·1)                 (−3·9 to −0·6)[\*](#TFN4){ref-type="table-fn"}         (−3·9 to −0·4)[\*](#TFN4){ref-type="table-fn"}         (−3·7 to −0·8)[\*](#TFN4){ref-type="table-fn"}

         Caries of permanent teeth                                                                                785\                           834\                                     1620\                      9·4%\                                                  9·5%\                                                  9·4%\                                                       20·0\                        21·3\                        20·7\                  −3·9%\                                                 −4·1%\                                                 −4·0%\
                                                                                                        (338 to 1490)                  (362 to 1590)                              (698 to 3090)                  (8·5 to 10·4)[\*](#TFN4){ref-type="table-fn"}          (8·5 to 10·5)[\*](#TFN4){ref-type="table-fn"}          (8·6 to 10·3)[\*](#TFN4){ref-type="table-fn"}          (8·6 to 38·0)                (9·2 to 40·4)                (8·9 to 39·2)                (−4·7 to −3·0)[\*](#TFN4){ref-type="table-fn"}         (−5·0 to −3·3)[\*](#TFN4){ref-type="table-fn"}         (−4·8 to −3·3)[\*](#TFN4){ref-type="table-fn"}

         Periodontal diseases                                                                                   2470\                          2720\                                      5190\                    25·1%\                                                 27·9%\                                                 26·6%\                                                        61·6\                        65·4\                        63·5\                    1·8%\                                                  3·6%\                                                  2·8%\
                                                                                                        (967 to 5070)                  (1080 to 5580)                             (2040 to 10 700)               (23·5 to 26·6)[\*](#TFN4){ref-type="table-fn"}         (26·3 to 29·3)[\*](#TFN4){ref-type="table-fn"}         (25·1 to 27·9)[\*](#TFN4){ref-type="table-fn"}         (24·2 to 127·0)              (25·9 to 134·2)              (25·0 to 130·3)              (1·3 to 2·3)[\*](#TFN4){ref-type="table-fn"}           (3·0 to 4·3)[\*](#TFN4){ref-type="table-fn"}           (2·3 to 3·2)[\*](#TFN4){ref-type="table-fn"}

         Edentulism and severe tooth loss                                                                       2770\                          4580\                                      7350\                    24·0%\                                                 25·1%\                                                 24·6%\                                                        73·5\                      108·0\                         91·7\                  −5·1%\                                                 −3·3%\                                                 −4·1%\
                                                                                                        (1850 to 3940)                 (3060 to 6480)                             (4890 to 10 400)               (23·1 to 24·8)[\*](#TFN4){ref-type="table-fn"}         (24·0 to 26·2)[\*](#TFN4){ref-type="table-fn"}         (23·7 to 25·5)[\*](#TFN4){ref-type="table-fn"}         (49·1 to 104·2)              (72·2 to 153·1)              (61·3 to 129·9)              (−5·8 to −4·4)[\*](#TFN4){ref-type="table-fn"}         (−3·9 to −2·5)[\*](#TFN4){ref-type="table-fn"}         (−4·7 to −3·4)[\*](#TFN4){ref-type="table-fn"}

         Other oral disorders                                                                                   1770\                          2250\                                      4020\                    15·5%\                                                 15·8%\                                                 15·7%\                                                        44·8\                        56·9\                        50·9\                    0·3%\                                                  0·2%\                                                  0·2%\
                                                                                                        (1100 to 2620)                 (1400 to 3310)                             (2510 to 5900)                 (14·7 to 16·3)[\*](#TFN4){ref-type="table-fn"}         (15·0 to 16·6)[\*](#TFN4){ref-type="table-fn"}         (15 to 16·3)[\*](#TFN4){ref-type="table-fn"}           (28·0 to 66·7)               (35·6 to 83·8)               (31·8 to 74·7)               (−0·2 to 0·7)                                          (−0·3 to 0·6)                                          (−0·1 to 0·5)

      Sudden infant death syndrome                                                                              2040\                          1450\                                      3490\                  −18·1%\                                                −16·1%\                                                −17·3%\                                                         59·4\                        45·4\                        52·7\                −20·9%\                                                −19·2%\                                                −20·2%\
                                                                                                        (816 to 3870)                  (572 to 3230)                              (1570 to 6730)                 (−32·9 to 2·1)                                         (−30·7 to 6·4)                                         (−28·6 to −1·4)[\*](#TFN4){ref-type="table-fn"}        (23·8 to 112·8)              (17·8 to 100·9)              (23·7 to 101·5)              (−35·2 to −1·4)[\*](#TFN4){ref-type="table-fn"}        (−33·2 to 2·5)                                         (−31·2 to −4·9)[\*](#TFN4){ref-type="table-fn"}

  **Injuries**                                                                                             **171 000**\                     **81 900**\                              **252 000**\                  **−1·8%**\                                               0·**7%**\                                            **−1·0%**\                                                **4397·9**\                  **2128·2**\                  **3267·0**\              **−13·5%**\                                            **−12·7%**\                                            **−13·3%**\
                                                                                                        **(161 000 to 182 000)**       **(74 500 to 90 000)**                     **(236 000 to 271 000)**       **(−3·6 to 0·2)**                                      **(−1·9 to 3·4)**                                      **(−2·8 to 1·0)**                                      **(4149·6 to 4678·6)**       **(1943·4 to 2330·6)**       **(3058·2 to 3505·1)**       **(−15·1 to −11·8)**[\*](#TFN4){ref-type="table-fn"}   **(−14·7 to −10·6)**[\*](#TFN4){ref-type="table-fn"}   **(−14·7 to −11·7)**[\*](#TFN4){ref-type="table-fn"}

      **Transport injuries**                                                                                 **54 900**\                    **20 400**\                                **75 300**\                 **−6·0%**\                                             **−3·3%**\                                             **−5·3%**\                                                **1403·5**\                    **528·6**\                   **967·6**\             **−16·8%**\                                            **−15·9%**\                                            **−16·6%**\
                                                                                                        **(52 000 to 57 800)**         **(18 700 to 22 300)**                     **(71 000 to 79 800)**         **(−8·7 to −3·2)**[\*](#TFN4){ref-type="table-fn"}     **(−6·1 to −0·3)**[\*](#TFN4){ref-type="table-fn"}     **(−7·7 to −2·8)**[\*](#TFN4){ref-type="table-fn"}     **(1328·7 to 1475·7)**       **(484·5 to 575·5)**         **(914·2 to 1023·9)**        **(−19·1 to −14·5)**[\*](#TFN4){ref-type="table-fn"}   **(−18·3 to −13·4)**[\*](#TFN4){ref-type="table-fn"}   **(−18·5 to −14·6)**[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Road injuries                                                                                          49 800\                        18 000\                                    67 800\                     −6·5%\                                                 −4·8%\                                                 −6·1%\                                                    1272·2\                        467·2\                       871·1\                 −17·3%\                                                −17·2%\                                                −17·2%\
                                                                                                        (47 300 to 52 100)             (16 600 to 19 400)                         (64 300 to 71 500)             (−9·3 to −3·6)[\*](#TFN4){ref-type="table-fn"}         (−7·8 to −1·9)[\*](#TFN4){ref-type="table-fn"}         (−8·5 to −3·5)[\*](#TFN4){ref-type="table-fn"}         (1209·4 to 1331·3)           (431·8 to 501·5)             (827·9 to 917·3)             (−19·6 to −14·8)[\*](#TFN4){ref-type="table-fn"}       (−19·7 to −14·7)[\*](#TFN4){ref-type="table-fn"}       (−19·2 to −15·1)[\*](#TFN4){ref-type="table-fn"}

         Pedestrian road injuries                                                                            16 500\                           7090\                                   23 600\                   −12·3%\                                                −11·2%\                                                −12·0%\                                                       423·2\                       184·9\                       304·1\                 −23·0%\                                                −23·2%\                                                −23·1%\
                                                                                                        (15 200 to 18 500)             (6430 to 7870)                             (22 000 to 25 800)             (−17·1 to −7·7)[\*](#TFN4){ref-type="table-fn"}        (−15·0 to −6·8)[\*](#TFN4){ref-type="table-fn"}        (−15·6 to −8·3)[\*](#TFN4){ref-type="table-fn"}        (390·0 to 474·3)             (167·7 to 204·9)             (283·9 to 332·1)             (−27 to −19·1)[\*](#TFN4){ref-type="table-fn"}         (−26·5 to −19·3)[\*](#TFN4){ref-type="table-fn"}       (−26·1 to −20·0)[\*](#TFN4){ref-type="table-fn"}

         Cyclist road injuries                                                                                  3290\                          1270\                                      4550\                      8·6%\                                                12·3%\                                                   9·6%\                                                       83·5\                        31·5\                        57·5\                  −6·4%\                                                 −5·6%\                                                 −6·3%\
                                                                                                        (2740 to 3790)                 (1050 to 1510)                             (3860 to 5270)                 (2·2 to 14·9)[\*](#TFN4){ref-type="table-fn"}          (6·8 to 17·3)[\*](#TFN4){ref-type="table-fn"}          (4·2 to 14·9)[\*](#TFN4){ref-type="table-fn"}          (69·6 to 96·5)               (26·2 to 37·6)               (48·8 to 66·3)               (−11·8 to −0·9)[\*](#TFN4){ref-type="table-fn"}        (−9·9 to −1·4)[\*](#TFN4){ref-type="table-fn"}         (−10·8 to −1·7)[\*](#TFN4){ref-type="table-fn"}

         Motorcyclist road injuries                                                                          11 700\                           2310\                                   14 000\                     −1·8%\                                                 −0·1%\                                                 −1·6%\                                                      295·8\                         59·0\                      177·9\                 −12·1%\                                                −12·8%\                                                −12·2%\
                                                                                                        (10 300 to 12 600)             (1960 to 2610)                             (12 300 to 15 100)             (−8·5 to 3·2)                                          (−7·8 to 10·0)                                         (−7·6 to 3·2)                                          (259·7 to 318·9)             (50·2 to 66·6)               (157·3 to 191·9)             (−17·8 to −7·8)[\*](#TFN4){ref-type="table-fn"}        (−19·4 to −4·4)[\*](#TFN4){ref-type="table-fn"}        (−17·3 to −8·1)[\*](#TFN4){ref-type="table-fn"}

         Motor vehicle road injuries                                                                         17 700\                           6850\                                   24 600\                     −6·5%\                                                 −3·7%\                                                 −5·7%\                                                      453·4\                       179·5\                       317·2\                 −16·6%\                                                −15·0%\                                                −16·1%\
                                                                                                        (16 500 to 19 000)             (6230 to 7410)                             (23 100 to 26 000)             (−9·8 to −1·7)[\*](#TFN4){ref-type="table-fn"}         (−7·1 to 1·9)                                          (−8·4 to −1·3)[\*](#TFN4){ref-type="table-fn"}         (423·2 to 485·8)             (162·8 to 193·5)             (297·9 to 335·1)             (−19·5 to −12·2)[\*](#TFN4){ref-type="table-fn"}       (−18·1 to −9·9)[\*](#TFN4){ref-type="table-fn"}        (−18·4 to −12·1)[\*](#TFN4){ref-type="table-fn"}

         Other road injuries                                                                                      640\                           491\                                     1130\                      1·7%\                                                30·2%\                                                 12·4%\                                                        16·3\                        12·3\                        14·3\                −11·8%\                                                  10·1%\                                                 −3·5%\
                                                                                                        (540 to 761)                   (380 to 629)                               (932 to 1380)                  (−5·2 to 17)                                           (22·0 to 40·2)[\*](#TFN4){ref-type="table-fn"}         (5·3 to 25·6)[\*](#TFN4){ref-type="table-fn"}          (13·8 to 19·4)               (9·6 to 15·6)                (11·9 to 17·4)               (−17·3 to 1·4)                                         (3·7 to 18·4)[\*](#TFN4){ref-type="table-fn"}          (−9·1 to 7·7)

      Other transport injuries                                                                                  5130\                          2400\                                      7530\                    −0·2%\                                                 10·0%\                                                   2·9%\                                                     131·3\                         61·3\                        96·5\                −12·1%\                                                  −5·3%\                                               −10·0%\
                                                                                                        (4510 to 5920)                 (1940 to 2960)                             (6480 to 8760)                 (−4·6 to 4·8)                                          (5·6 to 14·3)[\*](#TFN4){ref-type="table-fn"}          (−1·0 to 6·7)                                          (115·3 to 151·4)             (49·7 to 75·3)               (83·0 to 112·1)              (−15·9 to −7·9)[\*](#TFN4){ref-type="table-fn"}        (−9·1 to −1·6)[\*](#TFN4){ref-type="table-fn"}         (−13·3 to −6·7)[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      **Unintentional injuries**                                                                             **65 300**\                    **40 700**\                              **106 000**\                  **−5·0%**\                                               **2·3%**\                                            **−2·3%**\                                                **1715·6**\                  **1058·9**\                  **1389·0**\              **−17%**\                                              **−13%**\                                              **−15·6%**\
                                                                                                        **(58 800 to 72 800)**         **(35 400 to 46 700)**                     **(94 200 to 119 000)**        **(−8·1 to −1·5)**[\*](#TFN4){ref-type="table-fn"}     **(−1·6 to 6·3)**                                      **(−5·4 to 1·3)**                                      **(1548·7 to 1908·9)**       **(924·2 to 1207·6)**        **(1241·3 to 1560·2)**       **(−19·5 to −14·3)**[\*](#TFN4){ref-type="table-fn"}   **(−16·0 to −9·8)**[\*](#TFN4){ref-type="table-fn"}    **(−18·0 to −12·7)**[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Falls                                                                                                  21 000\                        15 000\                                    35 900\                     15·3%\                                                 24·4%\                                                 18·9%\                                                      549·9\                       367·2\                       459·4\                   −3·8%\                                                   0·3%\                                                −2·3%\
                                                                                                        (17 600 to 24 900)             (12 300 to 18 000)                         (30 200 to 42 900)             (10·3 to 20·3)[\*](#TFN4){ref-type="table-fn"}         (20·7 to 27·5)[\*](#TFN4){ref-type="table-fn"}         (15·4 to 22·7)[\*](#TFN4){ref-type="table-fn"}         (462·2 to 652·6)             (304·1 to 442·2)             (387·1 to 547·5)             (−7·7 to 0·4)                                          (−2·9 to 2·8)                                          (−5·0 to 0·7)

      Drowning                                                                                               11 600\                           5110\                                   16 700\                   −25·0%\                                                −27·8%\                                                −25·9%\                                                       311·4\                       145·9\                       229·9\                 −31·6%\                                                −34·6%\                                                −32·6%\
                                                                                                        (11 100 to 12 100)             (4680 to 5510)                             (15 900 to 17 500)             (−28·0 to −21·8)[\*](#TFN4){ref-type="table-fn"}       (−32·5 to −20·3)[\*](#TFN4){ref-type="table-fn"}       (−28·8 to −22·2)[\*](#TFN4){ref-type="table-fn"}       (298·2 to 325·9)             (133·3 to 158·3)             (219·0 to 241·2)             (−34·3 to −28·6)[\*](#TFN4){ref-type="table-fn"}       (−39·0 to −27·5)[\*](#TFN4){ref-type="table-fn"}       (−35·4 to −29·2)[\*](#TFN4){ref-type="table-fn"}

      Fire, heat, and hot substances                                                                            4060\                          4400\                                      8460\                    −7·3%\                                                 −5·2%\                                                 −6·3%\                                                      106·3\                       116·3\                       111·1\                 −18·8%\                                                −16·6%\                                                −17·7%\
                                                                                                        (3380 to 4770)                 (3560 to 5210)                             (7030 to 9880)                 (−13·1 to 4·9)                                         (−11·2 to 3·9)                                         (−11·7 to 1·2)                                         (88·5 to 124·6)              (94·1 to 136·7)              (92·8 to 129·3)              (−23·6 to −8·4)[\*](#TFN4){ref-type="table-fn"}        (−21·6 to −8·4)[\*](#TFN4){ref-type="table-fn"}        (−22·4 to −11·0)[\*](#TFN4){ref-type="table-fn"}

      Poisonings                                                                                                2320\                          1470\                                      3790\                  −12·4%\                                                  −8·2%\                                               −10·8%\                                                         60·6\                        39·5\                        50·1\                −22·4%\                                                −18·3%\                                                −20·9%\
                                                                                                        (1740 to 2620)                 (1090 to 1640)                             (2930 to 4210)                 (−20·1 to −0·3)[\*](#TFN4){ref-type="table-fn"}        (−14·8 to 2·6)                                         (−17·8 to −0·5)[\*](#TFN4){ref-type="table-fn"}        (45·2 to 68·5)               (29·3 to 43·9)               (38·8 to 55·6)               (−29 to −11·3)[\*](#TFN4){ref-type="table-fn"}         (−24·2 to −8·5)[\*](#TFN4){ref-type="table-fn"}        (−26·9 to −11·7)[\*](#TFN4){ref-type="table-fn"}

         Poisoning by carbon monoxide                                                                           1040\                            500\                                     1540\                  −19·6%\                                                −12·8%\                                                −17·5%\                                                         26·6\                        13·1\                        19·9\                −29·5%\                                                −23·3%\                                                −27·6%\
                                                                                                        (770 to 1150)                  (329 to 558)                               (1150 to 1690)                 (−27·6 to −11·0)[\*](#TFN4){ref-type="table-fn"}       (−20·8 to −5·4)[\*](#TFN4){ref-type="table-fn"}        (−25·3 to −10·1)[\*](#TFN4){ref-type="table-fn"}       (19·7 to 29·4)               (8·6 to 14·7)                (14·8 to 21·9)               (−36·4 to −21·9)[\*](#TFN4){ref-type="table-fn"}       (−30·3 to −16·6)[\*](#TFN4){ref-type="table-fn"}       (−34·5 to −21·0)[\*](#TFN4){ref-type="table-fn"}

         Poisoning by other means                                                                               1290\                            966\                                     2250\                    −5·6%\                                                 −5·6%\                                                 −5·6%\                                                        34·0\                        26·4\                        30·2\                −15·7%\                                                −15·6%\                                                −15·7%\
                                                                                                        (948 to 1500)                  (737 to 1090)                              (1780 to 2560)                 (−15·0 to 12·3)                                        (−13·5 to 6·8)                                         (−13·8 to 7·5)                                         (25·1 to 39·7)               (20·1 to 29·8)               (23·9 to 34·3)               (−24·1 to 0·8)                                         (−22·8 to −4·2)[\*](#TFN4){ref-type="table-fn"}        (−23·2 to −3·7)[\*](#TFN4){ref-type="table-fn"}

      Exposure to mechanical forces                                                                             8110\                          3240\                                   11 300\                     −3·5%\                                                 13·6%\                                                   0·8%\                                                     208·5\                         83·8\                      146·1\                 −15·8%\                                                  −2·4%\                                               −12·5%\
                                                                                                        (6970 to 9480)                 (2560 to 3980)                             (9620 to 13 500)               (−8·0 to 1·4)                                          (7·7 to 20·5)[\*](#TFN4){ref-type="table-fn"}          (−3·6 to 5·5)                                          (179·4 to 243·3)             (66·4 to 102·5)              (124·2 to 172·6)             (−19·2 to −12·2)[\*](#TFN4){ref-type="table-fn"}       (−7·1 to 2·8)                                          (−15·8 to −8·9)[\*](#TFN4){ref-type="table-fn"}

         Unintentional firearm injuries                                                                         1080\                            334\                                     1410\                    −4·6%\                                                 11·2%\                                                 −1·3%\                                                        28·0\                          8·7\                       18·4\                −14·6%\                                                  −2·9%\                                               −12·1%\
                                                                                                        (972 to 1250)                  (285 to 390)                               (1270 to 1620)                 (−9·4 to 2·8)                                          (3·5 to 21·7)[\*](#TFN4){ref-type="table-fn"}          (−5·8 to 4·2)                                          (25·1 to 32·5)               (7·4 to 10·2)                (16·6 to 21·2)               (−18·8 to −8·1)[\*](#TFN4){ref-type="table-fn"}        (−9·7 to 6·5)                                          (−16·2 to −7·3)[\*](#TFN4){ref-type="table-fn"}

         Other exposure to mechanical forces                                                                    7030\                          2900\                                      9930\                    −3·4%\                                                 13·9%\                                                   1·1%\                                                     180·5\                         75·1\                      127·6\                 −16·0%\                                                  −2·3%\                                               −12·5%\
                                                                                                        (5970 to 8340)                 (2260 to 3600)                             (8310 to 11 900)               (−8·2 to 1·8)                                          (8·0 to 21·4)[\*](#TFN4){ref-type="table-fn"}          (−3·6 to 6·1)                                          (153·2 to 213·8)             (58·4 to 93)                 (107·2 to 152·3)             (−19·7 to −12·1)[\*](#TFN4){ref-type="table-fn"}       (−7·1 to 3·3)                                          (−16·1 to −8·9)[\*](#TFN4){ref-type="table-fn"}

      Adverse effects of medical treatment                                                                      2490\                          2230\                                      4720\                      7·2%\                                                  5·5%\                                                  6·4%\                                                       66·6\                        58·7\                        62·6\                  −6·7%\                                                 −9·3%\                                                 −7·9%\
                                                                                                        (2070 to 3100)                 (1760 to 2660)                             (3940 to 5600)                 (1·0 to 14·4)[\*](#TFN4){ref-type="table-fn"}          (0 to 12·3)[\*](#TFN4){ref-type="table-fn"}            (1·2 to 13·2)[\*](#TFN4){ref-type="table-fn"}          (55·2 to 83·7)               (46·0 to 70·8)               (51·9 to 75·2)               (−11·9 to −0·8)[\*](#TFN4){ref-type="table-fn"}        (−13·9 to −3·5)[\*](#TFN4){ref-type="table-fn"}        (−12·3 to −2·2)[\*](#TFN4){ref-type="table-fn"}

      Animal contact                                                                                            2650\                          2340\                                      4990\                    −8·5%\                                                      0%\                                               −4·7%\                                                        69·3\                        63·2\                        66·1\                −19·1%\                                                −11·3%\                                                −15·6%\
                                                                                                        (1630 to 3090)                 (1180 to 2870)                             (3180 to 5830)                 (−16·1 to 5·5)                                         (−7·8 to 9·9)                                          (−10·7 to 3·6)                                         (42·6 to 81·1)               (31·6 to 77·4)               (42·1 to 77·4)               (−25·8 to −6·5)[\*](#TFN4){ref-type="table-fn"}        (−18·0 to −2·9)[\*](#TFN4){ref-type="table-fn"}        (−21·2 to −8·0)[\*](#TFN4){ref-type="table-fn"}

         Venomous animal contact                                                                                2160\                          1960\                                      4120\                  −10·3%\                                                  −0·4%\                                                 −5·8%\                                                        56·6\                        53·1\                        54·7\                −20·5%\                                                −11·3%\                                                −16·4%\
                                                                                                        (1250 to 2540)                 (898 to 2450)                              (2490 to 4910)                 (−18·2 to 4·6)                                         (−8·8 to 9·3)                                          (−11·7 to 2·8)                                         (32·7 to 66·6)               (23·8 to 66·6)               (32·8 to 65·3)               (−27·6 to −7·0)[\*](#TFN4){ref-type="table-fn"}        (−18·5 to −3·2)[\*](#TFN4){ref-type="table-fn"}        (−21·9 to −8·5)[\*](#TFN4){ref-type="table-fn"}

         Non-venomous animal contact                                                                              484\                           379\                                       863\                     0·3%\                                                  2·0%\                                                  1·1%\                                                       12·7\                        10·1\                        11·4\                −12·3%\                                                −11·1%\                                                −11·7%\
                                                                                                        (343 to 612)                   (247 to 648)                               (640 to 1140)                  (−8·5 to 9·4)                                          (−24·8 to 23·6)                                        (−16·0 to 10·7)                                        (9·0 to 16·1)                (6·5 to 17·8)                (8·4 to 15·1)                (−19·5 to −4·7)[\*](#TFN4){ref-type="table-fn"}        (−33·7 to 7·9)                                         (−26·2 to −3·4)[\*](#TFN4){ref-type="table-fn"}

      Foreign body                                                                                              4140\                          2710\                                      6860\                    −9·0%\                                                 −8·6%\                                                 −8·8%\                                                      113·7\                         77·0\                        95·4\                −17·7%\                                                −17·7%\                                                −17·7%\
                                                                                                        (3830 to 4500)                 (2500 to 2910)                             (6340 to 7350)                 (−13·1 to −4·5)[\*](#TFN4){ref-type="table-fn"}        (−15 to −3·2)[\*](#TFN4){ref-type="table-fn"}          (−12·6 to −5·0)[\*](#TFN4){ref-type="table-fn"}        (104·7 to 123·4)             (70·8 to 82·6)               (88·2 to 102·2)              (−21·3 to −13·8)[\*](#TFN4){ref-type="table-fn"}       (−23·5 to −12·8)[\*](#TFN4){ref-type="table-fn"}       (−21·2 to −14·3)[\*](#TFN4){ref-type="table-fn"}

         Pulmonary aspiration and foreign body in airway                                                        3460\                          2210\                                      5680\                  −11·4%\                                                −11·7%\                                                −11·5%\                                                         95·8\                        64·1\                        80·0\                −19·3%\                                                −19·5%\                                                −19·4%\
                                                                                                        (3250 to 3760)                 (2050 to 2350)                             (5350 to 6050)                 (−16 to −6·7)[\*](#TFN4){ref-type="table-fn"}          (−18·8 to −5·9)[\*](#TFN4){ref-type="table-fn"}        (−15·7 to −7·4)[\*](#TFN4){ref-type="table-fn"}        (89·8 to 104·1)              (59·1 to 68·3)               (75·2 to 85·5)               (−23·4 to −15·0)[\*](#TFN4){ref-type="table-fn"}       (−26·1 to −14·3)[\*](#TFN4){ref-type="table-fn"}       (−23·3 to −15·6)[\*](#TFN4){ref-type="table-fn"}

         Foreign body in eyes                                                                                     149\                            52·8\                                     202\                   21·6%\                                                 16·7%\                                                 20·3%\                                                          3·9\                         1·3\                         2·6\                   3·9%\                                                −0·9%\                                                   2·7%\
                                                                                                        (76·1 to 250)                  (28·0 to 85·9)                             (105 to 334)                   (20·0 to 23·8)[\*](#TFN4){ref-type="table-fn"}         (15·4 to 18·3)[\*](#TFN4){ref-type="table-fn"}         (18·8 to 22·1)[\*](#TFN4){ref-type="table-fn"}         (2·0 to 6·5)                 (0·7 to 2·2)                 (1·3 to 4·3)                 (2·6 to 4·7)[\*](#TFN4){ref-type="table-fn"}           (−2·7 to 0·4)                                          (1·3 to 3·6)[\*](#TFN4){ref-type="table-fn"}

         Foreign body in other body part                                                                          532\                           446\                                       978\                     2·1%\                                                  7·2%\                                                  4·4%\                                                       13·9\                        11·5\                        12·7\                −11·0%\                                                  −7·6%\                                                 −9·6%\
                                                                                                        (420 to 657)                   (357 to 547)                               (797 to 1180)                  (−7·5 to 9·6)                                          (−0·7 to 14·1)                                         (−1·9 to 10·2)                                         (11·0 to 17·3)               (9·2 to 14·1)                (10·4 to 15·4)               (−18·7 to −5·1)[\*](#TFN4){ref-type="table-fn"}        (−14·1 to −1·5)[\*](#TFN4){ref-type="table-fn"}        (−14·7 to −4·7)[\*](#TFN4){ref-type="table-fn"}

      Environmental heat and cold exposure                                                                      2240\                          1120\                                      3360\                    −9·3%\                                                   2·0%\                                                −5·8%\                                                        57·5\                        28·4\                        42·8\                −22·6%\                                                −13·7%\                                                −19·9%\
                                                                                                        (1690 to 2650)                 (817 to 1360)                              (2550 to 4000)                 (−13·9 to −5·0)[\*](#TFN4){ref-type="table-fn"}        (−3·3 to 6·6)                                          (−10·6 to −1·7)[\*](#TFN4){ref-type="table-fn"}        (43·2 to 68·2)               (20·5 to 34·7)               (32·4 to 51·1)               (−26·6 to −19)[\*](#TFN4){ref-type="table-fn"}         (−18·4 to −9·7)[\*](#TFN4){ref-type="table-fn"}        (−24·2 to −16·4)[\*](#TFN4){ref-type="table-fn"}

      Exposure to forces of nature                                                                                749\                           454\                                     1200\                  −18·7%\                                                −15·6%\                                                −17·6%\                                                         19·2\                        11·9\                        15·5\                −27·5%\                                                −25·8%\                                                −26·9%\
                                                                                                        (624 to 920)                   (370 to 564)                               (1000 to 1470)                 (−25·1 to −11·5)[\*](#TFN4){ref-type="table-fn"}       (−22·6 to −7·8)[\*](#TFN4){ref-type="table-fn"}        (−23·3 to −10·9)[\*](#TFN4){ref-type="table-fn"}       (16·0 to 23·5)               (9·7 to 14·8)                (13·0 to 18·9)               (−33·2 to −21·2)[\*](#TFN4){ref-type="table-fn"}       (−32·0 to −18·8)[\*](#TFN4){ref-type="table-fn"}       (−32·0 to −21·1)[\*](#TFN4){ref-type="table-fn"}

      Other unintentional injuries                                                                              5950\                          2640\                                      8580\                    −7·7%\                                                   5·4%\                                                −4·0%\                                                      152·7\                         67·0\                      110·0\                 −19%\                                                  −10·9%\                                                −16·8%\
                                                                                                        (5220 to 6860)                 (2110 to 3340)                             (7380 to 10 200)               (−11·4 to −3·6)[\*](#TFN4){ref-type="table-fn"}        (−0·3 to 10·8)                                         (−8·2 to 0·4)                                          (134·1 to 175·9)             (54·1 to 84·1)               (94·9 to 130·3)              (−21·9 to −15·8)[\*](#TFN4){ref-type="table-fn"}       (−15·2 to −6·8)[\*](#TFN4){ref-type="table-fn"}        (−19·9 to −13·6)[\*](#TFN4){ref-type="table-fn"}

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      **Self-harm and interpersonal violence**                                                               **50 300**\                    **20 800**\                                **71 100**\                   **8·1%**\                                              **1·7%**\                                              **6·2%**\                                               **1278·8**\                    **540·8**\                   **910·5**\               **−4·0%**\                                             **−8·6%**\                                             **−5·3%**\
                                                                                                        **(47 500 to 52 300)**         **(19 600 to 21 900)**                     **(68 100 to 73 700)**         **(4·7 to 10·9)[\*](#TFN4){ref-type="table-fn"}**      **(−1·3 to 4·1)**                                      **(3·8 to 8·2)[\*](#TFN4){ref-type="table-fn"}**       **(1206·1 to 1328·3)**       **(510·6 to 570·7)**         **(871·7 to 944·2)**         **(−7·0 to −1·5)[\*](#TFN4){ref-type="table-fn"}**     **(−11·2 to −6·3)[\*](#TFN4){ref-type="table-fn"}**    **(−7·4 to −3·5)[\*](#TFN4){ref-type="table-fn"}**

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

      Self-harm                                                                                              22 900\                        11 100\                                    34 000\                     −0·8%\                                                 −8·0%\                                                 −3·3%\                                                      577·3\                       282·2\                       429·0\                 −13·5%\                                                −18·3%\                                                −15·1%\
                                                                                                        (20 900 to 24 000)             (10 600 to 11 500)                         (31 800 to 35 100)             (−6·2 to 3·6)                                          (−12·6 to −5·1)[\*](#TFN4){ref-type="table-fn"}        (−6·9 to −0·8)[\*](#TFN4){ref-type="table-fn"}         (525·5 to 603·9)             (268·3 to 293)               (401·6 to 443·5)             (−18·2 to −9·7)[\*](#TFN4){ref-type="table-fn"}        (−22·4 to −15·7)[\*](#TFN4){ref-type="table-fn"}       (−18·3 to −12·9)[\*](#TFN4){ref-type="table-fn"}

         Self-harm by firearm                                                                                   2250\                            405\                                     2660\                      2·3%\                                                −6·2%\                                                   0·9%\                                                       57·0\                        10·3\                        33·5\                −10·6%\                                                −16·6%\                                                −11·5%\
                                                                                                        (1840 to 2880)                 (334 to 476)                               (2250 to 3290)                 (−3·7 to 7·8)                                          (−14·1 to 3·1)                                         (−3·5 to 5·5)                                          (46·5 to 72·8)               (8·4 to 12·1)                (28·3 to 41·7)               (−15·5 to −6·1)[\*](#TFN4){ref-type="table-fn"}        (−23·1 to −8·5)[\*](#TFN4){ref-type="table-fn"}        (−15·2 to −7·6)[\*](#TFN4){ref-type="table-fn"}

         Self-harm by other specified means                                                                  20 700\                        10 700\                                    31 400\                     −1·1%\                                                 −8·1%\                                                 −3·6%\                                                      520·3\                       271·9\                       395·4\                 −13·8%\                                                −18·4%\                                                −15·4%\
                                                                                                        (18 600 to 21 700)             (10 200 to 11 100)                         (29 200 to 32 600)             (−6·8 to 3·7)                                          (−12·8 to −5·0)[\*](#TFN4){ref-type="table-fn"}        (−7·4 to −1)[\*](#TFN4){ref-type="table-fn"}           (467·5 to 546·3)             (258·6 to 282·5)             (368·6 to 410·5)             (−18·8 to −9·6)[\*](#TFN4){ref-type="table-fn"}        (−22·5 to −15·7)[\*](#TFN4){ref-type="table-fn"}       (−18·7 to −13·1)[\*](#TFN4){ref-type="table-fn"}

      Interpersonal violence                                                                                 19 800\                           6250\                                   26 000\                       2·0%\                                                −2·6%\                                                   0·9%\                                                     503·0\                       163·2\                       334·3\                   −8·3%\                                               −13·0%\                                                  −9·4%\
                                                                                                        (17 800 to 21 000)             (5370 to 7230)                             (23 700 to 28 000)             (−0·7 to 5·2)                                          (−5·8 to 2·7)                                          (−1·4 to 3·6)                                          (451·5 to 534·9)             (139·9 to 188·5)             (304·7 to 360·5)             (−10·6 to −5·5)[\*](#TFN4){ref-type="table-fn"}        (−15·8 to −8·2)[\*](#TFN4){ref-type="table-fn"}        (−11·5 to −6·9)[\*](#TFN4){ref-type="table-fn"}

         Assault by firearm                                                                                     8690\                            968\                                     9660\                      6·8%\                                                −4·5%\                                                   5·5%\                                                     221·5\                         25·4\                      124·4\                   −2·7%\                                               −13·6%\                                                  −3·7%\
                                                                                                        (7330 to 9500)                 (804 to 1140)                              (8230 to 10 400)               (3·3 to 10·8)[\*](#TFN4){ref-type="table-fn"}          (−8·6 to 1·3)                                          (2·4 to 9·2)[\*](#TFN4){ref-type="table-fn"}           (186·8 to 242·3)             (21·0 to 30·0)               (105·8 to 134·0)             (−5·8 to 1·0)                                          (−17·2 to −8·4)[\*](#TFN4){ref-type="table-fn"}        (−6·6 to −0·4)[\*](#TFN4){ref-type="table-fn"}

         Assault by sharp object                                                                                4150\                            959\                                     5110\                  −11·8%\                                                −12·6%\                                                −11·9%\                                                       105·1\                         24·8\                        65·2\                −21·0%\                                                −22·1%\                                                −21·2%\
                                                                                                        (3240 to 5180)                 (792 to 1100)                              (4170 to 6160)                 (−15·8 to −6·2)[\*](#TFN4){ref-type="table-fn"}        (−15·7 to −7·4)[\*](#TFN4){ref-type="table-fn"}        (−15·5 to −7·1)[\*](#TFN4){ref-type="table-fn"}        (81·7 to 131·1)              (20·4 to 28·3)               (53·2 to 78·5)               (−24·6 to −16·0)[\*](#TFN4){ref-type="table-fn"}       (−25 to −17·5)[\*](#TFN4){ref-type="table-fn"}         (−24·3 to −16·9)[\*](#TFN4){ref-type="table-fn"}

         Sexual violence                                                                                          370\                         1770\                                      2140\                      9·4%\                                                13·0%\                                                 12·4%\                                                          9·4\                       45·4\                        27·3\                  −1·7%\                                                   1·0%\                                                  0·6%\
                                                                                                        (248 to 540)                   (1190 to 2570)                             (1450 to 3110)                 (7·7 to 11·1)[\*](#TFN4){ref-type="table-fn"}          (10·7 to 15·1)[\*](#TFN4){ref-type="table-fn"}         (10·2 to 14·3)[\*](#TFN4){ref-type="table-fn"}         (6·3 to 13·8)                (30·6 to 66·1)               (18·5 to 39·7)               (−2·3 to−1·0)[\*](#TFN4){ref-type="table-fn"}          (−0·2 to 2·3)                                          (−0·6 to 1·6)

         Assault by other means                                                                                 6540\                          2550\                                      9090\                      5·9%\                                                −6·9%\                                                   1·9%\                                                     167·0\                         67·6\                      117·4\                   −6·2%\                                               −17·0%\                                                  −9·5%\
                                                                                                        (5750 to 7730)                 (2140 to 2990)                             (8190 to 10 400)               (0·6 to 11·5)[\*](#TFN4){ref-type="table-fn"}          (−11·3 to 1·5)                                         (−1·9 to 6·2)                                          (147·0 to 197·4)             (56·2 to 79·4)               (105·7 to 134·4)             (−10·6 to−1·3)[\*](#TFN4){ref-type="table-fn"}         (−20·9 to−9·2)[\*](#TFN4){ref-type="table-fn"}         (−12·9 to−5·8)[\*](#TFN4){ref-type="table-fn"}

      Conflict and terrorism                                                                                    6840\                          3270\                                   10 100\                     81·9%\                                                 70·8%\                                                 78·1%\                                                      177·1\                         90·6\                      134·1\                   66·2%\                                                 58·4%\                                                 63·7%\
                                                                                                        (6400 to 7830)                 (2820 to 3870)                             (8980 to 11 400)               (55·6 to 112·4)[\*](#TFN4){ref-type="table-fn"}        (48·8 to 99·3)[\*](#TFN4){ref-type="table-fn"}         (58·6 to 101·2)[\*](#TFN4){ref-type="table-fn"}        (155·8 to 203·0)             (78·2 to 107·0)              (119·3 to 151·9)             (42·8 to 94·5)[\*](#TFN4){ref-type="table-fn"}         (36·9 to 86·4)[\*](#TFN4){ref-type="table-fn"}         (45·4 to 85·1)[\*](#TFN4){ref-type="table-fn"}

      Executions and police conflict                                                                              840\                           179\                                     1020\                  140·7%\                                                280·6%\                                                157·3%\                                                         21·4\                          4·8\                       13·1\                117·3%\                                                242·7%\                                                133·1%\
                                                                                                        (800 to 894)                   (170 to 190)                               (972 to 1080)                  (123·6 to 160·4)[\*](#TFN4){ref-type="table-fn"}       (245·5 to 309·1)[\*](#TFN4){ref-type="table-fn"}       (139·7 to 178·0)[\*](#TFN4){ref-type="table-fn"}       (20·4 to 22·8)               (4·5 to 5·1)                 (12·6 to 13·9)               (101·5 to 135·6)[\*](#TFN4){ref-type="table-fn"}       (210·3 to 269·5)[\*](#TFN4){ref-type="table-fn"}       (116·6 to 152·4)[\*](#TFN4){ref-type="table-fn"}
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DALY counts are quoted to three significant figures and percentage changes and rates to one decimal place. DALY=disability-adjusted life-year. G6PD=glucose-6-phosphate dehydrogenase. *H influenzae*=*Haemophilus influenzae*. NASH=non-alcoholic steatohepatitis.

Percentage changes that are statistically significant.

Incidence estimates for stroke represent first-ever stroke only.
